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Introduction
Sudden cardiac death
Sudden cardiac death (SCD) is defined as death from an unexpected circulatory arrest, 
mostly due to a cardiac arrhythmia in patients with coronary artery disease, occurring 
within an hour of the onset of symptoms.1-3 Approximately 50% of all deaths in patients 
with coronary heart disease are unexpected, occurring shortly after onset of symptoms. 
Due to the high number of patients with ischemic heart disease, the incidence of SCD is 
strongly correlated to the prevalence of coronary heart disease.4, 5 Astonishing numbers of 
patients die due to SCD each year in the United States with estimates ranging from 300 
000 to 350 000.4, 6-9 As event rates in Europe are similar to those in the United States more 
than 700 000 patients die each year in the Western world alone.5 Prodromal symptoms are 
often non-specific but, if present, can be related to the cause of SCD and include chest pain 
(ischemia), palpitations (tachyarrhythmia), or dyspnea (congestive heart failure). Major 
risk factors, increasing the risk of SCD include (risk factors for) coronary heart disease, 
prior coronary events, prior ventricular arrhythmia, poor left ventricular systolic function 
and symptoms of advanced heart failure.2 However, as is shown in Figure 1, an inverse 
relationship exists between the risk and total number of SCD in sub-groups of patients at 
increased risk.10 Most worrisome is that in the majority of cases patients were not known 
to have ischemic heart disease prior to SCD, stressing the importance of screening and 
treatment of cardiovascular risk factors.2, 3, 8, 10 
HFST 1. 
Figure 1. Absolute numbers of events rates of sudden cardiac death in the general 
population and in specific subpopulations over 1 year. Clinical trials that included 
specific subpopulations of patients are shown in the right side of the Figure.  
AVID = Antiarrhythmics Versus Implantable Defibrillator; CASH = Cardiac Arrest 
Study Hamburg; CIDS = Canadian Implantable Defibrillator Study; EF = ejection 
fraction; HF = heart failure; MADIT = Multicenter Automatic Implantation Trial; MI = 
myocardial infarction; MUSTT = Multicenter UnSustained Tachycardia Trial; SCD-
HeFT = Sudden Cardiac Death in Heart Failure Trial. 
 
 
Figure 2. Cardiac mortality with decreasing left ventricular ejection fraction (panel A) 
and increasing premature ventricular contractions per hour in the pre-77 and the post78-
thrombolytic era.  
Figure 1. Absolute numbers of events rates of sudden cardiac death in the general population and in 
specific subpopulations over 1 year. Clinical trials that included specific subpopulations of patients are 
shown in the right side of the Figure. 
AVID = Antiarrhyth ics Versus Implantable Defibrillator; CASH = Card ac A res  Study Hamburg; 
CIDS = Canadian Implantable Defibrillator Study; EF = ejection fraction; HF = heart failure; MADIT = 
Multicenter Automatic Implantation Trial; MI = myocardial infarction; MUSTT = Multicenter UnSustained 
Tachycardia Trial; SCD-HeFT = Sudden Cardiac Death in Heart Failure Trial.
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Ventricular fibrillation (VF) is the most frequent rhythm recorded prior to SCD. Stud-
ies have reported that 75-80% of cases originate from this arrhythmia whereas in the 
remaining 15-20% a bradyarrhythmia, including asystole and complete atrioventricular 
block is recorded.11 Concerning these figures, one should note that both causes of sudden 
death can intertwine: although the initial rhythm disorder can be VF, after some time VF 
extinguishes and asystole becomes the presenting rhythm when a first ECG is documented. 
Conversely, bradycardia or atrioventricular conduction delay can trigger VF, which makes a 
correct estimation of incidences difficult.6 Further research on the initial rhythm, causing 
SCD, conducted in 157 patients experiencing SCD during ambulatory Holter monitoring 
demonstrated VF in 62.4% of patients, a bradyarrhythmia in 16.5% of patients, an episode 
of torsades de pointes in 12.7% of patients, and a ventricular tachycardia (VT) in 8.3% 
of patients.12 
Since 40% of all cases of SCD are not witnessed, immediate and adequate treatment is 
difficult, resulting in high mortality rates.13 
Substrate for ventricular arrhythmias 
The substrate for ventricular arrhythmia and potential subsequent sudden arrhythmic death 
is highly dependent on the presence, type and extent of underlying cardiac disease. In the 
classification of substrates, a first division is made between ischemic cardiomyopathy and 
non ischemic cardiomyopathy. Ischemic cardiomyopathy is caused by (chronic) coronary 
artery disease, often with prior myocardial infarction and symptoms of stenotic coronary 
arteries (angina) or reduced LV function (heart failure). Most important types of non 
ischemic cardiomyopathy, related to an increased risk for ventricular arrhythmia and SCD 
are idiopathic dilated cardiomyopathy, hypertrophic cardiomyopathy, and arrhythmogenic 
right ventricular cardiomyopathy. Further substrates for SCD are Wolff-Parkinson-White 
syndrome, congenital (coronary) abnormalities and electrical heart disease.3, 10, 14-16 The 
progression of coronary artery disease with increasing age in contrast to the potentially 
heritable and congenital nature of other substrates causes the latter two to be frequent 
causes of SCD in younger patients.17-19
Ischemic cardiomyopathy
Most studies state coronary artery disease to be the most frequent cause of SCD, given 
its presence in 75% of cases, often with extensive and severe coronary atherosclerosis. 
Post-mortem plaque assessment shows acute changes in plaque morphology (i.e. plaque 
rupture or thrombus) in half of the cases of sudden coronary death, implicating ischemia 
as the trigger of the arrhythmic event.20
Following the acute phase of myocardial infarction, the reparative process is initiated. 
During this period, the formation of granulation and fibrotic tissue compensates for the 
loss of necrotic cardiomyocytes to maintain cardiac structure. This healing phase normally 
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takes 6 to 8 weeks to complete. Although the major changes in cardiac tissue occur during 
this healing phase, the formation of fibrous tissue is a continuous process.21 Following 
myocardial infarction, structural and anatomical remodeling is most apparent. However, 
remodeling also involves alterations in gap junction and ion channel protein expression 
and distribution (electrical remodeling).22 Although fibrosis is the major component for 
arrhythmogenicity in the infarcted heart, electrical remodeling due to changed connexin 
and ion channel expression and/or redistribution adds to changes in conduction and ar-
rhythmogenicity.23
In the past decades, early reperfusion therapies such as thrombolytic therapies and 
primary percutaneous coronary interventions have improved the outcome after acute myo-
cardial infarction significantly.24, 25 Early reperfusion during myocardial infarction results in 
myocardial salvage and improved ventricular function but also influences size, transmural-
ity and geometry of myocardial fibrosis, which may serve as a substrate for ventricular 
arrhythmias.26-30 
Dilated cardiomyopathy
Dilated cardiomyopathy is a common and largely irreversible form of heart muscle disease 
with an estimated prevalence of 1:2500 and first symptoms most commonly in the third or 
fourth decade but also in young children. In family screening studies with echocardiogra-
phy, asymptomatic or mildly symptomatic relatives may be identified.14, 31 Idiopathic dilated 
cardiomyopathy has heterogeneous etiologies but is familial in at least 40% of cases.32, 
33 Five year mortality in the population with diagnosed dilated cardiomyopathy has been 
estimated at 20% of which 8-51% can be attributed to SCD.31, 34 
Hypertrophic cardiomyopathy
With an estimated 0.2% (1:500) of the general population demonstrating the disease 
phenotype on echocardiography, hypertrophic cardiomyopathy is a relatively common au-
tosomal dominant genetic heart disease.14 Although most cases of hypertrophic cardiomy-
opathy are asymptomatic, the first manifestation may be SCD, usually caused by ventricular 
arrhythmia with varying contribution of triggers such as ischemia, outflow obstruction, or 
atrial fibrillation.14, 35-39 The annual case fatality from hypertrophic cardiomyopathy ranges 
from 6% in studies from tertiary centers to 1% or less in community-based studies.40-45 
Moreover, data from the United States suggest that  hypertrophic cardiomyopathy is the 
most common cause of SCD in the young and in trained athletes.46, 47
Arrhythmogenic right ventricular cardiomyopathy
Arrhythmogenic right ventricular cardiomyopathy is an uncommon (estimated 1:5000) 
form of heritable heart muscle disease, involving replacement of myocytes with fibrofatty 
tissue resulting in regional or global abnormalities.14 SCD, often the first manifestation of 
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the disease, occurs relatively frequently during stress or exercise, but SCD at rest is not 
uncommon.17 The annual incidence of SCD varies widely, ranging from 0.08% to 9%.17, 48-51 
Right ventricular dilation, precordial repolarization abnormalities, left ventricular involve-
ment, and certain genetic variants have been associated with an additionally increased risk 
of sudden death.51-53 Of note is that in a prospective investigation on SCD in the young in 
Italy, nearly 20% of fatal events in young people and athletes were caused by previously 
unknown arrhythmogenic right ventricular cardiomyopathy.17
Electrical heart disease
Genetic diseases, related to an increased risk for ventricular arrhythmia and sudden death 
include the long- and short-QT syndromes, Brugada syndrome,54, 55 idiopathic VF, and 
catecholaminergic polymorphic VT. These primary electrical conditions typically exist in 
the absence of any underlying structural heart disease and, with an estimated prevalence 
below 5 per 10 000, are rare.3 Although controversy still exists with regard to risk factors 
for sudden death with these conditions, there is consensus that those with prior cardiac 
arrest or syncope are at very high risk for recurrent arrhythmic events. Furthermore, SCD in 
relatives is considered to increase risk.56
Pharmacological treatment 
Since SCD is often multifactorial, it remains difficult to identify the underlying electrophysi-
ological mechanism in most patients. Consequently, although many studies have assessed 
the pharmacological treatment options in high risk patients, no randomized clinical trial 
has proven class I or III antiarrhythmic drugs to reduce total mortality SCD. However, a 
meta-analysis pooling over 6500 patients with prophylactic amiodarone use demonstrated 
an overall reduction of 13% in total mortality, attributed to a reduced rate of arrhythmic 
death in high-risk patients with recent myocardial infarction or congestive heart failure.57
Controversially, drugs without direct anti-arrhythmic activity but with a more general 
cardiac protective effect have thus far been shown most effective for the prevention of SCD. 
These drugs include beta blockers, ACE inhibitors, angiotensin II receptor antagonists, 
lipid-lowering agents, and spironolactone.58
Beta blockers
The anti-arrhythmic mechanism of beta blockers involves competitive adrenergic-receptor 
blockade of sympathetically mediated triggering mechanisms, slowing sinus rhythm and 
possibly inhibiting the release of excess calcium by the ryanodine receptor.59 Beta blockers 
have been shown to be effective in the suppression of ventricular ectopic beats and in 
decreasing the occurrence of SCD, as well as all-cause mortality, in a wide variety of 
cardiac diseases. These features, combined with a good safety and efficacy profile, makes 
it the drug of first choice in protecting patients against SCD.60, 61
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Amiodarone and sotalol
The major antiarrhythmic effect of amiodarone lies in the blockage of potassium repolariza-
tion which subsequently opposes ventricular arrhythmia by increasing re-entry wavelength. 
A few small studies and one meta-analysis show a positive effect of amiodarone in patients 
with LV dysfunction due to prior myocardial infarction and non ischemic cardiomyopathy,57, 
62-64 most studies do not demonstrate a beneficial effect of amiodarone over placebo.65 Ad-
ditionally, amiodarone is associated with a wide variety of adverse side effects, increasing 
with higher dose and extension of usage period. Although valuable in the suppression of 
ventricular arrhythmias, sotalol has, like amiodarone, not clearly been shown to increase 
survival. While side effects are significantly less frequent compared to amiodarone, sotalol 
use is associated with ventricular arrhythmias in 2-4% of patients.66
Implantable cardioverter defibrillators
First cardiac defibrillation
The first life-saving defibrillation dates back to 1947 when Dr Claude Beck was intraop-
eratively correcting a pectus excavatum in a 14-year-old boy. When VF occurred (probably 
secondary due to the use of anesthetics), Dr Beck initiated direct cardiac massage through 
the opened chest and, after more than a half hour of cardiac massage, used an animal 
cardiac defibrillator which he had developed while working in an animal laboratory many 
years earlier. The electrical defibrillation was successful and rhythm restored to sinus 
rhythm.67 This success immediately led to the general acceptance of electrical defibrillation 
for life-threatening arrhythmias, initiating the development of external and eventually inter-
nal implantable defibrillators. In 1980, Dr Michel Mirowski and his team implanted the first 
implantable cardioverter defibrillator (ICD) in patients and successfully defibrillated VF.68
Secondary prevention 
Epidemiological studies have demonstrated a two-year recurrence rate of 30-50% in 
patients with life-threatening arrhythmias. Therefore, the effects of ICD treatment were 
initially assessed in a population with life-threatening ventricular arrhythmias (second-
ary prevention).68-75 To be eligible for ICD treatment, patients had to survive at least one 
life-threatening ventricular arrhythmia such as VF or sustained VT. The first randomized 
trial to assess the effect of ICD treatment as the initial therapy in survivors of cardiac 
arrest was conducted by Wever et al.75 Fifty patients were randomized to be treated with 
antiarrhythmic drugs or an ICD. During a median follow-up of 24 months, the ICD treated 
group demonstrated lower rates of major outcome events (death, recurrent cardiac arrest 
or cardiac transplantation), underwent fewer invasive procedures and were hospitalized 
less frequently.75 Subsequently, three larger trials further evaluated the effectiveness of 
ICD therapy for the secondary prevention of arrhythmic death: the Antiarrhythmics Versus 
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Implantable Defibrillator (AVID), the Canadian Implantable Defibrillator Study and the 
Cardiac Arrest Study Hamburg.69-71 As is shown in Table 1, these trials included patients 
who had survived an episode of cardiac arrest or with a documented episode of sus-
tained VT. Patients were randomized to optimal pharmacological antiarrhythmic therapy 
or ICD treatment. Although only AVID demonstrated a significant reduction in mortality, a 
meta-analysis of these three trials, demonstrated a significant 28% reduction in all-cause 
mortality in favor of ICD treatment and, with these results, the survival benefit of the ICD 
was proven and ICD therapy for secondary prevention was generally accepted.76
Primary prevention
A major limitation of secondary prevention ICD treatment is that the survival rate of an 
episode of cardiac arrest is only 6% and, therefore, large number of patients will die 
prior to becoming eligible for ICD treatment.13 Consequently, focus shifted from secondary 
prevention of SCD to the identification of patients at high risk before the actual occurrence 
of a life-threatening ventricular arrhythmia (primary prevention). Previous trials in both the 
pre- and the post-thrombolytic era had shown that frequent (runs of) premature ventricular 
beats and a low left ventricular ejection fraction (LVEF) are risk factors, identifying patients 
at increased risk for SCD. More specifically, a LVEF of 40% demonstrated to be the cut-off 
point separating patients with a relatively low risk and patients with a higher risk for SCD 
(Figure 2).77, 78 Therefore, LVEF became the most important marker in the identification of 
patients at high risk for SCD. Furthermore, patients included in the first primary prevention 
trials required additional risk factors for life-threatening ventricular arrhythmias, such as 
the presence of non sustained VT on 24-hour Holter monitoring in patients with prior 
myocardial infarction and/or inducible non-suppressible (by pharmacological treatment) 
sustained VT/VF on electrophysiological study.79, 80 Large trials tested the hypothesis that 
primary prevention ICD treatment was beneficial in a selected population.65, 81-85 The first of 
these trials was the Multicenter Automatic Defibrillator Implantation Trial (MADIT) which 
enrolled patients with a prior myocardial infarction, LVEF less than 35%, documented 
non sustained VT and inducible/non-suppressible VT/VF during electrophysiological study.84 
Table 1. Major secondary prevention implantable cardioverter defibrillator (ICD) Trials. 
AVID69 CIDS70 CASH71
Sample size 1016 659 288
Design ICD vs. antiarrhythmic 
drugs
ICD vs. amiodarone ICD vs. amiodarone vs. 
metoprolol
Patients Resuscitated VF or 
postcardioversion from 
sustained VT
Resuscitated VF or 
VT with unmonitored 
syncope
Survivors of cardiac arrest 
secondary to documented 
ventricular arrhythias
Follow-up, months 18 36 57
Risk reduction with ICD 28% (p = 0.02) 20% (p = 0.14) 23% (p = 0.08)
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Patients were randomized to receive either an ICD or conventional medical therapy (chosen 
by the patient’s attending physician) and, after the inclusion of just 196 patients and 
with 27 months follow-up, the study demonstrated a 54% reduction in mortality in the 
ICD group. Limitations of the trial were the relatively small patient cohort and the signifi-
cantly higher use of beta blockers in the ICD treated patients then in those without this 
treatment. Further analysis of the survival benefit in the MADIT showed that the highest 
benefit was observed in patients with a LVEF less than 26%.86 This observation lead to 
a simplified design, the MADIT II trial, randomizing patients post infarction with a LVEF 
less than 30% to either an ICD or no ICD without additional electrophysiological testing. 
The study required premature closure since the efficacy boundary had been reached. Dur-
ing an average follow-up of 20 months, a mortality reduction of 28% was observed in 
patients treated with an ICD. Nanthakumar and co-workers conducted a meta-analysis of 
all primary prevention trials, showing a 25% mortality reduction in favor of ICD patients 
 2
 
Figure 3. Rates of all-cause mortality, sudden cardiac death, appropriate ICD therapy and 
inappropriate ICD therapy in major randomized clinical trials. Absent columns indicate 
data that were not available. AVID = Antiarrhythmics Versus Implantable Defibrillator; 
DEFINITE = Defibrillators in Non-Ischemic Cardiomyopathy Treatment Evaluation; 
MADIT = Multicenter Automatic Implantation Trial; MUSTT = Multicenter 
UnSustained Tachycardia Trial; SCD-HeFT = Sudden Cardiac Death in Heart Failure 
Trial.  
Figure 2. Cardiac mortality with decreasing left ventricular ejection fraction (panel A) and increasing 
premature ventricular contractions per hour in the pre-77 and the post78-thrombolytic era. 
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and, consequently, these findings led to the inclusion of primary prevention ICD treatment 
in the current guidelines.56, 8
Currently indicated population
In the current guidelines for ICD treatment, secondary prevention is defined by survival of 
cardiac arrest or sustained VT. Additionally, unexplained syncope in patients with cardiac 
condition associated with an increased risk for SCD is considered a secondary preven-
tion indication. Primary prevention is defined in patients without prior cardiac arrest or 
sustained VT.56 
Before patients can receive primary prevention ICD treatment, medical therapy has to 
be optimal and life expectancy has to be more than 1 year.56 Since clinical characteristics 
of individual patients differ from those in large clinical trials, the survival rates are often 
not applicable to the currently indicated population. Although factors increasing the risk 
for heart failure death (such as heart failure hospitalizations and reduced renal function) 
should correlate with increased mortality rates in this population as well, data on mortality 
estimations in the ‘real world’ remain scarce.88, 89
As is shown in Table 2, the LVEF used as inclusion criterion randomized clinical trials 
on the positive effect of primary prevention ICD treatment ranges from less than 40% in 
MUSTT to less than 30% in MADIT II.82, 85 The MADIT I and SCD-HeFT used an LVEF 
of less than 35% to include patients.65, 84 These differences in study population create 
heterogeneity in the indicated population with respect to LVEF, as well as other variables 
such as symptoms of heart failure, inducibility at electrophyisiological study and a history 
of non sustained VT.2 Consequently, the population presently receiving ICD treatment in the 
‘real world’ does not match the population assessed in all separate trials. This warrants 
thorough assessment of this ‘real world’ population. Firstly, with the current practice of 
Table 2. Major primary prevention implantable cardioverter defibrillator (ICD) trials. AAD = antiarrhyth-
mic drugs; CRT-D = cardiac resynchronization therapy-defibrillator; EF = ejection fraction; EPS = elec-
trophysiological study; I = ischemic; MI = myocardial infarction; NICM = non ischemic cardiomyopathy. 
MADIT84 MUSTT82 MADIT II85 COMPANION81 DEFINITE83 SCD-HeFT65
Sample size 196 704 1232 1520 458 2521
Design ICD vs AAD EPS-guided: 
no AAD vs 
ICD vs AAD 
ICD vs 
AAD
CRT vs CRT-D 
vs AAD
ICD vs AAD ICD vs AAD 
vs AAD + 
amiodarone








I & NICM, 
EF ≤0.35, 








27 39 20 14 29 46
Risk reduction 
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aggressive reperfusion strategies to limit the extent of the damage caused by the infarction 
it is not known how many patients will become candidate for ICD implantation in the period 
following the index event.90-93 To make an estimation of the currently indicated population, 
this should be evaluated. Secondly, the ICD treated population should be assessed in terms 
of baseline characteristics, mortality rate, occurrence of ventricular arrhythmia, and ad-
verse events. In fact, it is rather disappointing that, keeping in the mind the socio-economic 
consequences of ICD therapy, only limited data are available evaluating the efficacy of ICD 
therapy.
Appropriate therapy 
Currently the most debated issue in the validation of ICD treatment is the relatively low 
occurrence of ventricular arrhythmias, causing the need for defibrillator backup. In the AVID 
trial, assessing secondary prevention ICD recipients, ICD shocks occurred in over 60% of 
patients.69 However, more recent large randomized trials on the value of primary prevention 
ICD treatment demonstrate significantly lower incidences of appropriate device discharge. 
As is clearly shown in Figure 3, event rates dropped to 21% in the SCD-HeFT and 18% in 
the DEFINITE.65, 83 Remarkably, in the later trial the incidence of inappropriate ICD shocks 
(21%) even out-rated the occurrence of appropriate shocks! Additionally, when further as-
sessing randomized ICD trials, the large discrepancy between SCD incidence in the control  3
 
HFST 2. 
Figure 1. MISSION! protocol flowchart. 
Figure 3. Rates of all-cause mortality, sudden cardiac death, appropriate ICD therapy and inappropriate 
ICD therapy in major randomized clinical trials. Absent columns indicate data that were not available. 
AVID = Antiarrhythmics Versus Implantable Defibrillator; DEFINITE = Defibrillators in Non-Ischemic 
Cardiomyopathy Treatment Evaluation; MADIT = Multicenter Automatic Implantation Trial; MUSTT = 
Multicenter UnSustained Tachycardia Trial; SCD-HeFT = Sudden Cardiac Death in Heart Failure Trial.
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group and the rate of appropriate ICD shocks in ICD treated patients demonstrates that the 
occurrence of defibrillator discharge can not be used as a surrogate for arrhythmic death 
if the ICD had not been implanted (Figure 3).94 One could state that patients who do not 
receive potentially life-saving therapy from the implanted device should not have been 
implanted at all.94 The low rate of ventricular arrhythmias, combined with the high costs of 
ICD treatment ($34,000 to $70,200 per quality-adjusted life year gained),95 and the risk of 
adverse events following device implantation96 warrants improvement in risk stratification 
within the population, currently being treated with an ICD. Ideally, parameters for the 
identification of a population at high or at low risk for the need for defibrillator back-up 
should be non-invasive and easily acquired.
Drawbacks of ICD treatment
Large randomized trials have sufficiently shown the beneficial effect of ICDs in a large 
population at risk for SCD and with the inclusion of primary prevention ICD treatment in the 
current international guidelines, worldwide implantation rates have increased 20-fold over 
the last 15 years to an estimated 275 000 in 2008.56, 97 Nevertheless, the utilization of 
ICD therapy does have a few serious drawbacks. Firstly, clinicians have expressed concern 
that the number-needed-to-treat with a primary prevention ICD might be too high and that 
the population eligible for primary prevention ICD treatment is of such magnitude that ICD 
therapy will strain financial resources and the pool of trained personnel.98 Furthermore, 
even when pursuing maximized patient safety, approximately 6% of ICD patients experi-
ence severe device-related adverse events, some with lethal consequences.96 
Data on complication rates, such as defibrillation lead failure,99-104 coronary sinus lead 
dislodgement,105, 106 pocket infections,106-109 and inappropriate device discharge65, 69, 82, 83, 
85, 110, 111 vary widely and have scarcely been assessed outside the setting of a large clinical 
trial. Additionally, with increased survival of patients it is estimated that over 70% of 
implanted patients require an ICD replacement due to end-of-life of the device and 40% 
even require a second replacement.112 These figures imply that the number of replacements 
can be expected to outnumber first implantations in the near future.113 Previous studies 
have demonstrated that surgical re-interventions, such as device replacements, are cor-
related to an increased occurrence of device infections.108, 109 Additionally, Gould and Krahn 
reported that the consequences of an early re-intervention for a non-infectious cause can 
be considered more harmful than the underlying complication itself.114 However, the effect 
of replacement on non-infectious, pocket related complications and the effect of additional 
replacements has not yet been assessed. 
Finally, as the most frequent adverse event, inappropriate ICD shocks require more 
specific assessment. These inappropriate shocks are painful, psychologically disturbing 
and potentially arrhythmogenic.115-118 Recently, subgroup analysis of two major trials have 
reported on prognosis of ICD shocks and raised concern by establishing an association 
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between inappropriate shocks and increased mortality.119, 120 Incidence, predictors and 
effect of mortality should be assessed in the ‘real world’.
Aim and outline of the thesis
Although the beneficial effect of ICD treatment has been proven in selected patients, the 
population assessed in large clinical trials does not reflect the population with ICDs in the 
‘real world’. The aim of the current thesis was to clearly map the population presently 
receiving ICD treatment, to evaluate long-term follow-up, and to improve baseline risk 
stratification.
In part I, the clinical characteristics of the population currently indicated for ICD treat-
ment in the ‘real world’ was studied and the correlation of classic baseline variables to 
mortality and the occurrence of ventricular arrhythmia was assessed. Chapter 2 described 
what proportion of cases of myocardial infarction results in a deterioration of LV function to 
the extent that warrants ICD treatment. The long-term follow-up of secondary prevention 
ICD recipients was studied in Chapter 3. Further chapters assess the value of baseline 
characteristics in primary prevention ICD patients. Chapter 4 and 5 demonstrate the im-
portance of atrial fibrillation in patients with ICD and CRT-D respectively and in Chapter 6 
all classic baseline variables are combined to construct a clinically applicable mortality risk 
score. Finally, Chapter 7 evaluates the identification of patients who do not benefit from 
ICD treatment.
In part II, an attempt is made to identify new variables to improve risk stratification in 
primary prevention ICD patients. In the prediction of ventricular arrhythmia the follow-
ing novel variables were studied: 1) infarct tissue heterogeneity, assessed by magnetic 
resonance imaging (Chapter 8); 2) cardiac neuronal functioning, assessed by 123-iodine 
metaiodobenzylguanidine imaging (Chapter 9); 3) the planar and spatial QRS-T angle, as 
assessed on the ECG (Chapter 10); and 4) right ventricular pacing threshold, as assessed 
by post implant testing (Chapter 11). 
Part III described the occurrence of adverse events in an ICD treated population. In 
Chapter 12, the incidence, prediction and prognostic importance of inappropriate ICD 
shocks was studied and Chapter 13 assessed the long-term incidence of coronary sinus 
lead dislodgement. Chapter 14 showed the risk of lead failure of different types of defibrilla-
tion leads and Chapter 15 evaluated the results of the Sprint Fidelis advisories. Finally, the 
requirement for surgical re-interventions and the effect of device replacement was studied 
(Chapter 16).
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Aim: To assess the percentage of patients in daily clinical practice that meets criteria for 
implantation of an Implantable Cardioverter Defibrillator (ICD) following Acute Myocardial 
Infarction (AMI).
Methods: The MISSION! protocol contains pre-hospital, in-hospital and out-patient clinical 
framework for decision making and treatment of AMI patients and prevention of Sudden 
Cardiac Death (SCD) and is based on international guidelines. 
Results: A total of 676 consecutive AMI patients (78% male, mean age 59±12 years) 
treated according to the MISSION! protocol were included in this analysis. LVEF at 3 
months was 54±10%. Only 39 (6%) patients met criteria for implantation of an ICD <1 
year post-MI. These patients suffered more extensive infarctions as indicated by higher 
peak troponin T values (mean 14.5±8.3µg/l vs. 6.5±14.7µg/l; p<0.001) and had more 
LAD related infarctions (79% vs. 46%; p<0.001). Cumulative first appropriate therapy 
rate was 15% at 3 years follow-up. No sudden cardiac death was observed in the study 
population.
Conclusions: After implementation of an aggressive optimized treatment protocol for AMI 
patients, prophylactic ICD implantation was warranted in only 6% of patients. Accordingly, 
an easy-to-use, guideline-based protocol tailored to fit within routine practice is able to 
reduce the rate of severe deterioration of LV function and SCD to a minimum and helps 
maintain ICD implantation rates within manageable proportions.
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Patients after acute myocardial infarction (AMI) are at risk of sudden death due to life 
threatening ventricular arrhythmias.1 Large randomized trials demonstrated that both 
arrhythmic death and total mortality can be lowered by implantation of an Implantable 
Cardioverter Defibrillator (ICD) in post-MI patients with a low left ventricular ejection frac-
tion (LVEF) with or without ventricular arrhythmias.2-4 These findings resulted in a Class 
I indication for all patients with an ischemic cardiomyopathy and a low LVEF, even in 
the absence of ventricular arrhythmias.5,6 Most of these trials however included patients 
years after the index event (more than 75% of patients in the two Multicenter Automated 
Defibrillator Trials (MADIT) were enrolled >6 months after MI and 89% in the Multicenter 
Unsustained Tachycardia Trial (MUSTT) were enrolled >1 year post MI). Furthermore with 
the current practice of aggressive reperfusion strategies to limit the extent of the damage 
caused by the infarction it is not known how many patients will become candidate for ICD 
implantation in the year following the index event.
A regional AMI guideline implementation program (MISSION!) was developed to opti-
mize the use of evidence-based medicine in practice.7 MISSION! contains a pre-hospital, 
in-hospital and out-patient clinical framework for decision making and treatment of AMI 
patients. This prospective and well-defined cohort offers a unique opportunity to evaluate 
and follow patients after AMI and to assess the need for ICD treatment.
Methods
Patients and protocol
Since 2004, all patients presenting with AMI at Leiden University Medical Center were 
treated according to the MISSION! protocol, as previously described in detail.7 The protocol 
is based on the ACC/AHA/ESC guidelines for AMI and focuses on the reduction of onset of 
symptoms-to-balloon time, optimization of pharmacological treatment, and the structured 
prevention of SCD during follow-up.7-9  The global in-hospital and out-patient clinical 
framework for the decision-making process and treatment up to one year following the 
index event is outlined in Figure 1.
AMI diagnosis was confirmed by the presence of an unstable coronary lesion on angiog-
raphy and/or the elevation of cardiac biomarker(s) above normal levels.10 Patients without 
typical ST-elevation in-hospital, but with ischemic symptoms and elevated cardiac enzymes 
(CKMB and troponin T) were also diagnosed and included as AMI patients in the program. 
In the absence of complications, the hospital admission was limited to three days. Patients 
on mechanical ventilation at the time of the index event were excluded from the pre-
hospital and in-hospital MISSION! protocol. These patients did, however, receive the same 






out-patient treatment after discharge. Patients were excluded from the study population 
in case of death prior to the acquisition of the gated single photon emission computed 
tomography (SPECT) three months after the index event, or if the assessment of LV function 
on gated SPECT was not possible due to poor image quality.
Data of each MISSION! patient was collected prospectively in an electronic patient file 
and data management system (EPD-VISION 6.01, Leiden University Medical Center).
Follow-up
In the outpatient phase all patients were scheduled for regular clinical visits 30 days after 
the index event and after that every 3 months in the course of a year. 
Gated SPECT (99m tetrofosmin gated myocardial perfusion SPECT) was used as the pre-
ferred method for the assessment of LVEF and was conducted at 3 months follow-up.11,12
ICD eligibility
The ICD screening protocol was loosely based on large primary prevention ICD trials that 
contributed to the development of the guidelines.2-4,6 
Patients were subsequently divided into the following groups, according to the LVEF: 
(1) LVEF ≤30%; (2) LVEF 31-35%; and (3) LVEF >35%. Patients with LVEF ≤30% as 
determined from gated SPECT were directly assigned to ICD therapy as in MADIT II.4  4
 
Figure 2. Kaplan-Meier curve for the cumulative rate of first appropriate ICD-therapy. 
 
Figure 1. MISSION! protocol flowchart.
Jan-Willem BW new.indd   34 29-07-10   13:30
35















nPatients with LVEF 30-35% were considered eligible for ICD therapy when non sustained 
ventricular tachycardias (nsVT) were observed on 24-hour Holter monitoring similar to 
protocols of trials like MADIT I or MUSTT.2,3 Patients with a LVEF ≥35% and abnormal 
24-hour Holter monitoring revealing nsVT were also referred for an electrophysiological test 
to evaluate indication for antiarrhythmic therapy. 
Endpoints
The primary endpoint was ICD eligibility, as determined by the described protocol. Second-
ary endpoints were all-cause death, further subdivided into death from cardiac causes, 
sudden death (unwitnessed), or non-cardiac death. 
Furthermore, in patients receiving an ICD, secondary endpoints were appropriate and 
inappropriate defibrillator discharge (antitachycardia pacing [ATP] or shock).
ICD evaluation
Device interrogation was scheduled every 3 months. All printouts were checked for ap-
propriate and inappropriate ICD therapy (ATP or shocks). Therapies were classified as 
appropriate when they occurred in response to VT or ventricular fibrillation (VF) and as 
inappropriate when triggered by sinus or supraventricular tachycardia, T-wave oversensing, 
or electrode dysfunction. Cutoff rate of the monitor or first therapy zone was noted.
Statistical Analysis
Continuous data are expressed as mean ± SD; dichotomous data are presented as numbers 
and percentages. Differences at baseline were assessed using a Chi-square test using Yate’s 
correction or student t-test for independent samples where appropriate. Event rates over 
time were analyzed by method of Kaplan-Meier. 
Univariable and multivariable cox regression analyses were performed as appropriate 
to determine a relation between potential risk factors at baseline and the incidence of 
all cause death. All variables with a p value of <0.25 entered the multivariable regres-
sion analysis. Only adjusted Hazard Ratio (HR) is reported with the corresponding 95% 




From February 2004 until December 2006 799 patients were admitted with AMI at the 
Leiden University Medical Center and were treated according to the MISSION! protocol. 
Forty-seven (6%) patients died < 3 months after the index event (before the gated SPECT 





 1 test). Causes of death included progressive heart failure (41/47, 87%), sudden cardiac 
death (4/47, 9%), and non cardiac death (2/47, 4%). Additional patients were excluded 
from the analysis due to incomplete gated SPECT data (n=76, 10%).
Accordingly, a total of 123 (15%) patients were excluded from the analysis. The remain-
ing 676 were included and were followed for a median 32 months with an interquartile 
range (IQR) of 25 months (25th percentile) and 40 months (75th percentile). 
Study population
Baseline characteristics of the study population are reported in Table 1. Patients were mostly 
male (78%) and had a mean age of 59 ± 12 years (range 22-88). Frequent risk factors for 
cardiovascular disease included current smoking (50%), a family history of cardiovascular 
disease (43%), and hypertension (31%). Nearly all patients underwent a primary PCI 
procedure (97%); the remaining patients received thrombolytic therapy. The left anterior 
descending coronary artery (LAD) was the culprit vessel in 48%. Mean symptom-onset to 
balloon time was 288 ± 1282 minutes and the mean duration of hospitalization was 3 ± 
2 days. Medication at discharge was optimal and included aspirin in 95%, statin in 99%, 
ACE-inhibitor in 96%, clopidogrel in 99%, and β-blocker in 93%. When aspirin was not 
prescribed at discharge it was because anticoagulant treatment was prescribed instead 
(alongside clopidogrel treatment) in order to avoid increased risk of bleeding complications. 
Anticoagulants were prescribed for patients with atrial fibrillation, severely impaired LV 
function or LV aneurysm. 
Evaluating ICD eligibility
The mean LVEF, 3 months after the index event, was 54 ± 10%, as derived from gated 
SPECT. Twenty-five (4%) patients had a LVEF ≤30%, warranting ICD treatment. LVEF 
between 30% and 35% was observed in 27 (4%) patients, of whom 7 demonstrated 
nsVT on 24-hour Holter monitoring, indicating them for defibrillator implantation. Of the 
remaining 624 (92%) patients with LVEF ≥35%, another 7 patients were candidates for 
ICD based on inducible VT/VF during electrophysiological (EP) testing. Additionally, one 
patient received an ICD due to late (>48 hr) sustained VTs following the AMI and another 
3 patients were treated with an ICD as a result of deterioration of LV function during the 
year following the index event. 
Accordingly, 39 (6%) patients underwent ICD implantation, which was successful in all, 
without major complications.
ICD group characteristics
As is shown in Table 1, patients indicated for ICD therapy had more extensive AMI, evidenced 
by a higher maximum troponin T (no ICD 6.5 ± 14.7 µg/l, ICD 14.5 ± 8.3 µg/l, p<0.001) 
and creatine kinase (no ICD 2185 ± 1820 µg/l, ICD 4403 ± 2730 µg/l, p<0.001). 
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Furthermore, the LAD was more often the culprit vessel in the implanted group (no ICD 
46%, ICD 79%, p<0.001) and the duration of hospitalization was longer (no ICD 3 ± 2 
days, ICD 6 ± 5 days, p<0.001). No significant differences were observed in the occur-
rence of risk factors for cardiovascular disease, Killip class at admission, or medication at 
discharge. By definition, LV function was less in the ICD indicated group. 









Male 529 (78) 499 (78) 30 (77) 0.8
Age (years) 59 ± 12 59 ± 12 57 ± 13 0.2
Medical History
Diabetes 69 (10) 66 (10) 3 (7) 0.8
Hyperlipidemia 149 (22) 144 (23) 5 (13) 0.2
Hypertension 212 (31) 199 (31) 13 (33) 0.7
Current smokers 336 (50) 314 (49) 22 (56) 0.4
Family History 291 (43) 273 (43) 18 (46) 0.7
Previous myocardial infarction 42 (6) 39 (6) 3 (7) 1.0
Previous PCI 29 (4) 26 (4) 3 (7) 0.5
Previous CABG 7 (1) 7 (1) 0 (0) 1.0
Clinical characteristics
Culprit vessel LAD 325 (48) 294 (46) 31 (79) <0.001
Killip class at admission
   I 632 (93) 595 (93) 37 (95) 1.0
   II 23 (3) 22 (3) 1 (3) 1.0
   III/IV 21 (3) 20 (3) 1 (3) 1.0
Troponine T max (µg/l) 6.9 ± 14.5 6.5 ± 14.7 14.5 ± 8.3 <0.001
CK (µg/l) 2309 ± 1947 2185 ± 1820 4403 ± 2730 <0.001
Body mass index (kg/m²) 26.4 ± 4.0 26.4 ± 4.0 25.3 ± 3.9 0.1
Symptom-onset-balloon (minutes) 288 ± 1282 287 ± 1317 303 ± 321 0.1
Primary PCI 655 (97) 620 (97) 35 (90) 0.2
Duration of hospitalization (days) 3 ± 2 3 ± 2 6 ± 5 <0.001
LVEF 54 ± 12 55 ± 11 31 ± 9 <0.001
Medication at discharge
 Aspirin 642 (95) 604 (95) 38 (97) 0.7
 Statin 670 (99) 631 (99) 39 (100) 1.0
 ACE-inhibitor 651 (96) 612 (96) 39 (100) 0.7
 Beta-blocker 627 (93) 589 (93) 38 (97) 0.4
 Clopidogrel 671 (99) 632 (99) 39 (100) 1.0
 Anticoagulant 33 (5) 32 (5) 1 (3) 0.7





 1 Device therapy
During a median follow-up of the ICD treated population of 31 months (IQR 19 months 
and 42 months), 6 patients (15%) received appropriate device therapy for ventricular ar-
rhythmias. Cumulative event rate was 8% (95% CI 0-16%) after 6 months, 15% (95% CI 
4-27%) after one year, and 15% (95% CI 4-27%) after 3 years (Figure 2). No appropriate 
ICD discharge was observed in the implanted group with LVEF ≥35%. The group with LVEF 
≤30% and those with LVEF between 30 and 35% did not demonstrate differences in the 
occurrence of appropriate ICD therapy (appropriate therapy in LVEF ≤30%: 19% vs. LVEF 
30-35%: 29%, p=0.8). Inappropriate therapy occurred in 3 of 39 (8%) ICD recipients.
Mortality
In the population, 12 patients (2%) died during follow-up. The 2 deaths occurring in the 
ICD treated group were related to progressive heart failure. Causes of death in the group 
without a defibrillator were progressive heart failure in 5 (50%), and non-cardiac in the 
other 5 (50%) patients. Of note, no cases of sudden death were observed. The 4 sudden 
deaths that occurred <3 months after the acute MI happened due to uncertain, but likely 
cardiac etiology and took place after hospital discharge. They are best described as sudden 
unexplained death and took place at day 13, 16, 25 and 51 post-MI respectively. All four 
patients had a left ventricular ejection fraction calculated with biplane echocardiography 
as >35%.
As is shown in Figure 3, the cumulative event-free follow-up after 3 years is 98% (95% CI 
96-99%) for all-cause mortality, 99% (95% CI 98-100%) for cardiac mortality, and 100% 
for sudden death. 
 4
 
Figur  2. Kaplan-Meier curve for the cumulative rate of first appropriate ICD-therapy. 
 
Figure 2. Kaplan-Meier curve for the cumulative rate of first appropriate ICD-therapy.
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Multivariate cox regression analysis for mortality > 3 months after the index event re-
vealed hyperlidemia (HR 5.9, 95%CI 1.3-26.1), no aspirin use at hospital discharge (HR 
8.4, 95%CI 1.5-46.0) and no ACE-inhibitor use at discharge (HR 7.9, 95%CI 1.2-50.4) 
as independent predictors of death. Age, gender, peak troponine T, ICD treatment, culprit 
target vessel, other risk factors for CAD (including hypertension, smoking, diabetes, his-
tory of MI, family history of coronary artery disease) and LVEF could not be identified as 
independent predictors of death.
Discussion
In the assessment of an easy-to-use, structured protocol for the treatment of AMI patients 
and prevention of SCD, the findings can be summarized as follows: (1) Defibrillator implan-
tation was warranted in only 6% of AMI patients; (2) No SCD occurred in the study popula-
tion; (3) Compliance to evidence based medicine was excellent; (4) In ICD recipients, the 
cumulative event rate for appropriate ICD therapy was 15% at 3 years follow-up.
Structured care for AMI patients
In past decades important insights have been gained into the management of patients with 
AMI. Measures such as rapid triage and quick access to reperfusion therapy can reduce 
treatment delay, prevent unnecessary infarct extension, and save lives.13,14 Furthermore, 
the efficacy of early optimal pharmacological therapy has been recognized.15 International 
guidelines on the optimal treatment of patients with AMI advocate early and aggressive 
 5
Figure 3. Kaplan-Meier curve for the event-free follow-up for mortality. 
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Figure 1. Kaplan-Meier curve for appropriate therapy-free follow-up (bold line) and 
appropriate therapy for life-threatening VT-free follow-up (dashed line). 
 
Figure 3. Kaplan-Meier curve for the event-free follow-up for mortality.





 1 reperfusion strategies and recommend use of a combination of evidence-based medicine 
and support programs to stimulate a healthier lifestyle. 7,9  The degree of compliance to 
these guidelines has proven to be independently correlated to 1-year mortality after AMI.16 
We maximized the use of evidence-based medicine in daily clinical practice by developing 
and implementing a structured pre-hospital, in-hospital and out-patient AMI care program: 
MISSION!.7 By implementing this protocol in daily clinical practice a high compliance to 
evidence based medicine was achieved which was reflected by the consistent prescription 
of optimal medication at discharge and follow-up
Prevention of SCD
AMI survivors are at increased risk for sudden death from cardiac causes, in most patients 
due to a ventricular arrhythmia.1,17 Thus far, LV function has proven to be a strong indicator 
for an increased risk of SCD.18-20 Therefore, an important goal in reducing the risk of SCD 
in AMI patients is preserving LV function and the identification of patients with a low LVEF 
during follow-up. Prevention of severe LV dysfunction post-MI was addressed by focusing 
on minimal treatment delays, aggressive reperfusion therapy and the use of early and 
consistent optimal pharmacological therapy. Screening for SCD prevention commenced 3 
months after the acute event in contrast to guidelines recommending a period of 40 days 
post MI. However, of all deaths occurring in the first 3 months after MI, the vast majority 
(46/47, 98%) occurred <40 days after AMI and therefore could not have been prevented 
by commencing screening after 40 days. 
Nuclear imaging (gated SPECT) functioned as gatekeeper for risk stratification at 3 
months post-MI. It facilitated the first step toward the detection of patients at increased 
risk for SCD. A previous study highlighted the importance of scintigraphic evaluation of 
patients with coronary artery disease.12  Gated SPECT was able to detect patients with 
extensive scar tissue and LVEF ≤30%, which were at high risk for recurrence of ventricular 
arrhythmias. Patients that were excluded from the study population due to inconclusive 
gated SPECT results (n = 76, 10%) had either poor quality gated SPECT result (due to 
irregular heartbeat or attenuation artifacts) or did not undergo gated SPECT because they 
either refused protocol or were involved in other treatment protocols related to comorbidi-
ties. These patients did, however, all undergo echocardiography around the same time (±3 
months after the acute event) and had estimated biplane ejection fractions above 35% 
which excluded them as likely candidates for ICD implantation. Had they been included 
in the final study population, the ratio of patients with an ICD indication versus patients 
without an ICD indication, would have probably been even smaller. 
With implementation of the MISSION! protocol only 6% of patients had severe LV dys-
function warranting prophylactic ICD implantation and, more importantly, no SCD was 
observed in the study population. 
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Large randomized trials have proven the beneficial effect of primary prevention ICD treat-
ment in post-MI patients with a severely depressed LVEF.3,4,21 Implementation of these 
findings in the current international guidelines significantly and rapidly expanded the indi-
cations for ICD implantation.5 Correspondingly, while patients with LVEF 30-35% included 
in the present study were only considered eligible for ICD implantation when nsVT was 
observed on 24-hour Holter, the most current guidelines elevated ICD therapy for patients 
with LVEF <35% to a Class I indication regardless of nsVT.5 Due to these rapid changes, 
clinicians have expressed concern that the population, eligible for primary prevention ICD 
treatment, is of such magnitude that provision of ICD therapy will strain financial resources 
and the pool of trained personnel.22 Despite the in some ways more lenient ICD eligibility 
criteria as compared to current guidelines, the present study showed successfully that the 
proportion of post-MI patients potentially eligible for an ICD, when treated optimally and 
aggressively for AMI, is smaller than anticipated.23-25 By using the pre-specified protocol 
merely 6% of AMI patients were identified as candidates for ICD implantation and no 
sudden deaths occurred in the study population. 
Device therapy
In the ICD treated population, the cumulative event rate for first appropriate ICD therapy 
at 3 years follow-up was 15% (95% CI 4-27%), which is lower than the event rates 
reported from trials like MADIT II (35%).26 Possible reasons for this difference may be the 
smaller ICD patient group in the current study and the more preserved LV function in the 
current study’s ICD treated population (LVEF 31 ± 9%), when compared to the MADIT II 
population (LVEF 23 ± 5%). Furthermore, in MADIT II 42% of patients who underwent 
coronary revascularization, had the procedure >60 months before enrollment in the study 
(median 107 months) whereas patients in the current study were risk stratified for ICD 
implantation <1 year post-MI. The low arrhythmic event rate in the population selected 
with the MISSION! protocol suggests a low rate of potential SCD in these patients. 
As expected, appropriate ICD therapy was more common among patients with the low-
est LVEF. In the group with most preserved LVEF (≥35%) none of the patients benefited 
from “life-saving therapy”. Interestingly, all incidents of first appropriate therapy took place 
within the first year after ICD implantation, although the small number of ICD patients war-
rants caution in the interpretation of the data. An increased tendency for arrhythmic events 
in the first year after implant is consistent with prior reported data on ICD patients.27,28 
Nevertheless, results from the eight year follow-up of the MADIT II trial 29 provides sub-
stantial evidence for long term mortality benefit of ICDs and suggests that more long-term 
randomized trial data is needed to evaluate long-term benefit of ICD treatment. While ICD 
therapy was shown to result in significant survival benefits in the first four years of follow-





 1 up in MADIT II, long-term analysis proved that ICD therapy was associated with additional 
life-saving benefits during the extended four to eight years of follow-up.
Clinical implications
Using a standardized clinical protocol like the MISSION! algorithm can not replace personal 
judgment and individualized risk assessment, but can aid in applying evidence-based medi-
cine in clinical practice and can help in achieving optimal results at the lowest possible 
cost, in terms of health, quality of life and finance. Interestingly, results of the multivariable 
analysis suggested that by applying ICD therapy to all patients with low LVEF, low LVEF in 
itself was no longer an independent predictor of death in the studied population. Of note, 
when removing the variable ICD treatment from the multivariable cox regression analysis 
LVEF did become significantly associated with death. This seems to confirm that ICD treat-
ment is probably the reason why low LVEF was no longer associated with (all-cause) death 
in the study population after ICD screening. It remains possible that follow-up and relatively 
small patient numbers in the low LVEF group were not sufficient to see a significantly 
different distribution of (particularly heart failure related) deaths between the low LVEF and 
the high LVEF group.
The findings of the current study show that implementation of a guideline-based protocol 
for the treatment of AMI and structured prevention of SCD during follow-up reduces the 
rate of severe deterioration of LV function, and SCD during follow-up to a minimum. This 
suggests that such an easy-to-use, guideline-based protocol should be tailored to fit within 
daily clinical practice in the care for patients with AMI and during follow-up. 
Limitations
This is a single-center study based on the data of real clinical practice without the strict 
controlled conditions of a trial. Only patients with conclusive gated SPECT LVEF results 
were included in the study population.
Three-year event rates should be interpreted with caution due to relatively short follow-up 
and the small number of patients that received an ICD.
Conclusion
After implementation of an aggressive optimized treatment protocol for AMI patients, 
prophylactic ICD implantation was warranted in only 6% of patients. Accordingly, an easy-
to-use, guideline-based protocol tailored to fit within routine practice is able to reduce the 
rate of severe deterioration of LV function and SCD to a minimum and helps maintain ICD 
implantation rates within manageable proportions.
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 1 Abstract 
Aims: To assess the long-term rate of mortality and the recurrence of potentially life-threat-
ening ventricular arrhythmias in secondary prevention implantable cardioverter defibrillator 
(ICD) patients and to construct a model for baseline risk stratification.
Methods and results: Since 1996, all patients with ischemic heart disease, receiving 
ICD therapy for secondary prevention of sudden death were included in the current study. 
Patients were evaluated at implantation and during long-term follow-up. A total of 456 
patients were included in the analysis and followed for 54±35 months. During follow-up, 
100 (22%) patients died and ICD therapy was noted in 216 (47%) patients of which 
138 (30%) for fast, potentially life-threatening ventricular arrhythmia. Multivariate analysis 
revealed a history of atrial fibrillation or flutter (AF), ventricular tachycardia as presenting 
arrhythmia, wide QRS and poor left ventricular ejection fraction as independent predictors 
of life-threatening ventricular arrhythmias. The strongest predictor was AF with a hazard 
ratio of 2.1 (95% CI: 1.3-3.2). Based on the available clinical data it was not possible 
to identify a group which exhibited no risk on recurrence of potentially life-threatening 
ventricular arrhythmias.
Conclusions: Ischemic secondary prevention ICD recipients exhibit a high recurrence rate 
of potentially life-threatening ventricular arrhythmias. Factors, increasing risk can be identi-
fied but, even with these factors, it was not possible to distinguish a recurrence-free group. 
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Sudden cardiac death, mainly caused by ventricular arrhythmias in a population with coro-
nary artery disease, is a major cause of mortality in the western world.1, 2 Large randomised 
trials have proven the beneficial effect of  implantable cardioverter defibrillator (ICD) therapy 
in survivors of these life-threatening ventricular arrhythmias.3-5 Although implantation of a 
defibrillator has become common practice, little is known about the long-term recurrence 
rate of potentially life-threatening ventricular arrhythmias, mortality and device-related 
adverse events in this population outside the setting of a clinical trial. Furthermore, results 
from these randomised trials seldom differentiate in the type of arrhythmia, causing the 
need for appropriate device therapy. Finally, an attempt to identify a recurrence-free group 
within this high risk population has not yet been made. 
Since 1996, all survivors of life-threatening arrhythmias were screened according to the 
protocol of the Leiden Out of Hospital Cardiac Arrest STudy (LOHCAT).6 This well-defined 
cohort offers a unique opportunity to study the rate of recurrence and mortality after a 
life-threatening ventricular arrhythmia in patients with ischemic heart disease and to assess 
the possibility to identify a recurrence-free population.
Methods
Patients and study protocol 
Since 1996, all consecutive survivors of life-threatening ventricular arrhythmias at our 
hospital were evaluated systematically according to a standardised protocol as previously 
described.6, 7 All patients with ischemic heart disease, treated by implantation of an ICD, 
were included in the current evaluation. Life-threatening ventricular arrhythmias were de-
fined similarly to previous large randomised trials as ventricular arrhythmias causing loss of 
consciousness, requiring pharmacological or electrical cardioversion, or lasting longer than 
30 seconds.3, 4 Patients with ventricular tachycardia (VT) or ventricular arrhythmia due to 
myocardial infarction (<48 hours), patients with Wolff-Parkinson-White, and patients with 
adverse drug reactions were excluded from the current evaluation. An acute myocardial 
infarction was defined as the presence of persistent ST-segment elevation or electrocardio-
graphic signs of evolving myocardial infarction. Patients with minimally elevated creatinin 
kinase-MB (less than twice the upper limit of normal) were not considered to be patients 
with acute myocardial infarction.2 Ischemic heart disease was defined in the presence of 
significant coronary artery disease (a diameter stenosis of at least 50% in at least one 
coronary artery). 
At inclusion, the following variables were obtained: patient demographics, cardiovas-
cular history, co-morbidity, cardiovascular risk factors and medication. Additionally, an 





 1 electrocardiogram was acquired for determination of QRS duration, left ventricular ejection 
fraction (LVEF) was defined by echocardiography or single photon emission computed 
tomography and coronary anatomy was investigated by coronary angiography.6 
Device interrogation/long-term follow-up 
Device interrogation was scheduled every three-six months. All printouts were checked 
for appropriate and inappropriate ICD therapy (anti tachycardia pacing [ATP] or shocks). 
Therapies were classified as appropriate when they occurred in response to VT or ventricular 
fibrillation (VF) and as inappropriate when triggered by sinus or supraventricular tachycar-
dia, T-wave oversensing, or electrode dysfunction. In addition cycle length of all ventricular 
arrhythmias causing device therapy, were noted. Furthermore, follow-up included all-cause 
mortality, device infections, and device replacements. 
In the Dutch health care system, all patients are followed by the implanting centre. Since 
periodical follow-up was performed every three to six months, patients without data on the 
past six months were considered as lost to follow-up.
End points
Our primary end-point was the occurrence of a potentially life-threatening ventricular ar-
rhythmia, defined as a ventricular arrhythmia faster than 188 bpm. Secondary end-points 
were the occurrence of any appropriate ICD therapy (ATP or shock) and all-cause mortality. 
Furthermore, pocket infection, revascularization and device replacement were noted. 
Statistical analysis 
Continuous data are expressed as mean ± SD or median with 25th and 75th percentile 
where appropriate; dichotomous data are presented as numbers and percentages. Cumula-
tive event rates were analyzed by method of Kaplan-Meier and log-rank test. Univariate 
relationships between baseline parameters and end-points were assessed with Cox pro-
portional hazard regression analysis. For each variable a hazard ratio (HR) with a 95% 
confidence interval (95% CI) was calculated. Variables with a p-value <0.10 were further 
evaluated in a multivariate model, using backward stepwise selection. At each step, the 
least significant variable was discarded from the model, until all variables in the model 
reached a p-value <0.25. All analyses were performed with SPSS for Windows, version 
16.0 (SPSS, Chicago, IL). For all tests, a p-value <0.05 was considered statistically 
significant.
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During the study period, 875 survivors of a life-threatening ventricular were screened ac-
cording to the LOHCAT protocol. Two-hundred-and-eighty patients (32%) did not show 
ischemic heart disease and were therefore excluded from the current analysis. Of the 
population with ischemic heart disease, 119 (20%) patients were not treated with an ICD 
because of diagnosed acute myocardial infarction (108 patients) or patient’s refusal to 
receive ICD treatment (11 patients). The remaining 476 patients were treated with an ICD 
in the Leiden University Medical Center. Twenty patients (4.2%) were lost to follow-up. Of 
these patients, 3 (15%) died during an average follow-up of 21±25 months. No data on 
device interrogations could be obtained in these patients. The remaining 456 patient were 
included in the analysis. One-hundred-eighty-eight patients (41%) required cardiopulmo-
nary resuscitation at baseline before ICD implantation. Sixty percent of included patients 
were implanted after 2002 and mean follow-up was 54±35 months.
The majority of patient (86% men, mean age 65 years, range 33 to 86 years), had a de-
pressed LVEF (35±14%), wide QRS (119±30 ms), and a VT as the presenting arrhythmia 
(286, 63%). Medication at discharge included diuretics in 53%, beta-blockers (without 
sotalol) in 47%, sotalol in 20% and amiodarone in 32%. All baseline characteristics are 
summarised in Table 1. 
Occurrence of potentially life-threatening ventricular arrhythmias
Life-threatening ventricular arrhythmias (>188 bpm), triggering device therapy, occurred 
470 (range per individual patient: 1-59) times in 138 (30%) out of 456 patients. Cumula-
tive incidences of device therapy for life-threatening ventricular arrhythmias at one, five and 
eight years are 13%, 35% and 45% respectively (Figure 1).
The chance of a first occurrence of life-threatening ventricular arrhythmias causing an 
ICD therapy decreased during time following implantation. Still, 12% of patients experienc-
ing a life-threatening ventricular arrhythmia during follow-up had their first occurrence 
more than 60 months after implantation, as shown in Figure 2.
The multivariate Cox regression model (Figure 3) for the occurrence of life-threatening 
ventricular arrhythmias revealed the following variables as independent predictors: a history 
of atrial fibrillation or flutter (AF), VT as presenting arrhythmia (as compared to VF), wide 
QRS and poor LVEF. The strongest predictor was AF with a HR of 2.1 (95% CI: 1.3-3.2).
Based on the available clinical data it was not possible to identify a group which exhibited 
no risk on recurrence of potentially life-threatening, fast ventricular arrhythmias.







Ventricular arrhythmias, followed by any ICD therapy (ATP or shock) were noted in 216 
(47%) patients. In this group, a total number of 6500 ICD therapies was noted. These con-
sisted of 5890 (range per individual patient: 1-1948) episodes of ATP in 142 patients and 
610 (range per individual patient: 1-59) shocks in 152 patients. Cumulative incidences 
of appropriate therapy at one, five and eight years are 24%, 52% and 61% respectively 
(Figure 1). 
Seventy-nine patients (17%) received appropriate device therapy within six months fol-
lowing ICD implantation. Patients receiving device therapy within six months demonstrate 
Table 1. Baseline characteristics
All patients (n=456)
Clinical parameters
    Male gender 393 (86%)
    Age (yrs) 65±10
    Presenting arrhythmia is VT 286 (63%)
    Creatinin (µmol/L) 110±53
    Renal clearance (ml/min)* 75±39
    QRS-duration (ms) 119±30
    LVEF (%) 35±14
Medication
    Beta-blockers (without sotalol) 212 (47%)
    Sotalol 90 (20%)
    Ca-antagonist 47 (10%)
    Nitrates 145 (32%)
    ACE inhibitors / AT antagonist 362 (79%)
    Statins 325 (71%)
    Diuretics 241 (53%)
    Amiodarone 146 (32%)
    Aspirin / calcium carbasalate / ASA 186 (41%)
    Oral anticoagulant therapy 262 (58%)
Cardiovascular history
    History of atrial fibrillation or flutter 60 (13%)
    Previous infarction 424 (93%)
    Previous PCI 143 (31%)
    Previous CABG 154 (34%)
Risk factors
    Hypertension 153 (34%)
    Diabetes 77 (17%)
    Hypercholesterolemia 264 (58%)
    (History of) nicotine abuse 337 (74%)
* Renal clearance was determined with the formula of Cockroft-Gault.
ACE = angiotensin-converting enzyme; ASA =acetylsalycic acid; AT = angiotensin; CABG = coronary artery 
bypass graft; LVEF = left ventricular ejection fraction; PCI = percutaneous coronary intervention; VT = 
ventricular tachycardia
Jan-Willem BW new.indd   50 29-07-10   13:30
51
















an increased risk of subsequent device therapy during further follow-up. Early therapy 
exhibits a HR of 3.3 (95% CI: 2.4-4.6) when compared to patients without early therapy 
(Figure 4). Of interest, early device therapy had no negative effect on survival (HR 1.1, 
95% CI: 0.6-2.0).
All-cause mortality
Figure 5 shows the survival rates and the number of patient at risk. During follow-up, 100 
(22%) patients died 41±30 months after implantation. One, five and eight-year mortality 
rate was 4%, 20% and 36% respectively. 
 5
Figure 3. Kaplan-Meier curve for the event-free follow-up for mortality. 
 
HFST 3. 
Figure 1. Kaplan-Meier curve for appropriate therapy-free follow-up (bold line) and 
appropriate therapy for life-threatening VT-free follow-up (dashed line). 
 
Figure 1. Kaplan-Meier curve for appropriate therapy-free follow-up (bold line) and appropriate therapy 
for life-threatening VT-free follow-up (dashed line).
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Figure 2. First appropriate therapy or therapy for life-threatening ventricular arrhythmia 
after ICD-implantation. 
 
Figure 3. Multivariate Cox proportional hazard model for therapy for life-threatening 
ventricular arrhythmias. 
Figure 2. First appropriate therapy or therapy for life-threatening ventricular arrhythmia after ICD-
implantation.






A multivariate Cox regression model for the relation between patient characteristics and 
death is shown in Figure 6. AF, no statin usage, diuretics for congestive heart failure, diabe-
tes, high age, poor renal function, and wide QRS were independent predictors of mortality. 
Infections, revascularizations, inappropriate shocks and device replacement
Screening for adverse events related to ICD implantation, included pocket infections, 
revascularizations and inappropriate shocks. Pocket infections occurred in eight patients 
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Figure 4. Cumulative appropriate device therapy-free period in patients with vs. without 
early therapy. 
 
Figure 5. Kaplan-Meier curve for survival. 
Figure 3. Multivariate Cox proportional hazard model for therapy for life-threatening ventricular arrhyth-
mias.
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Figure 4. Cumulative appropriate device therapy-free period in patients with vs. without early therapy.
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(1.8%). Thus, with a mean follow-up of 54 months, the rate of pocket infections was 3.9 
per 1000 patient-years. 
During follow-up, a total of 33 (7%) patients required revascularization. These proce-
dures included 19 cases of percutaneous coronary angioplasty, 13 cases of coronary artery 
bypass graft and one patient received both types of revascularization. 
Two-hundred-and-ten episodes of inappropriate shocks, not caused by VT or VF, were 
noted in 75 (16%) patients. This brings the rate of inappropriate shocks to 102 per 1000 
patient-years. Of notice in patients receiving inappropriate shock therapy, 36% also received 
appropriate therapy for life-threatening ventricular arrhythmias, whereas 64% did not.
One-hundred-sixty-seven (37%) patients outlived the longevity of their first device and 
needed a replacement. Of these, 39 patients got a second replacement and 5 patients 
even received a fourth device. This gives a mean number of 1.5 ICDs per person during our 
follow-up or 325 ICDs per 1000 patient-years.
Discussion
In the current study on the long-term follow-up of ischemic secondary prevention ICD 
recipients, findings can be summarised as follows: 1) Ventricular arrhythmia, triggering 
device therapy occurred in 47% of patient with a cumulative incidence of 61% after eight 
years; 2) Device therapy for a fast, potentially life-threatening VT occurred in 30% with a 
cumulative incidence of 45% after eight years; 3) Factors independently correlated with an 
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Figure 5. Kaplan-Meier curve for survival.






increase in the risk of potentially life-threatening VT are a history of AF, a VT as the present-
ing arrhythmia, wide QRS and poor LVEF; 4) No recurrence-free group could be identified; 
5) Cumulative mortality was approximately 5% per year; 6) Factors that independently 
increased mortality were a history of AF, no statin usage, diuretics for congestive heart 
failure, diabetes, high age, poor renal function and wide QRS.
Potentially life-threatening ventricular arrhythmia 
Since previous studies demonstrated that device therapy should not be used as a surrogate 
end-point for death in case the ICD had not been implanted,8 it is hard to identify which 
part of the implanted population actually owns its life to the device. As done previously,9, 
10 the current study used cycle length to differentiate between possible life-threatening 
ventricular arrhythmias and slower, less dangerous arrhythmias. Given the fact that that 
all patients received an ICD as secondary prevention, use of potentially life-threatening 
arrhythmias as an end-point makes it possible to study the predicting factors of recurrence 
of these dangerous arrhythmias. The factors influencing the risk on recurrence of potentially 
life-threatening VT are AF, VT as presenting arrhythmia (as compared to VF), wide QRS and 
poor LVEF. No previous studies have been conducted on the prediction of fast ventricular ar-
rhythmias in secondary prevention. Factors, described in predicting any appropriate device 
therapy in secondary prevention ICD recipients are poor LVEF, VT as presenting arrhythmia 
(as compared to VF).11 A history of AF and wide QRS have not yet been described in the 
context of secondary prevention, but are known risk factors in the occurrence of ventricular 
arrhythmia in primary prevention.12, 13 Even with knowledge of these risk factors, it was still 
not possible to identify patients who would not have a recurrence of life-threatening VT at 
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Figure 6. Multivariate Cox proportional hazard model for all-cause mortality.
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nfollow-up, in which case device implantation might not have been necessary. This finding 
emphasises the importance of a defibrillator in all patients with ischemic heart disease, 
surviving sudden death or sustained VT.
Appropriate device therapy
During follow-up, 216 (47%) patients experienced appropriate device therapy (ATP or 
shock), triggered by ventricular arrhythmias. As expected in this high risk population, oc-
currence of ventricular arrhythmias is higher than observed in large trials on the effect of 
primary prevention, such as the MADIT II (cumulative event-rate at three years LOHCAT: 
40% vs. MADIT II: 35%).14 Previous studies on secondary prevention show a wide range in 
the need for defibrillator back-up during follow-up. One of the first large randomised trials, 
the Antiarrhythmics versus Implantable Defibrillator (AVID) trial, displays an incidence of 
up to 68% in 18 months and a cumulative incidence of 73% at three years.3, 8 A possible 
explanation for this much higher device therapy rate is the fact that the single-chamber 
ICDs used in AVID made it hard to discriminate between appropriate and inappropriate 
therapy. Furthermore, AVID used the composed end-point of device therapy and possible 
arrhythmic death, increasing event rates.15 Further studies on the follow-up in secondary 
prevention ICD recipients demonstrate an occurrence of 27% to 49% during a mean follow-
up of 11 to 32 months, which is in line with our findings.7, 9-11, 16 
The increased risk of recurrent ventricular arrhythmias in patients  with early ventricular 
arrhythmia was previously described by Freedberg and co-workers, who noted subsequent 
ventricular arrhythmias in 79% of patients receiving initial therapy.11 Additionally, even 
though the annual rate of first appropriate device therapy decreases in the time following 
implantation, the risk for device therapy persists during the entire follow-up, as previously 
described.17 The fact that patients receiving appropriate device therapy are at such an 
increased risk of recurrence stresses the need for close follow-up of this high risk population 
Mortality
Cumulative mortality was approximately 5% per year. Previously studied similar cohorts 
exhibit comparable yearly mortality rates ranging from 4.6% to 8.4%.4, 5, 7, 9, 16 Two trials 
describe a significant higher yearly mortality rate of 10%, which could be explained by the 
short follow-up of eleven and 18 months.3, 10 With such a short follow-up, the relatively 
high in-hospital mortality has a greater effect on the calculated yearly death rate than in 
trials with a longer follow-up. 
Baseline characteristics of independent value in the risk stratification on mortality are a 
history of AF, no statin usage, diuretics for congestive heart failure, diabetes, high age, poor 
renal function, and wide QRS. Most factors are markers for more severe cardiac dysfunction 
and all factors are known to increase mortality in a population with ischemic heart dise






This was a non-randomised prospective observational study, performed to assess the long-
term follow-up in ICD recipients at high risk for recurrence and to construct a model for 
the risk stratification of this population. Since previous large trials have shown the benefit 
of defibrillator implantation in this population, no control group could be used. Therefore, 
irrespectively of the end-point chosen to mark recurrence of life-threatening arrhythmia, 
this will never perfectly represent the occurrence of potentially life-threatening events in 
case the ICD would not have been implanted. This also holds true for a sustained VT at 
baseline which causes the patient to be labelled as secondary prevention ICD recipient 
but would not necessarily have degenerated in VF, causing arrhythmic death. Furthermore, 
since patients were collected over a period of eleven years, expanding guidelines for the 
implantation of defibrillators, treatment of acute myocardial infarction, and pharmacologi-
cal antiarrhythmic therapy could have created a heterogeneous population.  
Conclusion
Ischemic secondary prevention ICD recipients exhibit a high risk of recurrence of potentially 
life-threatening ventricular arrhythmia. The need for defibrillator back-up is highest in the 
first period following implantation but persists during long-term follow-up. Factors, increas-
ing risk can be identified but no recurrence-free group can be distinguished. 
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Objective: To assess the prevalence of different types of atrial fibrillation (AF) and their 
prognostic importance in implantable cardioverter defibrillator (ICD) patients.
Background: The prevalence of AF has taken epidemic proportions in the population with 
cardiovascular disease. The prognostic importance of different types of AF in ICD patients 
remains unclear.
Methods: Data on 913 (79% men, mean age 62±13 years) consecutive patients receiving 
an ICD at the Leiden University Medical Center were prospectively collected. Among other 
characteristics, the existence and type of AF (paroxysmal, persistent or permanent) was 
assessed at implantation. During follow-up, the occurrence of appropriate or inappropriate 
device therapy, as well as mortality was noted.
Results: At implantation, 73% of patients had no history of AF, 9% had a history of parox-
ysmal AF, 7% had a history of persistent AF and 11% had permanent AF. During 833±394 
days follow-up, 117 patients (13%) died, 228 patients (25%) experienced appropriate 
device discharge and 139 patients (15%) received inappropriate shocks. Patients with 
permanent AF exhibited more than double the risk for mortality, ventricular arrhythmias 
triggering device discharge, and inappropriate device therapy. Patients with paroxysmal or 
persistent AF did not show a significant increased risk for mortality or appropriate device 
therapy but demonstrated almost three times risk for inappropriate device therapy.
Conclusions: In the population currently receiving ICD treatment outside the setting of 
clinical trials a large portion has either a history of AF or permanent AF. Both types of AF 
have prognostic implications for mortality and appropriate, as well as inappropriate device 
discharge.
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Large randomized trials have shown a beneficial effect of implantable cardioverter defibril-
lator (ICD) therapy, initially in survivors of life-threatening arrhythmias,1-3 but more recently 
also in the primary prevention of sudden arrhythmic death in selected ischemic and non 
ischemic patients at high risk, based solely on a poor left ventricular ejection fraction 
(LVEF).4-7 The implementations of these results in the international guidelines have, besides 
a considerable increase in the number of implants, caused a significant change in the popu-
lation considered for ICD therapy as the majority of implantations now occurs in patients 
with a low LVEF and symptoms of heart failure (primary prevention patients) 8
Atrial fibrillation (AF) is common in patients with low LVEF and symptoms of heart 
failure with a reported prevalence of AF in congestive heart failure patients of up to 50% 
in patients with New York Heart Failure (NYHA) functional class IV.9-12. Furthermore, AF is 
associated with significant morbidity and mortality both in the general population and more 
specific in patients with heart failure.13, 14 
As the number of ICD implants in patients with low LVEF and heart failure is increasing, 
it can be expected that more patients with paroxysmal, persistent or permanent AF will 
receive an ICD. So far, most studies focused on a single type of AF (e.g. paroxysmal/persis-
tent or permanent AF) and were often conducted in the setting of a clinical trial.15-19 The 
prevalence and prognostic implications of a history of AF at ICD implant remain unclear. 
The present study aims at providing insight in the effects of AF on mortality, occurrence of 
ventricular arrhythmias and inappropriate device therapy during long-term follow-up in a 
large cohort of ICD patients.
Methods
Patients and study protocol 
Since 1996, all patients receiving an ICD at the Leiden University Medical Center were 
prospectively collected in the departmental Cardiology Information System (EPD-Vision®, 
Leiden University Medical Center). Characteristics at baseline, data of the implant proce-
dure, and data of all follow-up visits were recorded. 
Eligibility for ICD implantation in this population was based on international guidelines 
which, due to evolving guidelines, might have changed over time. Patients were implanted 
after surviving life-threatening ventricular arrhythmias or in the presence of a depressed 
LVEF with or without non sustained ventricular tachycardia.8, 20 





 1 Atrial fibrillation
At baseline, patients were grouped according to the type of AF. This resulted in the follow-
ing four groups: (1) patients without a history of (documented) AF, the “no AF” group; (2) 
patients with a history of paroxysmal AF as documented on ECG; (3) patients with a history 
of persistent AF as documented on ECG; and (4) patients with permanent, accepted AF. 
If the arrhythmia terminates spontaneously and within 7 days, AF is designated paroxys-
mal; when sustained beyond 7 days or being terminated by pharmacological or electrical 
cardioversion, AF is termed persistent. The category of persistent AF also includes cases 
of long-standing AF, usually leading to permanent AF, in which cardioversion has failed or 
has been foregone.10, 21
Device implantation
All defibrillator systems used were implanted transvenously and without thoracotomy. 
During the implant procedure testing of sensing and pacing thresholds and defibrillation 
threshold testing was performed. Used systems were manufactured by Biotronik (Berlin, 
Germany), Medtronic (Minneapolis, MN, United States), Boston Scientific (Natick, MA, 
United States, formerly CPI, Guidant [St. Paul, MN, United States]) and St. Jude Medical/
Ventritex (St. Paul, MN, United States).
Long-term follow-up 
Patient check-up was scheduled every three to six months. Device interrogation printouts 
were checked for appropriate and inappropriate ICD therapy (anti tachycardia pacing [ATP] 
or shocks). Therapies were classified as appropriate when they occurred in response to 
ventricular tachycardia or ventricular fibrillation and as inappropriate when triggered by 
sinus or supraventricular tachycardia, T-wave oversensing, or electrode dysfunction. Fur-
thermore, follow-up included all-cause mortality. 
In the Dutch health care system, all patients are followed by the implanting center. Since 
periodical follow-up was performed every three to six months, patients without data on the 
past six months were considered as lost to follow-up.
Statistical analysis
Continuous data are expressed as mean ± standard deviation; dichotomous data are 
presented as numbers and percentages. Comparison of continuous or dichotomous data 
was performed with the Student’s t test for paired and unpaired data and Chi-square tests 
with Yates correction when appropriate. Non-parametric data (NYHA functional class) was 
compared using the Mann-Whitney U-test. Cumulative event rates (all-cause mortality, 
appropriate device therapy, appropriate device shocks and inappropriate device shocks) 
were analyzed by the method of Kaplan-Meier. The relation between different types of AF 
at baseline and the occurrence of end-points was assessed using a Cox proportional hazard 
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nmodel, calculating a hazard ratio with a 95%-confidence interval (95% CI) and adjusting 
for age, sex, renal clearance, LVEF, QRS-duration, NYHA functional class, and usage of 
beta-blockers. For all tests, a p-value <0.05 was considered significant.
Results
Baseline characteristics 
Data of 955 consecutive patients receiving an ICD in the Leiden University Medical Center 
were prospectively collected. Forty-two patients (4.4%) were lost to follow-up. The remain-
ing 913 ICD recipients were included in the analysis. Mean follow-up time was 833±394 
days.
The majority of patients (79% men, mean age 62±13 years) had a depressed LVEF 
(32±14%), wide QRS complex (127±35 ms) and poor renal function (renal clearance 
83±38 ml/min). Medication included beta blockers in 76%, ACE inhibitors or AT antago-
nists in 82% and diuretics for heart failure in 70%. Baseline characteristics are summarized 
in Table 1.
Six-hundred-and-sixty-three (73%) out of all 913 patients had no history of AF (no 
AF), 84 (9%) patients had a history of paroxysmal AF, 64 (7%) patients had a history of 
persistent AF, and the remaining 102 (11%) patients had permanent AF. All patients with 
a history of paroxysmal or persistent AF were in sinus rhythm at discharge after device 
implantation. As is shown in Table 1, when compared to patients without a history of AF, 
patients with AF were older, had higher NYHA functional class and were more often treated 
with diuretics, amiodarone and oral anticoagulants. 
Mortality
During a mean follow-up of 833±394 days, 117 patients (13%) died. Study population 
mortality was 5% (95% CI 4-7%) at one year, 11% (95% CI 8-13) at two years and 15% 
(95% CI 12-17) at three years of follow-up. In the comparison of the four groups, survival 
analysis showed a three year cumulative event rate for mortality of 12% (95% CI 9-15%) 
for no AF, 15% (95% CI 8-24%) for paroxysmal AF, 17% (95% CI 7-27%) for persistent 
AF, and 32% (95% CI 20-43%) for permanent AF (Figure 1).
Of interest, patients with paroxysmal AF or persistent AF did not demonstrate a significant 
higher risk for mortality. However, patients with permanent AF exhibited a 70% increased 
risk for mortality (adjusted hazard ratio 1.7, 95% CI 1.0-2.7, p=0.033).
Appropriate device therapy
During follow-up, ventricular arrhythmias, causing appropriate device therapy (ATP or 
shocks), were observed in 228 (25%) patients. A total of 5116 episodes was noted, 






consisting of 4793 (range 1-2194) episodes terminated with ATP in 166 patients and 304 
(range 1-33) episodes terminated by ICD shock in 112 patients.  














    Male gender 722 (79%) 515 (78%) 64 (76%) 53 (83%) 90 (88%)†
    Age (yrs) 62±13 61±13 64±11* 66±10† 67±10‡
    Secondary prevention 140 (15%) 94 (14%) 22 (26%)† 9 (14%) 15 (15%)
        History of VT  93 (66%) 62 (66%) 15 (68%) 7 (78%) 9 (60%)
        History of VF 47 (34%) 32 (34%) 7 (32%) 2 (22%)§ 6 (40%)
    Primary prevention 773 (85%) 569 (86%) 62 (74%)† 55 (86%) 87 (85%)
        History of nsVT 201 (26%) 150 (26%) 17 (27%) 15 (27%) 19 (22%)
    Ischemic heart disease 561 (61%) 423 (64%) 49 (58%) 39 (61%) 50 (49%)†
    NYHA functional class
        I
        II
        III





















    Renal clearance (ml/min) 83±38 86±38 75±39† 77±43 72±29‡
    QRS-duration (ms) 127±35 125±34 123±33 129±35 140±34‡
    LVEF (%) 32±14 33±14 32±15 32±14 30±12
    Diabetes 177 (19%) 127 (19%) 16 (19%) 14 (22%) 20 (20%)
    History of smoking 380 (42%) 287 (43%) 36 (43%) 24 (38%) 33 (32%)*
    Body mass index (kg/m2) 26±4 26±4 26±4 26±4 26±4
Device type
    Single chamber 43 (5%) 20 (3%) 4 (5%)§ 2 (3%)§ 17 (17%)‡§
    Dual chamber 409 (45%) 234 (49%) 39 (46%) 26 (41%) 20 (20%)‡
    CRT-D 461 (51%) 319 (48%) 41 (49%) 36 (56%) 65 (64%)†
Medication
    Beta-blockers 691 (76%) 510 (77%) 63 (75%) 46 (72%) 72 (71%)
    ACE inhibitors / 
        AT antagonist
750 (82%) 548 (83%) 66 (79%) 49 (77%) 87 (85%)
    Ca-antagonists 64 (7%) 52 (8%) 3 (4%) 3 (5%)§ 6 (6%)
    Diuretics 641 (70%) 440 (66%) 65 (77%)* 47 (73%) 89 (87%)‡
    Statins 594 (65%) 445 (67%) 53 (63%) 44 (69%) 52 (51%)‡
    Amiodarone 125 (14%) 68 (10%) 19 (23%)‡ 15 (23%)† 23 (23%)‡
    Aspirin 364 (40%) 300 (45%) 32 (38%) 22 (34%) 10 (10%)‡
    Oral anticoagulants 504 (55%) 316 (48%) 51 (61%)* 42 (66%)† 95 (93%)‡
*p < 0.05; †p < 0.01; ‡p < 0.001. All  compared with no AF group. 
§Comparison was performed with Yates correction.
ACE = angiotensin-converting enzyme; AT = angiotensin; CRT-D = cardiac resynchronization therapy-
defibrillator; LVEF = left ventricular ejection fraction; nsVT = non sustained ventricular tachycardia; 
NYHA = New York Heart Association 
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Cumulative event rate for appropriate device therapy (ATP or shock) was 15% (95% CI 
13-18%) at one year, 24% (95% CI 21-27) at two years and 30% (95% CI 24-34) at 
three years of follow-up.
Figuren 
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Hoofdstuk 4 figuur 2 
 
 
Hoofdstuk 4 figuur 3 
Figure 1: All-cause mortality. Kaplan-Meier curve for all-cause mortality in patients without a history of 
AF (no AF), paroxysmal AF, persistent AF, or permanent AF.
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Figure 2: Appropriate device therapy. Kaplan-Meier curve for the occurrence of first appropriate device 
therapy in patients without a history of AF (no AF), paroxysmal AF, persistent AF, or permanent AF.






As is shown in Figure 2, three years cumulative event rate for appropriate device therapy 
was 29% (95% CI 24-33%) for no AF, 26% (95% CI 14-39%) for paroxysmal AF, 26% 
(95% CI 13-38%) for persistent AF, and 49% (95% CI 36-61%) for permanent AF. Patients 
with permanent AF exhibited twice the risk for appropriate therapy, when compared to 
patients without a history of AF (adjusted hazard ratio 2.2, 95% CI 1.6-3.2, p<0.001). 
The group with no history of AF demonstrated similar event rates as patients with a history 
of paroxysmal or persistent AF.
As is shown in Figure 3 and Table 2, the occurrence of appropriate shocks alone showed 
a similar distribution as the occurrence of all appropriate therapy among the four groups. 
No differences were observed between patients without a history of AF and those with a 
history of paroxysmal or persistent AF. Moreover, a doubled risk of appropriate shocks was 
observed in the permanent AF group when compared to patients with no history of AF 
(adjusted hazard ratio 2.4, 95% CI 1.5-4.0, p<0.001).
Inappropriate device shocks
One-hundred-thirty-nine (15%) patients experienced at least one inappropriate device dis-
charge. When comparing the four groups, major differences in event rates were observed. 
Three years event rate for inappropriate shocks was 13% (95% CI 10-17%) for no AF, 28% 
(95% CI 15-40%) for paroxysmal AF, 18% (95% CI 15-41%) for persistent AF, and 32% 
(95% CI 19-45%) for permanent AF (Figure 4). When compared to the group without a his-
tory of AF, the permanent AF group showed a more than doubled risk for the inappropriate 
 
 




References altijd op een nieuwe pagina. Is nog niet zo op pag 172 en 230. 
P3, ‘klokke 16.15‘  ‘klokke 16.15 uur‘ 
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Figure 3: Appropriate device shock. Kaplan-Meier curve for the occurrence of first appropriate shock in 
patient  without a history of AF (no AF), paroxysmal AF, persistent AF, or permanent AF.
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shocks (adjusted hazard ratio 2.7, 95% CI 1.7-4.4, p<0.001). Patients with a history of 
paroxysmal AF had the highest risk for inappropriate device shocks (adjusted hazard ratio 
2.9, 95% CI 1.7-4.8, p<0.001) during follow-up. It is of note that in the group without a 
history of AF, (new-onset) AF during follow-up was the cause of inappropriate device shocks 
in 27 patients (4%) 
Discussion
The main findings of the current study on the prognostic importance of AF in ICD patients 
can be summarized as follows: (1) in the population, currently receiving ICD treatment, 
9% have a history of paroxysmal AF, 7% have a history of persistent AF and 11% have 
permanent AF; (2) patients with permanent AF exhibited a more than doubled risk for 
mortality, ventricular arrhythmias triggering device discharge, and inappropriate device 
shocks than patients without AF; (3) patients with a history of paroxysmal or persistent AF 
did not show a significantly increased risk for mortality or appropriate device therapy but 
demonstrated a almost tripled risk for inappropriate device shocks.
The present analysis adds to prior literature in that it discriminates between different 
types of AF and that it assesses the population, presently considered for ICD treatment 
outside the setting of clinical trial.
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Figure 4: Inappropriate device shock. Kaplan-Meier curve for the occurrence of first inappropriate device 
shock in patients without a history of AF (no AF), paroxysmal AF, persistent AF, or permanent AF.
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Previous trials have demonstrated the importance of AF in the general population, as well 
as in a population with symptomatic or asymptomatic heart failure.13, 14 Benjamin and 
co-workers showed that the occurrence of AF was associated with a 1.5- to 1.9-fold risk 
for all-cause mortality, even after adjustment for further cardiovascular conditions related 
to AF.13 These findings seem comparable to the 1.7 times increased risk for mortality in 
patients with permanent AF, as observed in the current analysis. However, when specifi-
cally assessing a population with symptoms of heart failure, findings in current literature 
are inconsistent in the potential relation between AF and the risk for mortality.14, 22-25 In 
a post-hoc analyses of the second Multicenter Automatic Defibrillator Implantation Trial, 
Zareba and co-workers made a comparison between patients with sinus rhythm and AF. 
Since AF was defined by its presence on the ECG at enrollment, one might assume that all 
the patients identified with AF have permanent AF and those with paroxysmal or persistent 
AF, if not coincidentally present at enrollment, will have been classified as having sinus 
rhythm.7, 19 Furthermore, the trial only included primary prevention ICD recipients with a 
prior myocardial infarction. In contrast to the current study, Zareba at al. did not find a 
relationship between AF and mortality after adjustment for other variables.19
Appropriate ICD therapy
One might hypothesize that the occurrence of any type of AF is a marker of worse general 
cardiac status and therefore that AF will be positively correlated with the occurrence of 
ventricular arrhythmias. On the other hand, AF could initiate episodes of ventricular arrhyth-
mias and might therefore directly influence the occurrence of ventricular arrhythmias and 
consequent appropriate device therapy. The facilitation of AF in the initiation of ventricular 
tachyarrhythmias has been observed by Roy and co-workers during an electrophysiological 
study.26 Afterwards, Stein et al. observed 8.9% of the episodes of ventricular arrhythmia to 
be accompanied by AF.27 Earlier studies suggested that ventricular arrhythmias are evoked 
by rapid and uncontrolled AV conduction.28-30 More recently, Grönefeld et al. suggested that 
the AV nodal conduction pattern preceding ventricular tachyarrhythmia were short-long-
short sequences, rather than solely a rapid conduction.16 The irregular ventricular excitation 
leads to heterogeneous depolarization, which subsequently renders the myocardium more 
susceptible to ventricular arrhythmias.31, 32 In line with the current findings, prior studies 
confirm AF to have a positive correlation with the occurrence of ventricular arrhythmias.16-18 
Interestingly, a post-hoc analysis of the Multicenter Automatic Defibrillator Implantation 
Trial II did not demonstrate a difference in the occurrence of appropriate therapy when 
comparing (mostly permanent) AF with patients in sinus rhythm.19 A possible explanation 
for this difference could be that the permanent AF group in the current study is sicker in a 
manner not completely accounted for by post hoc statistical adjustment. The present study 
did not show an increase in appropriate device therapy in the groups with a history of 





 1 paroxysmal or persistent AF, which could imply that these patients do not have a deteriora-
tion of general cardiac status of such magnitude to consequently cause higher occurrence of 
ventricular arrhythmia. Thus far, no analysis had been reported on the prognostic implica-
tions of different types 
Inappropriate ICD shocks
Previous studies have demonstrated the relationship between the existence of AF and 
inappropriate device discharge and the consequent negative effect of inappropriate device 
discharge on patient quality of life.33-35 Furthermore, recent research has demonstrated 
the impact of inappropriate shock delivery on mortality.33, 36 These findings stress the 
importance of clear identification of patients at high risk for inappropriate shocks in order 
to better inform patients and to optimize individual patient treatment. The current study 
maps the importance of different types of AF on the occurrence of inappropriate shocks and 
highlights the high event rate in patients with persistent, permanent and, most outspoken, 
paroxysmal AF. A potential explanation of the higher event rate in the paroxysmal AF group, 
even when compared to the group with permanent AF, can be explained by the fact that 
clinicians will more often adjust their treatment (such as AV-node ablation) if AF is ongoing. 
Additionally, the higher occurrence of ventricular arrhythmias in the group with permanent 
AF might cause a more aggressive pharmacological antiarrhythmic treatment. 
Limitations
This was a non-randomized prospective observational cohort study, performed to assess 
the long-term follow-up in ICD patients outside the setting of a clinical trial. Since patients 
were collected over a period of four years, expanding guidelines for the implantation of 
defibrillators, treatment of acute myocardial infarction, and pharmacological antiarrhythmic 
therapy could have created an heterogeneous population. Furthermore, standard ICD set-
tings at discharge could have been altered during follow-up. Finally, applying a different 
classification of AF might have altered the results.
Conclusion
In the population, currently receiving ICD treatment outside the setting of a clinical trial, 
11% has permanent AF and 16% has a history of paroxysmal or persistent AF. The existence 
of permanent AF doubles the risk for mortality and appropriate, as well as inappropriate 
device therapy. Paroxysmal and persistent AF did not prove to have an effect on mortality or 
the occurrence of appropriate device discharge. However, the rate of inappropriate shocks 
is importantly increased in this group.
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 1 Abstract 
Background: Data on the occurrence and implications of new-onset atrial fibrillation (AF) 
following cardiac resynchronization therapy (CRT) are scarce. We studied the incidence 
of new onset AF in CRT-defibrillator (CRT-D) recipients. Furthermore, the influence of 
new-onset AF on echocardiographic response to CRT and the rate of adverse events were 
evaluated.
Objective: This study assessed the incidence and implications of new-onset atrial fibrilla-
tion following cardiac resynchronization therapy.
Methods: The study population consisted of 223 consecutive patients without a history of 
AF. New-onset AF was defined as atrial high-rate episodes >180 bpm during >10 min-
utes/day as detected by the device. Echocardiography was performed at baseline and after 
6 months of biventricular pacing. Long-term events included ICD therapy for ventricular 
arrhythmias, hospitalization for heart failure and all-cause mortality.
Results: Fifty-five patients (25%) developed new-onset AF during a mean follow up of 
32±16 months. When compared to the patients who maintained sinus rhythm (SR) dur-
ing follow-up, patients developing AF showed less left ventricular (LV) reverse remodeling 
(ΔLV end systolic volume 37±53 vs. 19±37 ml, p<0.05) and less improvement in LV 
function (ΔLV ejection fraction 6.7±8.9 vs. 3.5±10.3%, p<0.05) . Importantly, patients 
developing AF experienced more appropriate ICD shocks for ventricular arrhythmias, more 
inappropriate shocks and more hospitalizations for heart failure.
Conclusion: Recipients of CRT-D who develop new-onset AF show less echocardiographic 
response to CRT and more cardiac adverse events during long-term follow-up.
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Cardiac resynchronization therapy (CRT) is a well established therapy in selected patients 
with heart failure and cardiac dyssynchrony. The beneficial effects include improvement in 
heart failure symptoms and exercise capacity1-3 and also improvement in echocardiographic 
parameters such as left ventricular (LV) function, left atrial (LA) function and mitral regur-
gitation (MR).4-7
However, the impact of CRT on new-onset atrial fibrillation (AF) remains controversial.8-11 
Post-hoc analysis of the CARE-HF trial suggested that the CRT had no favorable impact on 
the incidence of AF when compared to medical therapy alone.10 
Still, since AF and heart failure often co-exist and are associated with worse clinical 
outcome,12 it is important to evaluate the incidence and implications of new-onset AF in 
CRT-recipients.  In addition, asymptomatic AF episodes, which appear to have important 
prognostic implications as reported in a sub-study of the MOST trial,13 can be monitored 
using device-based diagnostics. 
Therefore, the aim of the present study was to evaluate the incidence of new-onset 
AF after CRT using device-based diagnostics. In addition, clinical and echocardiographic 
parameters, including LA and LV function, were assessed during follow-up and compared 
between patients developing AF and patients maintaining sinus rhythm (SR). Importantly, 
long-term clinical outcome is addressed in both groups.
Methods
Patients and study protocol 
From January 2000 to July 2005, all patients eligible for cardiac resynchronization with 
defibrillator therapy (CRT-D) without a history of AF were included in this single-center 
retrospective study. A history of AF was defined as one or more episodes of AF in the two 
years preceding implantation, lasting at least 30 seconds as verified by electrocardiogram.14 
Eligibility for CRT-D was based on the standard guidelines and included advanced heart 
failure (New York Heart Association [NYHA] class III or IV), depressed LV function (LV ejec-
tion fraction [LVEF] <35%) and wide QRS complex (>120 ms).15-17 The study protocol was 
as follows: before and 6 months after CRT-D implantation, all patients underwent clinical 
and echocardiographic evaluation. Occurrence of atrial and ventricular arrhythmias after 
device implantation was assessed, as well as hospitalization and survival during long-term 
follow-up. 





 1 Clinical evaluation  
Clinical status was assessed routinely at baseline and 6 months follow-up, including as-
sessment of NYHA functional class, quality of life (QoL, using the Minnesota Living with 
Heart Failure questionnaire),18 and evaluation of exercise capacity using the 6-minute 
walking test (6-MWT).19
Echocardiographic evaluation 
All patients underwent routine echocardiography in the left lateral decubitus position before 
and 6 months after CRT-D device implantation. Studies were performed using a commer-
cially available echocardiographic system (VIVID 7, General Electric Vingmed Ultrasound, 
Milwaukee, USA). Images were obtained using a 3.5 MHz transducer, at a depth of 16 
cm in the parasternal (long- and short-axis) and apical (2- and 4-chamber images) views. 
Standard 2D and color Doppler data, triggered to the QRS complex, were saved in cineloop 
format. A minimum of 3 consecutive beats were recorded from each view and the im-
ages were digitally stored for off-line analysis (EchoPac 6.0.1, General Electric Vingmed 
Ultrasound, Milwaukee, USA). 
LV end-diastolic volumes (LVEDV), LV end-systolic volumes (LVESV) and LVEF were 
measured from the apical 2- and 4-chamber images, using the modified biplane Simpson’s 
rule.20 The LA volume was calculated using the ellipsoid model with the measured LA 
diameters in parasternal long axis (LA PLAX) and the LA long-axis (LA LAX) and short-axis 
(LA SAX) in the apical 4-chamber view.21 All LA volumes were indexed by body surface 
area.22 LV diastolic function was estimated using the ratio of early transmitral flow velocity 
(E) over early diastolic septal mitral annulus velocity (E’) and categorization into normal 
filling pattern, abnormal relaxation filling pattern = I, pseudonormal filling pattern = II, 
and restrictive filling pattern = III.23, 24 For quantification of MR, the apical 4-chamber 
images were used. MR was characterized as: none, mild = 1+ (jet area/LA area <10%), 
moderate = 2+ (jet area/LA area 10% to 20%), moderate-severe = 3+ (jet area/LA area 
20% to 45%), and severe = 4+ (jet area/LA area >45%).25 Baseline LV dyssynchrony 
was assessed using tissue Doppler imaging. The sample volume was placed in the LV 
basal portions of the anterior, inferior, septal, and lateral walls (using the apical 2- and 
4-chamber views) and, per region, the time interval between the onset of the QRS complex 
and the peak systolic velocity was derived. LV dyssynchrony was defined as the maximum 
delay between peak systolic velocities among the four walls within the LV (most frequently 
observed between the interventricular septum and the lateral wall).26 Based on previous 
observations, a delay of ≥65 ms reflects substantial LV dyssynchrony.27
CRT-D interrogation/long-term follow-up 
During follow-up device interrogation was scheduled every 3-6 months. All printouts were 
checked for new-onset AF, appropriate and inappropriate shocks. New-onset AF after 
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nimplantation was defined as atrial high-rate episodes (≥180 bpm) lasting at least 10 min-
utes, determined with device based diagnostics.10 Shocks were classified as appropriate 
when they occurred in response to ventricular tachycardia or ventricular fibrillation and as 
inappropriate when triggered by sinus or supraventricular tachycardia, T-wave oversensing, 
or electrode dysfunction.
In addition, long-term follow-up included all hospitalizations for cardiac cause (unstable 
angina, decompensated heart failure or symptomatic ventricular arrhythmias), and all-
cause mortality.
CRT-D implantation 
A coronary sinus venogram was obtained using a balloon catheter, followed by the insertion 
of the LV pacing lead into 1 of the posterolateral veins through an 8-F guiding catheter 
(Easytrak 4512-80, Guidant Corp., St. Paul, Minnesota; or Attain-SD 4189, Medtronic 
Inc., Minneapolis, Minnesota). The right atrial and ventricular (pacing and shock) leads 
were positioned conventionally. All leads were connected to a dual-chamber CRT-D de-
vice (Contak CD or Renewal, Guidant Corporation; Insync Sentry, Insync-III or Marquis, 
Medtronic Inc; Epic, St Jude Medical). Procedural success was accomplished when pulse 
generator and the 3 leads were positioned without complications. 
Defibrillators were programmed as follows:  ventricular arrhythmia faster than 150 bpm 
was monitored by the device without consequent defibrillator therapy. Ventricular arrhyth-
mias faster than 188 bpm were initially attempted to be terminated with two bursts of anti 
tachycardia pacing and, after continuation of the arrhythmia, with defibrillator shocks. In 
the case of a ventricular arrhythmia faster than 210 bpm, device shocks were the initial 
therapy. Furthermore, atrial arrhythmia detection was set to >170 bpm with SVT discrimi-
nators enabled. Settings were adapted, only when clinically indicated (i.e. hemodynamic 
well tolerated ventricular tachycardia at high rate; ventricular tachycardia in the monitor 
zone).
Statistical analysis 
Continuous data are expressed as mean ± SD; dichotomous data are presented as num-
bers and percentages. Comparison of data was performed with the Student’s t test for 
paired and unpaired data and Chi-square tests with Yates correction when appropriate. 
Non-normally distributed data within patient groups (NYHA, MR and grade of LV diastolic 
function) were compared by the use of the Wilcoxon signed-rank test. Differences in event 
rates (hospitalizations, appropriate and inappropriate shocks and death) over time were 
analyzed by method of Kaplan-Meier and log-rank test. For all tests, a p-value <0.05 was 
considered significant.







A total of 320 consecutive heart failure patients who received a CRT-D device were screened 
with 97 patients having a history of AF. The remaining 223 patients (171 men, mean age 
65±11 years) without a history of AF were included in the current study. The baseline 
characteristics are summarized in Table 1. Before implantation, mean NYHA functional 
class was 3.0±0.5 and QRS duration was 161±31 ms. Patients had severe LV systolic 
dysfunction (LVEF 23±7%) with LV dilatation (LVEDV 246±89 ml and LVESV 190±77 
ml). Medication included diuretics in 90%, ACE-inhibitors in 85% and β-blockers in 65%. 
Patients with versus without new-onset AF 
During follow-up (33±16 months), new-onset AF was documented in 55 of 223 patients 
(25%). The first episode of AF occurred 13±11 months (range 0 to 41 months) after 
CRT-D implantation. In patients developing AF during follow-up, the average burden of 
AF since CRT-D implantation was 6.7%. The percentage of biventricular pacing during 
follow-up did not differ significantly between both groups (biventricular pacing in AF group 
97±6% vs. no AF group 96±4%, p=0.7).Baseline characteristics between the patients 
developing AF (AF group) and the patients remaining in sinus rhythm (SR group) were 
comparable, except for a larger LA volume index in the AF group (25±10 vs. 30±14 ml/
m2, p=0.011), caused mainly by longitudinal LA enlargement (LA LAX  49±7 vs. 52±9 
mm, p=0.038) (see Table 2). 
Six-month follow-up clinical evaluation: Patients with versus without new-onset 
AF 
After 6 months of follow-up, patients in the SR group showed significant improvement in 
clinical parameters; mean NYHA class improved from 3.0±0.4 to  2.0±0.6, QoL score 
reduced from 39±16 to 22±16 and exercise tolerance improved as demonstrated by an 
increase in 6-MWT from 303±120 to 404±138 meters (p<0.001 for all). Similar clinical 
improvements were noticed in the patients developing new-onset AF; mean NYHA class 
improved from 2.9±0.5 to 2.1±0.8, QoL score reduced from  34±17 to  22±20 and 
exercise tolerance improved as demonstrated by an increase in 6-MWT from  308±133 
to 391±142 meters (p<0.001 for all). As demonstrated in Table 3 the magnitude of 
improvement in clinical parameters was not significantly different in both groups. However, 
a trend towards a larger improvement in QoL could be seen in the SR group (Δ QoL SR 
17±17 vs. AF 11±16, p=0.065).
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Six-month follow-up echocardiographic evaluation: Patients with versus without 
new-onset AF 
Regarding echocardiographic changes after 6 months of follow-up, the SR group showed 
significant improvements in LV volumes and function (LVEDV at baseline 246±86 vs. at 6 
Table 1. Baseline characteristic
All patients (n=223)
Clinical parameters
    Male gender 171 (77%)
    Age (yrs) 65±11
    Ischemic etiology 138 (62%)
    Renal clearance (ml/min)* 68±31
    NYHA class (II / III / IV) 26 / 177 / 20
    QoL score 38±17
    6-MWT (m) 305±123
    QRS-duration (ms) 161±31
Echocardiographic parameters
    LVEF (%) 23±7
    LVEDV (ml) 246±89
    LVESV (ml) 190±77
    MR (none / 1 / 2 / 3 / 4) 42 / 65 / 68 / 34 / 14
    LV dyssynchrony (ms) 84±54
Medication
    Diuretics 201 (90%)
    ACE inhibitors 189 (85%)
    Beta-blockers 145 (65%)
Cardiovascular history
    Previous infarction 107 (48%)
    Previous PCI 46 (21%)
    Previous CABG 47 (21%)
    Previous valve surgery 20 (9%)
    Previous device
        Pacemaker 17 (8%)
        ICD 33 (15%)
Co-morbidity
    Diabetes 45 (20%)
    Stroke/TIA 23 (10%)
    Peripheral vascular disease 22 (10%)
    COPD 28 (13%)
* Renal clearance was determined with the formula of Cockroft-Gault.
6-MWT = six-minute walking test; ACE = angiotensin-converting enzyme; CABG = coronary artery bypass 
graft; COPD = chronic obstructive pulmonary disease; ICD = implantable cardioverter defibrillator; LV = left 
ventricular; LVEDV = left ventricular end-diastolic volume; LVEF = left ventricular ejection fraction; LVESV = 
left ventricular end-systolic volume; MR = mitral regurgitation; NYHA = New York Heart Association; PCI = 
percutaneous coronary intervention; QoL = quality of life; TIA = transient ischemic attack.






months follow-up 212±77 ml, LVESV 190±74 vs. 151±68 ml, LVEF 23±7 vs. 30±9%, 
p<0.001 for all). In addition, a modest decrease in LA PLAX was noted from 47±7 
to 45±8 mm (p<0.05). The other LA parameters remained unchanged. Furthermore, 
diastolic function improved (mean grade 1.5±0.9 vs. 1.2±0.8, p=0.007, Figure 1) and 
mitral regurgitation decreased (mean grade 1.7±1.1 vs. 1.4±1.1, p<0.005). 
In the AF group, significant LV reverse remodeling was noted as well; LVEDV decreased 
from 246±99 to 221±91 ml, LVESV from 191±86 to 168±85 ml and LVEF increased 
from 24±7 to 27±10% (p<0.05 for all). No changes were observed in LA dimensions. 
Furthermore, MR did not change significantly (mean grade 1.4±1.2 vs. 1.2±1.1, p=0.2) 
and diastolic function showed a trend towards worsening in function (mean grade 1.4±1.1 
vs. 1.7±0.9, p=0.1, Figure 1).
Thus, at 6 months follow-up both groups showed significant improvements in echo-
cardiographic parameters regarding LV function. However, the magnitude of LV reverse 
remodeling and improvement in LV function was significantly less in the AF-group (Table 
3). Decrease in LVESV was 37±53 ml for the SR group and 19±37 ml for the AF group 
(p=0.024). Systolic function showed less improvement in the AF group (ΔLVEF SR 
6.7±8.9 vs. AF 3.5±10.3 %, p=0.034).
Table 2. Differences in baseline characteristics between patients remaining in sinus rhythm after device 
implant (SR) and patients developing atrial fibrillation during follow-up (AF).
SR AF p-value
Variables (n = 168) (n = 55)
Men 131 (78%) 40 (73%) 0.4
Age (yrs) 65±11 65±10 0.9
Ischemic etiology 101 (60%) 37 (67%) 0.3
NYHA class (II / III / IV) 18 / 135 / 15 9 / 42 / 4 0.4
QRS-duration (ms) 161±30 161±32 1.0
LVEF (%) 23±7 24±7 0.5
LVEDV (ml) 246±86 246±99 1.0
LVESV (ml) 190±74 191±86 1.0
LA PLAX (mm) 47±7 49±9 0.1
LA LAX (mm) 49±7 52±9 0.038
LA SAX (mm) 39±7 41±8 0.3
LA Volume Index (ml/m2) 25±10 30±14 0.011
LV diastolic function 
    (normal / I / II / III) 23 / 69 / 47 / 29 11 / 22 / 9 / 13 0.7
E/E’ 17±10 20±15 0.2
MR (none / 1 / 2 / 3 / 4) 29 / 45 / 56 / 27 / 11 13 / 20 / 12 / 7 / 3 0.1
LV dyssynchrony (ms) 88±53 72±54 0.1
LA = left atrial; LAX = long axis; LV = left ventricular; LVEDV = left ventricular end-diastolic volume; 
LVEF = left ventricular ejection fraction; LVESV = left ventricular end-systolic volume; MR = mitral 
regurgitation; NYHA = New York Heart Association; SAX = short axis.
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During follow-up, 41 patients (18%) received appropriate shocks and 27 patients (12%) 
received inappropriate shocks. Patients developing AF experienced significantly more ap-
propriate shocks (27% vs. 16%, p<0.050), as well as significantly more inappropriate 
shocks (31% vs. 6%, p<0.001, Figure 2). 
In addition, 52 patients (23%) died and 50 patients (22%) were hospitalized for cardiac 
causes. Patients in the AF group accounted for more hospitalizations as compared to the SR 
group (36% vs. 18%, p<0.005). However, survival was not significantly different between 
the 2 groups (18% vs. 25%, p=0.3).
Importantly, patients developing new-onset AF showed worse event-free (hospitalizations, 
appropriate and inappropriate shocks) survival as compared to the SR group; 1-year event-
free survival was 65% and 76% in respectively AF and SR patients (log-rank p=0.021) 
(Figure 3).
Further stratification by AF burden did not result in a better estimation of the risk for 
adverse events during follow-up.
Table 3. Clinical and echocardiographic changes in LV systolic function after 6 months of CRT-D in 
patients remaining in sinus rhythm (SR) as compared to patients with new-onset atrial fibrillation (AF) 
after implantation. 
SR AF p-value
Variables (n = 168) (n = 55)
Δ NYHA class -1.0±0.6 -0.8±0.8 0.3
Δ QoL score -17±17 -11±16 0.065
Δ 6-MWT (m) +105±106 +90±118 0.4
Δ LVEF (%) +6.7±8.9 +3.5±10.3 0.034
Δ LVEDV (ml) -31±58 -21±43 0.2
Δ LVESV (ml) -37±53 -19±37 0.024
Abbreviations as in Table 2. 
Figuren 
Zullen in de gedrukte versie de figuren die door de zwart-wit weergave nu in grijstinten 
(ipv kleur) worden weergegeven nog wel leesbaar zijn? Het is belangrijk dat men de 
verschillende groepen in de figuren uit elkaar kunnen houden. Het gaat hierbij om de 
figuren in hoofdstuk 4 (fig 1, 2, 3 en 4), 6 (fig 2 en 3) en 7 (fig 1 en 2). Als het 
onderscheid volgens jou niet te maken is, lever ik de figuren opnieuw aan. 
 
Een aantal figuren die nog niet zo mooi waren heb ik in hogere resolutie gezet: 
Chapter 5, Figuur 1 
 
 
Chapter 5, Figuur 2 
Figure 1. Changes in LV diastolic function at baseline and after 6 months of follow-up in patients with 
sinus rhythm (SR) and patients with new-onset atrial fibrillation (AF) after CRT-D implantation. 







The findings in the current study can be summarized as follows: 1) During long-term 
follow-up, 25% of CRT-D implanted patients without a history of AF, developed new-onset 
AF; 2) Patients developing AF showed similar clinical improvements after 6 months of 
biventricular pacing as patients remaining in SR; 3) However, regarding echocardiographic 
parameters, the AF patients revealed less LV reverse remodeling and less improvement in 
LV function without improvement in MR, LA volumes and diastolic function as compared 
to SR patients; 4) Patients with new-onset AF showed worse event-free survival after long-
term CRT-D.
Incidence of new-onset AF after CRT-D
Data on the incidence of new-onset AF after CRT-D device implantation are scarce. 
Post-hoc analysis of the CARE-HF trial reported an incidence of new-onset AF after CRT 
(mean follow-up of 29 months) of 16% using frequent ECG recordings. Using device based 
diagnostics, the number of patients with new-onset AF was even higher (23%). However, 
of all implanted patients, 19% had a history of AF, which was strongly associated with 
 
Chapter 5, Figuur 3 
 
 
Chapter 14, Figuur 2 
Figure 2. Occurrence of events (panel A appropriate shocks, panel B inappropriate shocks, panel C 
hospitalization for cardiac causes and panel D death) during long-term follow-up in patients with sinus 
rhythm (SR) as compared to patients with new-onset atrial fibrillation (AF) after device implantation. 
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the development of AF during follow-up. Unfortunately, no data were presented on the 
incidence of new-onset AF in the group without episodes of AF prior to CRT implantation.4, 
10 Another study, by Hügl et al reported that one-third of the patients developed AF (defined 
as episode >30 sec using devise based diagnostics) within the first few months after 
implantation. Similarly, 40% of the patients had a history of AF.11 
The novelty of the current study is the reporting on the incidence of new-onset AF after 
CRT-D in patients without a history of AF. Episodes of AF lasting more than 10 minutes 
were documented by device-based diagnostics in 55 of 223 (25%) of CRT-D recipients.
New-onset AF and response after CRT-D
Previous large trials have shown a beneficial effect of CRT on clinical and echocardio-
graphic parameters in SR patients with severe heart failure, depressed LVEF and wide QRS 
complex.1-3 In addition, a positive response has been reported in patients with paroxysmal 
or persistent AF.10, 28-30 In contrast, limited data are available on the echocardiographic 
response of patients without a history of AF who develop AF after CRT-D implantation. The 
findings in the current study demonstrated significantly lesser reverse LV remodeling with 
a lesser increase in LVEF after CRT-D in patients who developed AF as compared to the 
patients who remained in SR. Furthermore, the AF-group showed no improvement in MR 
and a trend towards worsening of LV diastolic function. 
During long-term follow-up, patients in the AF-group had significantly more adverse 
cardiac events, including cardiac hospitalizations, appropriate shocks for ventricular 
arrhythmias and inappropriate shocks. These findings are in line with previous studies 
 
Chapter 5, Figuur 3 
 
 
Chapter 14, Figuur 2 
Figure 3. Event-free survival curves for patients with sinus rhythm (SR) and new-onset atrial fibrillation 
(AF) after device implantation.





 1 showing an increase in hospitalizations,12 an increase in ventricular arrhythmias causing 
defibrillator therapy,31, 32 and more inappropriate shocks in patients with AF.33 
Clinical implications
LA size is a powerful predictor of adverse clinical events including mortality in patients 
with cardiovascular disease.34, 35 Indeed, patients developing AF showed significantly larger 
LA volumes and larger LA LAX at baseline. In addition, reduction in LA diameter was only 
noted in patients with SR. Consequently, one may assume that in patients with severe 
heart failure, small LA at baseline or an improvement in LA diameter may be important for 
maintaining SR after device implantation. It remains hard however, to differentiate between 
cause and effect; less response to biventricular pacing and the concomitant less favorable 
echocardiographic changes, may predispose for future development of AF. On the other 
hand, the development of AF during follow-up may be a marker of an initially worse cardiac 
status, less capable to show significant response to biventricular pacing.
The present findings extend the results of a sub-study of the MOST trial, showing that 
(asymptomatic) atrial tachyarrhythmias as detected by the device are an independently 
predictive of death, stroke or symptomatic AF.13 An incidence of new-onset AF of 25% 
was demonstrated using device-based diagnostics in patients without a history of AF. Im-
portantly, these patients exhibited less echocardiographic benefit from biventricular pacing 
with more adverse events during follow-up. These results emphasize the clinical relevance 
of (asymptomatic) atrial tachyarrhythmias, as detected by the device. Furthermore, the 
findings may warrant a more aggressive strategy to maintain SR.
Study limitations
The definition of AF was arbitrarily defined as episodes of atrial high rate (>180 bpm) 
lasting longer than 10 minutes, similar to a large sub-study of the CARE-HF trial reported 
by Hoppe and coworkers.10 Other studies have used a variety of different definitions for 
AF, which makes comparison with the current study difficult.  Furthermore, some of the 
patients might have had unrecognized AF prior to implantation causing them to be as-
sumed without a history of AF and consequently to be erroneously included in the study. 
Finally, asymptomatic or symptomatic episodes of AF were not differentiated; it may be of 
potential interest to evaluate in future studies whether asymptomatic and symptomatic AF 
episodes have a different prognostic value.
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A substantial proportion of patients undergoing CRT-D developed new-onset AF. These 
patients showed less echocardiographic improvement at mid-term follow-up which was 
associated with less favorable outcome during long-term follow-up.
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Aims: To assess survival and to construct a baseline mortality risk score in primary preven-
tion implantable cardioverter defibrillator (ICD) patients with non-ischemic or ischemic 
heart disease.
Methods and results: Since 1996, data of all consecutive patients who received an ICD 
system in the Leiden University Medical Center were collected and assessed at implanta-
tion. For the current study, all 1036 patients (age 63 (SD 11) years, 81% male) with a 
primary indication for defibrillator implantation were evaluated and followed for 873 (SD 
677) dayDuring follow-up, 138 patients (13%) died. Non-ischemic and ischemic patients 
demonstrated similar survival but exhibited different factors that influence risk for mortality. 
A risk score, consisting of simple baseline variables could stratify patients in low, intermedi-
ate and high risk for mortality. In non-ischemic patients, annual mortality was 0.4% (95% 
CI 0.0-2.2%) in low risk and 9.4% (95% CI 6.6-13.1%) in high risk patients. In ischemic 
patients, mortality was 1.0% (95% CI 0.2-3.0%) in low risk and 17.8% (95% CI 13.6-
22.9%) in high risk patients.
Conclusion: Utilisation of an easily applicable baseline risk score can create an individual 
patient-tailored estimation on mortality risk to aid clinicians in daily practice. 


















Sudden cardiac death, mainly caused by ventricular arrhythmias degenerating into 
ventricular fibrillation, is responsible for 50% of all cardiac mortality worldwide.1-3 Large 
randomised trials have shown a beneficial effect of an implantable cardioverter defibrillator 
(ICD), initially in survivors of life-threatening arrhythmias,4-6 but more recently also as 
primary prevention of sudden arrhythmic death in selected non-ischemic and ischemic 
patients at high risk.7-10 Since the implementation of primary prevention in the international 
guidelines, implantation rates have increased drastically to 160 000 yearly in the United 
States.11-13 So far, data on the survival of primary prevention ICD patients are limited to 
post-hoc analyses of large randomised trials requiring specific patient characteristics for 
inclusion. This could cause the results to be less applicable to the more diverse, presently 
indicated population outside the setting of a clinical trial.
Since 1996, all ICD recipients in the Leiden University Medical Center have been as-
sessed and followed up. This cohort offers a unique opportunity to study mortality and to 
identify baseline parameters that influence risk. Furthermore, an easy-to-use and clinically 
applicable algorithm is created to aid clinicians in patient tailored survival estimations for 
patients with non-ischemic or ischemic heart disease.
Methods
Patients and study protocol 
From 1996 to 2007, all consecutive patients who received an ICD system in the Leiden 
University Medical Center were prospectively collected in the departmental Cardiology 
Information System (EPD-Vision®, Leiden University Medical Center). Characteristics at 
baseline, data of the implant procedure, and data of all follow-up visits were recorded. 
For the current study, patients with a primary indication for defibrillator implantation were 
evaluated. 
Eligibility for ICD implantation in this population was based on international guidelines 
for primary prevention which, due to evolving guidelines, might have changed over time. In 
the majority of patients, indication for an ICD was made in the presence of a depressed left 
ventricular ejection fraction [LVEF] with or without non sustained ventricular tachycardia 
(nsVT).11, 14 Ischemic heart disease was defined as the presence of significant coronary ar-
tery disease (a diameter stenosis of at least 50% in at least one coronary artery).15 Patients 
with congenital structural or monogenetic heart disease (associated with an increased risk 
of sudden arrhythmic death) were excluded from the analysis.





 1 Definitions of variables
All tested variables were acquired at defibrillator implantation and were defined and cat-
egorised according to literature or common practice. Age was categorised in ≥ 70 years or 
< 70 years;16 a history of nsVT was defined as a run of 3 to 30 ventricular ectopic beats 
at a rate > 120 beats per minute;9 renal clearance was estimated with the formula of 
Cockroft-Gault and categorised in normal or stage 1 renal failure (> 90 ml/min), stage 2 
renal failure (60-90 ml/min), or stage 3-5 renal failure (≤ 60 ml/min);17 QRS duration was 
categorised as ≥ 130 ms or < 130 ms; LVEF was categorised as ≤ 25% or > 25%;18 atrial 
fibrillation (AF) was defined as a history of AF, as documented on ECG; a history of smoking 
was defined if a patient had a positive answer when asked for past or present smoking;19 
and body mass index was defined as ≥ 30 kg/m2 or < 30 kg/m2.20 
Device implantation
All defibrillator systems used were implanted transvenously and without thoracotomy. 
During the implant procedure testing of sensing and pacing thresholds and defibrillation 
threshold testing was performed. Used systems were manufactured by Biotronik (Berlin, 
Germany), Medtronic (Minneapolis, MN, United States), Boston Scientific (Natick, MA, 
United States, formerly CPI, Guidant [St. Paul, MN, United States]) and St. Jude Medical/
Ventritex (St. Paul, MN, United States).
Defibrillators were programmed as follows: a ventricular arrhythmia monitor zone was 
programmed in all patients (150-188 bpm) No therapy was programmed in this zone until 
during follow-up arrhythmias were detected. Ventricular arrhythmias faster than 188 bpm 
were initially attempted to be terminated with two bursts of ATP and, after continuation of 
the arrhythmia, with defibrillator shocks. In the case of a ventricular arrhythmia faster than 
210 bpm, device shocks were the initial therapy. Furthermore, atrial arrhythmia detection 
was set to >170 bpm with SVT discriminators enabled. Settings were adapted, only when 
clinically indicated (i.e. hemodynamic well tolerated ventricular tachycardia at high rate; 
ventricular tachycardia in the monitor zone).
Long-term follow-up 
Patient check-up was scheduled every three-six months. Device interrogation printouts 
were checked for appropriate and inappropriate ICD therapy (ATP or shocks). Therapies 
were classified as appropriate when they occurred in response to ventricular tachycardia 
or ventricular fibrillation and as inappropriate when triggered by sinus or supraventricular 
tachycardia, T-wave oversensing, or electrode dysfunction. Furthermore, follow-up included 
all-cause mortality. 
In the Dutch health care system, all patients are followed by the implanting centre. Since 
periodical follow-up was performed every three to six months, patients without data on the 
past six months were considered as lost to follow-up.


















Continuous data are expressed as mean with standard deviation (SD) or median with 25th 
and 75th percentile where appropriate; dichotomous data are presented as numbers and 
percentages. Event rates for all-cause mortality were analyzed by method of Kaplan-Meier. 
Differences in event rates (non-ischemic vs. ischemic heart disease) were assessed using 
logistic regression. Missing values were imputed using the single imputation procedure.21 
Last follow-up data were acquired in November 2008. 
To obtain a risk score, composed of robust, reproducible and non clinician driven variables, 
the use of medication at baseline was not used in its construction. All other baseline vari-
ables were entered as categorical variables. Firstly, the variables were studied in univariate 
logistic regression models, with all-cause mortality as outcome. Variables with a p-value 
<0.10 were further evaluated in a multivariate logistic model, using backward stepwise 
selection. At each step, the least significant variable was discarded from the model, until all 
variables in the model reached a p-value <0.25. With the variables’ regression coefficient 
in this multivariate model, a simple risk stratification score was designed by giving a base 
regression coefficient the value of one point on the risk score and giving all variables the 
associating score, according to their multiplication of this base regression coefficient and 
rounding it of to the nearest whole or half number. Subsequently, the patient specific values 
for the predictors in the score were summed to obtain a score for each patient. The ability 
of the score to discriminate between patients who did and patients who did not reach the 
end-point was estimated by the area under the curve of the receiver operator curve. After 
the determination of the individual risk score per patients, cut offs were determined for a 
population at low, intermediate and high risk of mortality. These cut-offs were chosen to 
optimize the discriminative effect of the model without making groups too small. Bootstrap 
with 1000 resamples was used for internal validation and to assess the stability of variable 
selection.22 In the calculation of the 95% confidence interval (95% CI) for event rates, a 
Poisson distribution of the observed number of events was presumed. All analyses (except 
bootstrapping analysis) were performed with SPSS for Windows, version 14.0 (SPSS, 
Chicago, IL). For the bootstrapping analysis, R (version 2.9.1) was used.
Results
Baseline characteristics 
Since 1996, data of 1086 consecutive patients receiving an ICD for primary prevention and 
without diagnosed congenital heart disease or monogenetic heart disease (associated with 
an increased risk of sudden arrhythmic death) were prospectively collected. Fifty patients 
(4.6%) were lost to follow-up. The remaining 1036 ICD recipients were included in the 
analysis. Median follow-up time was 721 days (interquartile range, 308 to 1271 days).





 1 The majority of patients (81% men, mean age 63 (SD 11) years) had a depressed LVEF 
(29 (SD 12) %), wide QRS (131 (SD 35) ms) and poor renal function (renal clearance 78 
(SD 35) ml/min). Medication included beta blockers in 73%, ACE inhibitors or AT antago-
nists in 85% and diuretics for congestive heart failure in 75%. Baseline characteristics are 
summarised in Table 1.
Seven-hundred-and-four (68%) out of all 1036 patients had ischemic heart disease. 
The remaining 332 (32%) patients were considered non-ischemic. Ischemic ICD recipients 
were more often male (87% vs. 66%, p<0.001), had a higher age (64 (SD 11) vs. 61 
(SD 12) years, p<0.001) and shorter QRS duration (126 (SD 34) vs. 140 (SD 36) ms, 
p<0.001), as is shown in Table 1.







p-value Patients with 
missing data
Clinical parameters
    Male gender (%) 835 (81) 220 (66) 615 (87) <0.001 0
    Age, mean (SD), years
        median (interquartile range),









    History of nsVT (%) 287 (28) 96 (29) 191 (27) 0.5 0
    Renal clearance, mean (SD), 
    ml/min*
78 (35) 80 (37) 77 (34) 0.3 41 (4)
    QRS-duration, mean (SD), ms 131 (35) 140 (36) 126 (34) <0.001 8 (1)
    LVEF, mean (SD), % 29 (12) 29 (14) 29 (11) 0.7 59 (6)
    History of atrial fibrillation (%) 283 (27) 107 (32) 176 (25) 0.015 2 (0)
    Diabetes (%) 226 (22) 54 (16) 172 (24) 0.003 35 (3)
    History of smoking (%) 491 (47) 146 (44) 345 (49) 0.130 63 (6)
    Body mass index, mean (SD), 
    kg/m2
26 (4) 26 (4) 26 (4) 0.3 51 (5)
Implantable cardioverter defibrillator
    Single chamber 50 (5%) 17 (5%) 33 (5%) 0.8 0
    Dual chamber 409 (40%) 83 (25%) 326 
(46%)
<0.001 0




    Beta-blocker (%) 647 (63) 212 (64) 435 (62) 0.5 0
    Sotalol (%) 112 (11) 27 (8) 85 (12) 0.057 0
    ACE inhibitors / AT antagonist (%) 879 (85) 284 (86) 595 (85) 0.7 0
    Statins (%) 681 (66) 106 (32) 575 (82) <0.001 0
    Diuretics for CHF (%) 781 (75) 271 (82) 510 (72) <0.001 0
    Amiodarone (%) 149 (14) 44 (13) 105 (15) 0.5 0
* Renal clearance was determined with the formula of Cockroft-Gault.
ACE = angiotensin-converting enzyme; AT = angiotensin; CHF = congestive heart failure; LVEF = left 
ventricular ejection fraction; nsVT = non sustained ventricular tachycardia 



















During a median follow-up time was 721 days (interquartile range, 308 to 1271 days), 
138 patients (13%) died. Total follow-up was 2475 patient-years. Survival analysis showed 
a cumulative mortality of 6% (95% CI 4-7%) at one year, 17% (95% CI 13-20%) at three 
years and 27% (95% CI 22-32%) at six years follow-up. Stratification by type of underlying 
disease did not demonstrate differences in survival (Figure 1) (odds ratio, adjusted for age: 
1.0, 95% CI 0.7-1.5).
A total of 6575 episodes of ventricular arrhythmia, causing appropriate device therapy, 
was noted in 220 (21%) patients. These consisted of 6220 arrhythmia episodes being 
terminated by ATP in 148 (14%) patients and 355 episodes being terminated by ICD 
shocks in 113 (11%) patients.
Mortality risk score in non-ischemic heart disease
Univariate and subsequent multivariate logistic regression identified the following variables 
as suitable for the construction of a predictive model: (1) poor renal function, (2) poor LVEF, 
(3) history of AF and (4) high age. The strongest predictor of mortality was a renal clear-
ance ≤60 ml/min (odds ratio 5.4, 95% CI 1.7-17.5), when compared to renal clearance > 
90 ml/min (Table 2). Bootstrap analysis showed that renal clearance, LVEF, a history of AF 
and high age were selected in 97%, 95%, 60%, and 49% respectively. As base regression 
coefficient, 0.4 was used. For each variable, the appropriate risk score was determined by 




Figure 1: All-cause mortality. Kaplan-Meier curve for cumulative all-cause mortality in 
patients with non-ischemic heart disease vs. ischemic heart disease. 
 
 
Figure 1: All-cause mortality. Kaplan-Meier curve for cumulative all-cause mortality in patients with non-
ischemic heart disease vs. ischemic heart disease.






the receiver operator curve of the acquired risk score was reasonably good: 0.76 (95% 
CI 0.69 – 0.82). Application of this risk score on the study population with non-ischemic 
heart disease facilitates the stratification in three risk categories: (1) low risk (0-2 points); 
(2) intermediate risk (2.5-4 points); and (3) high risk (4.5-8 points).
In patients with low risk for all-cause mortality (91/332, 27%), one patient (1%) died 
during 256 patient-years, corresponding to an event-rate of 0.4 (95% CI 0.0-2.2) per 
100 patient-years (Table 3). Survival analysis showed a cumulative mortality of 1% (95% 
CI 0-3%) at one year, three years and at six years follow-up (Figure 2). In the population 
with intermediate risk (91/332, 27%), eight patients (9%) died during 226 patient-years. 
Therefore, the calculated event rate is 3.5 (95% CI 1.5-7.0) per 100 patient-years. Survival 
analysis showed a survival of 1% (95% CI 0-4%) at one year, 11% (95% CI 2-19%) at 
three years and 18% (95% CI 6-31%) at six years follow-up. Finally, in the population with 
a risk score ≥ 4.5 points (150/332, 45%), 35 patients died during 372 patients-years, 
which corresponds to an event rate of 9.4 (95% CI 6.6-13.1) per 100 patients-years. For 
this group, survival was 8% (95% CI 3-12%) at one year, 26% (95% CI 17-35%) at three 
years and 46% (95% CI 30-62%) at six years follow-up.








    ≤60 ml/min 1.694 5.444 (1.696 – 17.472) 4
    61-90 ml/min 0.837 2.309 (0.722 – 7.381) 2
LVEF ≤ 25% 0.991 2.694 (1.321 – 5.493) .006 2.5
History of atrial fibrillation 0.481 1.693 (0.853 – 3.360) .132 1
Age ≥ 70 yrs 0.401 1.493 (0.715 – 3.117) .286 1
* Renal clearance was determined with the formula of Cockroft-Gault.
CI = Confidence interval; LVEF = left ventricular ejection fraction 
Table 3. Risk stratification and corresponding event rates for mortality in patients with non-ischemic 
heart disease.
Risk score Patients Patient-years Events Event rate per 100 
patient-years
(95% CI)
Low risk 0-2 91 256 1 0.4 (0.0-2.2)
Intermediate risk 2.5-4 91 226 8 3.5 (1.5-7.0)
High risk 4.5-8 150 372 35 9.4 (6.6-13.1)
Total 332 854 44 5.2 (3.7-6.9)


















Mortality risk score in ischemic heart disease
In ICD patients with ischemic heart disease, the multivariate logistic model contained the 
following variables: (1) poor renal function, (2) history of smoking, (3) diabetes, (4) poor 
LVEF, (5) high age and (6) long QRS duration. Similar to the non-ischemic population, the 
strongest predictor of mortality was a renal clearance ≤60 ml/min (odds ratio 4.5, 95% 
CI 2.1-9.7), when compared to renal clearance > 90 ml/min (Table 4). Bootstrapping 
analysis showed that renal clearance, history of smoking, diabetes, LVEF, high age, and 
long QRS duration were selected in 100%, 100%, 98%, 99%, 97%, and 84% respectively. 
The area under the receiver operator curve of the acquired risk score was reasonably good: 
0.81 (95% CI 0.76 – 0.87). Using 0.4 as the base regression coefficient, the risk score for 
each variable was determined. Stratification resulted in three risk categories: (1) low risk 
(0-2 points); (2) intermediate risk (3-7 points); and (3) high risk (8-13 points). 
As can be seen in Table 5, event rates varied from 1.0 (95% CI 0.2-3.0) per 100 patient-
years in the low-risk group, to 17.8 (95% CI 13.6-22.9) per 100 patient-years in the high 
risk group. Six-year survival was 4% (95% CI 0-10%) in ischemic low risk patients, and 
66% (95% CI 49-82%) in the high risk population (Figure 3).
 15
Figure 2: Risk stratification for all-cause mortality in non-ischemic cardiomyopathy. 
Kaplan-Meier curve for cumulative all-cause mortality in patients with non-ischemic 
heart disease with low, intermediate, or high risk. 
 
 
Figure 3: Risk stratification for all-cause mortality in ischemic cardiomyopathy. Kaplan-
Meier curve for cumulative all-cause mortality in patients with ischemic heart disease 
with low, intermediate, or high risk. 
Figure 2: Risk stratification for all-cause mortality in non-ischemic cardiomyopathy. Kaplan-Meier curve 
for cumulative all-cause mortality in patients with non-ischemic heart disease with low, intermediate, 
or high risk.













    ≤60 ml/min 1.509 4.523 (2.119 – 9.657) 4
    61-90 ml/min 0.388 1.474 (0.667 – 3.256) 1
History of smoking 1.146 3.145 (1.884 – 5.252) .000 3
Diabetes 0.889 2.434 (1.466 – 4.041) .001 2
LVEF ≤ 25% 0.870 2.388 (1.465 – 3.892) .000 2
Age ≥ 70 yrs 0.788 2.200 (1.283 – 3.773) .004 2
QRS duration ≥ 130 ms 0.498 1.694 (1.035 – 2.772) .036 1
* Renal clearance was determined with the formula of Cockroft-Gault.
CI = Confidence interval; LVEF = left ventricular ejection fraction 
Table 5. Risk stratification and corresponding event rates for mortality in patients with ischemic heart 
disease.
Risk score Patients Patient-years Events Event rate per 100 
patient-years
(95% CI)
Low risk 0-2 127 291 3 1.0 (0.2-3.0)
Intermediate risk 3-7 416 993 31 3.1 (2.1-4.4)
High risk 8-13 161 337 60 17.8 (13.6-22.9)





Figure 1. Risk stratification for non-benefit. Kaplan-Meier curve for non-benefit in 
patients with low, intermediate or high risk 
Figure 3: Risk stratification for all-cause mortality in ischemic cardiomyopathy. Kaplan-Meier curve for 
cumulative all-cause mortality in patients with ischemic heart disease with low, intermediate, or high 
risk.


















In the current study on the long-term follow-up and the construction of an easy-to-use mor-
tality risk score in non-ischemic and ischemic primary prevention ICD patients, the findings 
can be summarised as follows: 1) Cumulative mortality was approximately 5% per year; 2) 
Non-ischemic and ischemic patients demonstrated an equal survival; 3) Non-ischemic and 
ischemic ICD recipients exhibited a different risk profile in the prediction of mortality; 4) A 
baseline risk score can easily estimate an individual patient’s risk for mortality. 
Using the presented risk score, a patient, considered for primary prevention ICD treat-
ment, could be stratified as follows: 1) determine if the patient has ischemic or non-ischemic 
heart disease to determine the risk factors, influencing mortality risk (Table 2 or Table 4); 2) 
add the risk score points, associated with patient’s risk factors; 3) allocate patient as low, 
intermediate or high risk for mortality en estimate event-rate (Table 3 or Table 5). 
Mortality
In the current analysis, 138 patients (13%) died during a mean follow-up of median follow-
up time was 721 days (interquartile range, 308 to 1271 days). Cumulative mortality 
after one, three and six year was 6%, 17% and 27% respectively and was not different in 
non-ischemic or ischemic ICD recipients. Previously, few trials have been conducted on a 
population containing non-ischemic, as well as ischemic patients. Bardy and co-workers 
show a beneficial effect of defibrillator implantation in ICD recipients with non-ischemic 
or ischemic heart disease and congestive heart failure.7 In their population, crude annual 
death rates reach up to 5.7% which are comparable to our annual crude death rate of 
5.6%. Other large trials assessing the effect of an ICD in patients with ischemic heart 
disease only, demonstrate an annual death rate of 7.0% to 8.5%.9, 10 These higher rates 
can be explained by the poor patient characteristics, required to be eligible for inclusion. 
The study population might therefore not prove to be completely representative for the “real 
life” population considered for defibrillator implantation. 
Risk factors
The current study reveals different factors influencing risk for mortality for either type of 
heart disease. For all-cause mortality in non-ischemic patients, a history of AF, depressed 
LVEF, poor renal function and high age are predictors of mortality during follow-up. A 
depressed LV function has proven to be one of the most powerful markers of cardiac death 
in patients without an ICD, causing it to be the current main criterion for primary prevention 
defibrillator eligibility.1, 23 Furthermore, AF, renal failure and high age have been described 
in the prediction of death in a population with, as well as without an ICD.23-27 Furthermore, 
renal failure has previously been noted as one of the strongest predictors of mortality in a 
population with cardiac disease.26, 28 





 1 Characteristics increasing risk for mortality in ischemic patients were more diverse: renal 
failure, a history of smoking, diabetes, poor LV function, high age and prolonged QRS 
duration.  Risk stratification in the ischemic ICD recipients of MADIT II revealed similar 
risk factors, as described by Goldenberg et al.27 Additionally, a sub-analysis of the MUSTT 
exposed these factors as predictors of mortality in the non-ICD treated arm.25 
Risk score
Previous studies constructing a risk score were mainly limited to patients in the setting of 
large clinical trials, requiring specific characteristics to be eligible for inclusion, and fol-
lowed patients for a relatively short time. This might cause the findings to be less applicable 
to the more diverse population, currently receiving an ICD for primary prevention in a “real 
life” population. In a sub-study of the MUSTT, Buxton and co-workers constructed a model 
containing eight factors in patients with ischemic heart disease.25 Since the MUSTT study 
was designed to test the ability of electrophyiologically (EP) guided therapy to reduce risk 
of arrhythmic events, all included patients underwent EP testing. Inducibility of VT at EP 
testing was one of the factors, found to increase risk for all-cause mortality. In the current 
study, as in the present population receiving ICD treatment, not all patients underwent EP 
testing, therefore making it hard to assess its prognostic value. The power of the presented 
model to correctly identify patients in the MUSTT was 0.78, which is comparable to the 
0.81 in the current study. 
Goldenberg and co-workers constructed a model with five factors in the post-myocardial 
infarction population of the MADIT II.27 This model, containing New York Heart Association 
functional class, AF, a wide QRS, high age and renal failure, shows substantial resemblance 
with the model constructed in the current study. 
Clinical implications
The results of this study imply that the large population, currently indicated for ICD treat-
ment, can be easily stratified for mortality risk. The proposed risk score can prove an easily 
applicable mean to aid clinicians in making individual patient-tailored statements on risk 
for mortality, prior to defibrillator implantation in daily practice. Its utilisation could greatly 
increase survival estimation for the clinician, as well as the patient. Of note that the pro-
posed risk score does require validation. Furthermore, clinicians have shown concern that 
the population, eligible for primary prevention ICD treatment, is of such magnitude that 
provision of ICD therapy will strain financial resources and the pool of trained personnel.29, 
30 In current daily practice, the choice on the most efficient allocation of ICD treatment 
is mostly based on the life expectancy of the patient. With the current study, a group of 
patients, currently indicated for ICD treatment, can be identified who have a very short life 
expectancy, regardless of ICD implantation. These findings could aid clinicians in current 
daily practice in their choices for the optimal allocation of ICD treatment


















This was a non-randomised prospective observational study, performed to assess the 
long-term follow-up in non-ischemic or ischemic primary prevention ICD patients outside 
the setting of a clinical trial. Since patients were collected over a period of eleven years, 
expanding guidelines for the implantation of defibrillators, treatment of acute myocardial 
infarction, and pharmacological antiarrhythmic therapy could have created a heteroge-
neous population.11, 14 The currently constructed risk score does not take pharmacological 
treatment in consideration since inclusion of these clinician driven variables would lead to 
a less robust and reproducible score. Furthermore, since no control group was assessed, no 
statements can be made on the effect of ICD treatment. Finally, the constructed risk score 
requires external validation.
Conclusion
Non-ischemic and ischemic primary prevention ICD recipients demonstrate similar survival 
during long-term follow-up but exhibit different factors that influence risk for mortality. 
Utilisation of an easily applicable baseline risk score can create an individual patient-
tailored estimation on mortality risk to aid clinicians in daily practice. 
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Context: Although the beneficial effect of implantable cardioverter defibrillator (ICD) therapy 
has been well established as primary prevention in a selected population at high risk for 
sudden arrhythmic death, a substantial part does not benefit from ICD treatment during 
long-term follow-up.
Objective: To assess the risk for non-benefit from ICD treatment in primary prevention ICD 
patients with ischemic heart disease
Design, setting and patients:  Since 1996, all ICD recipients in the Leiden University Medi-
cal Center have been clinically assessed at implantation. For the current study, patients 
with ischemic heart disease and a primary indication for implantation have been included. 
During follow-up, all-cause mortality and device therapy (anti-tachycardia pacing or shock) 
were noted. Non-benefit was defined as death, prior to first appropriate ICD therapy. Out of 
baseline variables, a baseline risk score was constructed to estimate risk for non-benefit. 
Results: Nine-hundred patients (87% men, mean age 64 ± 10 years) were included in the 
analysis. During a median follow-up of 669 days (interquartile range, 363 to 1322 days), 
150 patients (17%) died and 191 (21%) patients received appropriate device therapy. 
A total of 114 (13%) patients were considered the non-benefit group. Stratification for 
non-benefit resulted in risk categorization of patients as low, intermediate or high-risk. 
Advanced age was the strongest predictor of non-benefit. Five-year cumulative incidence 
for non-benefit ranged from 12% (95%CI 5–18%) in low-risk patients to 49% (95%CI 
38–60%) in high-risk patients. 
Conclusions: The risk of non-benefit can be predicted in primary prevention ICD patients 
with ischemic heart disease. The use of a baseline risk score facilitates patient-tailored risk 
estimation.
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Large randomized trials have demonstrated that implantable cardioverter defibrillator (ICD) 
treatment is the treatment of choice for patients with prior life-threatening arrhythmias 
(secondary prevention)1-3 and for selected patients at high risk for sudden cardiac death, 
regardless of prior arrhythmia (primary prevention).4-7 Since implementation of primary 
prevention in the international guidelines, implantation rates have increased drastically to 
an estimated 275000 devices in 2008.8,9 However, with the inclusion of primary preven-
tion in the currently ICD indicated population, rates of appropriate therapy for ventricular 
arrhythmias have decreased to 35% during long-term follow-up in the second Multicenter 
Automatic Defibrillator Implantation Trial (MADIT-II) compared to 64% in secondary 
prevention patients.1,10 Furthermore, clinicians have expressed concern that the number 
of patients needed to treat with a primary prevention ICD might be too high and that 
the population, eligible for primary prevention ICD treatment, is of such magnitude that 
provision of ICD therapy will strain financial resources and the pool of trained personnel.11 
In addition, ICD therapy is associated with adverse events such as pocket related infections 
and inappropriate shocks.12 The relatively low actual need for defibrillator therapy during 
follow-up, combined with the associated adverse events and the incapability to implant all 
indicated patients, urges for refinement of the current selection criteria for ICD treatment. 
Therefore, it would be of interest to identify a population, currently receiving ICD treatment, 
not benefiting from ICD therapy (i.e. death prior to appropriate ICD therapy).  
Since 1996, all patients receiving an ICD at the Leiden University Medical Center have 
been assessed and followed up. This thoroughly screened cohort provided an opportunity 
to identify ICD recipients who do not benefit from ICD treatment and to assess whether 
baseline parameters influence the risk of non-benefit. Finally, a clinically applicable risk 
model is constructed to aid clinicians in individual risk estimations for primary prevention 
ICD patients with ischemic heart disease.
Methods
Patients and study protocol 
Since 1996, all patients who received an ICD at the Leiden University Medical Center were 
prospectively collected in the departmental Cardiology Information System (EPD-Vision®, 
Leiden University Medical Center, Leiden, the Netherlands). Characteristics at baseline, 
data of the implant procedure and of all follow-up visits were recorded. For the current 
analysis, patients with a primary indication for defibrillator implantation and ischemic heart 
disease were selected.





 1 It should be noted that, due to evolving guidelines, eligibility for ICD implantation in this 
population might have changed over time.13,14 Nonetheless, in the majority of patients, 
indication for an ICD was made in the presence of a depressed left ventricular ejection 
fraction (LVEF) with or without non sustained ventricular tachycardia.8,13 Ischemic heart 
disease was defined as the presence of significant coronary artery disease (a diameter 
stenosis of at least 50% in at least one coronary artery).15,16 Exclusion criteria for the 
current analysis consisted of congenital structural or monogenetic heart disease (associated 
with an increased risk of sudden arrhythmic death).
Clinical variables
All tested variables were collected at device implantation and defined and categorized ac-
cording to literature or common practice. Age was categorized as <65 years, 65–74 years 
and ≥75 years; a history of non sustained ventricular tachycardia was defined as a run of 
3 to 30 ventricular ectopic beats at a rate >120 beats per minute;6 renal clearance was 
estimated with the formula of Cockroft-Gault and categorized in normal or stage 1 renal 
failure (>90 ml/min), stage 2 renal failure (60-90 ml/min), or stage 3-5 renal failure (<60 
ml/min);17 QRS duration was categorized as <100 ms, 100-130 ms, or >130 ms; LVEF 
was categorized as ≤25% or >25%;18 Heart failure symptoms were categorized as mild 
(New York Heart Association (NYHA) functional class I-II) or as severe (NYHA functional 
class III-IV);19 atrial fibrillation was defined as a history of atrial fibrillation as documented 
on ECG; a history of smoking was defined if a patient had a positive answer when asked 
for past or present smoking;20 and body mass index was categorized as <30 kg/m2 or ≥30 
kg/m.21
Device implantation
All ICD systems used were implanted in the pectoral region. Used systems were manufac-
tured by Biotronik (Berlin, Germany), Medtronic (Minneapolis, MN, United States), Boston 
Scientific (Natick, MA, United States, formerly CPI, Guidant [St. Paul, MN, United States]) 
and St. Jude Medical/Ventritex (St. Paul, MN, United States).
Defibrillators were programmed as follows: a ventricular arrhythmia monitor zone was 
programmed in all patients (150-188 bpm). Ventricular arrhythmias faster than 188 bpm 
were initially attempted to be terminated with two bursts of anti-tachycardia pacing (ATP) 
and, after continuation of the arrhythmia, with defibrillator shocks. In the case of a ven-
tricular arrhythmia faster than 210 bpm, device shocks were the initial therapy. Settings 
were adapted, only when clinically indicated.
Follow-up 
All patients were seen at the implanting center. Follow-up started at the time of implanta-
tion and lasted until death or last date of data acquisition (February 2009). Devices were 
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ninterrogated every three to six months or more frequent when clinically indicated. Printouts 
of device interrogations were checked for delivered therapy, which was classified as ap-
propriate when occurring in response to ventricular tachycardia or ventricular fibrillation. 
Furthermore, all-cause mortality was noted. Patients without data on the past six months 
were considered lost to follow-up. As previously reported, non-benefit from ICD treatment 
was defined as death from any cause, prior to appropriate ICD therapy (ATP or shock).22,23 
Statistical analysis 
Continuous data are expressed as mean with standard deviation (SD) or median with 25th 
and 75th percentile where appropriate. Dichotomous data are presented as numbers and 
percentages. Baseline characteristics in the non-benefit group and the remaining study 
population were compared with the chi-square test and unpaired Student’s t-test as appro-
priate. All-cause mortality, appropriate therapy and non-benefit were analyzed by method of 
Kaplan-Meier and evaluated using the log rank test.24 In the calculation of the cumulative 
incidence of non-benefit, appropriate therapy was considered a censoring event.  
Baseline medication was excluded from risk score construction, since this clinician driven 
variable could bias the results and impede reproducibility. All other baseline variables were 
entered as categorical variables. Initially, the variables were entered in univariate logistic 
regression models, with non-benefit from ICD treatment as only outcome. Variables with 
a P-value <.10 were further analyzed in a multivariate logistic regression model, using 
backward stepwise selection until all variables in the model reached a P-value <.25. 
Based on the variables’ regression coefficient in this multivariate model, a risk stratification 
score was constructed by giving a base regression coefficient the value of one point on the 
risk score and giving all variables the associating score, according to their multiplication 
of this base regression coefficient and rounding it off to the nearest whole or half number. 
Subsequently, the patient specific values for the predictors in the score were summed to 
obtain a score for each patient. After the determination of the individual patient risk score, 
cut-offs were determined for a population at low, intermediate and high risk of non-benefit 
from ICD treatment. These cut-offs were chosen to optimize the discriminative effect of the 
model without reducing the sizes of the groups. For internal validation and to assess the 
stability of variable selection, bootstrap with 1000 resamples was used.25 All analyses were 
performed with SPSS for Windows, version 14.0 (SPSS, Chicago, IL).







From 1996 to 2008, 935 patients with ischemic heart disease underwent ICD implantation 
for primary prevention. Thirty-five (3.7%) patients were lost to follow-up. Median follow-up 
of the remaining 900 patients was 669 days (interquartile range, 363-1322 days).
Baseline characteristics are provided in Table 1. The majority of patients (mean age 
64±10 years) were male (87%), had a depressed LVEF (29±11%) and wide QRS 
(125±33 ms). Beta blockers were used by 63% of the patients, sotalol by 12% and ACE 
inhibitors or AT antagonists by 85%. 
Table 1. Baseline characteristics 
Ischemic
(n=900)
Patients with missing data
Clinical parameters
    Male gender (%) 779 (87) 0
    Age, mean (SD), years 64 (10) 0
        median (interquartile range), years 66 (57-72)
    NYHA functional class 17 (2)
        I 193 (21)
        II 352 (39)
        III 325 (36)
        IV 30 (3)
    History of nsVT (%) 221 (25) 0
    Renal clearance, mean (SD), ml/min 78 (37) 53 (6)
    QRS-duration, mean (SD), ms 125 (33) 10 (1)
    LVEF, mean (SD), % 29 (11) 52 (6)
    History of atrial fibrillation (%) 228 (25) 3 (0)
    Diabetes (%) 227 (25) 36 (4)
    History of smoking (%) 429 (48) 50 (6)
    Body mass index, mean (SD), kg/m2 27 (4) 54 (6)
Implantable cardioverter defibrillator 0
    Single chamber (%) 40 (4)
    Dual chamber (%) 423 (47)
    Cardiac resynchronization therapy (%) 437 (49)
Medication 0
    Beta-blocker (%) 570 (63)
    Sotalol (%) 106 (12)
    ACE inhibitors / AT antagonist (%) 767 (85)
    Statins (%) 742 (82)
    Diuretics for CHF (%) 651 (72)
    Amiodarone (%) 126 (14)
Abbreviations: ACE, angiotensin-converting enzyme; AT, angiotensin; LVEF, left ventricular ejection frac-
tion; nsVT, non sustained ventricular tachycardia; NYHA, New York Heart Association. 
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nIncidence of all-cause mortality and first appropriate ICD therapy
During follow-up, 150 patients (17%) died. Cumulative incidence of all-cause mortality 
in the study population was 7% (95%CI 6-9%) after one year, 19% (95%CI 16-23%) 
after three years and 27% (95%CI 22-31%) after five years. A total of 3638 episodes 
of ventricular arrhythmia, causing appropriate device therapy, were noted in 191 (21%) 
patients. These consisted of 3333 arrhythmia episodes being terminated by ATP in 128 
(14%) patients and 298 episodes being terminated by ICD shocks in 100 (11%) pa-
tients. Cumulative incidence of first appropriate therapy in the study population was 12% 
(95%CI 10-15%) after one year, 26% (95%CI 22-30%) after three years and 39% (95%CI 
34-44%) after five years follow-up. For first appropriate shock, the cumulative incidence 
was 6% (95%CI 4-8%) after one year, 13% (95%CI 10-16%) after three years and 21% 
(95%CI 16-26%) after five years.
Non-benefit from ICD treatment 
During follow-up, 114 (13%) patients died without prior appropriate ICD treatment and 
were considered the non-benefit group. Cumulative incidence of death without prior ICD 
treatment was 7% (95%CI 6-8%) after one year, 18% (95%CI 15-22%) after three years 
and 24% (95%CI 21-27%) after 5 years. 
Comparison of the non-benefit group with the remaining study population demonstrated 
that the non-benefit group was older, had higher NYHA functional class, worse renal func-
tion, longer QRS duration, lower LVEF, and more often a history of diabetes and smoking 
(Table 2). Subsequently, multivariate logistic modeling for the prediction of non-benefit 
from ICD treatment contained the following variables: (1) age (65-74 and ≥75 years), (2) 
diabetes, (3) LVEF ≤25%, (4) NYHA functional class III-IV and (5) a history of smoking. 
The strongest predictor of non-benefit from ICD treatment was age ≥75 years (odds ratio 
2.95, 95%CI 1.7-5.1%) (Table 3). Bootstrap analysis demonstrated that age, diabetes, 
LVEF, NYHA and smoking were selected in 99, 99, 98 96, 97%, respectively.
For construction of the non-benefit prediction model, the following risk point cut-offs 
were used: (1) low risk (0-1.5 points); (2) intermediate risk (2-2.5 points); and (3) high 
risk (3-5.5 points). When extrapolated to the total study population, 371(41%) patients 
exhibited low risk of non-benefit, 323 (36%) patients intermediate risk and 206 (23%) 
patients high risk. Cumulative incidence of non-benefit after 5 years was 12% (95%CI 
5-18%) in low risk patients, 22% (95%CI 12-32%) in intermediate risk patients and 49% 
(95%CI 38-60%) in high risk patients (Figure 1). 













Male gender (%) 102 (90) 677 (86) .33
Age < .001
< 65 years (%) 41 (36) 386 (49)
65 - 74 years (%) 40 (35) 286 (36)
≥ 75 years (%) 33 (29) 114 (15)
NYHA functional class < .001
I or II (%) 45 (39) 500 (64)
III or IV (%) 69 (61) 286 (36)
History of nsVT (%) 25 (22) 196 (25) .49
Renal failure < .001
Stage 1 ( > 90ml/min) (%) 15 (13) 262 (33)
Stage 2 (60 – 90 ml/min) (%) 23 (20) 311 (40)
Stage 3 (< 60 ml/min) (%) 76 (67) 213 (27)
QRS-duration .01
< 100 ms (%) 15 (13) 163 (21)
100-130 ms (%) 42 (37) 344 (44)
>130 ms (%) 57 (50) 279 (35)
LVEF ≤ 25% (%) 66 (58) 280 (36) < .001
History of atrial fibrillation (%) 35 (31) 193 (25) .10
Diabetes (%) 46 (40) 181 (23) < .001
History of smoking (%) 65 (57) 364 (46) .03
Body mass index ≥ 30 kg/m2 (%) 18 (16) 144 (18) .31
Implantable cardioverter defibrillator .003
Single chamber (%) 2 (5) 38 (2)
Dual chamber (%) 40 (49) 383 (35)
Cardiac resynchronization therapy (%) 72 (46) 365 (63)
Abbreviations: LVEF, left ventricular ejection fraction; nsVT, non sustained ventricular tachycardia; NYHA, 
New York Heart Association. 








65 – 74 years .26 1.30 (.81 – 2.10) .28 .5
≥ 75 years 1.08 2.95 (1.69 – 5.14) < .001 2
LVEF ≤ 25% .76 2.13 (1.40 – 3.24) < .001 1.5
Diabetes .72 2.05 (1.33 – 3.15) .001 1
NYHA functional class III-IV .64 1.89 (1.23 – 2.90) .003 1
History of smoking .65 1.91 (1.25 – 2.94) .004 1
Abbreviations: CI, confidence interval; LVEF, left ventricular ejection fraction; NYHA, New York Heart 
Association.
Jan-Willem BW new.indd   114 29-07-10   13:30
115

















Figure 1. Risk stratification for non-benefit. Kaplan-Meier curve for non-benefit in patients with low, 
intermediate or high risk
Comment
In the current study on the identification of primary prevention ICD patients with ischemic 
heart disease who do not benefit from ICD treatment, the findings can be summarized as 
follows: 1) Five-year cumulative incidence was 27% for all-cause mortality and 39% for 
first appropriate ICD therapy; 2) Five-year cumulative incidence of non-benefit was 24%; 3) 
Strongest predictor of non-benefit was advanced age; 4) Almost 50% of high risk patients 
did not benefit from ICD treatment after five years follow-up. 
The current study adds to current literature in that it is the first to propose a risk model 
for the estimation of non-benefit in primary prevention ICD patients with ischemic heart 
disease.
Risk model application
When using the proposed risk score, patients with ischemic heart disease, considered for 
primary prevention ICD treatment, could be stratified as follows: 1) assess the patient’s 
characteristics for the presence of variables, influencing risk for non-benefit; 2) use the 
scorecard to determine patient’s risk as low, intermediate or high-risk for non-benefit from 
device treatment (Figure 2). 






Drawbacks of ICD treatment
Large randomized trials have sufficiently shown the beneficial effect of ICDs in a large 
population at risk for sudden cardiac death and with the inclusion of primary preven-
tion ICD treatment in the current international guidelines, worldwide implantation rates 
have increased 20-fold over the last 15 years.9,14 Nevertheless, the utilization of ICD 
treatment does have a few serious drawbacks. Firstly, even when pursuing maximized 
patient safety, approximately 6% of ICD patients experience severe device-related adverse 
events.26 Furthermore, currently the most debated issue in the validation of ICD treatment 
is the relatively low occurrence of ventricular arrhythmia, causing the need for defibrillator 
backup.27 In the first trial on secondary prevention, ICD shocks occurred in over 60% of 
patients and follow-up studies clearly demonstrated the need for ICD treatment in this 
population.1,16 However, more recent large trials on the value of primary prevention ICD 
treatment demonstrate significantly lower incidences of appropriate device therapy ranging 
from 21% during 46 months follow-up in the Sudden Cardiac Death in Heart Failure Trial to 
35% during a mean 20 months follow-up in the MADIT-II.4,10 These data are comparable to 
a rate of 21% during a median 22 months follow-up, as observed in the current study and 
emphasis the relatively low actual need for defibrillator backup. This issue, in combination 
with the mentioned drawbacks, urges for baseline risk stratification in the population cur-
rently indicated for primary prevention ICD treatment. 
 18
Figure 2. Scorecard for risk of non-benefit from ICD treatment. By using patient’s 
characteristics, the risk for non-benefit can be determined as low (green), intermediate 
(yellow) or high (red). 
 
Abbreviations: LVEF, left ventricular ejection fraction; NYHA, New York Heart 
Association. 
HFST 8. 
Figure 1. Assessment of the infarct gray zone: Short-axis contrast-enhanced MRI of a 
patient with a previous myocardial infarction. 1A.Endocardial (red) and epicardial 
(green) borders were outlined m nually. Subsequently, the maximum signal intensity (SI) 
within the infarct region was determined. 1B.The infarct core was defined as myocardium 
with SI ≥ 50% of the maximum SI (red area). 1C.The infarct gray zone was defined as 
myocardium with SI ≥ 35% but with SI < 50% of the maximum SI (yellow area). 
Summation of the infarct core and infarct gray zone yielded the total infarct size (red plus 
yellow area).  
Figure 2. Scorecard for risk of non-benefit from ICD treatment. By using patient’s characteristics, the risk 
for non-benefit can be determined as low (green), intermediate (yellow) or high (red). 
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In recent literature, several subgroup analyses of the MADIT-II focused on the identification 
of patients who were most likely to receive appropriate device therapy. These analyses men-
tioned interim hospitalization for heart failure or a coronary artery event, no beta-blocker 
usage, current smoking, NYHA class >II, renal dysfunction, high body mass index and 
digitalis use as factors increasing the risk of ventricular arrhythmia during follow-up.20,28,29 
Interestingly, these baseline predictors for ICD therapy were similar to baseline variables as-
sociated with an increased risk for mortality.28,30 Consequently, the patients with the highest 
risk of receiving potentially life-saving appropriate device therapy have the worst prognosis, 
regardless of the implanted device. This paradox makes the findings in literature difficult 
to interpret. Therefore, a different approach to assess ICD efficacy was necessary. Koller 
and co-workers combined appropriate ICD therapy with all-cause mortality and defined 
non-benefit from ICD treatment as death prior to appropriate therapy, instead of focusing 
on patients with the lowest occurrence of ICD therapy. They demonstrated that usage of 
diuretics for heart failure – which was considered a surrogate of advanced heart failure – 
compared with nonuse was found to be the only significant predictor of non-benefit from 
ICD treatment. The current analysis demonstrated that besides advanced heart failure, a 
history of smoking, diabetes and higher age were also associated with non-benefit from ICD 
treatment. Differences between the study by Koller et al and the current analysis might be 
explained by the limited set of variables, smaller population size and heterogeneity (e.g. 
primary and secondary prevention ICD patients) of the study population assessed in the 
analysis of Koller and co-workers.23 
Goldenberg et al demonstrated in a risk analysis of MADIT-II that benefit from ICD treat-
ment is following a U-shaped pattern with evident benefit for patients with intermediate risk 
of all-cause mortality and little benefit in low and high-risk patients.31 This principle implies 
two non-benefiting groups at both ends of this efficacy curve. One group comprises patients 
with major comorbidities, in whom the risk of non-arrhythmic mortality exceeds the risk 
of arrhythmic (sudden) death. The other group consists of relatively healthy ICD patients 
who exhibit very low risk for life-threatening ventricular arrhythmia. It should be noted 
that, according to the observed risk factors, the current risk stratification identified the first 
mentioned group of non-benefit ICD patients with high risk of non-arrhythmic mortality. To 
identify the other group (i.e. with low-risk for ventricular arrhythmia) a different approach 
is desirable. Hallstrom and co-authors focused on predictors of recurrent arrhythmia in 
a subgroup analysis of the Antiarrhythmics versus Implantable Cardioverter Defibrillator 
Trial as secondary prevention of sudden cardiac death and identified, based on sextiles of 
the hazard distribution, a subgroup for which ICDs did not render survival advantage over 
amiodarone.22 Indeed, they reported on a ‘healthy’ subgroup, presenting with an isolated 
episode of ventricular fibrillation, few comorbidities and moderate preserved LVEF, which 
was not likely to benefit from ICD treatment over amiodarone. 





 1 Concisely, for further prospective research to refine the current selection criteria for ICD 
treatment of sudden cardiac death one should be aware of the U-shaped pattern of ICD 
efficacy.
Usage of risk model in clinical practice
As mentioned earlier, refinement of the current selection criteria for primary prevention 
patients with ischemic heart disease is essential. The current study provides a model to 
predict the individual risk for non-benefit, which may assist physicians in the decision-
making process whether or not to prophylactically implant an ICD. It is however important 
to realize that patients at high-risk for non-benefit do not per se receive no appropriate ICD 
therapy at all. Some of the parameters that were associated with high risk of non-benefit 
were interestingly also identified as predictors of all-cause mortality, sudden cardiac death 
or appropriate therapy, like advanced age, depressed ejection fraction and smoking.28,31,32 
This paradox could be explained with the short life-expectancy of this very sick group of 
patients. Consequently, even if an ICD terminates a life-threatening arrhythmia, non-benefit 
patients are still likely to die within a short period of time from other causes than sudden 
cardiac death. Thus, despite the fact that ICD therapy is not uncommon is this subset of 
patients, the survival advantage of prophylactic ICD implantation is limited. 
Limitations
This was a non-randomized prospective observational study, performed to predict the non-
benefit risk in primary prevention ICD patients with ischemic heart disease outside the 
setting of a clinical trial. Since patients were collected over a long period of time, evolving 
guidelines could have created a heterogeneous population. Additionally, the proposed risk 
score does not take clinician driven variables (medication) or follow-up acquired variables 
(hospitalizations, adverse events) in account since this could lead to a decrease in baseline 
applicability and reproducibility. Finally, the constructed risk score requires validation.
Conclusion
A significant number of primary prevention ICD patients with ischemic heart disease does 
not benefit from ICD treatment during long-term follow-up. The use of a baseline risk 
score can facilitate patient-tailored risk estimation of the non-benefit (death, prior to first 
appropriate ICD therapy).
Jan-Willem BW new.indd   118 29-07-10   13:30
119
















 1. A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients re-
suscitated from near-fatal ventricular arrhythmias. The Antiarrhythmics versus Implantable 
Defibrillators (AVID) Investigators. N Engl J Med. 1997;337:1576-1583.
 2. Connolly SJ, Gent M, Roberts RS, et al. Canadian implantable defibrillator study (CIDS) : a 
randomized trial of the implantable cardioverter defibrillator against amiodarone. Circulation. 
2000;101:1297-1302.
 3. Kuck KH, Cappato R, Siebels J, Ruppel R. Randomized comparison of antiarrhythmic drug 
therapy with implantable defibrillators in patients resuscitated from cardiac arrest : the Cardiac 
Arrest Study Hamburg (CASH). Circulation. 2000;102:748-754.
 4. Bardy GH, Lee KL, Mark DB, et al. Amiodarone or an implantable cardioverter-defibrillator for 
congestive heart failure. N Engl J Med. 2005;352:225-237.
 5. Kadish A, Dyer A, Daubert JP, et al. Prophylactic defibrillator implantation in patients with 
nonischemic dilated cardiomyopathy. N Engl J Med. 2004;350:2151-2158.
 6. Moss AJ, Hall WJ, Cannom DS, et al. Improved survival with an implanted defibrillator in 
patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic 
Defibrillator Implantation Trial Investigators. N Engl J Med. 1996;335:1933-1940.
 7. Moss AJ, Zareba W, Hall WJ, et al. Prophylactic implantation of a defibrillator in patients with 
myocardial infarction and reduced ejection fraction. N Engl J Med. 2002;346:877-883.
 8. Epstein AE, DiMarco JP, Ellenbogen KA, et al. ACC/AHA/HRS 2008 Guidelines for Device-Based 
Therapy of Cardiac Rhythm Abnormalities: a report of the American College of Cardiology/
American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise 
the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and 
Antiarrhythmia Devices) developed in collaboration with the American Association for Thoracic 
Surgery and Society of Thoracic Surgeons. J Am Coll Cardiol. 2008;51:e1-62.
 9. Maisel WH, Moynahan M, Zuckerman BD, et al. Pacemaker and ICD generator malfunctions: 
analysis of Food and Drug Administration annual reports. JAMA. 2006;295:1901-1906.
 10. Moss AJ, Greenberg H, Case RB, et al. Long-term clinical course of patients after termination of 
ventricular tachyarrhythmia by an implanted defibrillator. Circulation. 2004;110:3760-3765.
 11. Hlatky MA, Mark DB. The high cost of implantable defibrillators. Eur Heart J. 2007;28:388-
391.
 12. van Erven L, Schalij MJ. Troubleshooting implantable cardioverter-defibrillator related prob-
lems. Heart. 2008;94:649-660.
 13. Zipes DP, Camm AJ, Borggrefe M, et al. ACC/AHA/ESC 2006 Guidelines for Management of 
Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: a report of 
the American College of Cardiology/American Heart Association Task Force and the European 
Society of Cardiology Committee for Practice Guidelines (writing committee to develop Guide-
lines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden 
Cardiac Death): developed in collaboration with the European Heart Rhythm Association and 
the Heart Rhythm Society. Circulation. 2006;114:e385-e484.
 14. Epstein AE, DiMarco JP, Ellenbogen KA, et al. ACC/AHA/HRS 2008 Guidelines for Device-Based 
Therapy of Cardiac Rhythm Abnormalities: a report of the American College of Cardiology/
American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise 
the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and 






Antiarrhythmia Devices): developed in collaboration with the American Association for Thoracic 
Surgery and Society of Thoracic Surgeons. Circulation. 2008;117:e350-e408.
 15. van der Burg AE, Bax JJ, Boersma E, et al. Standardized screening and treatment of patients 
with life-threatening arrhythmias: the Leiden out-of-hospital cardiac arrest evaluation study. 
Heart Rhythm. 2004;1:51-57.
 16. Borleffs CJ, van Erven L, Schotman M, et al. Recurrence of ventricular arrhythmias in ischaemic 
secondary prevention implantable cardioverter defibrillator recipients: long-term follow-up of 
the Leiden out-of-hospital cardiac arrest study (LOHCAT). Eur Heart J. 2009;30:1621-1626.
 17. Levey AS, Coresh J, Balk E, et al. National Kidney Foundation practice guidelines for chronic 
kidney disease: evaluation, classification, and stratification. Ann Intern Med. 2003;139:137-
147.
 18. Moss AJ, Fadl Y, Zareba W, Cannom DS, Hall WJ. Survival benefit with an implanted defibrilla-
tor in relation to mortality risk in chronic coronary heart disease. Am J Cardiol. 2001;88:516-
520.
 19. Hunt SA, Abraham WT, Chin MH, et al. 2009 focused update incorporated into the ACC/
AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report 
of the American College of Cardiology Foundation/American Heart Association Task Force on 
Practice Guidelines: developed in collaboration with the International Society for Heart and 
Lung Transplantation. Circulation. 2009;119:e391-e479.
 20. Goldenberg I, Moss AJ, McNitt S, et al. Cigarette smoking and the risk of supraventricular 
and ventricular tachyarrhythmias in high-risk cardiac patients with implantable cardioverter 
defibrillators. J Cardiovasc Electrophysiol. 2006;17:931-936.
 21. Pietrasik G, Goldenberg I, McNitt S, Moss AJ, Zareba W. Obesity as a risk factor for sustained 
ventricular tachyarrhythmias in MADIT II patients. J Cardiovasc Electrophysiol. 2007;18:181-
184.
 22. Hallstrom AP, McAnulty JH, Wilkoff BL, et al. Patients at lower risk of arrhythmia recurrence: 
a subgroup in whom implantable defibrillators may not offer benefit. Antiarrhythmics Versus 
Implantable Defibrillator (AVID) Trial Investigators. J Am Coll Cardiol. 2001;37:1093-1099.
 23. Koller MT, Schaer B, Wolbers M, Sticherling C, Bucher HC, Osswald S. Death without prior 
appropriate implantable cardioverter-defibrillator therapy: a competing risk study. Circulation. 
2008;117:1918-1926.
 24. Donders AR, van der Heijden GJ, Stijnen T, Moons KG. Review: a gentle introduction to imputa-
tion of missing values. J Clin Epidemiol. 2006;59:1087-1091.
 25. Steyerberg EW, Harrell FE, Jr., Borsboom GJ, Eijkemans MJ, Vergouwe Y, Habbema JD. Internal 
validation of predictive models: efficiency of some procedures for logistic regression analysis. J 
Clin Epidemiol. 2001;54:774-781.
 26. Rosenqvist M, Beyer T, Block M, den Dulk K, Minten J, Lindemans F. Adverse events with 
transvenous implantable cardioverter-defibrillators: a prospective multicenter study. European 
7219 Jewel ICD investigators. Circulation. 1998;98:663-670.
 27. Tung R, Zimetbaum P, Josephson ME. A critical appraisal of implantable cardioverter-defibrillator 
therapy for the prevention of sudden cardiac death. J Am Coll Cardiol. 2008;52:1111-1121.
 28. Singh JP, Hall WJ, McNitt S, et al. Factors influencing appropriate firing of the implanted 
defibrillator for ventricular tachycardia/fibrillation: findings from the Multicenter Automatic 
Defibrillator Implantation Trial II (MADIT-II). J Am Coll Cardiol. 2005;46:1712-1720.
Jan-Willem BW new.indd   120 29-07-10   13:30
121
















 29. Brodine WN, Tung RT, Lee JK, et al. Effects of beta-blockers on implantable cardioverter defibril-
lator therapy and survival in the patients with ischemic cardiomyopathy (from the Multicenter 
Automatic Defibrillator Implantation Trial-II). Am J Cardiol. 2005;96:691-695.
 30. Cygankiewicz I, Gillespie J, Zareba W, et al. Predictors of long-term mortality in Multicenter 
Automatic Defibrillator Implantation Trial II (MADIT II) patients with implantable cardioverter-
defibrillators. Heart Rhythm. 2009;6:468-473.
 31. Goldenberg I, Vyas AK, Hall WJ, et al. Risk stratification for primary implantation of a cardio-
verter-defibrillator in patients with ischemic left ventricular dysfunction. J Am Coll Cardiol. 
2008;51:288-296.
 32. Levy WC, Lee KL, Hellkamp AS, et al. Maximizing survival benefit with primary preven-
tion implantable cardioverter-defibrillator therapy in a heart failure population. Circulation. 
2009;120:835-842.
Jan-Willem BW new.indd   121 29-07-10   13:30
Jan-Willem BW new.indd   122 29-07-10   13:30
Part II
New parameters in risk 
stratification
Jan-Willem BW new.indd   123 29-07-10   13:30
Jan-Willem BW new.indd   124 29-07-10   13:30
Chapter 8
Infarct Tissue Heterogeneity 
Assessed with Contrast-
Enhanced Magnetic 
Resonance Imaging Predicts 
Spontaneous Ventricular 




Stijntje D Roes SD, MD1, C Jan Willem Borleffs, MD2, 
Rob J. van der Geest, MSc3, Jos JM Westenberg, PhD1, 
Nina Ajmone Marsan, MDb, Theodorus AM Kaandorp, 
MD1, Johan HC Reiber, PhD3, Katja Zeppenfeld, MD2, 
Hildo J Lamb, MD1, Albert de Roos, MD1, Martin J. 
Schalij, MD2, Jeroen J. Bax, MD2
1Department of Radiology, 2Department of Cardiology, 
3Division of Image Processing, Leiden University Medical 
Center, Leiden, The Netherlands
Circ Cardiovasc Imaging 2009; 2:183-190







Background: The relation between infarct tissue heterogeneity on contrast-enhanced mag-
netic resonance imaging (MRI) and the occurrence of spontaneous ventricular arrhythmia 
(VA) (or sudden cardiac death (SCD)) is unknown. Therefore, the study purpose was to evalu-
ate the predictive value of infarct tissue heterogeneity assessed with contrast-enhanced MRI 
on the occurrence of spontaneous VA with subsequent implantable cardioverter-defibrillator 
(ICD) therapy (as surrogate of SCD) in patients with previous myocardial infarction (MI).
Methods and results: Ninety-one patients (65±11 years) with previous MI scheduled 
for ICD implantation underwent cine-MRI to evaluate left ventricular (LV) function and 
volumes and contrast-enhanced MRI for characterization of scar tissue (infarct gray zone as 
measure of infarct tissue heterogeneity, infarct core and total infarct size). Appropriate ICD 
therapy was documented in 18 patients (20%) during a median follow-up of 8.5 months 
(interquartile range 2.1-20.3). Multivariable Cox proportional hazards analysis revealed 
that infarct gray zone was the strongest predictor of the occurrence of spontaneous VA with 
subsequent ICD therapy (hazard ratio 1.49/10g, confidence interval 1.01-2.20, chi-square 
4.0, p=0.04). 
Conclusions: Infarct tissue heterogeneity on contrast-enhanced MRI is the strongest predic-
tor of spontaneous VA with subsequent ICD therapy (as surrogate of SCD) among other 
clinical and MRI variables e.g. total infarct size, LV function and volumes, in patients with 
previous MI. 












Sudden cardiac death (SCD) is a common cause of death in developed countries and 
coronary artery disease (CAD) is the most frequent underlying disease.1  Implantable 
cardioverter-defibrillator (ICD) implantation is an established therapy in patients with a 
history of life threatening ventricular arrhythmia (VA).2 The effect of ICD implantation on 
survival in patients without a history of life threatening VA, but who are at risk for SCD, has 
been evaluated by several important clinical trials.3-5 The second Multicenter Automated 
Defibrillator Implantation Trial (MADIT II) demonstrated that prophylactic ICD implantation 
was associated with improved survival in patients with previous myocardial infarction (MI) 
and left ventricular (LV) dysfunction (LV ejection fraction (LVEF) ≤30%) without the require-
ment for spontaneous or inducible VA.4 Subsequently, the Sudden Cardiac Death in Heart 
Failure Trial (SCD-HeFT) demonstrated that ICD implantation reduced mortality in patients 
with evidence of CAD on coronary angiography (CAG) or previous MI,  LV dysfunction (LVEF 
≤35%), and New York Heart Association (NYHA) class II and III.5 These studies resulted in 
a class I indication for prophylactic ICD implantation in patients with prior MI, LVEF ≤35% 
and NYHA class II or III and in patients with prior MI, LVEF ≤30% and NYHA class 1.2
However, post-hoc analysis of the MADIT II study population showed that only 35% of 
the patients that received an ICD developed VA requiring ICD therapy, during 3-year follow-
up.6 Accordingly, there is a need for refinement of selection criteria for ICD implantation.   
Although the exact mechanism underlying lethal VA is not clear, it has been demonstrated 
that scar tissue may serve as a substrate for these arrhythmias.1, 7 Contrast-enhanced 
magnetic resonance imaging (MRI) is a reliable non-invasive technique enabling accurate 
assessment of scar tissue.8 Bello et al. reported that infarct size on contrast-enhanced 
MRI was superior to LVEF for identification of patients with inducible monomorphic 
ventricular tachycardia (VT) during programmed ventricular stimulation (PVS).9 Yan et al. 
demonstrated that infarct tissue heterogeneity characterized by contrast-enhanced MRI 
is a powerful predictor of mortality in patients after MI.10 Subsequently, Schmidt et al. 
showed that infarct tissue heterogeneity on contrast-enhanced MRI was the only significant 
predictor of inducibility of sustained monomorphic VT during PVS or device testing.11 The 
results presented in these studies suggest that infarct tissue heterogeneity on contrast-
enhanced MRI may identify patients at risk for SCD and consequently enable superior risk 
stratification for ICD implantation among patients with prior MI compared to conventional 
variables as LVEF and NYHA class. 
However, inducibility of monomorphic VT during PVS does not completely predict the 
occurrence of spontaneous VA in physiological conditions (or SCD). 
No studies have reported yet on the predictive value of infarct tissue heterogeneity on 
contrast-enhanced MRI on the occurrence of spontaneous VA in patients with ischemic car-
diomyopathy. Accordingly, the purpose of this study was to evaluate patients with ischemic 






cardiomyopathy who underwent contrast-enhanced MRI before ICD implantation and to 
assess the predictive value of infarct tissue heterogeneity on the occurrence of spontaneous 
VA with subsequent ICD therapy (as surrogate of SCD).
Methods
Study population and protocol
The study was conducted at the Leiden University Medical Center, Leiden, the Netherlands. 
The study population consisted of 91 consecutive patients with ischemic cardiomyopathy, 
who were referred for cardiac MRI to evaluate cardiac function and extent of scar tissue for 
clinical reasons and who were scheduled for ICD implantation. Patients received an ICD as 
primary or secondary preventive therapy. Survivors of life-threatening VA were evaluated 
according to a standardized protocol12 and subsequent ICD implantation was considered 
a secondary preventive therapy. In patients with poor LV function, without a history of life 
threatening VA, ICD implantation was performed as primary preventive therapy.13 Patients 
eligible for cardiac resynchronization therapy (CRT) according to previously described 
criteria received a combined CRT-ICD device.14 
Before ICD implantation, clinical characteristics were registered and patients underwent 
an MRI examination consisting of a cine MRI to evaluate LV function, LV volumes and 
LV mass and contrast-enhanced MRI for characterization of scar tissue (infarct gray zone 
as measure of infarct tissue heterogeneity, infarct core and total infarct size). Follow-up 
started at ICD implantation and the occurrence of spontaneous VA with subsequent ICD 
therapy (e.g. appropriate ICD therapy) and mortality were documented. Subsequently, the 
clinical characteristics and MRI variables were related to appropriate ICD therapy (primary 
endpoint) and the composite of appropriate ICD therapy or cardiac mortality (secondary 
endpoint).
Magnetic Resonance Imaging: data acquisition
A 1.5-T Gyroscan ACS-NT/Intera MRI scanner (Philips Medical Systems, Best, The Neth-
erlands) equipped with powertrack 6000 gradients and 5-element cardiac synergy coil 
was used. Patients were positioned in the supine position. Images were acquired during 
breath-holds of approximately 15 seconds using vector electrocardiographic gating.
The heart was imaged from apex to base,15 with 10-12 imaging levels (dependent on 
heart size, one slice per breath-hold) in short-axis view using a balanced turbo-field echo 
sequence with parallel imaging (SENSE, acceleration factor 2). Typical parameters were 
a field of view (FOV) 400×320mm2, matrix  256×206 pixels, slice thickness 10mm, no 
slice gap, flip angle (α) 35°, time to echo (TE) 1.67ms, and time to repeat (TR) 3.3ms. 
Temporal resolution was 25-39 ms. 











Contrast-enhanced images were acquired approximately 15 minutes after bolus injec-
tion of gadolinium diethylenetriamine penta-acetic acid (Magnevist, Schering/Berlin, Ger-
many;0.15 mmol/kg) with an inversion-recovery 3-dimensional turbo-field echo sequence 
with parallel imaging (SENSE, acceleration factor 2). Inversion time was determined with 
real-time plan scan in order to null normal myocardial signal. The heart was imaged in 
one breath-hold with 20-24 imaging levels (dependent on heart-size) in short-axis view. 
Signal outside the field-of-view was suppressed (using two saturation slabs) to avoid fold-
over artifacts. Typical parameters were FOV 400×400mm2, matrix 256×206 pixels, slice 
thickness 5mm, α 15°, TE 1.06ms, and TR 3.7ms.
Magnetic Resonance Imaging: data analysis
Data analysis was performed with previously validated software (MASS, research software 
developed at our institution). Endocardial and epicardial borders were outlined manually 
on short-axis cine images. Papillary muscles were regarded as part of the ventricular cavity, 
and epicardial fat was excluded. LV end-systolic (ESV) and LV end-diastolic volume (EDV) 
and LV end-diastolic mass (LV mass) were computed. Subsequently, ESV was subtracted 
from EDV and LV ejection fraction (EF) was calculated.
Contrast-enhanced images were analyzed to calculate the size of the infarct core, infarct 
gray zone (as measure of infarct tissue heterogeneity) and total infarct size (infarct core 
plus infarct gray zone).  First, endocardial and epicardial borders were outlined manually on 
the short-axis contrast-enhanced images (Figure 1A). Subsequently, the maximum signal 
intensity (SI) within the infarct region in the study was determined. The infarct core was 
defined as myocardium with SI≥50% of the maximum SI (red area Figure 1B).11 The infarct 
gray zone was defined as myocardium with SI≥35% but with SI<50% of the maximum SI 
(yellow area Figure 1C). Summation of the infarct core and infarct gray zone yielded the 
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Figure 2.Kaplan-Meier curve analysis showing the difference in appropriate ICD therapy 
when patients are stratified according the median value of infarct gray zone (16.7g). 
Fifteen patients (33%) with a large extent of infarct gray zone (infarct gray zone>16.7 g) 
received appropriate therapy compared to only 3 patients (6.5%) with a small extent of 
infarct gray zone (infarct gray zone≤16.7 g). 
 
 
Figure 1. Assessment of the infarct gray zone: Short-axis contrast-enhanced MRI of a patient with a 
previous myocardial infarction. 1A.Endocardial (red) and epicardial (green) borders were outlined manu-
ally. Subsequently, the maximum signal intensity (SI) within the infarct region was determined. 1B.The 
infarct core was defined as myocardium with SI ≥ 50% of the maximum SI (red area). 1C.The infarct gray 
zone was defined as myocardium with SI ≥ 35% but with SI < 50% of the maximum SI (yellow area). 
Summation of the infarct core and infarct gray zone yielded the total infarct size (red plus yellow area). 






total infarct size. In each patient, the infarct core, infarct gray zone and total infarct size 
were expressed in grams of myocardium.    
Infarct gray zone measurements were repeated in 18 patients by the same observer and 
by a second observer to assess intra- and inter-observer agreement. 
ICD devices 
Patients received a CRT-ICD device (Contak, Contak renewal, Cognis, Boston Scientific 
(Natick, United States [formerly Guidant Corp.]);Lumax, Biotronik (Berlin, Germany); In-
Sync III and InSync Sentry, Medtronic Inc. (Minneapolis, United States); Epic, Atlas or Atlas 
II, St. Jude Medical (St. Paul, United States)), a dual chamber ICD (Lumax, Biotronik; Vital-
ity 2, Teligen, Boston Scientific; Entrust, Marquis DR, Medtronic Inc.) or a single chamber 
ICD (Vitality 2, Ventak Mini,Boston Scientific). 
Follow-up and events
Follow-up was performed by device interrogation, scheduled every three-six months and 
chart review. The median follow-up duration was 8.5 months (interquartile range 2.1-
20.3).  Appropriate ICD therapy, the primary endpoint, was defined as anti-tachycardia 
pacing (ATP) and/or shock in response to VT or ventricular fibrillation (VF). ICD therapy was 
classified as inappropriate when triggered by sinus or supraventricular tachycardia, T-wave 
oversensing, or electrode dysfunction. Furthermore, total mortality was reported, which 
was further classified as cardiac and non-cardiac mortality. Cardiac mortality included 
death caused by end-stage heart failure, acute MI or SCD. The composite of appropriate 
ICD therapy or cardiac mortality was regarded as the secondary endpoint.
Statistical analysis
Continuous variables are presented as means±standard deviation (SD) and categorical data 
are summarized as frequencies and percentages. Differences in baseline characteristics 
between patients who reached the primary endpoint and those who did not were analyzed 
using the independent samples t-test or Fisher’s exact tests, as appropriate.
The a-priori aim of this study was to evaluate the association between infarct tissue 
heterogeneity and the primary endpoint (appropriate ICD therapy) and secondary endpoint 
(composite of appropriate ICD therapy or cardiac mortality) during follow-up. Univariable 
and multivariable Cox proportional hazards regression models were constructed to study 
the relation between infarct tissue heterogeneity and the primary and secondary endpoint. 
Adjusted hazard ratios were obtained after adjustment for potential confounders.Only 
variables that appeared to be associated with the primary or secondary endpoint at the 
p<0.10 level in univariable analysis were included since we had to limit the number of 
covariables because of the number of events (primary endpoint:LVEF, total infarct size and 
infarct gray zone; secondary endpoint:extent of CAD, LVEF, total infarct size and infarct gray 











zone). Total infarct size and infarct gray zone could however not be included simultaneously 
in one multivariable Cox proportional hazards regression model, since these variables were 
strongly interrelated (Pearson’s correlation 0.8, p<0.001). Therefore, infarct core instead 
of total infarct size was included in the multivariable models. Unadjusted and adjusted 
hazard ratios (HR) with their corresponding 95% confidence intervals (CI) are reported. 
To check the proportional hazard assumption (i.e.,that the hazard ratio for 2 subjects 
with fixed predictors is constant over time) log(−log[survival probability]) for different 
categories was plotted against time to ensure that the curves were reasonably parallel. In 
general, all proportionality assumptions were appropriate. 
Since infarct gray zone extent was significantly related with the primary endpoint, the 
study population was divided into 2 groups, based on the observed median value of the 
infarct gray zone, and the event-rate of both cohorts was further analyzed by the method of 
Kaplan-Meier. Difference in event-rate over time was evaluated by a log-rank test. Further-
more, the negative predictive value of a small extent of infarct gray zone (≤ median value 
of 16.7 g) was calculated.
Intra- and inter-observer agreement for infarct gray zone measurements was calculated 
using the intraclass correlation coefficient (ICC) for absolute agreement.
All tests were 2-sided and p<0.05 was considered statistically significant.   T h e 
authors had full access to the data and take responsibility for its integrity. All authors have 
read and agreed to the manuscript as written.
Results
Study population
The baseline characteristics are listed in Table 1. The mean age of the study population was 
65±11 years. All patients had a previous MI, of which 9 patients (18%) had a clinically 
unrecognized MI. Ten patients (11%) received an ICD as secondary preventive therapy; the 
remaining 81 patients (89%) as primary preventive therapy. A combined CRT-ICD device 
was implanted in 73 patients (80%). Sixteen patients (18%) received a dual chamber ICD 
and 2 patients (2%) a single chamber ICD. 
Follow-up and events
Appropriate ICD therapy (primary endpoint) was documented in 18 patients (20%). The 
first VA episode was terminated by ATP in 12 patients (67%) and 6 patients (33%) received 
ATP directly followed by shock or shock only. The total mortality in the study population 
was 16% (15 patients). Non-cardiac death was reported in 4 patients (4%). Cardiac death 
occurred in 11 patients (12%):10 patients (11%) died of end-stage heart failure and 1 
patient (1%) died after recurrent acute MI. Three patients (3%) who died of cardiac causes 











ICD therapy          
(n=73)
Appropriate 
ICD therapy    
(n=18)
p-value
Age,yrs 65±11 64±11 65±11 0.9
Male gender 74(81) 59(81) 15(83) 1.0
Indication ICD implantation
      Secondary prevention









     Non-sustained ventricular tachycardia
     Sustained ventricular tachycardia 











Cardiac resynchronization therapy 73(80) 57(78) 16(89) 0.5
LBBB 31(45) 24(33) 7(39) 0.8
QRS duration(ms) 130±33 142±38 127±31 0.08
Previous PCI 40(44) 34(47) 6(33) 0.4
Previous CABG 44(48) 36(49) 8(44) 0.8
Extent of CAD 
     1-vessel 
     2-vessel 











Diabetes 23(25) 19(26) 4(22) 1.0
Hypertension 36(40) 29(40) 7(39) 1.0
Hypercholesterolemia 67(74) 54(74) 13(72) 1.0
Smoking 44(48) 33(45) 11(61) 0.3
NYHA functional class
    
2.5±0.7 2.5±0.7 2.5±0.8 0.9
Medication 
     β-blockade (including Sotalol)
     Amiodarone
     Calcium channel blocker
     ACE inhibitor/ATII antagonist
     Oral anticoagulant
     Statin
     Nitrate

































Continuous data are expressed mean±standard deviation, categorical data as number of patients (%).
*p-value of Fisher’s exact test based on 2x2 tables after combining non-sustained ventricular tachycar-
dia, sustained ventricular tachycardia, ventricular fibrillation
 †p-value of Fisher’s exact test based on 2x2 tables after combining 2-and 3-vessel disease.
ACE:angiotensin converting enzyme, ATII:angiotensin II, CABG:coronary artery bypass grafting, 
CAD:coronary artery disease, ICD:implantable cardioverter-defibrillator, PCI: percutanous coronary inter-
vention, LBBB:left bundle branch block, NYHA:New York Heart Association











received appropriate ICD therapy (>1 month) before death. Accordingly, the composite 
secondary endpoint of appropriate ICD therapy or cardiac mortality occurred in 26 patients 
(29%).
MRI variables
MRI findings are listed in Table 2. Mean LVEF in the entire study population was 28±9%. A 
non-significant difference in LVEF was reported between patients who received appropriate 
ICD therapy compared to patients who did not receive appropriate ICD therapy (25±7 vs. 
29±9%, p=0.06). No difference in LV EDV, LV ESV and LV mass was observed between 
the two groups.
All patients had evidence of scar tissue on contrast-enhanced MRI. The mean total infarct 
size in the entire study population was 46±25g. The mean infarct core was 26±17g and 
the mean infarct gray zone was 20±13g. The total infarct size (58±29g vs. 43±23g, 
p=0.02) and infarct gray zone (28±16g vs. 18±11g, p=0.002) were significantly larger 
in patients who received appropriate ICD therapy compared to those who did not receive 
appropriate ICD therapy.
The ICC for infarct gray zone measurements was 0.97 and 0.91 for respectively intra- 
and inter-observer agreement (p<0.001).
Predictors of appropriate ICD therapy
As demonstrated in Table 3 and 4, the infarct gray zone was the only significant predictor of 
appropriate ICD therapy in univariable analysis. Univariable analysis yielded similar results 
when we focused on patients who received an ICD as primary preventive therapy (HR 
1.59/10g, CI 1.15-2.20, chi-square 7.8, p=0.005). In the total study population, after 
adjustment for LVEF and infarct core (See Methods section), the infarct gray zone remained 





ICD therapy       
(n=73)
Appropriate 
ICD therapy    
(n=18)
p-value
LVEF (%) 28±9 29±9 25±7 0.06
LV EDV (ml) 333±112 331±117 339±95 0.8
LV ESV (ml) 245±107 241±110 259±94 0.5
LV mass (g) 148±40 148±41 149±38 0.9
Total infarct (Infarct core+gray zone)(g) 46±25 43±23 58±29 0.02
Infarct core (g) 26±17 25±16 30±17 0.2
Infarct gray zone (g) 20±13 18±11 28±16 0.002 
Data are expressed as mean±standard deviation
LV:left ventricular, LV EDV:LV end-diastolic volume, LV ESV:LV end-systolic volume, LVEF:LV ejection 
fraction






the only significant predictor of appropriate ICD therapy (Table 5). Total infarct size was 
not a significant predictor of appropriate ICD therapy when entered simultaneously with 






Age 0.94/10yr 0.61-1.46 0.1 0.8
Male gender
Indication ICD implantation









Previous ventricular arrhythmia*    1.89 0.66-5.35 1.4 0.2
Cardiac resynchronization therapy 0.63 0.17-2.31 0.5 0.5
LBBB 0.93 0.36-2.41 0.0 0.9
QRS duration (ms) 1.00 0.99-1.02 0.4 0.5
Previous PCI 0.69 0.26-1.84 0.5 0.5
Previous CABG 0.91 0.36-2.30 0.0 0.8
Extent of CAD†
     2-vessel 









Diabetes 0.82 0.27-2.49 0.1 0.7
Hypertension 0.83 0.32-2.18 0.1 0.7
Hypercholesterolemia 1.03 0.37-2.89 0.0 1.0
Smoking 2.10 0.80-5.55 2.3 0.1
NYHA functional class 0.76 0.37-1.56 0.6 0.5
Medication 
   β-blockade (including Sotalol)
   Amiodarone
   Calcium channel blocker
ACE inhibitor/ATII antagonist
   Oral anticoagulant
   Statin
   Nitrate

































*Non-sustained ventricular tachycardia, sustained ventricular tachycardia and ventricular fibrillation 
combined, †Increased risk of event as compared to 1-vessel disease.
ACE:angiotensin converting enzyme, ATII:angiotensin II, CABG:coronary artery bypass grafting, 
CAD:coronary artery disease, ICD:implantable cardioverter-defibrillator, PCI:percutanous coronary inter-
vention, LBBB:left bundle branch block. 











LVEF in one multivariable model (HR 1.07/10g, CI 0.89-1.29, chi-square 0.6, p=0.4, 
HR 0.62/10%, CI 0.28-1.41, chi-square 1.3, p=0.3 for resp. total infarct size and LVEF).
The median value of infarct gray zone on contrast-enhanced MRI (16.7g) was used to 
separate patients with a large extent of infarct gray zone (infarct gray zone>16.7g, n=45) 
from those with a small extent of infarct gray zone (infarct gray zone≤16.7g, n=46). Fifteen 
patients (33%) with a large extent of infarct gray zone received appropriate ICD therapy 
compared to only 3 patients (7%) with a small extent of infarct gray zone (p=0.003,Figure 
2).
The negative predictive value of a small extent of infarct gray zone (infarct gray zone 
≤16.7g) was 93% for the entire study population and 95% if only patients who received 
an ICD as primary preventive therapy (n=81) were included.
Predictors of appropriate ICD therapy or cardiac mortality
In univariable analysis, LVEF (HR 0.56/10%, CI 0.32-0.96, chi-square 4.4, p=0.04) total 
infarct size (HR 1.15/10g, CI 1.03-1.29, chi-square 5.7, p=0.02) and the infarct gray 
zone (HR 1.56/10g, CI 1.19-2.06, chi-square 10.1, p=0.001) were significant predictors 
of the secondary endpoint. A non-significant association was observed between the extent 
of CAD and the secondary endpoint (HR 3.99, CI 0.86-18.55, chi-square 3.1, p=0.08, HR 
2.62, CI 0.59-11.57, chi-square 1.6, p=0.2, resp.2-and 3-vessel compared to 1-vessel 
Table 4.Univariable analysis of MRI variables for prediction of appropriate ICD therapy 
Hazard Ratio 95%Confidence 
Interval
Chi-square p-value
LVEF 0.53/10% 0.27-1.04 3.4 0.06
LV EDV 1.00/10ml 0.95-1.04 0.0 0.9
LV ESV 1.00/10ml 0.97-1.05 0.2 0.7
LV mass 0.97/10g 0.86-1.11 0.2 0.7
Total infarct size (Infarct core+gray zone) 1.15/10g 0.99-1.33 3.4 0.06
Infarct core 1.10/10g 0.87-1.37 0.6 0.4
Infarct gray zone 1.56/10g 1.14-2.14 7.6 0.006
LV:left ventricular, LV EDV:LV end-diastolic volume, LV ESV:LV end-systolic volume, LVEF:LV ejection 
fraction 





















LVEF:left ventricular ejection fraction






disease). In multivariable analysis including the extent of CAD, LVEF, infarct gray zone and 
infarct core (see Methods section), the infarct gray zone was the only significant predictor 
of the composite secondary endpoint of appropriate ICD therapy or cardiac mortality (HR 
1.47/10g, CI 1.04-2.08, chi-square 4.7, p=0.03). 
Total infarct size was not a significant predictor of appropriate ICD therapy or cardiac 
death when entered simultaneously with extent of CAD and LVEF in one multivariable 
model (CAD: HR 2.91, CI 0.60-14.02, chi-square 1.8, p=0.2, HR 2.26, CI 0.51-10.11, 
chi-square 1.1, p=0.3, resp.2-and 3-vessel compared to 1-vessel disease, total infarct 
size: HR 1.08/10g, CI 0.93-1.26, chi-square 1.0, p=0.3, LVEF: HR 0.74/10%, CI 0.38-
1.42, chi-square 0.8, p=0.4).
Discussion
The main finding in this study is that infarct tissue heterogeneity assessed with contrast-
enhanced MRI is the strongest predictor of spontaneous VA with subsequent ICD therapy 
(as surrogate of SCD) among other clinical and MRI variables e.g. total infarct size, LV 
function and volumes, in patients with previous MI. Furthermore, infarct tissue heterogene-
ity is the strongest predictor of the composite endpoint of spontaneous VA with subsequent 
ICD therapy (as surrogate of SCD) and cardiac mortality in these patients.
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Figure 2.Kaplan-Meier curve analysis showing the difference in appropriate ICD therapy 
when patients are stratified according the median value of infarct gray zone (16.7g). 
Fifteen patients (33%) with a large extent of infarct gray zone (infarct gray zone>16.7 g) 
received appropriate therapy compared to only 3 patients (6.5%) with a small extent of 
infarct gray zone (infarct gray zone≤16.7 g). 
 
 
Figure 2.Kaplan-Meier curve analysis showing the difference in appropriate ICD therapy when patients 
are stratified according the median value of infarct gray zone (16.7g). Fifteen patients (33%) with a large 
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The annual incidence of sudden arrhythmic deaths has been estimated between 184,000 
and 462,000 in the United States.16 Although measures including early access to medical 
care, early cardiopulmonary resuscitation and early defibrillation have improved survival, 
overall mortality from cardiac arrest remains high. 16 During the last decades, ICD devices 
have been developed and ICD implantation is now an established secondary preventive 
therapy in patients with a history of life threatening VA.(2) In addition, the MADIT studies 
and SCD-HeFT demonstrated improved survival of patients with previous MI and depressed 
LVEF, but without a history of life threatening VA.3-5 
However, post-hoc analysis of the MADIT II study revealed that only 35% of the patients 
received appropriate therapy at 3 years after implantation.6 Furthermore, ICD therapy is 
costly and the incidence of inappropriate shocks associated with an adverse effect on 
the patient’s quality of life ranges between 10% to 35%.17-19 Accordingly, refinement of 
selection criteria for ICD implantation is necessary. 
The vast majority of patients with cardiac arrest is diagnosed with an underlying struc-
tural heart disease; predominantly CAD1 and VT and VF are the most common underlying 
arrhythmias accounting for 70% of the cases.20 In patients with previous MI, scar tissue 
may serve as a substrate for VA, most likely through areas of slow conduction due to 
intermingling of viable myocytes and fibrous tissue, leading to reentrant tachycardia.21-23 
Contrast-enhanced MRI is a valuable technique that allows for accurate delineation of 
scar tissue in patients with CAD.8. Bello et al. studied patients with chronic MI using con-
trast-enhanced MRI and demonstrated that infarct size identified patients with a substrate 
for inducible VT during electrophysiological examination.9 A more recent study by Ashigaka 
et al. evaluated the relation between 3D scar geometry assessed with contrast-enhanced 
MRI and VT reentry circuits in a swine model with chronic MI. MRI revealed scar with 
spatially complex structures containing a mixture of viable and necrotic tissue, particularly 
at the isthmus, that serve as a substrate for multiple VT morphologyWhile most previous 
contrast-enhanced MRI studies used a binary approach for assessment of scar tissue by 
categorizing myocardium into scar tissue versus normal (remote) myocardium,8, 25 two 
recent studies have used a more differentiated method for analysis of contrast-enhanced 
images.10, 11 These studies assessed infarct tissue heterogeneity by quantifying myocardium 
with an intermediate SI (the peri-infarct border zone or gray zone), most likely reflecting an 
admixture of scar tissue and viable myocardial strands.10, 11 Yan et al. demonstrated that 
infarct tissue heterogeneity characterized by contrast-enhanced MRI is a powerful predictor 
of mortality in patients after MI.10 Subsequently, Schmidt et al. showed that infarct tissue 
heterogeneity on contrast-enhanced MRI was the only significant predictor of inducibility of 
sustained monomorphic VT during PVS or device testing.11
However, inducibility of VT during PVS or device testing does not completely predict 
occurrence of spontaneous VA.26 Studying patients who have received an ICD though, 






enables unraveling the relation between infarct tissue heterogeneity and the occurrence 
spontaneous VA (as surrogate of SCD). 
Several studies evaluated the prognostic value of infarct size and/or infarct tissue het-
erogeneity on contrast-enhanced MRI in patients with ischemic cardiomyopathy.9-11, 27-32 
The prognostic value of scar tissue on contrast-enhanced MRI has also been recognized in 
patients with non-ischemic cardiomyopathy; however, these studies have not evaluated in-
farct tissue heterogeneity.33-35 Accordingly, until now only 2 studies evaluated infarct tissue 
heterogeneity and this is the first study that evaluated the predictive value of infarct tissue 
heterogeneity assessed with contrast-enhanced MRI on the occurrence of spontaneous VA, 
which can be regarded as a substitute for SCD. 
The two previous studies evaluating infarct tissue heterogeneity used different criteria 
to discriminate the infarct gray zone from the infarct core. Yan et al. defined the infarct 
core as areas with SI  > mean SI plus 3 SD of remote myocardium and areas with SI 
between mean SI plus 2 SD and 3 SD was recognized as the infarct gray zone.10 Schmidt 
et al.however, used a simplified version of the full-width half-maximum method and defined 
myocardium with SI >50% of maximal SI in the hyperenhanced areas as the infarct core 
and the infarct gray zone as myocardium with SI>peak SI of remote myocardium but 
<50% of maximum SI.11 The thresholds used by Yan et al. were not applicable in our 
dataset, since they resulted in a large overestimation of both infarct core and infarct gray 
zone.10 Accordingly, the definition for infarct core described by Schmidt et al. was applied 
in the current study. However, using the peak SI of remote myocardium to define infarct 
gray zone might be unfavorable, since this approach may be susceptible to suboptimal 
signal suppression of remote myocardium (T1 nulling) and image artifacts, both affecting 
the SI of the remote myocardium. Furthermore, the presence of (minimal) fibrosis in the 
area indicated as remote myocardium cannot be completely excluded. Therefore, and to 
minimize the variability due to user-interaction, the definitions used in the current study are 
based exclusively on the maximum SI in the hyper enhanced infarct area. The thresholds 
used to identify the infarct gray zone and infarct core in the current study (35% versus 
50% of maximum SI) were selected in line with the study of Yan et al. in which the ratio 
of the threshold SI  for infarct gray zone versus infarct core was also 2:3 (assuming good 
signal suppression of remote myocardium).10 Nonetheless, as previously emphasized,36 
these novel methods for assessment of infarct tissue heterogeneity should be evaluated 
in additional studies and experimental studies comparing the extent of infarct gray zone 
assessed with contrast-enhanced MRI and the histological extent of heterogeneous myocar-
dium containing both fibrosis and viable myocardium are highly desirable. 
An important limitation of this study is the relatively small sample size and the limited 
follow-up duration; therefore the present conclusion requires confirmation in larger study 
groups with longer follow-up duration. In addition, larger studies may help to identify the 
best definition for characterization of the infarct gray zone.











Furthermore, in the present study an inversion recovery 3D technique was used, whereas 
an inversion recovery 2D technique was applied in the previous studies that measured 
infarct heterogeneity, which resulted in a differently defined infarct gray zone.10, 11 Ac-
cordingly, comparative studies evaluating the relative value of the different techniques for 
assessment of infarct tissue heterogeneity and its predictive value for the occurrence of VA 
are needed. 
Conclusions
Infarct tissue heterogeneity on contrast-enhanced MRI is the strongest predictor of spon-
taneous VA with subsequent ICD therapy (as surrogate of SCD) among other clinical and 
MRI variables e.g. total infarct size, LV function and volumes, in patients with previous MI. 
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Objectives To evaluate whether 123-iodine metaiodobenzylguanidine (123-I MIBG) imaging 
predicts ventricular arrhythmias causing appropriate implantable cardioverter-defibrillator 
(ICD) therapy (primary endpoint) and the composite of appropriate ICD therapy or cardiac 
death (secondary endpoint).
Background Although cardiac sympathetic denervation is associated with ventricular ar-
rhythmias, limited data are available on the predictive value of sympathetic nerve imaging 
with 123-I MIBG on the occurrence of arrhythmias.
Methods Before ICD implantation, patients underwent 123-I MIBG and myocardial perfu-
sion imaging. Early and late 123-I MIBG (planar and SPECT) imaging was performed to 
assess cardiac innervation (heart-to-mediastinum ratio, cardiac washout rate and 123-I 
MIBG SPECT defect score). Stress-rest myocardial perfusion imaging was performed to 
assess myocardial infarction and perfusion abnormalities (perfusion defect scores). During 
follow-up, appropriate ICD therapy and cardiac death were documented.
Results One-hundred sixteen heart failure patients referred for ICD therapy were enrolled. 
During a mean follow-up of 23±15 months, appropriate ICD therapy (primary endpoint) 
was documented in 24 (21%) patients and appropriate ICD therapy or cardiac death 
(secondary endpoint) in 32 (28%) patients. Late 123-I MIBG SPECT defect score was an 
independent predictor for both endpoints. Patients with a large late 123-I MIBG SPECT 
defect (summed score >26) showed significantly more appropriate ICD therapy (52% vs. 
5%, p<0.01) and appropriate ICD therapy or cardiac death (57% vs. 10%, p<0.01) than 
patients with a small defect (summed score ≤26) at 3-year follow-up.
Conclusions Cardiac sympathetic denervation predicts ventricular arrhythmias causing ap-
propriate ICD therapy as well as the composite of appropriate ICD therapy or cardiac death.












Sudden cardiac death (SCD) represents a leading cause of death in the developed world 
with an estimated annual incidence of 300.000 to 350.000 patients in the United States.1 
Implantable cardioverter-defibrillator (ICD) treatment is well established in patients at high 
risk for arrhythmic death. Initially, ICD treatment was indicated in survivors of sustained 
ventricular tachycardia or ventricular fibrillation and more recently, in a population at high 
risk, regardless of prior ventricular tachyarrhythmias.2,3 Based on large randomized trials, 
current guidelines recommend ICD treatment based solely on a poor left ventricular (LV) 
systolic function with or without nonsustained ventricular tachycardia as a class I indica-
tion.4
Post-hoc analysis of the second Multicenter Automated Defibrillator Implantation Trial 
(MADIT II) population showed that only 35% of patients received appropriate ICD therapy 
after 3-year follow-up.5 Additionally, the majority of arrhythmic deaths occurs in a population 
without ICD indication.6 Although the benefits of ICD treatment have been demonstrated, 
the question has been raised whether improvements in patient selection can be made.
Dysfunction of the autonomic nervous system (which can be assessed with 123-iodine 
metaiodobenzylguanidine (123-I MIBG) imaging) is thought to play an important role in the 
development of ventricular tachyarrhythmias.7,8 Observational studies have demonstrated 
that cardiac denervation (as evidenced by reduced 123-I MIBG uptake) is associated with 
the occurrence of ventricular tachyarrhythmias.9,10 Moreover, it was recently shown that 
inducibility of ventricular tachyarrhythmias was related to regional cardiac sympathetic 
denervation as assessed with 123-I MIBG imaging.10
At present, limited data are available on the role of 123-I MIBG imaging for prediction 
of ventricular arrhythmias. Moreover, the value of 123-I MIBG imaging in identification of 
patients who may benefit from ICD treatment is unclear. Accordingly, this study evaluated 
the role of cardiac sympathetic nerve imaging with 123-I MIBG for the prediction of ven-
tricular arrhythmias causing appropriate ICD therapy (primary endpoint) and the composite 
of appropriate ICD therapy or cardiac death (secondary endpoint).
Materials and methods
Patient population and protocol
The patient population consisted of consecutive advanced heart failure patients undergoing 
cardiac 123-I MIBG imaging for heart failure risk stratification. The patients were clinically 
referred for ICD implantation based on poor LV function with or without nonsustained 
ventricular tachycardia (primary prevention) or prior sustained ventricular tachycardia or 
ventricular fibrillation (secondary prevention).4






Prior to ICD implantation, 123-I MIBG imaging and gated myocardial perfusion single 
photon emission computed tomography (SPECT) imaging with 99m-technetium tetrofos-
min (99mTc-tetrofosmin) were performed in all patients. 123-I MIBG imaging was clinically 
performed to assess cardiac sympathetic innervation for risk stratification of heart failure 
patients.11 Stress-rest myocardial perfusion imaging was performed to assess myocardial 
infarction (location and extent) and perfusion abnormalities (ischemia).
During follow-up, ventricular arrhythmia with subsequent ICD therapy (appropriate ICD 
therapy) and cardiac mortality were documented. The occurrence of primary endpoints (ap-
propriate ICD therapy) and secondary endpoints (the composite of appropriate ICD therapy 
or cardiac death) was assessed for all patients. Subsequently, the value of 123-I MIBG and 
myocardial perfusion imaging variables in the prediction of endpoints was studied.
123-I MIBG imaging
Patients were pretreated with 120 mg sodium iodide to block uptake of free iodine-123 by 
the thyroid gland. Sodium iodide was given orally one hour before intravenous administra-
tion of 185 MBq 123-I MIBG (General Electric Healthcare, UK). 123-I MIBG planar and 
SPECT imaging was performed in supine position. A 10-minute planar image was acquired 
from an anterior thoracic view (256 x 256 matrix) 10-15 minutes after tracer administra-
tion.
Thereafter, a SPECT study (step and shoot mode, 90 projections, imaging time 30 
minutes) was performed using a dual-head camera system (GCA-7200, Toshiba Corp., 
Tokyo, Japan) equipped with low-energy, parallel-hole high-resolution collimators. A 128 x 
128 matrix was used for SPECT studies and a 20% energy peak was centered around the 
159-keV energy peak of 123-I MIBG. Planar and SPECT imaging were repeated after 3-4 
hours after tracer administration.
Heart-to-mediastinum (H/M) ratio was calculated from planar imaging using manual 
drawn regions of interest (7 x 7 pixels), placed over the entire heart and upper mediasti-
num.10 
123-I MIBG SPECT studies were processed with filtered back-projection and recon-
structed into standard long- and short-axis, perpendicular to the heart axis.12 Data analysis 
was performed by 2 blinded and independent observers. Three late SPECT studies were 
uninterpretable and excluded from evaluation of late 123-I MIBG SPECT imaging.
From planar images, the H/M ratio was computed by dividing the mean counts per pixel 
within the myocardium by the mean counts per pixel within the mediastinum. H/M ratio 
was computed for early and late planar imaging. Cardiac washout rate was calculated using 
the following formula: [(early H/M ratio) – (delayed H/M ratio)] / (early H/M ratio) x 100. 
No background correction was performed in this study.
From SPECT images, the 123-I MIBG SPECT defect score was calculated by assessment 
of patient’s segmental 123-I MIBG tracer uptake score using the 17-segment model.12 











Each myocardial segment was scored according to the following tracer uptake scale: 0 = 
normal tracer uptake, 1 = mildly reduced tracer uptake, 2 = moderately reduced tracer 
uptake, 3 = severely reduced tracer uptake, 4 = no tracer uptake. Subsequently, the 123-I 
MIBG SPECT defect score was calculated by summation of segmental tracer uptake scores. 
The 123-I MIBG SPECT defect score was calculated for early and delayed SPECT imaging.
Gated myocardial perfusion SPECT
Stress-rest gated myocardial perfusion SPECT imaging with 99mTc-tetrofosmin (500 MBq, 
MYOVIEW, General Electric Healthcare, United Kingdom) was performed as previously 
described.13 Myocardial perfusion images were analyzed by 2 blinded observers.
The myocardium was divided into 17 segments and patient’s segmental perfusion score 
was assessed using a similar tracer uptake scale as used for 123-I MIBG images.12 The 
rest perfusion defect score was calculated by summation of segmental perfusion scores 
on resting myocardial perfusion imaging. Stress perfusion defect score was calculated by 
summation of segmental perfusion scores on stress myocardial perfusion imaging. Accord-
ingly, both rest and stress perfusion defect scores could range from 0 to 68 (17 x 4) points. 
Subsequently, the summed perfusion difference score (indicating the extent of reversible 
myocardial perfusion defects) was calculated by subtracting the rest perfusion defect score 
from the stress perfusion defect score. Finally, the 123-I MIBG/perfusion mismatch score 
was calculated by subtracting the rest perfusion defect score from the late 123-I MIBG 
SPECT defect score.
ICD implantation
ICDs were implanted transvenously and without thoracotomy. Testing of sensing and pacing 
thresholds and defibrillation threshold testing was performed during implantation. In the 
study population, the following ICDs were used: Entrust, Marquis DR (Medtronic Inc., 
Minneapolis, Minnesota, United States); Endotak, Vitality 2 (Boston Scientific, Natick, 
Massachusetts, United States); Epic DR (St. Jude Medical, St. Paul, Minnesota, United 
States).
In case of patient eligibility for cardiac resynchronization therapy (CRT), a combined 
CRT-D device (InSync Sentry, Consulta, Medtronic Inc.; Atlas HF, St. Jude Medical; Contak, 
Contak Renewal, Boston Scientific; Lumax, Biotronik, Berlin, Germany) was implanted.14
Clinical follow-up and endpoints
Clinical follow-up was performed by evaluation of device interrogation printouts and patient 
medical record data every 3 to 6 months.
The primary endpoint was defined as the occurrence of appropriate ICD therapy. Ap-
propriate ICD therapy was defined as anti-tachycardia pacing (ATP) or shock triggered 
by ventricular tachycardia or ventricular fibrillation. ICD discharges were evaluated at the 






outpatient pacemaker clinic using ICD stored electrocardiographic data by 2 experienced 
electrophysiologists, blinded to other study data.
The secondary endpoint was a combined endpoint consisting of appropriate ICD therapy 
or cardiac death. Cardiac mortality included death caused by progressive heart failure or 
acute myocardial infarction.
Statistical analysis
Continuous variables are expressed as mean ± standard deviation, and categorical data 
are expressed in numbers and percentages. Cox proportional hazards regression analysis 
was performed to evaluate which variables were associated with the primary or second-
ary endpoint. At first, univariable analysis of baseline characteristics was performed to 
determine significant predictors for both endpoints. All variables that were significantly 
associated with the primary or secondary endpoint at the p<0.15 level were included in a 
multivariable analysis. When early and late 123-I MIBG imaging variables showed strong 
interrelation (Pearson’s correlation coefficient >0.8), early 123-I MIBG imaging variables 
were excluded from multivariable analysis. Only late 123-I MIBG imaging variables were 
included in the multivariable analysis as they are the most commonly used 123-I MIBG 
imaging parameters.11 For each variable, a hazard ratio (HR) with a 95% confidence inter-
val (CI) was calculated.
Cumulative event rates were assessed using the method of Kaplan-Meier and log rank 
test. Additionally, late 123-I MIBG SPECT defect score was subdivided using the median 
value (summed score of 26) as a cutoff. All analyses were two-sided and a p-value <0.05 
was considered statistically significant. Statistical analyses were performed with SPSS 
software package, version 15.0 (SPSS Inc., Chicago, Illinois, USA). 
Results
Patient population
A total of 116 patients (80 men, mean age 65±9 yrs) were enrolled. Baseline characteris-
tics of all patients are summarized in Table 1. One-hundred three (89%) patients received 
an ICD as primary prevention and 13 (11%) patients as secondary prevention for SCD. 
Eighty-six (74%) patients were diagnosed with ischemic cardiomyopathy and 30 (26%) 
patients with nonischemic cardiomyopathy. The mean NYHA functional class was 2.9±0.6 
and the mean LV ejection fraction was 28±8%. A combined CRT-D device was implanted 
in 101 patients.











123-I MIBG and myocardial perfusion imaging
Baseline variables of 123-I MIBG and myocardial perfusion imaging are shown in Table 2. 
Mean values of early and late H/M ratio were 1.58±0.18 and 1.47±0.18. Accordingly, the 
mean value of cardiac washout rate was 6.80±6.37. Furthermore, the early 123-I MIBG 
SPECT defect score had a mean value of 21.6±10.1 and the late 123-I MIBG SPECT 
defect score had a mean value of 26.8±10.0.
The mean rest perfusion defect score was 16.8±10.3, whereas the mean stress perfu-
sion defect score was 18.3±10.6. Accordingly, the mean summed perfusion difference 
score was 1.7±3.6.
The mean 123-I MIBG/perfusion mismatch score was 9.9±12.3, indicating larger 123-I 
MIBG defects as compared to perfusion defects (26.8±10.0 vs. 16.8±10.3, p<0.01). 
Figure 1 shows an example of normal resting myocardial perfusion with a defect on late 
123-I MIBG SPECT imaging in a patient who received appropriate ICD therapy after 18 
months of follow-up.
Table 1. Baseline characteristics of the study population (n = 116)
Characteristics Values
Age (yrs) 65 ± 9
Male gender 80 (69)
CRT-D 101 (87)
ICD indication
    Primary prevention 103 (89)
    Secondary prevention 13 (11)
Ischemic cardiomyopathy 86 (74)
NYHA functional class 2.9 ± 0.6
LVEF (%) 28 ± 8
Cardiovascular risk factors
    Diabetes 16 (14)
    Hypertension 37 (32)
    Hypercholesterolemia 30 (26)
    Smoking 31 (27)
    Family history of CAD 35 (30)
Medication use
    Beta-blocker 82 (71)
    Amiodarone 22 (19)
    ACE-I / ATII antagonist 98 (85) 
    Oral anticoagulant 76 (66)
    Statin 79 (68) 
    Diuretic 102 (88)
Data are represented as mean ± standard deviation or as number (%).
ACE-I = angiotensin converting enzyme - inhibitor; AT = angiotensin; CAD = coronary artery disease; 
CRT-D = cardiac resynchronization therapy - defibrillator; ICD = implantable cardioverter defibrillator; 
LVEF = left ventricular ejection fraction; NYHA = New York Heart Association.






Primary endpoint: appropriate ICD therapy
During 23±15 months follow-up, 86 episodes of ventricular tachycardia or ventricular 
fibrillation were terminated by appropriate ICD therapy in 24 (21%) patients. Appropriate 
ICD therapy consisted of 44 episodes of ATP in 16 (14%) patients and 42 ICD shocks in 
15 (13%) patients.
Univariable analyses demonstrated that ICD indication (secondary vs. primary preven-
tion), ischemic cardiomyopathy, early 123-I MIBG SPECT defect score, late 123-I MIBG 
SPECT defect score, summed perfusion difference score, and the 123-I MIBG/perfusion 
mismatch score were significantly associated with appropriate ICD therapy (Table 3). The 
Table 2. Baseline variables of 123-I MIBG and myocardial perfusion imaging
123-I MIBG imaging
    Early planar H/M ratio 1.58 ± 0.18  
    Late planar H/M ratio 1.47 ± 0.18
    Cardiac washout rate (%) 6.80 ± 6.37 
    Early 123-I MIBG SPECT defect score 21.6 ± 10.1
    Late 123-I MIBG SPECT defect score 26.8 ± 10.0
Myocardial perfusion imaging
    Rest perfusion defect score 16.8 ± 10.3
    Stress perfusion defect score 18.3 ± 10.6
    Summed perfusion difference score 1.7 ± 3.6
    123-I MIBG/perfusion mismatch score 9.9 ± 12.3
Data are represented as mean ± standard deviation. H/M ratio = heart-to-mediastinum ratio; 123-I 
MIBG = 123-iodine metaiodobenzylguanidine; SPECT = single photon emission computed tomography.
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Figure 1. Example of resting myocardial perfusion (panel A) and late 123-I MIBG (panel 
B) imaging in an ICD patient. In this patient, showing normal myocardial perfusion and 
abnormal 123-I MIBG imaging, an appropriate ICD therapy (ATP) was documented after 
18 months of follow-up. 
 
 
Figure 2. Kaplan-Meier curve analysis showing the difference in appropriate ICD therapy 
(primary endpoint) between patients with a large (summed score >26) or small (summed 
score ≤26) late 123-I MIBG SPECT defect. 
Figure 1. Example of resting myocardial perfusion (panel A) and late 123-I MIBG (panel B) imaging in 
an ICD patient. In this patient, showing normal myocardial perfusion and abnormal 123-I MIBG imaging, 
an appropriate ICD therapy (ATP) was documented after 18 months of follow-up.











Table 3. Univariable and multivariable analyses of baseline variables for appropriate ICD therapy (pri-
mary endpoint)
Univariable analysis Multivariable analysis
HR (95% CI) p-value HR (95% CI) p-value
Age (yrs) 1.02 (0.98 - 1.08) 0.4
Male gender 1.52 (0.57 - 4.06) 0.4 
CRT-D 1.15 (0.34 - 3.86) 0.8
ICD indication 4.55 (1.95 - 10.65) < 0.01* 
3.85 (1.43 - 
10.37) <0.01**
(secondary vs. primary prevention)
Ischemic cardiomyopathy 3.16 (0.94 - 10.60) 0.06* 2.10 (0.58 - 7.64) 0.3
NYHA functional class 1.10 (0.54 - 2.24) 0.8
LVEF (%) 1.02 (0.97 - 1.07) 0.5
Cardiovascular risk factors
    Diabetes 0.60 (0.14 - 2.54) 0.5
    Hypertension 1.13 (0.48 - 2.65) 0.8
    Hypercholesterolemia 1.08 (0.43 - 2.73) 0.9
    Smoking 1.39 (0.61 -3.19) 0.4 
    Positive family history of CAD 0.87 (0.36 - 2.09) 0.7
Medication use
    Beta-blockade 1.03 (0.43 - 2.47) 1.0
    Amiodarone 1.64 (0.65 - 4.12) 0.3
    ACE-I / ATII antagonist 1.23 (0.37 - 4.14) 0.7
    Oral anticoagulant 0.61 (0.27 - 1.37) 0.2
    Statin 1.45 (0.57 - 3.65) 0.4
    Diuretic 1.13 (0.27 - 4.83) 0.9
123-I MIBG imaging
    Early H/M ratio 0.35 (0.04 - 3.30) 0.4
    Late H/M ratio 0.27 (0.03 - 2.32) 0.2
    Cardiac washout rate (%) 1.02 (0.95 - 1.09) 0.6
    Early 123-I MIBG SPECT defect score 1.07 (1.03 - 1.12) <0.01*
    Late 123-I MIBG SPECT defect score 1.14 (1.08 - 1.20) <0.01* 1.13 (1.05 - 1.21) <0.01**
Myocardial perfusion imaging 
    Rest perfusion defect score 1.02 (0.98 - 1.06) 0.4
    Stress perfusion defect score 1.03 (0.99 - 1.07) 0.2
    Summed perfusion difference score 1.08 (0.98 - 1.20) 0.14* 0.93 (0.83 - 1.05) 0.3
123-I MIBG/perfusion mismatch score 1.06 (1.02 - 1.09) <0.01* 1.01 (0.97 - 1.06) 0.5
* Significant association with appropriate ICD therapy at a level of p<0.15 in univariate analysis. 
**Significant association with appropriate ICD therapy in multivariate analysis. ACE-I = angiotensin 
converting enzyme - inhibitor; AT = angiotensin; CAD = coronary artery disease; CRT-D = cardiac resyn-
chronization therapy - defibrillator; H/M ratio = heart-to-mediastinum ratio; 123-I MIBG = 123-iodine 
metaiodobenzylguanidine; LVEF = left ventricular ejection fraction; NYHA = New York Heart Association; 
SPECT = single photon emission computed tomography.






early 123-I MIBG SPECT defect score was excluded for multivariable analysis as it showed 
strong interrelation (r=0.82) with the late 123-I MIBG SPECT defect score.
Subsequently, multivariable analysis demonstrated that ICD indication (secondary vs. 
primary prevention) (HR 3.85, 95% CI 1.43-10.37, p<0.01) and late 123-I MIBG SPECT 
defect score (HR 1.13, 95% CI 1.05-1.21, p<0.01) were independent predictors for 
appropriate ICD therapy.
Risk stratification for appropriate ICD therapy
Twenty-two (40%) patients with a large late 123-I MIBG SPECT defect (summed score 
>26) versus 2 (3%) patients with a small late 123-I MIBG SPECT defect (summed score 
≤26) received appropriate ICD therapy (p<0.01).
The cumulative event rate at 3-year follow-up for appropriate ICD therapy was 52% 
(95% CI 36-68%) for patients with a large late 123-I MIBG SPECT defect versus 5% (95% 
CI 0-11%) for patients with a small late 123-I MIBG SPECT defect (Figure 2). Appropriate 
ICD therapy was significantly more often documented in patients with a large late 123-I 
MIBG SPECT defect when compared to patients with a small late 123-I MIBG SPECT 
defect during a mean follow-up of 23±15 months (log rank test, p<0.01). Moreover, the 
risk for appropriate ICD therapy was 13 times higher in patients with a large late 123-I 
MIBG SPECT defect as compared to patients with a small defect (HR 12.81, 95% CI 
3.01-54.50, p<0.01).
Figure 2. Kaplan-Meier curve analysis showing the difference in appropriate ICD therapy (primary end-
point) between patients with a large (summed score >26) or small (summed score ≤26) late 123-I MIBG 
SPECT defect.











Secondary endpoint: appropriate ICD therapy or cardiac mortality
Appropriate ICD therapy or cardiac mortality was documented in 32 (28%) patients. In 
total, 24 (21%) patients received appropriate ICD therapy and 8 (7%) patients died of 
progressive heart failure without previous appropriate ICD therapy. In total, cardiac death 
was documented in 13 (11%) patients, including 5 (4%) patients who received appropriate 
ICD therapy before cardiac death.
Univariable analysis demonstrated that ICD indication (secondary vs. primary preven-
tion), ischemic cardiomyopathy, delayed H/M ratio, early 123-I MIBG SPECT defect score, 
late 123-I MIBG SPECT defect score and 123-I MIBG/perfusion mismatch score were 
significant predictors for the secondary endpoint (Table 4). Since early and late 123-I MIBG 
SPECT defect score were strongly interrelated (r=0.82), early 123-I MIBG SPECT defect 
score was excluded for multivariable analysis.
Late 123-I MIBG SPECT defect score (HR 1.12, 95% CI 1.05-1.19, p<0.01) was the 
only independent predictor in multivariable analysis.
Risk stratification for appropriate ICD therapy or cardiac mortality
Appropriate ICD therapy or cardiac mortality was documented in 28 (51%) patients with a 
large late 123-I MIBG SPECT defect (summed score >26) and in 4 (7%) patients with a 
small late 123-I MIBG SPECT defect (summed score ≤26) (p<0.01).
The cumulative event rate at 3-year follow-up for appropriate ICD therapy or cardiac 
mortality was 57% (95% CI 43-72%) for patients with a large late 123-I MIBG SPECT 
defect as compared to 10% (95% CI 0-20%) for patients with a small defect (Figure 3). 
Appropriate ICD therapy or cardiac death was significantly more documented in patients 
with a large late 123-I MIBG SPECT defect as compared to patients with a small defect 
during a mean follow-up of 23±15 months (log rank test, p<0.01). Moreover, the risk 
for appropriate ICD therapy or cardiac death was 8 times higher in patients with a large 
late 123-I MIBG SPECT defect than patients with a small defect (HR 8.29, 95% CI 2.91-
23.63, p<0.01).
Discussion
The main findings of the study can be summarized as follows. Late 123-I MIBG SPECT 
defect score was an independent predictor for ventricular arrhythmias causing appropriate 
ICD therapy (primary endpoint) as well as the composite of appropriate ICD therapy or 
cardiac death (secondary endpoint). In addition, cumulative event rates for appropriate ICD 
therapy (52% vs. 5%, p<0.01) and appropriate ICD therapy or cardiac death (57% vs. 
10%, p<0.01) were significantly higher in patients with a large late 123-I MIBG SPECT 
defect (summed score >26) as compared to patients with a small late 123-I MIBG SPECT 






Table 4. Univariable and multivariable analyses of baseline variables for appropriate ICD therapy or 
cardiac death (secondary endpoint)
Univariable analysis Multivariable analysis
HR (95% CI) p-value HR (95% CI) p-value
Age (yrs) 1.02 (0.98 - 1.06) 0.4
Male gender 1.03 (0.48 - 2.22) 0.9
CRT-D 1.61 (0.49 - 5.27) 0.4
ICD indication 3.06 (1.37 - 6.81) <0.01* 
1.94 (0.81 - 
4.63) 0.1
(secondary vs. primary prevention)
Ischemic cardiomyopathy 2.44 (0.94 - 6.35) 0.07*
1.51 (0.53 - 
4.30) 0.4
NYHA functional class 1.24 (0.67 - 2.29) 0.5
LVEF (%) 1.00 (0.96 - 1.05) 1.0
Cardiovascular risk factors
    Diabetes 1.53 (0.63 - 3.72) 0.4
    Hypertension 0.89 (0.41 - 1.92) 0.8
    Hypercholesterolemia 1.08 (0.48 - 2.40) 0.9
    Smoking 1.22 (0.59 - 2.53) 0.6
    Positive family history of CAD 0.82 (0.38 - 1.78) 0.6
Medication use
    Beta-blockade 0.93 (0.44 - 1.97) 0.9
    Amiodarone 1.63 (0.73 - 3.62) 0.2
    ACE-I / ATII antagonist 0.96 (0.37 - 2.50) 0.9
    Oral anticoagulant 0.63 (0.31 - 1.28) 0.2
    Statin 1.23 (0.57 - 2.67) 0.6
    Diuretic 1.54 (0.37 - 6.47) 0.6
123-I MIBG imaging
    Early H/M ratio 0.25 (0.04 - 1.80) 0.2
    Late H/M ratio 0.17 (0.03 - 1.13) 0.07*
0.79 (0.10 - 
6.10) 0.8
    Cardiac washout rate (%) 1.03 (0.97 -1.09) 0.3
    Early 123-I MIBG SPECT defect score 1.08 (1.04 - 1.12) <0.01*
    Late 123-I MIBG SPECT defect score 1.13 (1.08 - 1.18) <0.01*
1.12 (1.05 - 
1.19) <0.01**
Myocardial perfusion imaging 
    Rest perfusion defect score 1.02 (0.99 - 1.06) 0.2
    Stress perfusion defect score 1.02 (0.99 - 1.06) 0.2
    Summed perfusion difference score 1.04 (0.94 - 1.16) 0.5
123-I MIBG/perfusion mismatch score 1.05 (1.02 - 1.08) <0.01*
1.00 (0.97 - 
1.04) 0.9
* Significant association with appropriate ICD therapy at a level of p<0.15 in univariate analysis. 
**Significant association with appropriate ICD therapy in multivariate analysis. ACE-I = angiotensin 
converting enzyme - inhibitor; AT = angiotensin; CAD = coronary artery disease; CRT-D = cardiac resyn-
chronization therapy - defibrillator; H/M ratio = heart-to-mediastinum ratio; 123-I MIBG = 123-iodine 
metaiodobenzylguanidine; LVEF = left ventricular ejection fraction; NYHA = New York Heart Association; 
SPECT = single photon emission computed tomography.











defect (summed score ≤26) at 3-year follow-up. Importantly, only 2 (3%) patients with a 
small late 123-I MIBG SPECT defect received appropriate ICD therapy during follow-up.
Sudden cardiac death and substrate imaging
ICD therapy has become a cornerstone treatment in patients at high risk for sudden arrhyth-
mic death.4 Although the benefits of ICD treatment have been demonstrated, the question 
has been raised whether patient selection according to the current guidelines is adequate, 
as it is still unclear which patients will benefit from ICD treatment.2,3,5 Post-hoc analysis 
of the second Multicenter Automated Defibrillator Implantation Trial (MADIT II) population 
demonstrated that 35% of patients received appropriate ICD therapy after 3-year follow-
up.5 Moreover, the majority of arrhythmic deaths occurs in patients without ICD indication.6
Accordingly, attention has shifted towards improved risk stratification of patients cur-
rently indicated for ICD therapy. Recently, the AHA/ACC/HRS scientific statement on the 
noninvasive risk stratification in patients at risk for sudden arrhythmic death was published, 
indicating that the optimal method for risk stratification is unclear.15 Although an LV ejec-
tion fraction (LVEF) of <40% is most commonly used for stratification of patients at risk 
for ventricular arrhythmias, it does not allow accurate discrimination of patients with or 
without sudden arrhythmic death.15 Moreover, sudden arrhythmic death is often occurred 
in patients with an LVEF of >40%.6,15
Since the majority of patients with documented arrhythmic death is diagnosed with 
structural heart disease, predominantly coronary artery disease, risk stratification should 
Figure 3. Kaplan-Meier curve analysis showing the difference in appropriate ICD therapy or cardiac death 
(secondary endpoint) between patients with a large (summed score >26) or small (summed score ≤26) 
late 123-I MIBG SPECT defect.






focus on further identification of the underlying substrate for arrhythmic death.15,16 Al-
though the exact mechanisms of ventricular arrhythmias have been a matter of debate, 
it has been recognized that scar tissue and myocardial ischemia may serve as important 
substrates for ventricular arrhythmias. In acute myocardial infarction, ischemia may serve 
as a substrate for ventricular arrhythmias by inducing electrical instability.17 In chronic 
myocardial infarction, areas of slow conduction are present that facilitate the development 
of reentrant tachycardia.17
Different imaging techniques (predominantly myocardial perfusion imaging) have been 
used to provide information on the underlying substrate. Borger van der Burg et al.18 evalu-
ated the occurrence of ventricular arrhythmia and cardiac death in relation to ischemia, 
viability and scar tissue in 156 survivors of sudden arrhythmic death. Extent of scar tissue 
and reduced LV function (LVEF ≤30%) were significantly associated with occurrence of 
ventricular arrhythmias and cardiac death in univariable and multivariable analysis. In 
the present study, ischemia (summed perfusion difference score) was significantly associ-
ated with appropriate ICD therapy in univariable analysis. However, myocardial infarction 
(resting perfusion defect score) and ischemia were not significantly associated with both 
endpoints in multivariable analysis. One of the potential explanations for these findings 
is the fact that the current study included patients with nonischemic cardiomyopathy, 
whereas in the study performed by Borger van der Burg et al.18 all patients were diagnosed 
with significant coronary artery disease.
The autonomic nervous system may also play an important role in the pathogenesis 
of ventricular arrhythmias.7,8 Observational studies have associated the occurrence of 
ventricular arrhythmias with abnormalities in cardiac sympathetic innervation.9,10 Although 
the pathophysiologic mechanisms are unclear, it has been suggested that denervated but 
viable myocardium may be hypersensitive to circulating catecholamines. As compared to 
regions with normal cardiac innervation, denervated myocardium may respond differently 
to sympathetic activation with increased automaticity and enhanced triggering.7 In particu-
lar, the borderzone of infarct tissue may be predisposed to develop reentrant circuits as 
these regions are viable but may have damaged sympathetic nerves. Viable myocardium 
may already exhibit areas of denervation (innervation/perfusion mismatch), as sympathetic 
nerve fibers are more susceptible to myocardial ischemia than cardiac tissue.19,20
Recently, the innervation/perfusion mismatch score was assessed in 50 patients with 
LV systolic dysfunction referred for electrophysiologic testing.10 The innervation/perfusion 
mismatch score was not significantly associated with inducibility of tachyarrhythmias in 
univariable and multivariable analysis.10 Although the current study showed that 123-I 
MIBG/perfusion mismatch score was associated with the occurrence of ventricular arrhyth-
mias in univariable analysis, no significant association was found in multivariable analysis.











Risk stratification in heart failure patients with 123-I MIBG imaging
Several studies using 123-I MIBG imaging have demonstrated that abnormalities in global 
cardiac innervation were predictive for overall cardiac mortality in heart failure patients.21,22 
Merlet et al.22 showed that impaired cardiac sympathetic innervation, as assessed with 
planar 123-I MIBG imaging, was associated to adverse cardiac outcomes in 112 patients 
with heart failure and a poor LV function. Over a mean follow-up of 27±20 months, the 
only independent predictors for adverse cardiac events (cardiac transplantation and cardiac 
death) were low 123-I MIBG uptake (p<0.01) and LV function (p=0.02). Recently, Agos-
tini et al.11 confirmed the predictive value of cardiac 123-I MIBG imaging in 290 patients 
with moderate-to-severe heart failure. Most important, the study showed that patients 
with normal 123-I MIBG uptake showed a significant higher 2-year event-free survival as 
compared to patients with reduced 123-I MIBG uptake (95% vs. 62%, p<0.01).
123-I MIBG imaging to predict ventricular arrhythmia
Various studies have related sympathetic denervation to the occurrence of ventricular ar-
rhythmias.9,10 Arora et al.23 performed a pilot study that evaluated cardiac sympathetic 
innervation in 17 patients with ICD treatment. ICDs were implanted because of sustained 
ventricular tachycardia or ventricular fibrillation. Patients with a documented ICD discharge 
showed significantly more global (early H/M ratio) and regional sympathetic denervation 
(early and late 123-I MIBG defect score) than patients without an ICD discharge. In ad-
dition, Nagahara et al.24 evaluated in a small study population whether abnormalities in 
cardiac sympathetic innervation were related to appropriate ICD therapy or lethal cardiac 
events. During a mean follow-up of 15 months, global cardiac sympathetic innervation (as-
sessed with delayed H/M ratio) was independently associated with appropriate ICD therapy. 
More recently, the relation between cardiac sympathetic innervation and inducibility of 
ventricular arrhythmias during electrophysiologic testing was evaluated in 50 patients with 
previous myocardial infarction and reduced LV systolic function.10 Although no significant 
association between global cardiac denervation and inducible ventricular arrhythmias was 
found, regional cardiac denervation was significantly higher in patients with positive electro-
physiologic tests than patients with negative electrophysiologic tests. In addition, Mitrani et 
al.9 evaluated whether patients with documented ventricular arrhythmias showed abnormal 
sympathetic innervation. Patients with ventricular tachycardia showed significantly more 
regional sympathetic denervation as compared to patients without ventricular tachycardia. 
Likewise, this study demonstrated that regional cardiac sympathetic denervation derived 
from late 123-I MIBG SPECT was significantly associated with ventricular arrhythmias 
causing appropriate ICD therapy. Moreover, late 123-I MIBG SPECT defect score was an 
independent predictor for appropriate ICD therapy. Importantly, the risk for appropriate ICD 
therapy was 13 times higher in patients with a large late 123-I MIBG SPECT defect than 
patients with a small defect.







Although the current study clearly demonstrated that cardiac sympathetic denervation on 
late 123-I MIBG SPECT imaging was predictive for both study endpoints, some limitations 
need to be considered. In this study, a heterogeneous patient population was enrolled, 
including patients with ischemic and nonischemic cardiomyopathy. Additional studies 
are needed to establish the specific role of 123-I MIBG imaging in these subpopulations. 
In addition, innervation and perfusion scans were scored visually, whereas an automatic 
quantitative approach would be preferred.
Conclusion
Cardiac sympathetic denervation on late 123-I MIBG imaging predicts ventricular arrhyth-
mia causing appropriate ICD therapy (primary endpoint) as well as the composite of appro-
priate ICD therapy or cardiac death (secondary endpoint). Cardiac sympathetic denervation 
as assessed with delayed 123-I MIBG SPECT imaging may improve risk stratification for 
arrhythmic death in patients who have an indication for ICD treatment.
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Background: In primary prevention implantable cardioverter defibrillator (ICD) patients, the 
incidence of life-threatening ventricular arrhythmias resulting in ICD therapy is relatively 
low, prompting for better risk stratification. The aim of this study was to assess the value of 
the QRS-T angle for prediction of ICD therapy and mortality in primary prevention patients 
with ischemic heart disease (IHD).
Methods and results: ICD patients (n=412, 361 male, age 63±11 years) with IHD and 
a left ventricular ejection fraction ≤ 40% were included. After device implantation, the 
occurrence of appropriate ICD therapy and mortality was noted. A survival analysis was 
performed comparing patients with a planar QRS-T angle ≤ 90º (n=124, 30%) to patients 
with a planar QRS-T angle > 90º before device implantation. Furthermore, patients with a 
spatial QRS-T angle ≤ 100º (n=56, 14%) were compared to patients with a spatial QRS-T 
angle > 100º, prior to implant.
For patients with a planar QRS-T angle >90º as compared to ≤ 90º, the adjusted hazard 
ratio for the occurrence of appropriate device therapy was 2.4 (95% CI 1.1-5.2);  a spatial 
QRS-T angle > 100º was associated with an adjusted hazard ratio of 7.3 (95% CI 1.0-
53.8). Furthermore, a spatial QRS-T angle ≤ 100º exhibited a positive predictive value of 
98% (95% CI 95-100%) for the prediction of an appropriate therapy-free follow-up.
Conclusions: A wide QRS-T angle is a strong predictor of appropriate device therapy in 
primary prevention ICD recipients with IHD. Furthermore, a spatial QRS-T angle ≤ 100º 
might be of value in the identification of patients in whom, although currently indicated, 
ICD treatment should be reconsidered.












Sudden cardiac death (SCD), mainly caused by ventricular arrhythmias, accounts for 
approximately 50% of all cardiac mortality worldwide.1-3 It is recognised that patients 
with ischemic heart disease and depressed left ventricular ejection fraction (LVEF) are at 
high risk of SCD,4, 5 and large randomised trials have demonstrated that  implantable 
cardioverter defibrillator (ICD) therapy reduces all-cause mortality, as well as SCD. 6-10 
Implementation of these results in the international guidelines resulted in a significant in-
crease of the number of ICD implantations.11, 12 However, long-term follow-up studies in 
currently indicated patients show a relatively low incidence of ventricular arrhythmias that 
trigger ICD therapy.13 Additionally, approximately 6% of ICD patients experience severe 
device-related adverse events (i.e. pocket infections, sepsis), causing the need for surgical 
re-intervention, additional hospitalization, or even death.14, 15 This led to critical appraisal 
of the wide-spread application of ICD therapy and stressed the need for more precise risk 
stratification criteria.16 In an attempt to identify those criteria, post-hoc analyses of the 
second Multicenter Automatic Defibrillator Implantation Trial (MADIT II) revealed several 
clinical criteria associated with an increased risk for ventricular arrhythmias resulting in 
appropriate device therapy.17-19 So far, however, in low LVEF patients no criteria have 
been recognised which may identify patients at low risk of ventricular arrhythmias during 
follow-up. If possible to identify a low risk population, ICD therapy in this group may be 
reconsidered.
Recently, a wide angle between the QRS and T axes, the QRS-T angle, on the standard 
12-lead ECG was recognised as a novel and easy applicable marker of increased risk 
for cardiovascular mortality.20, 21 Subsequently,  a wide QRS-T angle was found to be 
associated with the increased incidence of appropriate device therapy and mortality in 
primary prevention ICD recipients with non-ischemic cardiomyopathy.22 However, no data 
are available on the value of the QRS-T angle in ICD patients with IHD.
The aim of the current study was, to assess the value of the QRS-T angle in predict-
ing life threatening ventricular arrhythmias in primary prevention ICD patients with IHD. 
Furthermore the value of the QRS-T angle was evaluated as a parameter to identify patients 
at low risk for ventricular arrhythmias.
Methods
Patients
Patients with IHD who underwent implantation of an ICD, based on the international treat-
ment guidelines, in the Leiden University Medical Center were selected for the current 
study.11 Criterion for inclusion were a depressed LVEF (<40%) with or without a history 






of non sustained ventricular tachycardia. Since 1996, these patients were prospectively 
registered in the departmental Cardiology Information System (EPD-Vision®).23 Prior to 
implantation, a comprehensive assessment of patient characteristics was performed as 
described previously.24 
During follow-up, the occurrence of appropriate ICD therapy and patient mortality was 
noted. In addition, for the purpose of this study, the ECG made before implantation was 
analyzed.
Implantable cardioverter defibrillator implantation and follow-up
All defibrillator systems were implanted transvenously without thoracotomy. Device follow-
up was scheduled every three to six months. All printouts were carefully checked for 
appropriate and inappropriate ICD therapy. In case of any ICD therapy, an electrophysiolo-
gist, blinded to QRS-T measurements, determined whether or not the ICD therapy was 
appropriate. All therapies, either anti-tachycardia pacing (ATP) or shock, were classified 
as appropriate when they occurred in response to life threatening arrhythmias; ventricular 
tachycardia (VT) or ventricular fibrillation (VF) and as inappropriate when triggered by sinus 
or supraventricular tachycardia (SVT), T-wave oversensing, or electrode dysfunction.
Defibrillators were programmed as follows:  ventricular arrhythmia faster than 150 
bpm was monitored by the device without consequent defibrillator therapy. Ventricular 
arrhythmias faster than 188 bpm were initially attempted to be terminated with two bursts 
of ATP and, after continuation of the arrhythmia, with defibrillator shocks. In the case 
of a ventricular arrhythmia faster than 210 bpm, device shocks were the initial therapy. 
Furthermore, atrial arrhythmia detection was set to >170 bpm with SVT discriminators 
enabled. Settings were adapted, only when clinically indicated (i.e. hemodynamic well 
tolerated ventricular tachycardia at high rate; ventricular tachycardia in the monitor zone).
Electrocardiographical analysis
First, the quality of ECGs was evaluated. If electrode displacement, missing leads or signal 
noise was present, the ECGs were excluded from the analysis. Since right ventricular pacing 
alters normal cardiac conduction and results, by definition, in an abnormal QRS-T angle, 
patients with a pacemaker were excluded from the analysis.25 Subsequently, the ECGs 
were analyzed with a dedicated computer program (LEADS, Leiden ECG Analysis and 
Decomposition Software).26 Full details on the computation method and LEADS based val-
ues of vector characteristics in healthy subjects, have been extensively described earlier.27 
In short, the software converts the standard ECG into a vectorcardiogram and computes 
the three dimensional orientation of the QRS- and T-axes. Thereafter, the QRS-T angle is 
calculated in the plane formed by the QRS- and T-axes, the spatial QRS-T angle. In addi-
tion, the more commonly used but less precise projection of the spatial QRS-T angle in the 
frontal plane, the planar QRS-T angle, was computed. Previous studies demonstrated that 











a spatial QRS-T angle wider than 100º is associated with the presence of cardiac disease 
and increased cardiovascular mortality.20, 21 Pavri et al. recently demonstrated that a planar 
QRS-T angle wider than 90º is associated with an increased incidence of appropriate device 
shocks and mortality22. In the present study, these cut-offs (100º for the spatial and 90º for 
the planar QRS-T angle) were applied. 
Statistical analysis
A survival analysis, comprising of the following end-points, was performed: (1) first ap-
propriate ICD therapy (ATP and/or shock); (2) all-cause mortality; and (3) a composite 
end-point of all-cause mortality and first appropriate device therapy, whichever occurs 
first. ICD recipients with a narrow QRS-T angle were compared to those with a wide QRS-T 
angle. The points of cut-off were pre-defined as described above, 100º for the spatial and 
90º for the planar QRS-T angle. Cumulative event rates of end-points were analyzed by 
the method of Kaplan-Meier. Relationships between baseline parameters and end-points 
were assessed with Cox’s proportional hazard regression analysis. For the composite end-
point, survival time was defined as time to all-cause death or appropriate device therapy, 
whichever occurred first. For each variable a hazard ratio with a 95%-confidence interval 
(95% CI) was calculated. Therapy-free follow-up was defined as a study follow-up without 
the occurrence of appropriate ICD therapy.
Continuous data are expressed as mean ± standard deviation or median and quartiles 
where appropriate; dichotomous data are presented as numbers and percentages. Com-
parison of data at baseline was performed with the Student’s t test for unpaired data and 
Chi-square tests with Yates correction when appropriate. 
The authors had full access to the data and take responsibility for its integrity. All authors 
have read and agree to the manuscript as written.
Results
Patients and follow-up
A total of 460 patients with ischemic heart disease and a LVEF ≤ 40% underwent ICD 
implantation for primary prevention of sudden cardiac death in the Leiden University Medi-
cal Center. Thirty-two (7%) patients were excluded due to the presence of a pacemaker 
and 16 (3%) patients were excluded since their ECG prior to device implantation could not 
be analyzed because of technical reasons such as electrode displacement, missing leads, 
or signal noise. The remaining 412 (90%) ICD recipients (63±11 yrs, 88% male) were 
included in the analysis and were followed for 22±17 months (range 0 to 77 months). 
Baseline characteristics are summarised in Table 1.






During follow-up, 46 (11%) patients died, and a total of 482 episodes of appropriate device 
therapy for ventricular arrhythmias occurred in 56 (14%) patients; 386 episodes of ventricular 
arrhythmia, terminated by ATP in 35 (8%) patients, and 96 episodes triggering device shocks 
in 28 (7%) patients. During follow-up, the first end-point (first appropriate device therapy) 
was reached in 56 patients (24 shock, 32 ATP), the second end-point (all-cause death) was 
reached in 46 patients and the composite end-point (death or first appropriate device therapy) 
was reached in 96 patients (40 patients all cause deaths, 56 appropriate therapy).






Yes No Yes No
Patients 412 124 (30%) 288 (70%) 56 (14%) 356 (86%)
Clinical parameters
    Age (yrs) 63±11 61±11 64±10* 62±11 63±10
    Male (%) 361 (88%) 110 (89%) 251 (87%) 51 (91%) 310 (87%)
    Biventricular ICD (%) 194 (47%) 43 (35%) 151 (52%)† 22 (39%) 172 (48%)
    LVEF (%) 26±7 28±7 25±7† 30±6 26±7†
    NYHA functional class
        I-II











    History of diabetes mellitus (%) 110 (27%) 24 (19%) 86 (30%)* 6 (11%) 104 (29%)†
    History of nicotine abuse (%) 190 (46%) 55 (44%) 135 (47%) 29 (52%) 161 (45%)
    Current nicotine abuse (%) 86 (21%) 25 (20%) 60 (21%) 12 (21%) 74 (21%)
    History of atrial fibrillation /
    flutter (%)
98 (24%) 24 (19%) 74 (26%) 10 (18%) 88 (25%)
    Atrial fibrillation / 
    flutter at implantation (%)
39 (9%) 8 (6%) 31 (11%) 2 (4%) 37 (10%)
    History of non sustained VT (%) 81 (20%) 24 (19%) 57 (20%) 10 (18%) 71 (20%)
    Body mass index (kg/m2) 27±4 26±4 27±5 27±3 27±4
Medication
    Beta blocker (%) 317 (77%) 99 (80%) 218 (76%) 42 (75%) 275 (77%)
    ACE inhibitor / AT antagonist (%) 358 (87%) 110 (89%) 248 (86%) 49 (88%) 309 (87%)
    Diuretics for CHF (%) 317 (77%) 90 (73%) 227 (79%) 38 (68%) 279 (78%)
    Statins (%) 349 (85%) 111 (90%) 238 (83%) 53 (95%) 296 (83%)*
    Amiodarone (%) 57 (14%) 15 (12%) 42 (15%) 1 (2%) 56 (16%)†
ECG parameters
    Heart rate (bpm) 66±16 66±15 66±16 67±16 66±15
    QRS duration (ms) 130±33 120±29 134±34† 115±28 132±33†
    QTc Bazett (ms) 431±51 431±52 431±51 434±50 431±52
    Frontal QRS-T angle (º) 116±52 47±24 146±26† 62±33 125±50†
    Spatial QRS-T angle (º) 139±32 112±35 151±22† 75±18 149±20†
* p<0.05; † p<0.01 as compared to patients with a narrow planar/spatial QRS-T angle.
ACE = angiotensin converting enzyme; AT = angiotensin; CHF = congestive heart failure; ICD = im-
plantable cardioverter defibrillator; LVEF = left ventricular ejection fraction; NYHA = New York Heart 
Association; VT = ventricular tachycardia.











QRS-T angle and all-cause mortality
In 124 (30%) patients, a planar QRS-T angle smaller or equal to 90º was measured on 
the baseline ECG. As summarised in Table 1, patients with a narrow planar QRS-T angle 
were more likely to be younger (61±11 yr vs. 64±10 yr, p<0.05), to have a better LVEF 
(28±7% vs. 25±7%, p<0.001), and shorter QRS duration (120±29 ms vs. 134±34 
ms, p<0.001). The hazard ratio of a planar QRS-T angle > 90º for mortality was 3.1 (95% 
CI 1.3-7.3) as compared to patients with a narrow planar QRS-T angle. The cumulative 
event-free follow-up for all cause mortality in patients with a narrow planar QRS-T angle 
was 99% (95% CI 98-100%) at one year, 92% (95% CI 87-98%) at two years, and 92% 
(95% CI 87-98%) at four years of follow-up (Figure 1).
Fifty-six (14%) patients had a baseline spatial QRS-T angle smaller than or equal to 
100º. These patients were younger, had a more preserved LVEF (30±6% vs. 26±7%, 




Figure 2. Kaplan-Meier curve for cumulative event rate for appropriate therapy in 
patients with a planar QRS-T angle ≤ 90º vs. a planar QRS-T angle > 90º (panel A) and 
with a spatial QRS-T angle ≤ 100º vs. a spatial QRS-T angle > 100º (panel B). 
Figure 1. Kaplan-Meier curve for cumulative event rate for all cause mortality in patients with a planar 
QRS-T angle ≤ 90º vs. a planar QRS-T angle > 90º (panel A) and with a spatial QRS-T angle ≤ 100º vs. 
a spatial QRS-T angle > 100º (panel B).






more often (95% vs. 83%, p<0.05) and were using amiodarone less frequently (2% vs. 
16%, p<0.01) (Table 1). As is shown in Table 2, patients with a wide spatial QRS-T angle 
exhibited a hazard ratio for all-cause mortality of 1.7 (95% CI 0.6-4.9). 
QRS-T angle and ventricular arrhythmia 
The hazard ratio of a planar QRS-T angle wider than 90º for the occurrence of ventricular 
arrhythmia triggering appropriate device therapy was 2.9 (95% CI 1.4-6.1). When ad-
justed for age, sex, LVEF and QRS duration, the hazard ratio was 2.4 (95% CI 1.1-5.2). 
Furthermore, this group demonstrated an almost threefold risk increase (hazard ratio 2.9, 
95% CI 1.6-5.0) for the composite end-point of appropriate therapy and mortality (Table 
2). The cumulative event-free follow-up for appropriate therapy in patients with a narrow 
planar QRS-T angle was 95% (95% CI 90-99%) at one year, 93% (95% CI 87-98%) at two 
years, and 89% (95% CI 81-98%) at four years of follow-up (Figure 2).
As is shown in Table 2, patients with a wide spatial QRS-T angle exhibited a near tenfold 
risk for the occurrence of ATP or shocks (hazard ratio 9.9, 95% CI 1.4-71.7) during follow-
up. When adjusted for age, sex, LVEF, and QRS duration the hazard ratio was 7.3 (95% CI 
1.0-53.8). Strikingly, the cumulative event-free follow-up for ventricular arrhythmia which 
triggered device therapy was 100% at two years and 96% (95% CI 87-100%) at four years 
of follow-up, as can be readily seen in Figure 2.
Identification of patients free of life-threatening arrhythmias
Evaluation of the usefulness of a planar QRS-T angle smaller than or equal to 90º at base-
line in the prediction of an appropriate therapy-free follow-up revealed a positive predictive 
value of 94% (95% CI 89-98%) and a negative predictive value of 17% (95% CI 12-21%). 
Table 2. Event rates, hazard ratios, and p-values for end-points 








































































*Hazard ratio was adjusted for age, sex, LVEF, and QRS duration.
CI = confidence interval; HR = hazard ratioFigure Legends 











The spatial QRS-T angle had a positive predictive value of 98% (95% CI 95-100%) and 
a negative predictive value of 15% (95% CI 12-19%) for the prediction of an appropriate 
therapy-free follow-up. Most importantly, only 2% of the patients with a spatial QRS-T 
angle ≤ 100º had appropriate device discharges during follow-up, the only event occurring 
after 745 days (Figure 2).
Discussion
In the current study on the clinical application of the planar and spatial QRS-T angle in 
the prediction of ventricular arrhythmias in ischemic primary prevention ICD patients, the 





Figure 1: Kaplan-Meier Plot of Cumulative Incidence of first appropriate ICD therapy 
and appropriate shocks in the total study population. 
App = appropriate; ICD = Implantable Cardioverter Defibrillator 
Figure 2. Kaplan-Meier curve for cumulative event rate for appropriate therapy in patients with a planar 
QRS-T angle ≤ 90º vs. a planar QRS-T angle > 90º (panel A) and with a spatial QRS-T angle ≤ 100º vs. 
a spatial QRS-T angle > 100º (panel B).






QRS-duration, 1) patients with a wide planar QRS-T angle exhibited a nearly 2.5-fold risk 
for mortality, as well as for appropriate device therapy; 2) patients with a wide spatial 
QRS-T angle had a sevenfold risk for ventricular arrhythmias triggering appropriate device 
therapy; and 3) patients with a spatial QRS-T ≤ 100º prior to implantation, exhibited an 
absolute risk of 2% for appropriate therapy during follow-up.
With primary prevention ICD therapy as a class I indication in international guidelines in 
patients with a low LVEF, the indicated population, and therefore the worldwide defibrillator 
implantation rates, have increased significantly.11, 12 This expansion is of such magnitude 
that health care systems might lack the logistic capacity and financial means to meet the 
demand of ICD implantations.16, 28 Furthermore, MADIT II demonstrated a cumulative 
incidence of the need for defibrillator back-up of only 35% of patients after three years.13 
Moreover, 6% of ICD treated patients, experience severe device-related adverse events.14 
These issues underscore the need for better risk stratification within the indicated popula-
tion. 
Ideally, a parameter for the identification of a population at high or at low risk for the 
need for defibrillator back-up should be non-invasive and easily acquired. An ECG derived 
parameter such as the QRS-T angle, validated in the current analysis, would fit these 
demands.
Risk stratification with the QRS-T angle
The QRS-T angle is the angle between the electrical axes of depolarisation and repolarisa-
tion. In the present study, clinical application of both the planar as well as the spatial QRS-
T angle has been investigated in primary prevention ICD recipients with ischemic heart 
disease. The planar QRS-T angle is the projection of the spatial QRS-T angle in the frontal 
plane. As with any projection, it is sensitive to variations of the anatomical position of the 
heart in thorax. Therefore, the spatial QRS-T angle, which is calculated in the plane that 
the QRS- and T-axes form, is a more robust clinical tool. This is an important issue as the 
results from this study demonstrate that a narrow spatial angle is associated with a lower 
risk of ventricular arrhythmias. And although the spatial QRS-T angle cannot be derived 
directly from the surface ECG, recent studies have provided easy methods to acquire the 
spatial QRS-T angle from the standard 12-lead ECG.29 
In our population of ischemic primary prevention ICD recipients, patients with a wide 
planar QRS-T angle demonstrated a hazard ratio of 2.5 for the need of defibrillator back-up 
and 3.1 for all-cause mortality. In the recently published post hoc analysis of the DEFINITE 
trial, by Pavri and co-workers22, the planar QRS-T angle was analyzed as a predictor of 
the composite end-point of appropriate device therapy, mortality, and resuscitated cardiac 
arrest in a population with non-ischemic cardiomyopathy. In this study, the hazard ratio 
of a planar QRS-T angle wider than 90º for the occurrence of appropriate device therapy 











was 1.95 (95% CI 1.24-3.08). The hazard ratio for all-cause mortality was 1.81 (95% CI 
1.04-3.13). 
After adjustment for other commonly used risk factors, the presence of a spatial QRS-T 
angle wider than 100º was associated with a hazard ratio of 7.3 for the occurrence of 
device therapy for ventricular arrhythmias as compared to patients with a spatial QRS-T 
angle ≤ 100º, in our population. More importantly, all patients with a spatial QRS-T angle 
≤ 100º were free of device generated therapy during two years following implantation. This 
indicates that the spatial QRS-T angle may have an important potential for risk stratification 
in patients with ischemic heart disease. 
Previous studies on the spatial QRS-T angle have already indicated its high value in the 
risk stratification for cardiac death in a population without ICDs.20, 21 In a large cohort of 
patients, Yamazaki et al. observed a hazard ratio of 1.9 (95% CI 1.7-2.1) on cardiovascular 
death for a spatial QRS-T angle > 100º after correction for other ECG parameters.21 
As a consequence of the balanced regulation of electrical activation and recovery of the 
ventricles, a narrow QRS-T angle is generally observed in healthy individuals.27 Ventricular 
scar or residual ischemia, which is the arrhythmic substrate in ischemic cardiomyopathy, 
causes a disbalance of this process, sometimes referred to as electrical heterogeneity or 
discordance of de- and repolarisation.30 Vectorcardiographically, these alterations in cardiac 
electrophysiology become, amongst others, apparent through directional changes of the 
QRS and T vectors and consequent widening of the QRS-T angle. When patients with isch-
emic cardiomyopathy have a narrow QRS-T angle, which is then associated with electrical 
homogeneity, it could be postulated that the amount of arrhythmic substrate is limited and 
may even be absent. The high incidence of ventricular arrhythmias in patients with a wide 
QRS-T angle and the low incidence in patients with a narrow QRS-T angle, as observed in 
the current study, underscores this principle. 
Clinical implications
Several non-invasive parameters that could improve patient selection for ICD therapy 
have been proposed. These include LVEF, QRS duration, QT interval, heart rate variability, 
ventricular ectopy on ambulatory monitoring, exercise capacity, and T-wave alternans.31 
In addition, total cosine R to T, which is also a measure of QRS-T concordance like the 
QRS-T angle, has been proven a promising parameter in the mortality risk stratification in 
patients following myocardial infarction.32, 33 However, this variable has not been assessed 
in an ICD treated population, to our knowledge. Although the majority of these param-
eters appear promising, only LVEF has proven its usefulness in patient selection for ICD 
implantation and is currently the most important factor in the clinician’s choice whether or 
not an ICD is indicated.11 Still, in the implanted ischemic population, identified as being 
at high risk for ventricular arrhythmia based on depressed LVEF, 35% of patients actually 
experiences appropriate device therapy during follow-up, prompting for the identification 






of a sub-population at low risk.13 In our population of ischemic primary prevention ICD 
recipients, patients with a spatial QRS-T angle ≤100º demonstrated no ventricular ar-
rhythmias during the first two years following implantation and only 2% during further 
follow-up. These results imply that this parameter could be used in the discrimination of 
patients in whom the beneficial effects of an ICD might not exceed the costs and potential 
morbidity accompanying ICD therapy.
Limitations
This was a non-randomised prospective observational study, performed to assess the long-
term follow-up in ischemic primary prevention ICD recipients and to assess the value of 
the planar and spatial QRS-T angle in baseline risk stratification. Adjustment for additional 
variables in the multivariable Cox model was limited by the number of end-points reached. 
Furthermore, some patients without therapy during study follow-up might have reached an 
end-point, had follow-up been longer. Additionally, since not all patients had post-mortem 
ICD interrogation, some cases of death might have been arrhythmic. Finally, since patients 
were included over a period of 11 years, expanding guidelines for the implantation of de-
fibrillators, treatment of acute myocardial infarction, and pharmacological anti-arrhythmic 
therapy could have created an inhomogeneous population.  
Conclusion
In patients with ischemic heart disease, currently indicated for primary prevention ICD 
therapy, a baseline spatial QRS-T angle > 100º is associated with a sevenfold risk for the 
occurrence of appropriate device therapy, even after adjustment for commonly used risk 
factors. More importantly, a spatial QRS-T angle ≤ 100º on the ECG prior to implantation 
can identify patients with very low risk of life-threatening ventricular arrhythmias in whom 
the beneficial effect of ICD treatment might not exceed the costs and potential complica-
tions.
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Background: Myocardial excitability is known (amongst other reasons) to be related to the 
degree of ischemia, contractile dysfunction and heart failure. It was hypothesized that the 
right ventricular (RV) stimulation threshold has prognostic value with respect to the occur-
rence of ventricular arrhythmias (VAs) and patient survival in recipients of an implantable 
cardioverter defibrillator (ICD). 
Methods: Ischemic heart disease patients receiving an ICD at Leiden University Medical 
Center as primary prevention for sudden cardiac death were included in this study. RV-
thresholds were determined at ICD implant. Data was collected on VAs triggering ICD 
therapy and on all-cause mortality. 
Results: A total of 689 consecutive patients were included (87% male, age 63±11 years, 
left ventricular ejection fraction [LVEF] 29±11%) and followed for a median 28 months. 
Post-implant RV-threshold was 0.7±0.5volt (V) at 0.5ms pulse duration. Best dichotomous 
separation was reached at a cut-off of 1V. During follow-up, 167(24%) patients received 
appropriate ICD therapy, 88(13%) had appropriate shocks and 134(19%) died. Cumula-
tive appropriate shock incidence for patients with RV-threshold ≥1V (n=166) was 16% at 
1 year, 24% at 3 years and 34% at 5 years compared to 4%, 11% and 17% for patients 
with a RV-threshold <1V (n=523). Adjusted Hazard Ratio (HR) of RV-threshold ≥1V was 
1.8 (95% CI 1.3-2.6) for appropriate therapy, 3.3 (95%CI 2.0-5.4) for appropriate shocks 
and 1.6 (95%CI 1.1-2.5) for mortality.
Conclusion: The RV stimulation threshold at ICD implant has a strong independent 
prognostic value for the occurrence of ventricular arrhythmias triggering appropriate ICD 
therapy, appropriate shocks and mortality. 
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Following the results of several large randomized trials, current guidelines for prevention of 
sudden cardiac death (SCD) advocate implantation of an implantable cardioverter defibril-
lator (ICD) in patients with a low left ventricular ejection fraction (LVEF) without a prior 
life-threatening ventricular arrhythmia.1-5 This strategy has led to an increasing number 
of ICD implantations in recent years and currently, a low LVEF is still the most effective 
and consistent parameter used to select patients at risk of SCD.6-9 However, the rate of 
ventricular arrhythmias, triggering appropriate device therapy is relatively low (35-40%)10 
in this group of patients, warranting better risk-stratification for ICD implantation.
As the structure of cardiac tissue is affected by the pathological processes of infarction 
and subsequent fibrosis, the electrophysiological properties of the myocardium are altered 
significantly.11-13 The changes in cardiac tissue structure caused by myocardial infarction 
may increase the risk of ventricular arrhythmias to occur. Furthermore these changes may 
increase the myocardial excitability threshold.11-13 Consequently an increased excitability 
threshold may reflect an increased risk of ventricular arrhythmias.
In the current study, it was hypothesized that alterations of myocardial excitability caused 
by ischemic heart disease and reflected in part by changes in the stimulation threshold, 




Since 1996, all patients who received an ICD system in the Leiden University Medical 
Center were prospectively documented in the departmental Cardiology Information System 
(EPD-Vision®, Leiden University Medical Center). Patients included in this study received 
an ICD between 1999 and 2007. Characteristics at baseline, data of the implant proce-
dure, and data of all follow-up visits were recorded. For the current study, only patients 
with ischemic heart disease and a primary indication for defibrillator implantation were 
evaluated. We excluded patients with congenital structural, monogenetic heart disease, 
or non-ischemic heart disease for the present analysis. Furthermore, patients without a 
documented RV-threshold at implant were excluded for the present analysis.
Eligibility for ICD implantation in this population was based on international guidelines 
for the prevention of sudden cardiac death which, due to evolving guidelines may have 
changed over time. In the majority of patients, indication for an ICD was based on a 
depressed LVEF with or without non sustained ventricular tachycardia. Ischemic heart 
disease was defined as a history of myocardial infarction (presence of an unstable coronary 






lesion on angiography and/or the elevation of cardiac biomarker(s) above normal levels), 
or a history of significant coronary artery disease (an angiographically estimated diameter 
stenosis of at least 50% in at least one coronary artery and exercise induced myocardial 
ischemia/perfusion defect) that resulted in coronary revascularization.
ICD implantation
All defibrillator systems used were implanted transvenously without thoracotomy. The right 
ventricular lead was positioned in the right ventricular apex near the septum and adjust-
ments, if necessary, were made to achieve an optimal pacing threshold. During the implant 
procedure standard testing of sensing and pacing thresholds and defibrillation threshold 
testing was performed. Used systems were manufactured by Biotronik (Berlin, Germany), 
Medtronic (Minneapolis, MN, United States), Boston Scientific (Natick, MA, United States, 
formerly CPI, Guidant [St. Paul, MN, United States]) and St. Jude Medical/Ventritex (St. 
Paul, MN, United States).
In this primary prevention patient cohort, defibrillators were programmed as follows: a 
monitor zone was programmed in all patients to detect ventricular arrhythmias faster than 
150 bpm. No therapy was programmed in this zone. Ventricular arrhythmias faster than 
188 bpm were initially attempted to be terminated with two bursts of antitachycardiapacing 
(ATP) and, after continuation of the arrhythmia, with defibrillator shocks. In the case of a 
ventricular arrhythmia faster than 210 bpm, device shocks were the initial therapy. Further-
more, atrial arrhythmia detection was set to >170 bpm with supraventricular tachycardia 
(SVT) discriminators enabled. Settings were adapted, only when clinically indicated (i.e. 
hemodynamic well tolerated ventricular tachycardia at high rate; ventricular tachycardia in 
the monitor zone). The stimulation threshold was determined by automatic decrementation 
of the stimulus voltage at constant pulse duration of 0,5ms after implant.
Follow-up and Endpoints
All patients visited the clinic for follow-up assessments every 3 to 6 months. Patients 
were followed up to February 2009. At each patient visit, a trained device specialist or 
cardiologist performed device interrogation and determined sensing, pacing thresholds, and 
lead impedance.
The primary endpoint was ventricular arrhythmia triggering appropriate defibrillator 
therapy (antitachycardia pacing [ATP] or shock) or appropriate shock only. Secondary 
endpoint was all-cause death.
ICD evaluation
All printouts were checked for appropriate and inappropriate ICD therapy (ATP or shocks). 
Therapies were classified as appropriate when they occurred in response to ventricular 
tachycardia (VT) or ventricular fibrillation (VF) and as inappropriate when triggered by 
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sinus or SVT, T-wave oversensing, or electrode dysfunction. Cutoff rate of the monitor or 
first therapy zone was noted.
Statistical Analyses
Continuous data are expressed as mean (±standard deviation) or as median (25th/75th 
percentile); dichotomous data are presented as numbers and percentages. Differences 
at baseline were tested for statistical significance using a Chi-square test using Yate’s 
correction or student t-test for independent samples where appropriate. Event rates over 
time were analyzed by method of Kaplan-Meier with corresponding log-rank test for differ-
ences in distribution between the curves. Since follow-up was performed every three to six 
months, patients without data in the past six months were censored at the date of their 
last visit. 
We used multivariable Cox regression analyses to assess the association between stimu-
lation threshold and ventricular arrhythmias independent of an increasing number of other 
risk factors including age (years), gender (male/female), cardiac resynchronization therapy 
(yes/no), LVEF (%), history of atrial fibrillation/atrial flutter (any/none), use of amiodarone 
(yes/no), use of beta-blocker (yes/no), use of sotalol (yes/no), anterior MI (yes/no), lateral 
MI (yes/no), inferior MI (yes/no), and posterior MI (yes/no) as potential confounders. Hazard 
Ratio (HR) is reported with the corresponding 95% confidence interval (CI). All tests were 
two-sided, a p-value of < 0.05 was considered statistically significant. Missing values of 
all the variables were seen only for the variable atrial fibrillation/atrial flutter, in less than 
0.3% (n=2/689) of all patients. The regression models were done on the patients without 
missing values.
A receiver operating characteristic (ROC) curve analysis was used to measure the ability 
of the RV-threshold to discriminate between patients that received appropriate therapy and 
patients that did not.
Results
Patient population
A total of 1086 consecutive ICD recipients with a primary prevention indication were 
registered in the electronic database system. Fifty patients (5%) were excluded due to 
incomplete follow-up data, 332 patients (31%) due to non-ischemic heart disease and 15 
patients (1%) due to non-documented baseline RV-threshold measurements. The remain-
ing 689 patients were included in the present analysis and followed for a median 28 
months (interquartile range (IQR) 16 to 46 months).
The majority of patients (87% male, 63 ± 11 years, LVEF 29 ± 11%) had a history 
of myocardial infarction (84%) or coronary revascularization procedure (PCI 28%, CABG 






43%)(Table 1). Median RV-threshold was 0.5V (IQR 0.5 to 0.8V) at 0.5ms pulse duration. 
ROC curve analysis of the RV-threshold suggested that a cutoff of 1V provided the best 
clinically useful dichotomous separation for assessment of the primary endpoint. A RV 
stimulation-threshold ≥1V was observed in 166 (24%) patients. 








Male sex 600 (87) 459 (88) 141 (85) 0.35
Age (years) 63 ± 11 63 ± 11 63 ± 11 0.81
Hypertension 318 (46) 239 (46) 79 (48) 0.72
Diabetes 176 (26) 130 (25) 46 (28) 0.40
Smoking 151 (22) 118 (23) 33 (20) 0.50
Prior myocardial infarction 578 (84) 436 (83) 142 (86) 0.55
   Anterior† 304 (53) 237 (54) 67 (47) 0.13
   Inferior† 161 (28) 112 (26) 49 (35) 0.043*
   Lateral† 76 (13) 54 (12) 22 (16) 0.32
   Posterior† 49 (9) 36 (8) 13 (9) 0.76
Prior PCI 192 (28) 145 (28) 47 (28) 0.92
Prior CABG 296 (43) 226 (43) 70 (42) 0.86
hypercholesterolemia 463 (67) 364 (70) 99 (60) 0.051
Family History of CAD 300 (44) 220 (42) 80 (48) 0.21
Atrial fibrillation/flutter 
documented
170 (25) 123 (24) 47 (28) 0.26
QRS width 126 ± 34 125 ± 34 130 ± 34 0.10
Creatinine clearance (ml/min) 78 ± 35 78 ± 32 77 ± 43 0.70
Ejection Fraction 29 ± 11 29 ± 10 29 ± 13 0.90
Cardiac resynchronization 
therapy
335 (49) 263 (50) 72 (43) 0.13
Medication
   Beta-blocker 425 (62) 345 (66) 80 (48) <0.001*
   Sotalol 75 (11) 47 (9) 28 (17) 0.006*
   ACE-inhibitor/ATII-antagonist 580 (84) 443 (85) 137 (83) 0.54
   Diuretics 502 (73) 375 (72) 127 (77) 0.27
   Statin 560 (81) 426 (82) 134 (81) 0.82
   Aspirin 332 (48) 255 (49) 77 (46) 0.76
   Oral anticoagulation 400 (58) 304 (58) 96 (58) 1.00
   Amiodarone 110 (16) 70 (13) 40 (24) 0.002*
Values are expressed as n (%) or as mean ± standard deviation. * p <0.05
†Patients could fall into more than one infarction location category (i.e. anterolateral, inferoposterior 
infarction).
Jan-Willem BW new.indd   180 29-07-10   13:30
181









Baseline characteristics distributed according to RV-threshold are reported in table 1. 
With the exception of infarct localization (higher number of inferior wall infarctions in the 
>1 RV threshold group (p=0.04)) baseline characteristics were similar. Cardiac resynchro-
nization therapy was combined with the defibrillator device in approximately 50% of cases 
of either group (RV-threshold <1V: 50%, RV-threshold ≥1V: 43%; p = 0.13). Concerning 
the use of drugs: Patients with a higher threshold more often used sotalol and amiodarone 
than patients with a threshold < 1V. Patients with lower threshold more often used beta-
blockers. The use of other drugs was similar in both groups.
Device therapy
During follow up, a total of 1615 episodes of ventricular arrhythmia were appropriately 
terminated by the ICD in 24% (n=167) of patients either by ATP or by shock delivery. 
A total number of 278 shocks were delivered appropriately by the ICD in 13% (n=88) 
of patients. Furthermore, 68 patients (10%) experienced inappropriate shocks. Figure 1 
shows the distribution over time of first appropriate therapy and -shocks for the total patient 
cohort.  
Appropriate therapy during follow-up occurred more often in patients with a RV-threshold 
≥1V (37%, 62 of 166 patients) when compared to patients with a RV-threshold <1V (20%, 
105 of 523 patients). Furthermore, the number of patients that experienced appropriate 
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Figure 2: A. Kaplan-Meier Plot of Cumulative Incidence of first appropriate ICD therapy. 
B. Kaplan-Meier Plot of Cumulative Incidence of first appropriate ICD shocks. 
RV = Right Ventricular; Thresh = threshold; other abbreviations as in Figure 1. 
Figure 1: Kaplan-Meier Plot of Cumulative Incidence of first appropriate ICD therapy and appropriate 
shocks in the total study population.
App = appropriate; ICD = Implantable Cardioverter Defibrillator






ICD shocks was more than three times higher in the group with a RV-threshold ≥1V (26%, 
43 of 166 patients) than in the group with a RV-threshold <1V (9%, 45 of 523 patients).
Figure 2 illustrates the time course of first appropriate therapy (panel A) and for first 
appropriate shocks (panel B) for patients with a RV-threshold <1V and a RV-threshold ≥1V. 
A significantly higher cumulative incidence of first ICD therapy and shocks was observed 
in the group with a RV-threshold ≥1V. Cumulative appropriate shock rate for patients with 
a RV-threshold ≥1V was 16% (95%CI 10-22%) at 1 year, 24% (95%CI 17-31%) at 3 
years and 34%(95%CI 24-43%) at 5 years compared to 4% (95%CI 2-5%) at 1 year, 
11% (95%CI 7-14%) at 3 years and 17% (95%CI 12-23%) at 5 years for patients with a 
RV-threshold <1V (log-rank p<0.001). 
Post-implant RV-threshold ≥1V was found to be an independent and significant predictor 


















































































































































































Figure 3: Kaplan-Meier Plot of Cumulative Incidence of Death. 
Abbreviations as in Figure 2. 
Figure 2: A. Kaplan-Meier Plot of Cumulative Incidence of first appropriate ICD therapy.
B. Kaplan-Meier Plot of Cumulative Incidence of first appropriate ICD shocks.
RV = Right Ventricular; Thr sh = threshold; other abbreviati ns as in Figure 1.
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ate shocks (adjusted HR model 3: 3.3, 95%CI 2.0-5.4) after correcting for other potential 
confounders as listed. 
As the measured RV-threshold increased, the percentage of patients experiencing appro-
priate shocks increased. The area under the ROC curve for RV-threshold was significantly 
greater than 0.5 (area under ROC curve 0.7; 95%CI 0.6-0.7; p<0.001). A high specificity 
was observed at a cut-off value around ≥1V (specificity 80% [95%CI 76-83%]) at the 
expense of sensitivity (49% [95%CI 38-60%]). The negative predictive value of the RV-
threshold cut-off value of 1V was 91%.
Mortality
One-hundred and thirty-four (19%) patients died during the follow-up period. Total mortal-
ity in patients with a RV-threshold ≥1V (28%, 47 of 166 patients) was higher compared to 
the group of patients with a RV-threshold <1V (17%, 87 of 523).
Cumulative survival (%) for the two study groups is displayed in Figure 3. A trend exists 
toward decreased patient survival in the patient group with a RV-threshold ≥1V. Cumulative 
survival in this group is 90% (95%CI 86-95%) at 1 year, 78% (95%CI 72-85%) at 3 years 
and 70% (95%CI 61-78%) at 5 years, compared to 94% (95%CI 92-96%) at 1 year, 
81% (95%CI 77-85%) at 3 years and 73% (95%CI 67-79%) at 5 years in the group with 
a RV-threshold <1V. The log-rank test for this difference was not statistically significant 
(p=0.12).
However, post-implant RV-threshold ≥1V was found to be an independent and significant 
predictor of mortality after correcting for potential confounders as listed in table 2. After 
 27































Figure 1. First inappropriate device shock 
 
 
Figure 3: Kaplan-Meier Plot of Cumulative Incidence of Death.
Abbreviations as in Figure 2.






adjustment the mortality rate was 60 percent higher among those with RV-threshold ≥1V 
as compared to patients with RV-threshold <1V (adjusted HR model 3: 1.6, 95%CI 1.1-
2.5) (Table 2). 
Discussion
In this cohort of ICD treated patients with ischemic heart disease and a primary prevention 
indication for ICD treatment, a post-implant right ventricular stimulation threshold ≥1V was 
independently associated with (1) a higher occurrence of ventricular arrhythmias triggering 
appropriate therapy, (2) a 3-fold higher occurrence of ventricular arrhythmia triggering 
appropriate shocks and (3) a 60% higher risk of mortality compared to patients with a 
threshold <1V. 
Risk stratification for SCD
LV function is an established indicator for an increased risk of SCD.6-8 Results of a series of 
randomized trials have resulted in a rise in the number of ICD implantations due to a great 
expansion in the indications for primary prevention ICD use.1, 3-5 However, the relatively 
low percentage of ICD patients who receive appropriate therapy (35-40% of patients in 
MADIT II and SCD-Heft)1, 10 suggested a considerable risk heterogeneity in the low LVEF-
population. This has prompted a series of studies and secondary analyses from the major 
ICD trials in an attempt to identify factors that can be used to stratify patients with reduced 
LVEF into high- and low risk subgroups.14-22 Given the complexity and limitations of some 
of these proposed stratification strategies, the RV stimulation threshold is a relatively easy 
to use, straightforward prognostic parameter. It may assist clinicians in identifying ICD 
treated patients at high risk of receiving appropriate ICD therapy and a higher risk of death, 
therefore facilitating better evaluation of the prognosis post-implant. 
Ischemic heart disease, poor excitability and arrhythmogenesis
Prior myocardial infarction leaves a residue of poorly excitable cardiac tissue. Findings 
from a canine study suggested that disruptions in cell-to-cell electrical continuity may 
contribute to slow conduction in the infarcted region.12 In later experiments a persistent 
reduction of the space constant existed in chronically infarcted canine myocardium 5-8 
days after persistent occlusion and reperfusion which is directly related to slow conduction 
velocity.13 The investigators hypothesized that these alterations were due to a depression 
in action potential depolarization, an increase in internal axial resistance (by modification 
of the low resistance gap junctions, therefore increasing anisotropy) and an increase in the 
axial resistance of the extracellular space (due to the fibrotic matrix in which surviving cells 
are distributed within the mottled infarcted myocardium). Furthermore, wavefront-obstacle 
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interactions in a poorly excitable medium may reflect an arrhythmogenic process that 
permits formation of separate new wavelets which in vivo may lead to flutter, fibrillation, 
and sudden cardiac death.23 
Arrhythmias leading to sudden cardiac death are often associated with the presence 
of inhomogeneities (obstacles) in cardiac tissue and reduced excitability of cardiac cells. 
Observations of fast arrhythmias in a medium of reduced excitability, combined with me-
dium inhomogeneities provide a substrate for formation of multiple wavelets leading to 
high-frequency arrhythmias.11, 24-26
Device therapy and stimulation threshold
Stimulation thresholds vary immediately following implant due to lead-myocardium 
maturation and chronically due to changes in underlying myocardium, ischemia, infarction, 
metabolic state, or drug therapy.27-30 The present findings suggest that properties of the 
baseline RV stimulation threshold may be used clinically as an indicator of chronic changes 
caused by ischemic heart disease, increasing the risk of arrhythmic events requiring ICD 
therapy and the risk of mortality. A high RV stimulation threshold was used as a marker of 
the degree of poor myocardial excitability to indirectly indicate potentially arrhythmia-prone 
conditions. The association was found to be independent of infarction location despite the 
essentially local measurement position at the RV apex, which implies that the parameter 
reflects not only a localized effect but rather a sum of effects. While the cumulative survival 
analysis was not able to demonstrate a significant difference in mortality incidence between 
the two study groups (Figure 3), post-implant RV-threshold ≥1V was nevertheless found to 
be independently associated with a 60% increased hazard of mortality after adjusting for 
confounders as listed in table 2. As its association with ventricular arrhythmia triggering 
appropriate shocks was strongest, the risk parameter may be most valuable for the estima-
tion of fast, potentially life-threatening, arrhythmias. 
Though the optimal cut-off value of the RV stimulation threshold for its best predictive 
value may vary slightly in post-MI patient subgroups with different baseline characteristics 
or for a different time point of baseline measurement, its ability to identify patient with 
a higher risk of arrhythmic events leading to appropriate ICD therapy and shocks will 
most likely not be affected. This is supported by results of the multivariate analyses that 
showed that the effect was independent of other predictors. Antiarrhythmic drugs such as 
beta-blockers tend to increase the stimulation threshold, but paradoxically in the current 
study were used more frequently in the group with RV-threshold <1V, suggesting a limited 
clinical effect. Amiodarone treatment was more prevalent in patients with RV-threshold 
≥1V, but whether the type III antiarrhythmic drug has similar effects is as yet unclear. 
Virtually all antiarrhythmic drugs may influence the pacing threshold but usually become 
clinically important only at high serum concentrations.29







This is a single-center follow-up study based on data of routine clinical practice. However, 
missing data in the enrolled population was seen in less than 1% which limited potential 
over- or underestimation of findings. Guidelines for ICD eligibility might have changed over 
time, creating a more heterogeneous patient population than in the strict controlled condi-
tions of a clinical trial. Potentially confounding effects of these heterogeneities were limited 
by using the multivariable Cox analysis to assess the independent association between 
stimulation threshold and ventricular arrhythmias. Of note, clinical usefulness of the stimu-
lation threshold before the implantation of the ICD still remains to be investigated. Findings 
of the present study would need to be confirmed by further studies and may eventually be 
included in a risk score for occurrence of ventricular arrhythmias. Lastly, while appropriate 
ICD therapy was used as a primary endpoint throughout the current study, it should be 
noted that it is not a perfect surrogate for life-threatening ventricular arrhythmia or SCD.
Conclusion
In ICD treated patients with a primary prevention indication and ischemic heart disease 
the RV stimulation threshold at implantation has an independent prognostic value for the 
prediction of potentially life-threatening ventricular arrhythmia and death.
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Objectives: To assess the incidence, predictors and outcome of inappropriate shocks in 
implantable cardioverter defibrillator (ICD) patients.
Background: Despite the benefits of ICD therapy, inappropriate defibrillator shocks continue 
to be a significant drawback. The prognostic importance of inappropriate shocks outside 
the setting of a clinical trial remains unclear. 
Methods: From 1996 to 2006, all recipients of defibrillator devices equipped with intra-
cardiac electrogram storage were included in the current analysis and clinically assessed at 
implantation. During follow-up, the occurrence of inappropriate ICD shocks and all-cause 
mortality were noted. 
Results: A total of 1544 ICD patients (79% male, 61 ± 13 years) were included in 
the analysis. During the follow-up period of 41 ± 18 months, 13% experienced one or 
more inappropriate shocks. The cumulative incidence steadily increased to 18% at 5 years 
follow-up. Independent predictors for the occurrence of inappropriate shocks consisted of 
history of atrial fibrillation (HR 2.0, p<0.01) and age below 70 years (HR 1.8, p=0.01). 
Experiencing a single inappropriate shock resulted in an increased risk for all-cause mortal-
ity (HR 1.6, p=0.01). Mortality risk increased with every subsequent shock, up to a HR of 
3.7 after 5 inappropriate shocks.
Conclusions: In a large cohort of ICD patients, inappropriate shocks were common. Most 
important finding is the association between inappropriate shocks and mortality, indepen-
dently of interim appropriate shocks. 











Ventricular tachycardia (VT), deteriorating into ventricular fibrillation (VF) is responsible 
for an estimated one third of all cardiovascular mortality worldwide 1-3. Several important 
clinical trials have shown that the implantable cardioverter defibrillator (ICD) provides a 
substantial and significant reduction in mortality in survivors of sudden cardiac arrest and 
high-risk patients with cardiovascular disease 4-9. Despite proven survival benefits, ICD 
treatment is still subjected to drawbacks, one of the most important being shocks delivered 
for causes other than potentially life-threatening VT or VF. These inappropriate shocks are 
painful, psychologically disturbing and potentially arrhythmogenic 10-13. Recently, subgroup 
analysis of two major ICD clinical trials have reported on prognosis of ICD shocks and 
raised concern by establishing an association between inappropriate shocks and increased 
mortality 14, 15. However, extrapolating these results to ICD recipients into everyday or rou-
tine clinical practice is difficult, since these clinical trials comprised a selected population. 
Therefore, we analyzed a large population of ICD patients with long term follow-up outside 
the setting of a clinical trial to evaluate the occurrence of inappropriate ICD shocks, to 
identify potential predictive parameters for inappropriate shocks, and to assess the impact 
of inappropriate shocks on long term outcome. 
Methods
Patient population
Since 1996, all patients who received an ICD at the Leiden University Medical Center were 
recorded in the departmental Cardiology Information System (EPD®-vision, Leiden Univer-
sity Medical Center). For the current analysis, all ICDs implanted up to 2006 were included 
to assure a minimum in follow-up duration. Eligibility for ICD treatment was determined 
in accordance with the international guidelines and included patients with sustained VT 
and patients with a severely depressed left ventricular ejection fraction (LVEF), regardless 
of prior ventricular arrhythmia 16-18. As a result of advancing guidelines, the eligibility have 
changed over time.
To retrieve accurate information about the origin and classification (i.e. appropriate vs in-
appropriate) of ICD shocks, only recipients of ICDs equipped with intracardiac electrogram 
storage were included in the current analysis. Baseline characteristics were collected to 
identify potential predictors of inappropriate shocks. In addition, the effect of inappropriate 
shocks on mortality was assessed.






Device implantation and programming
All defibrillator systems were implanted in the pectoral region. During the implant procedure 
testing of sensing and pacing thresholds and defibrillation threshold testing was performed. 
Used systems were manufactured by Biotronik (Berlin, Germany), Medtronic (Minneapolis, 
MN, United States), Boston Scientific (Natick, MA, United States) and St. Jude Medical 
(St. Paul, MN, United States).
Defibrillators were programmed as follows: ventricular arrhythmia faster than 150 beats 
per minute was monitored by the device without consequent defibrillator therapy (zone 
1). Ventricular arrhythmias faster than 188 beats per minute were initially attempted to 
be terminated with two bursts of anti tachycardia pacing and, after continuation of the 
arrhythmia, with defibrillator shocks (zone 2). In the case of a ventricular arrhythmia faster 
than 210 beats per minute, device shocks were the initial therapy (zone 3). Furthermore, 
atrial arrhythmia detection was set to >170 beats per minute with supraventricular tachy-
cardia discriminators enabled. In all devices, “stability” and “sudden onset” algorithms 
were activated to reduce the occurrence of inappropriate shocks 19. Moreover, additional 
discriminators were activated in dual-chamber ICDs and cardiac resynchronization therapy 
– defibrillators (CRT-Ds).20, 21 Settings were adapted, only when clinically indicated (i.e. 
hemodynamic well tolerated VT at high rate; VT in the monitor zone).
Follow-up
In the Dutch health care system, the implanting center is responsible for the device follow-
up which is performed every 3 – 6 months after implantation. During every interrogation, 
device storage was checked for delivered therapy (appropriate / inappropriate). Adjudica-
tion of the delivered therapy was performed by a trained electrophysiologist.
An inappropriate shock was defined as an episode, starting with a shock not delivered 
for VT or VF and ending if sinus rhythm was redetected by the ICD. Consequently, it was 
possible that multiple inappropriate shocks occur within one episode. If a subsequent 
episode started within 5 minutes after the previous episode ended, it was not considered 
as a new episode. Furthermore, the cause of an inappropriate shock was categorized into 
supraventricular tachycardia (including atrial fibrillation (AF)), sinus tachycardia or abnor-
mal sensing. 
Patients with missing data for more than 6 months were considered lost to follow-up.
Statistical analysis
Continuous variables were presented as mean values ± standard deviation and categorical 
variables as numbers and percentages. Cumulative event rates were calculated by using the 
Kaplan-Meier method and log-rank test, in which patient death and device replacement were 
considered censoring events. Causes of inappropriate shocks for the different device types 
were compared using the chi-square test. Predictors of inappropriate shocks were determined 










by the method of Cox proportional hazards regression. First, univariate analysis was per-
formed, containing all baseline variables and interim appropriate shocks. Subsequently, all 
variables with a p-value of < 0.10 were included in the multivariate analysis. A p-value of 
< 0.25 was considered as statistically significant for the multivariate regression. To examine 
differences in the occurrence of inappropriate shocks per time span of ICD implantations, 
patients were divided into two groups by the median calendar year of ICD implantations. A 
log rank test was used to compare the cumulative event rates between both groups. 
The relation between inappropriate shocks and all-cause mortality was assessed using 
a Cox proportional hazard model with first inappropriate shock or multiple inappropriate 
shocks (up to 5) as a time-dependent covariate, adjusting for commonly used predictors of 
all-cause mortality (history of AF, age > 70 years,22 New York Heart Association (NYHA) 
class > II, renal clearance < 90 ml/min (determined with the formula of Cockroft-Gault),23 
QRS duration >120 ms, usage of β-blockers22 and interim appropriate shocks15). 
Interim appropriate shocks were defined as appropriate ICD shocks prior to an inap-
propriate ICD shock and considered time-dependent covariates in analyses for prediction of 
inappropriate shocks as well as for prediction of all-cause mortality. The calculated relation 
was presented as a hazard ratio (HR) with a 95% confidence interval (CI). 
The statistical software program SPSS 16.0 (SPSS, Chicago, Illinois) was used for 




From 1996 to 2006, 1658 patients received an ICD-system with intracardiac electro-
gram technology according to the international guidelines.16-18 One-hundred-and-fourteen 
patients (7%) were lost to follow-up. The remaining 1544 (93%) patients constituted 
the patient population. Of these patients (79% men, average age 61 ± 13 years), 56% 
received an ICD for primary prevention and 64% had ischemic heart disease. Baseline 
patient characteristics are summarized in Table 1. 
Incidence of inappropriate shocks
During the follow-up period of 41 ± 18 months, 204 of 1544 patients (13%) experienced 
a total of 665 inappropriate ICD shocks. The average time from implantation to first inap-
propriate shock was 17 ± 16 months. The cumulative event rate for first inappropriate 
shocks was 7% (95%CI 6 – 9%) at 1 year, 13% (95%CI 11 – 14%) at 3 years and 18% 
(95%CI 15 – 20%) at 5 years (Figure 1). A second inappropriate shock was experienced 
by 73 of 204 patients (36%) with an average time from first to second shock of 11 ± 11 






months. The cumulative event rate for a second inappropriate shock was 28% (95%CI 
22 – 34%) at 1 year, 49% (95%CI 40 – 58%) at 3 years and 55% (95%CI 44 – 66%) at 
5 years follow-up (Figure 2). 
Predictors of inappropriate shocks
To determine specific clinical parameters predicting the occurrence of inappropriate device 
discharges, the univariate Cox model disclosed that age < 70 years (HR 1.7 95%CI 
1.1 – 2.3, p<0.01), history of AF (HR 2.0 95%CI 1.5 – 2.7, p<0.01), non-ischemic 
heart disease (HR 1.3 95%CI 1.0 – 1.8, p=0.04), non-usage of statins (HR 1.4 95%CI 
1.0 – 1.8, p=0.03) and interim appropriate shocks (HR 1.6 95%CI 1.0 – 2.7, p=0.04) 
were independent predictors of inappropriate shocks (Table 2). By multivariate analysis, 
age < 70 years (1.8 95%CI 1.3 – 2.5, p<0.01), history of AF (HR 2.0 95%CI 1.5 – 2.7, 
p<0.01), no statin usage (HR 1.3 95%CI 1.0 – 1.7, p=0.10) and interim appropriate 
shocks (HR 1.6 95%CI 1.0 – 2.6, p=0.06) were predictors of the occurrence of inap-
propriate shocks. 
Table 1. Baseline characteristics of patient population (n=1544)
Clinical parameters
Age (years) 61 ± 13 
Male gender 1220 (79%)
Primary prevention 865 (56%)
Ischemic heart disease 988 (64%)
LVEF (%) 35% ± 16%
QRS duration (ms) 125 ± 35
NYHA III or IV 510 (33%)
History of AF 355 (23%)
History of smoking 818 (53%)
Diabetes 293 (19%)
Medication




ACE inhibitors/AT antagonists 1112 (72%)
Ca antagonists 154 (10%)
Amiodarone 309 (20%)
Devices
Single chamber ICD 188 (12%)
Dual chamber ICD 819 (53%)
CRT-D 537 (35%)
ACE=angiotensin-converting enzyme; AF=atrial fibrillation; AT=angiotensin; CRT-D=cardiac resynchro-
nization therapy – defibrillator; ICD=implantable cardioverter defibrillator; LVEF=left ventricular ejection 
fraction; NYHA=New York Heart Association. 










Period of ICD implantation 
To explore whether differences over time could be observed in the occurrence of inap-
propriate shocks, two ICD patient groups were designated according to the median of 
calendar years of ICD implantations (May 2004). The first group underwent ICD implanta-
tion from 1996 to May 2004 and comprised 772 patients. The cumulative event rate for 
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Figure 1. First inappropriate device shock 
 
 
Figure 1. Kaplan-Meier curve for the occurrence of first inappropriate ICD shock.
ICD = implantable cardioverter defibrillator.
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Figure 2. Second inappropriate device shock 
 
 
Figure 3. First inappropriate shock comparing time periods of ICD implantation. 
 
Figure 2. Kaplan-Meier curve for the occurrence of second inappropriate ICD shock, received after the 
first inappropriate ICD shock. 
ICD = implantable cardioverter defibrillator






first inappropriate shock was 7% (95%CI 5 – 9%) at 1 year, 10% (95%CI 7 – 12%) at 2 
years and 11% (95%CI 9 – 14%) at 3 years. The second group consisted of 772 patients 
who received an ICD system from May 2004 to 2006. The cumulative event rate for first 
inappropriate shock was 8% (95%CI 6 – 10%) at 1 year, 12% (95%CI 9 – 14%) at 2 years 
and 14% (95%CI 11 – 16%) at 3 years (Figure 3). 
In multivariate risk analysis, adjusted for baseline and interim variables (history of AF, 
age below 70 years, no statin usage and interim appropriate shocks), patients who received 
an ICD after May 2004, compared with before May 2004, tended to experience more 
inappropriate shocks (HR 1.3 95%CI 1.0 – 1.8, p=0.05).
Causes and differences between device types
The main cause of inappropriate shocks was misdiagnosis of supraventricular tachycardia, 
occurring in 155 (76%) of the 204 patients. The mean cycle length at the time of a 
patient’s first inappropriate shock for supraventricular tachycardia was 299 ± 39 ms and 
occurred predominantly in ICD program zone 2 (60%). 
As can be seen in Table 3, comparison per device type did not show significant differences 
in the occurrence of inappropriate shocks. However, the cause of inappropriate shocks did 
differ between device types. Patients with a single-chamber ICD received significantly more 
shocks resulting from misdiagnosis of sinus tachycardia than patients with a dual-chamber 
ICD (24% vs 8%, p=0.02). Furthermore, patients with a CRT-D tended to experience 
more inappropriate discharges due to abnormal sensing than ICD recipients with a single 
chamber ICD (15% vs 8%, p=0.28).
Table 2. Predictors of ≥ 1 inappropriate shocks
Univariate Multivariate
HR 95%CI p-value HR 95%CI p-value
Female 0.8 0.6 – 1.2 0.34
Age < 70 years 1.7 1.1 – 2.3 <0.01* 1.8 1.3 – 2.5 0.01
History of AF 2.0 1.5 – 2.7 <0.01* 2.0 1.5 – 2.7 <0.01
History of smoking 1.2 0.9 – 1.6 0.32
Secondary indication for ICD 1.1 0.8 – 1.5 0.48
Non-ischemic heart disease 1.3 1.0 – 1.8 0.04*
No statins at baseline 1.4 1.0 – 1.8 0.03* 1.3 1.0 – 1.7 0.09
β-blocker 0.8 0.6 – 1.1 0.22*
NYHA class III-IV 1.0 0.7 – 1.3 0.96
Interim appropriate shocks 1.6 1.0 – 2.7 0.04* 1.6 1.0 – 2.6 0.06
AF=atrial fibrillation; HR=hazard ratio; ICD=implantable cardioverter defibrillator; NYHA=New York 
Heart Association. *variable was included in multivariate analysis










Effect of inappropriate shocks on survival
A total of 298 (19%) patients died during study follow-up. When compared to patients 
without inappropriate shocks, the occurrence of the first inappropriate shock tended to 
increase risk for all-cause mortality (HR 1.4, 95%CI 1.0 – 2.0, p = 0.07). Adjustment 
for potential confounders (history of AF, age > 70 years, NYHA class > II, renal clearance 
< 90ml/min, QRS duration > 120 ms, β-blockers usage and interim appropriate shocks) 
demonstrated that the occurrence of an initial inappropriate shock was related to a 60% 
increase in risk for mortality (HR 1.6 95%CI 1.1 – 2.3, p = 0.01). Moreover, adjusted 
time-dependent mortality risk for subsequent inappropriate shocks showed a HR of 1.4 
(95%CI 1.2-1.7, p<0.01) per additional shock, up to a HR of 3.7 after experiencing 5 




Figure 1. Cumulative requirement for CS lead intervention. 
 
Figure 3: Kaplan-Meier Plot of Cumulative Incidence of Death.
Abbreviations as in Figure 2.









Patients with ≥1 inappropriate shock 204 (13%) 29 (15%) 122 (15%) 53 (10%)
Rhythm misdiagnosis 
Supraventricular tachycardia 155 (76%) 19 (65%) 96 (79%) 40 (75%)
AF 92 (45%) 14 (48%) 55 (45%) 23 (43%)
Other than AF 63 (31%) 5 (17%) 41 (34%) 17 (32%)
Abnormal sensing 25 (12%) 2 (8%) 15 (12%) 8 (15%)
Sinus tachycardia 22 (11%) 7 (24%) 10 (8%) 5 (10%)
Unclassified 2 (1%) 1 (3%) 1 (1%) 0 (0%)
AF=atrial fibrillation; CRT-D=cardiac resynchronization therapy – defibrillator; ICD=implantable cardio-
verter defibrillator.







The main findings of the current study on the incidence, predictors and outcome of inappro-
priate shocks can be summarized as follows: (1) the cumulative incidence of inappropriate 
shocks was 7% at 1 year, 13% at 3 years and 18% at 5 years follow-up, (2) misdiagnosis 
of supraventricular tachycardia was the leading cause (76%) of inappropriate shocks, (3) 
age below 70 years, history of AF, no statin usage and interim appropriate shocks were 
predictors of inappropriate shocks, and (4) inappropriate shocks were associated with a 
higher risk of all-cause mortality. 
Incidence 
In major randomized clinical trials, the occurrence of inappropriate ICD therapy (i.e. an-
titachycardia pacing and shocks) is well assessed, ranging from 10% to 24% over 20 to 
45 months of follow-up.24 However, lower incidences were reported when assessing inap-
propriate shocks only, such as 9% in the Antiarrhythmics versus Implantable Defibrillators 
trial and 11.5% in the Multicenter Automatic Defibrillator Implantation Trial II (MADIT II), 
both reported during 2 years follow-up. The current analysis demonstrated a comparable 
cumulative event rate of 10% at 2 years follow-up and showed that this incidence steadily 
increased to 18% at 5 years follow-up. In addition, more than half of patients who received 
a single inappropriate shock experienced another one within 5 year follow-up. 
Predictors
Since more than half of all inappropriate shocks are due to misdiagnosis of AF, several 
studies have reported on a history of AF as the most significant baseline clinical predictor 
Table 4. Predictors of all-cause mortality
Univariate Multivariate
HR 95%CI p-value HR 95%CI p-value
Baseline variables
History of atrial fibrillation* 1.3 1.0 – 1.7 0.11 1.4 1.0 – 1.7 <0.01
Age > 70 years* 2.7 2.2 – 3.4 <0.01 1.9 1.5 – 2.5 <0.01
NYHA > II* 2.0 1.6 – 1.5 <0.01 1.5 1.1 – 1.9 0.03
Renal clearance <90 ml/min* 2.7 2.0 – 3.7 <0.01 1.7 1.2 – 2.4 0.02
QRS duration > 120ms* 2.0 1.6 – 2.5 <0.01 1.4 1.1 – 1.8 0.02
Non-usage of β-blockers* 1.3 1.0 – 1.7 0.01
Interim events
Inappropriate shock 1.4 1.0 – 2.0 0.07 1.6 1.1 – 2.3 0.01
Per inappropriate shocks (up to 5)† 1.3 1.1 – 1.6 <0.01 1.4 1.2 – 1.7 <0.01
Interim appropriate shocks* 2.5 1.9 – 3.3 <0.01 1.6 1.2 – 2.1 <0.01
CI=confidence interval; HR=hazard ratio; NYHA=New York Heart Association. *Adjusted in multivariate 
analysis for single inappropriate shock †In multivariate adjusted for all baseline variables and for interim 
appropriate shocks










of inappropriate shocks.15, 25-30 Then again, these studies have shown less consistency in 
identifying other predictors. For instance, Hreybe and co-workers demonstrated patients 
with severe symptomatic heart failure (NYHA class III and IV) to be at increased risk 
for inappropriate shocks, whereas Nanthakumar et al. demonstrated NYHA class I as an 
independent predictor of inappropriate shocks.26, 27 Furthermore, other predictors included 
absence of coronary artery disease, usage of β-blockers, ICD device type, history of smok-
ing, non-statin usage, lower age and elevated diastolic blood pressure.15, 25, 26, 28, 30
In the current study, multivariate analysis demonstrated that ICD-recipients with a his-
tory of AF have a significantly higher risk for inappropriate shocks (HR 2.0, p<0.01). 
Additionally, the present study showed that age below 70 years independently predicted 
the occurrence of inappropriate shocks (HR 1.8, p<0.01). Most likely this is due to the 
fact that 23% of all inappropriate shocks were caused by abnormal sensing and sinus 
tachycardia, both associated with lower age.31 
Possibly, the large cohort and long follow-up, assessed in the current analysis, might 
provide more accurate identification of predictors of inappropriate shocks than proposed in 
previous studies. 
Prevention of inappropriate shock over time
Ever since the first implantation, ICDs are under constant development to improve treat-
ment of tachyarrhythmias and diminish adverse events. Advanced algorithms, multiple 
sensing leads and improved device programming should reduce the occurrence of inap-
propriate shock.19-21 Interestingly, the current study did not confirm this theory. Patients, 
who received their ICD system after May 2004, as compared to before May 2004, did not 
experience less inappropriate shocks (Figure 3). In addition, multivariate analysis, adjusted 
for baseline and interim variables, even showed that these patients were at increased risk to 
experience inappropriate shocks. The most plausible explanation for this paradox is found 
within the evolving guidelines, which intermittently change ICD patient population from 
mostly secondary prevention patients to mostly primary prevention patients. In general, this 
last mentioned group is older and has poor cardiac condition, which could result in higher 
risk and prevalence of AF – the strongest predictor for the occurrence of inappropriate 
shocks. Hence, the increasing number of primary prevention patients could downgrade 
the effect of advanced ICD technology in reducing the occurrence of inappropriate shock. 
Single-chamber vs. dual-chamber vs. CRT-D
With supraventricular arrhythmias as the principal cause of inappropriate shocks, one might 
hypothesize that additional sensing information would improve discrimination between 
supraventricular tachyarrhythmias and ventricular tachyarrhythmias in order to prevent 
inappropriate therapy. Therefore, in theory, dual-chamber ICDs should perform better than 
single-chamber ICDs. However, in literature there are doubts regarding the performance of 






devices with extra sensing/pacing leads, when compared to single-chamber ICDs. Theuns 
and co-workers performed a prospective, randomized study to evaluate the performance 
of tachyarrhythmia detection algorithms in single- and dual-chamber ICDs, but did not 
find a significant reduction in the number of inappropriate arrhythmia classifications.32 
Other studies have reported similar results.20, 33, 34 On the contrary, a randomized trial 
conducted by Friedman and co-workers demonstrated a small but significant reduction of 
inappropriate supraventricular tachyarrhythmias detection (8.6%) when using optimized 
programmed dual-chamber ICDs in comparison to single-chamber ICDs.35 These findings 
were supported by Soundarraj et al.28
Besides single-chamber and dual-chamber ICDs, the current analysis analyzed the occur-
rence of inappropriate shocks in CRT-D patients. Since these devices have the possibility to 
pace and sense through three separate leads (i.e. one atrial lead and two ventricular leads), 
one might expect better tachyarrhythmia discrimination in CRT-Ds than in non-biventricular 
ICDs. However, several studies have reported that sensing through both ventricular leads 
could result in double counting and T-wave oversensing, eventually leading to inappropriate 
device discharges.36, 37 In the present study, no significant differences were observed in the 
incidence of inappropriate shocks, when comparing the three different device types.
Long term outcome
Recent subgroup analysis of the MADIT II and the Sudden Cardiac Death In Heart Fail-
ure Trial (SCD-HeFT) reported on an association between increased mortality risk and 
ICD shocks, irrespective of appropriateness.14, 15 For appropriate shocks, this association 
is explicable since patients who receive appropriate shocks also have VT or VF due to 
progressively deteriorating cardiac condition. On the contrary, it was unforeseen that this 
association also applied to inappropriate shocks.
The present study confirmed this finding in routine clinical practice, outside the setting 
of a clinical trial, by demonstrating a significant correlation between inappropriate shocks 
and death. Moreover, the risk for all-cause mortality increased per delivered inappropriate 
shock; up to a HR of 3.7 after experiencing 5 inappropriate shocks. 
One might postulate different explanations for the increased risk for death, including 1) 
myocardial injury resulting in deterioration of LVEF; 2) increased anxiety and depression, 
associated with increased mortality; 3) indirect result of AF, being the leading mechanism 
for inappropriate shocks, and also associated with an increased risk for mortality.38-40. 
From the current study, it is difficult to favor one explanation over another. However, vari-
ous studies have supported the first explanation, since they reported on raised markers 
for myocardial damage after uncomplicated ICD testing at implantation, implying cardiac 
tissue damage due to these high-voltage electrical discharges.38, 41, 42 
When comparing the results of the subgroup analysis of MADIT II and SCD-HeFT with 
the current study, a notable difference was seen in the risk for all-cause mortality after 










experiencing an inappropriate shock (respectively HR 2.2 vs. HR 2.0 vs. HR 1.6). This 
difference could be explained if one assumed that (inappropriate) ICD shocks indeed 
cause myocardial tissue injury. In addition, ICD patients with poor cardiac condition and 
left ventricular function have less reserve to withstand extra cardiac damage. Therefore, 
inappropriate shocks will have more adverse consequences in a population with reduced 
cardiac function, as assessed in the MADIT II and SCD-HeFT.5, 14
Overall, it remains difficult to state that the higher risk for death was indeed caused by 
inappropriate ICD shocks, but so far, three large independent studies have demonstrated 
an adverse relation between ICD shocks and patient survival. 
Limitations
The current study used prospectively collected data from a single center ICD registry. Since 
ICDs were implanted over a period of 10 years, evolving and expanding guidelines for the 
implantation of ICDs, device programming and pharmacological treatment of arrhythmias 
could have created a heterogeneous population. Furthermore, we attempted to control for 
potential confounders using multivariate statistical with time-dependent covariate analysis. 
However, the influence of potentially included unknown confounders could not be ruled out. 
Conclusion
The current study demonstrates that in an ICD patient cohort, outside the setting of a clini-
cal trial, inappropriate shocks occur in 13% of ICD recipients, mainly due to misdiagnosis 
of supraventricular tachycardia. Clinical predictors for inappropriate shocks were low age, 
history of AF, no statin usage and interim appropriate shocks. Finally, inappropriate shocks 
were associated with a higher risk for all-cause mortality, which increased per delivered 
inappropriate shock and was independently of interim appropriate shocks.
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Aims: To assess the requirement for coronary sinus (CS) lead intervention after cardiac 
resynchronization therapy (CRT) and to evaluate the effectiveness of endovascular replace-
ment.
Methods: All patients receiving a CRT device with CS lead in the Leiden University Medical 
Center in the period from 1999 to 2007 were prospectively evaluated and followed. 
Results: Five-hundred-seventy-seven patients were successfully implanted with a CRT 
device. Nine (1.6%) patients were lost to follow-up. The remaining 568 patients were 
included in the analysis. During a median follow-up time of 645 days (interquartile range, 
260 to 1148), 7% of patients required a CS lead intervention. Cause of the intervention 
was an elevated threshold (n=13), loss of capture (n=20), or intractable phrenic nerve 
stimulation (n=6). Fifteen patients (38%) required a CS lead intervention before first 
scheduled follow-up (two months after implantation). Thirteen patients (33%) warranted 
a CS lead intervention more than six months after implantation. The first endovascular 
replacement was successful in 86% (32 out of 37), while a second endovascular approach 
failed in 66% (2 out of 3).
Conclusion: The long-term requirement for CS lead interventions is 7%. Endovascular 
repositioning or replacement is successful in the majority of cases. 
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Cardiac resynchronization therapy (CRT) plays an important role in the treatment of 
advanced heart failure in patients with cardiac dyssynchrony. Biventricular pacing has a 
positive effect on mortality, exercise tolerance, quality of life and number of heart failure 
related hospitalizations.1-5 
Furthermore, a significant clinical improvement, as measured by a change in New York 
Heart Association (NYHA) functional class occurs in approximately 70-80% of the patients 
receiving resynchronization therapy.6-8 The clinical non-response in 20-30% of all CRT 
recipients is the most important setback in the use of CRT. Further important complicating 
factors are the success rate of coronary sinus (CS) lead positioning, which is 88-96% in 
large trials,3, 8, 9 and the occurrence of CS lead dysfunction in 5-10% of the patients during 
follow-up.9, 10 However, currently available follow-up data is often limited to six months 
following CRT implantation.
Endovascular placement of the CS lead in a branch of the coronary sinus is the approach 
of first choice. However, this technique has a number of setbacks and is not applicable 
to all patients because of coronary sinus anatomy, coronary vein anatomy, phrenic nerve 
stimulation (PNS) and/or dislocation of the CS lead.11 In all cases of CS lead failure, the 
clinician has three options of intervening: (1) endovascular replacement; (2) replacement 
of the endovascular lead by an epicardial lead by means of a (minimally invasive) surgical 
implant; or (3) transseptal or transapical approach.12-14 The current study evaluated the 




All 577 patients receiving a CRT device with CS lead in the Leiden University Medical Cen-
ter in the period from 1999 to 2007 were prospectively evaluated and followed. Patients in 
whom it was not possible to implant a CS lead during the initial procedure were excluded 
from the current analysis. Eligibility for CRT was based on the standard guidelines and 
included advanced heart failure, depressed left ventricular ejection fraction (LVEF <35%) 
and wide QRS complex (>120 ms).15
Device implantation
A coronary sinus venogram was obtained using a balloon catheter, followed by the insertion 
of the CS lead into one of the posterolateral veins through an 8-F guiding catheter. The 
following CS lead models were used: Easytrak, Easytrak 2, and Acuity manufactured by 






Boston Scientific (Natick, MA [formerly, Guidant, St. Paul, MN]); Attain and Attain-SD, 
manufactured by Medtronic Inc. (Minneapolis, MN); Aescula, by St. Jude Medical, (St. 
Paul, MN); and the Enpath, by Enpath Medical Inc. (Minneapolis, MN). The right atrial 
and right ventricular leads were positioned conventionally. All leads were connected to a 
dual-chamber CRT or CRT-defibrillator (CRT-D) device of the following models: Contak TR, 
Contak CD, or Contak Renewal, Guidant Corp.; Insync III, Insync CD, Insync III Marquis, or 
Insync Sentry, Medtronic Inc; Epic or Atlas, St Jude Medical. Procedural success was ac-
complished when pulse generator and the 3 leads were positioned without complications. 
Before patient discharge, all leads were systematically screened for adequate function-
ing. This included testing for pacing threshold, sensing, and lead impedance. Additionally, 
possible presence of PNS was ruled out. 
Follow-up
All devices and leads were technically assessed at 3 to 6 months intervals. In case of 
loss of capture at maximum output, increase of threshold to sub-maximal (>5.5V/1.0ms) 
values or intolerable PNS a chest roentgenogram was made to evaluate whether gross 
dislodgement of the CS lead had occurred. In case of PNS, all effort was made to prevent 
its occurrence, using different technical settings.
In the Dutch health care system, all patients are followed by the implanting center. Since 
periodical follow-up was performed every three to six months, patients with more than six 
months of missing data were considered as lost to follow-up. 
Left ventricular lead intervention
Before admittance for repositioning of the CS lead, the retrograde venogram of the coronary 
sinus made at first CS lead implant was reevaluated in order to assess coronary sinus 
anatomy and to predict the probability of successful endovascular replacement of the CS 
lead. After repositioning or replacement of the CS lead in an area with a good threshold 
and sensing, the occurrence of PNS was tested by pacing with high output (10 V). In 
case of PNS with low output pacing, the CS lead was repositioned to a better location. 
Furthermore, the CS lead position after replacement was compared with its position after 
the initial implantation. Endovascular repositioning or replacement of the CS lead was 
performed by an electrophysiologist at our centre.
Statistical analysis
Continuous data are expressed as mean and standard deviation or range, median and 
first and third quartile where appropriate; nominal data are presented as numbers and 
percentages. Comparison of data was performed with the Student’s t test for unpaired data 
and Chi-square tests with Yates correction when appropriate. Non-normally distributed 
data (NYHA functional class) were compared using the Mann-Whitney U test. Cumulative 
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incidences were analyzed by method of Kaplan-Meier. Death or heart transplantation were 
counted as censoring events. For all tests, a p-value <0.05 was considered significant.
Results 
Patient characteristics
During the study period, 596 patients were implanted with a CRT device. Five-hundred-
seventy-seven patients (97%) successfully received a CS lead. Nine (1.5%) patients were 
lost to follow-up. The remaining 568 patients were included in the analysis. One-hundred-
thirty-four patients died (n=130) or underwent heart transplantation (n=4) with their lead 
still intact at last follow-up. Median follow-up time was 645 days (interquartile range, 260 
to 1148).
Implanted leads consisted mostly of models manufactured by Boston Scientific (n=365) 
or Medtronic (n=185). The majority of patients (80% men, mean age 66 years, range 36 
to 87 years) had ischemic heart disease (60%) and a poor LVEF (25±8%). Leads were 
connected to a CRT only device in 10% (n=56) or CRT-D device in 90% (n=512). All data 
are summarized in Table 1.
Requirement for CS lead intervention
During follow-up, 39 (7%) patients required CS lead intervention. Median time to this 
event was 85 days (interquartile range, 35 to 211 days). Patients with a CS lead, needing 
Table 1. Patient characteristics.
All CS lead 




Age (yrs) 66±10 64±11 0.1
Male gender 452 (80%) 30 (77%) 0.7
Ischemic etiology 343 (60%) 18 (46%) 0.1
LVEF (%) 25±8 24±9 0.4
NYHA functional class
   II / III / IV 105 / 420 / 43 9 / 30 / 0 0.4
QRS (ms) 159±32 164±31 0.3
Medication
   Diuretics
   ACE inhibitors
   Spironolactone
   B-blockers
















CRT-D 512 (90%) 33 (85%) 0.2
CRT-D: cardiac resynchronization therapy-defibrillator; LVEF: left ventricular ejection fraction; NYHA: 
New York Heart Association






intervention, showed no significant differences in clinical parameters (Table 1: patient 
characteristics). The incidence of surgical CS lead intervention was found to be 3.3 per 
100 patient years (95% CI 2.3-4.5 per 100 patient years). Cumulative event-rate (Figure 
1) at one year was 5.8% (95% CI 1.9-9.7%), at two years 6.6% (95% CI 2.3-10.9%), and 
at five years 8.6% (95% CI 2.2-14.9%). Additionally, no technical failure of the CS lead 
was observed. In case of reintervention, no difficulties were encountered during removal of 
CS leads, that was performed by traction.
In 6 (15%) cases, requirement of CS lead intervention was based on the occurrence of 
intractable PNS. The remaining cases of CS lead intervention were diagnosed by findings 
during periodical examination. In 20 (51%) patients a complete loss of capture was found 
and in 13 (33%) cases the intervention was warranted due to an elevated threshold more 
than 5.5V/0.5ms. In the 20 cases of complete loss of capture and consequently loss of 
biventricular pacing, 13 patients (65%) had experienced an increase in heart failure symp-
toms. In addition, dislocation could be verified on roentgenogram in 14 out of 20 (70%) 
cases of complete loss of capture. In the remaining 25 cases, no sign of dislodgement was 
visible on roentgenogram. Elevated thresholds, causing the need for lead intervention oc-
curred longest after implantation with a median duration of 180 days (interquartile range, 
4 to 376 days), whereas complete loss of capture occurred after the shortest period of time 
(median 83 days, interquartile range 55 to 174) (Table 2: reasons for the requirement 
and type of CS lead intervention). The shorter time to diagnosis and the fact that 14 out 
of 20 (70%) cases of lead dysfunction could be verified on roentgenogram, implies a more 
severe dislodgement in the patients with a complete loss of capture. Fifteen patients (38%) 
required a CS lead intervention before first scheduled follow-up two months after implanta-
tion. Thirteen patients (33%) were indicated for CS lead intervention more than six months 
after implantation. It is of note that one patient required a CS lead intervention because of 
a severely elevated threshold 1415 days after implantation. 
Endovascular replacement 
Of the 39 patients warranting CS lead re-intervention, two directly received an epicardial 
left ventricular (LV) lead because of unfavorable CS anatomy. In 37 patients, endovascular 
replacement was attempted of which 86% (n=32) was successful during follow-up. In 
these patients, a median of 867 days (interquartile range, 647 to 1123 days) of stable 
long-term biventricular pacing was achieved after repositioning. The remaining five patients 
needed a second intervention during further follow-up. In two of these patients, clinicians 
chose to implant an epicardial lead because of unfavorable CS anatomy and the experience 
during the previous attempt. In three patients, a (second) attempt of endovascular replace-
ments was made in which the rate of success was 33% (n=1) (Figure 2). This patient 
demonstrated adequate biventricular pacing during a follow-up of 1574 days after the sec-
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ond replacement. The two patients with an unsuccessful second attempt for endovascular 
intervention both received an epicardial lead.
It is of note that the same branch of the CS could be used in 21 out of 37 (57%) first 
attempts at endovascular intervention and most leads were placed at the posterolateral 
region.
Out of the 37 performed first endovascular CS lead replacements, the old lead was 
re-used 11 (30%) times. Cases, in which leads could be re-used occurred a shorter period 
after the initial implantation (re-use of lead: 126±128 days after implantation vs. usage of 
a new lead: 213±311 days after implantation, p=0.5). The angiographic study, performed 
at CS lead intervention, demonstrated changes in coronary venous anatomy, such as oc-
clusion or narrowing of the initially used branch, in six cases.  In the three cases of second 





Figure 1. Cumulative requirement for CS lead intervention. 
 
Figure 1. Cumulative requirement for CS lead intervention.
Table 2. Reasons for the requirement of CS lead intervention.
Reason for intervention Median time to intervention
N Days (1st – 3rd quartile)
Total 39 (100%) 85 (35-211)
   Elevated threshold 13 (33%) 180 (4-376)
   Loss of capture 20 (51%) 83 (55-174)
   Phrenic nerve stimulation 6 (15%) 83 (16-167)







The current study aimed to specifically describe the need for CS lead intervention during 
long-term follow-up and to assess the successfulness of endovascular repositioning. The 
main findings of the current study can be summarized as follows: 1) Endocardial CS lead 
performance during long-term follow-up is excellent; 2) Replacement or repositioning was 
necessary in 7% of patients; 3) Cases in which evaluation of the coronary sinus venogram 
favored an attempt of endovascular replacement of the CS lead had a success rate of 86% 
(32 out of 37) at first attempt and 33% (1 out of 3) in second attempt; 4) Thirty-three 
percent (n=13) of CS lead interventions were made more than six months after implanta-
tion; 5) In case of clinical or technical evidence for CS lead malfunction, only 36% (n=14) 
could be verified on roentgenogram.
Although CRT has become an established treatment in patients with advanced heart 
failure, clinical use of biventricular pacing still has to cope with some serious setbacks. 
Firstly, 20-30% of implanted patients does not show clinical improvement.6-8 Secondly, 
implantation of a biventricular system succeeds only in 88-96% of patients,3, 8, 9 and finally, 
during follow-up the need for CS lead intervention is warranted in 5-10% of implanted 
patients.9, 10 Since endovascular replacement of the CS lead is the least invasive (in contrast 
to epicardial placement), the current study sought to evaluate the incidence and causes of 
the requirement of CS lead intervention and the effectiveness of endovascular replacement. 
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Figure 1. Kaplan-Meier curve for all-cause lead removal or capping. 
Figure 2. Flow-chart of the requirement and type of CS lead intervention.
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During follow-up, high thresholds, complete loss of capture, or intractable PNS prevented 
adequate left ventricular pacing in 7% of our population. Compared with other device-
related complications, this is a substantial number of cases requiring an invasive procedure 
to resolve. To replace a CS lead, the clinician has to find the best side branch of the 
coronary sinus, which can be assessed by reevaluation of the retrograde venogram of the 
coronary sinus, made at the initial implantation. Due to more experience and improved 
technical possibilities there is a high success rate in the initial endovascular implantation 
of CS lead into one of the branches of the coronary sinus.1, 8 Our data show that in case 
of a subsequent CS lead intervention, the endovascular approach is successful in 86% of 
cases, making it a very reasonable therapeutic option to restore biventricular pacing and its 
accompanying beneficial effects.
CS lead dislodgement can occur shortly after implantation but was seen as late as 4 
year after implantation. Although the median follow up in our population was 645 days 
(interquartile range, 260 to 1148), there might well be an underestimation of the percent-
age CS lead dislodgements. This is also shown in our analysis of the cumulative incidence, 
which can reach up to 8.6% five years after implantation. The same underestimation is 
likely to have occurred in some large studies with relatively short follow of less than one 
year.3, 8 Only the CARE-HF study has a comparable long mean follow of 29.4 months and 
also showed a 6% CS lead dislodgement, results comparable to our CRT population.16
Phrenic nerve stimulation is tested during implantation by high-voltage pacing (up to 10 
V). Nevertheless, chronic PNS is reported in up to 12% of CRT recipients.8 During follow-
up PNS can also arise de novo because of changes in body position or (micro) dislodgement 
of the CS lead. Changing the pacing output and/or pacing configuration can resolve the 
problem most of the time but repositioning of the CS lead is necessary in some cases. In our 
population only 6 patients (1.3%) needed a CS lead replacement due to intolerable PNS, 
which is 15% (6/39) of all patients with CS lead failure. 
Three patients underwent a successful second endovascular replacement but during 
further follow-up, two of them needed an epicardial lead placement after renewed CS 
lead malfunction. A second replacement procedure should therefore be carefully evaluated. 
However, the number of patients receiving a secondary replacement in this study is limited.
In total, six patients received an epicardial LV lead without complications periprocedural 
or during follow-up. Nevertheless, taking in account the invasiveness and time consump-
tion of an epicardial approach and the 86% effectiveness of the endovascular approach, 
clinicians should favor the endovascular. It is of note that before intervening, all cases in 
the current study were reevaluated by venogram of the coronary sinus to determine the 
possibility of endovascular replacement.







The long-term requirement for CS lead interventions is 7%. Endovascular repositioning or 
replacement is successful in the majority of cases. 
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Background: Despite the positive effect on mortality in selected patients, implantable 
cardioverter defibrillator (ICD) therapy is also associated with potential malfunction of the 
implanted system. The present study provides the long-term lead failure rate in a large 
single-center cohort.
Methods and Results: Since 1992, a total of 2068 ICD patients with 2161 defibrillation 
leads were prospectively collected. Data of the implant procedure and all follow-up visits 
were recorded. All cases of lead removal or capping, or placing of an additional pace or 
sense lead were noted and analyzed. Lead models were grouped by manufacturer and ap-
proximate lead diameter in French (Fr). During a mean follow-up of 36 months, 82 (3.8%) 
cases of lead failure were identified. Cumulative incidence of lead failure at one year was 
0.6%, at five years 6.5% and 16.4% at ten years. The highest risk of lead failure was found 
in small-diameter leads. Adjusted hazard ratio was 6.4 (95% CI 3.2-12.8) for Medtronic 7 
Fr leads, when compared to all other leads.
Conclusions: In this large single-center experience, the overall incidence of lead failure was 
1.3 (95% CI 1.0-1.6) per 100 lead-years. Comparison of different groups of leads shows 
major differences in event rates. Specific manufacturer’s small diameter defibrillation leads 
may have a higher risk of early lead failure.
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Large randomized trials have shown a beneficial effect on mortality of an implantable 
cardioverter defibrillator (ICD) in the secondary and primary prevention of sudden cardiac 
death in selected groups of patients.1-7 With the rapid expansion of indications, the world-
wide annual implant rate has increased to over 100 000 units in 2007. Despite the positive 
effect on mortality in selected patients, ICD therapy is also associated with some serious 
drawbacks which potentially may harm patients and increase the costs of ICD therapy. 
One of the most important is the limited lifespan of the ICD necessitating the replacement 
of the ICD every 4 to 5 years. Furthermore, in the survival of an implanted system, the 
right ventricular defibrillation lead, as shown by several studies, is the weakest link and a 
recent study has revealed that lead failure can reach 20% in 10-year old leads.8, 9 When in 
need of information about specific leads, practitioners have to rely on data reported by the 
manufacturers on lead survival. These data are usually based on the leads returned to the 
manufacturer after removal. However, in daily practice lead failure is often not reported to 
the manufacturer either because the lead is simply not returned or instead of removing, the 
lead is capped and an additional pace or sense (P/S) lead is inserted.  Initiatives such as 
nationwide data registries in the USA and some European countries may help to improve 
surveillance of ICD and lead performance. 
We have determined the survival and failure rate in a large number (n= 2161) of de-
fibrillation leads, implanted over a 16-year period in a large university hospital in the 
Netherlands.
Methods
Patient and lead characteristics
Since 1992, all patients who received an ICD system in the Leiden University Medical 
Center were registered in the departmental Cardiology Information System (EPD-Vision®, 
Leiden University Medical Center). Data of the implant procedure and all follow-up visits 
were recorded (Table 1). At the first of February 2008, this registry contained information 
about 2249 defibrillation leads. Leads connected to an abdominal system and leads with 
a coaxial construction or polyurethane coating were excluded from this analysis since these 
are known to be prone to failure and are no longer in use.10-16 
Eligibility for ICD implantation was based on international guidelines and included second-
ary prevention (survival of a life-threatening ventricular arrhythmia) and primary prevention 
(poor left ventricular ejection fraction [LVEF]).17, 18 Due to evolving guidelines the indica-
tions have changed over time. All patients were screened before implantation according to a 
standardized protocol adapted from the international guidelines as described previously.19, 






20 All leads in this analysis were implanted transvenously and without thoracotomy. During 
the implant procedure testing of sensing and pacing thresholds and defibrillation threshold 
testing was performed.
End-points and follow-up
The follow-up was from lead implantation, occurring between 1992 and 2007, to February 
1st 2008. In the Dutch health care system, all patients are followed by the implanting 
center. Since periodic follow-up was performed every three to six months, patients without 
data after the first of August 2007 were considered as lost to follow-up. 
During these examinations, all leads were systematically screened for adequate function 
and integrity. Any case of lead removal or capping, placing of an additional P/S lead, or lead 
repositioning because of dislodgement was recorded. All cases were individually analyzed 
by the technician and supervisor and classified as “lead failure” or “non lead failure”. The 
current analysis used three end-points: (1) all-cause lead removal or capping; (2) lead 
failure; (3) lead failure or dislodgement within six months. 
Definition of lead failure
Defibrillation lead removal or capping was classified as lead failure according to the report 
of the North American Society of Pacing and Electrophysiology.21 At least one of the follow-
ing criteria had to be met to define suspected lead failure (1 and 2) or verified lead failure (3 
to 6): (1) loss of capture or markedly elevated thresholds; (2) loss of sensing, oversensing, 
or skeletal muscular stimulation; (3) a visible conductor fracture or insulation defect seen 
at surgery; (4) a change in lead impedance, judged to be caused by conductor or insulation 
failure; (5) an evident fracture seen on chest roentgenogram; (6) manufacturer’s returned 
product report confirming the failure. 
Table 1: Patient characteristics.
All leads
All removal or 
capping
lead failure
lead failure or 
dislodgement
Variable (n=2161) (n=146) (n=82) (n=93)
Base-line characteristics
   Age, years 61±13 57±16 56±16 56±16
   Male sex, % 80 84 83 83
   Ejection fraction, % 34±15 35±16 35±16 37±17
   Ischemic etiology, % 65 72 73 71
   Primary indication, % 55 41 37 42
Implanted ICD
   Single chamber, % 15 32 37 34
   Dual chamber, % 49 48 44 48
   Biventricular, % 36 21 20 17
Continuous variables are expressed as mean ± SD. 
ICD indicates implantable cardioverter defibrillator.
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For analysis purposes, leads were grouped per manufacturer and per recommended intro-
ducer diameter. This classification divides the different generations of leads. Manufacturers 
of implanted leads were Biotronik (Berlin, Germany), Medtronic (Minneapolis, MN, United 
States), Boston Scientific (Natick, MA, United States) (formerly CPI, Guidant [St. Paul, MN, 
United States]) and St. Jude Medical/Ventritex (St. Paul, MN, United States). Classification 
on lead diameter in French (Fr) resulted in nine groups, as shown in Table 2: (1) Biotronik 
8 Fr; (2) Boston Scientific 11 Fr; (3) Boston Scientific 9 Fr; (4) Medtronic 10.5 Fr; (5) 
Medtronic 9 Fr; (6) Medtronic 7 Fr; (7) St Jude Medical 11 Fr; (8) St Jude Medical 8 Fr; 
(9) St Jude Medical 7 Fr. The leads with a recommended introducer diameter of 7 Fr were 
described as small diameter leads.
Continuous data are expressed as mean and standard deviation or range, median and 
first and third quartile where appropriate; nominal data are presented as numbers and per-
centages. Cumulative incidences were analyzed by method of Kaplan-Meier. Cox regression 
analysis was performed as multivariable modeling, to obtain age-adjusted hazard ratios as 
an estimate of the incidence ratio. Event rates were corrected for age, sex, and LVEF. Death 
or heart transplantation was counted as censoring events. 
The authors had full access to the data and take responsibility for its integrity. All authors 
have read and agree to the manuscript as written.
Results
Patient and lead characteristics
A total of 2249 defibrillation leads were implanted in 2145 patients between 1992 and 
2007. For the current analysis, all leads connected to an abdominal system, with coaxial 
construction or polyurethane coating (n=39, 1.7%) were excluded. Forty-nine (2.2%) 
patients were lost to follow-up. The remaining 2161 defibrillation (2068 patients) leads 
Table 2: Classification of defibrillation leads by manufacturer and lead diameter.
Lead group Lead models
Biotronik 8 Fr Linox
Boston Scientific 11 Fr Endotak 0125, 0144, 0145 and 0155
Boston Scientific 9 Fr Endotak 0138, 0147, 0148, 0161, 0164, 0165, 0175, 0181 and 0185
Medtronic 10.5 Fr Sprint 6932, 6942 and 6945
Medtronic 9 Fr Sprint Quattro 6944 and 6947
Medtronic 7 Fr Sprint Fidelis 6930, 6931, 6948 and 6949
St. Jude Medical 11Fr SPL SP01 and SP02
St. Jude Medical 8 Fr Riata 1570, 1580 and 1582
St. Jude Medical 7 Fr Riata 7000 and 7002
Fr indicates French






were included in the analysis. Three-hundred-and-eight patients died (n=300) or under-
went heart transplantation (n=8) with their lead still intact at last follow-up. Median time 
between last follow-up and death was 62 days (interquartile range, 29 to 109 days).
Implanted leads consisted mostly of models manufactured by Boston Scientific (n=1074) 
or Medtronic (n=774). Median follow-up time was 885 days (interquartile range, 375 to 
1618). The majority of patients (80% men, mean age 61 years, range 5 to 86 years) had 
ischemic heart disease (65%) and a poor LVEF (34±15% Table 1: patient characteristics). 
Leads were connected to a single chamber device in 15% (n=332), dual chamber device 
in 49% (n=1052) or resynchronization ICD in 36% (n=777). 
Lead survival
One-hundred-forty-six leads (6.8%) were removed or capped during follow-up (in 139 
patients). The cause of removal or capping was found to be other than lead failure in 
64 patients, consisting mostly of pocket infections (n=36) or decubitus ulcers (n=14). 
Median time to all-cause lead removal or capping was 892 days (interquartile range, 352 
to 1710 days). The overall incidence rate of all-cause removal or capping was found to be 
2.2 per 100 lead-years (95% CI 1.9-2.6 per 100 lead-years). Cumulative (Figure 1) lead 
failure at one year was 1.9%, at two years 3.5%, at five years 10.4% and at ten years 
26.9% meaning that after 10 years, 73.1% of all implanted leads were still functioning.
Lead failure 
During follow-up, 82 (3.8%) cases of lead failure were identified with a median time to 




Figure 2. Kaplan-Meier curve for lead failure comparing all leads to the leads from 
Boston Scientific, Medtronic and St Jude Medical, grouped by lead diameter in French 
(Fr). 
Figure 1. Kaplan-Meier curve for all-cause lead removal or capping.
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additional P/S lead was implanted and the failing lead was capped. Forty-two leads were 
completely removed and replaced with a new defibrillation lead. Diagnosis was made at 
a routine device follow-up (61%), after the occurrence of inappropriate shocks (27%) or 
during elective ICD replacement (12%). Inappropriate shocks were caused by mal-sensing 
in 64%, fracture of the sense lead in 18%, T-wave oversensing in 14% and P-wave over-
sensing in 5%.
Cumulative incidence of lead failure-free follow-up at one year was 99.4%, at two years 
98.6%, at five years 93.5% and 83.6% at ten years. Kaplan-Meier curves for the dif-
ferent groups of leads are shown in Figure 2, where the bold line represents all 2161 
leads together and the dashed lines the specific group. No lead failure occurred in the 
leads manufactured by Biotronik. Median follow-up for leads by Biotronik was 155 days 
(interquartile range, 88 to 296 days).
Over a total of 6540 lead-years in the current analysis, the incidence rate for lead-failure 
per 100 lead-years was 1.3 (95% CI 1.0-1.6). Incidence rates for lead failure were found 
to be higher in the small diameter defibrillation leads with 2.7 (95% CI 1.6-4.4) per 
100 lead-years for the Medtronic 7 Fr leads. Data for all groups are shown in Table 3. 
The hazard ratio (adjusted for age, sex, and LVEF) for small diameter leads, compared to 
the other leads was 10.9 (95% CI 1.4-85.5) for St Jude Medical and 6.4 (95% CI 3.2-
12.8) for Medtronic. Implantation with either group of Boston Scientific defibrillation leads 
decreased the risk of lead failure: For the group with 11 Fr and 9 Fr diameter, adjusted 
hazard ratios were 0.3 (95% CI 0.2-0.8) and 0.5 (95% CI 0.3-0.9) respectively, relative 
to all other leads.
After categorization by manufacturer and generation, other, previously reported, risk fac-
tors for lead failure (subclavian vs cephalic venous (HR 1.0 (95% CI 0.6-1.5), p=0.9), 
active vs. passive lead fixation (HR 1.2 (95% CI 0.6-2.4), p=0.6), dual vs. single coil 
leads (HR 0.8 (95% CI 0.4-1.9), p=0.6) and dedicated vs. integrated bipolar leads (HR 
0.8 (95% CI 0.1-6.2), p=0.8) did not influence the risk on lead survival in our series.
Lead failure and lead dislodgement
Twelve cases of defibrillation lead dislodgement occurred within the six months following 
implantation with a median time to event of 34 days (interquartile range, 4 to 68 days). 
After relocation, one of the leads (Medtronic 7 Fr) failed during follow-up which brings the 
number of leads reaching the combined end-point of lead failure and lead dislodgement to 
93. Overall incidence rate was 1.4 (95% CI 1.2-1.7) per 100 lead-years.







In this large single-center experience, the findings can be summarized as follows: 1) Overall 
incidence of all-cause lead removal or capping is 2.2 (95% CI 1.9-2.6) per 100 lead-years, 
with a 10-year event-free lead-survival of 73.1%; 2) The incidence of lead failure is 1.3 
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Running title Chapter 11 “Right Ventricular Stimulation Threshold”  “Right 
ventricular stimulation threshold” 
Figure 2. Kaplan-Meier curve for lead failure comparing all leads to the leads from Boston Scientific, 
Medtronic and St Jude Medical, grouped by lead diameter in French (Fr).
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revealed major differences in event rates; 4) Specific manufacturer’s small diameter defi-
brillation leads exhibit a higher failure rate.
Lead failure
Results of previous studies on the frequency of lead failure vary widely, mostly depending 
on the lead types and the duration of follow-up. Lead survival in non-abdominal leads varies 
from 91% to 99% at two years,22 85% to 98% at five years,8, 12, 23-25 and 60% to 72% at 
eight years.8, 10, 24 In comparison to these figures, our rates of lead failure tend to be average 
during the first five years (93.5% failure-free). However, in long-term follow-up our cohort 
(83.6% failure-free at ten years) demonstrates far less lead failures than the 40% failure at 
eight years found by Kleemann and coworkers.8 A plausible explanation for this lower rate of 
failure is the exclusion of leads connected to an abdominal system, leads with a coaxial con-
struction, and leads with a polyurethane coating. Characteristically, polyurethane insulated 
leads show a rapid increase in failure rate after five years follow-up.12 Therefore, exclusion of 
these leads from the current analysis could explain that our event rates are similar to other 
Table 3: Defibrillation leads, grouped by manufacturer and groups of implanted transvenous defibrillation 
leads models with events and incidence rates (IR).
Total Follow-up
All removal or 
capping
lead failure














































































































































studies in the first five years of follow-up and significantly lower during follow-up longer 
than five years. Furthermore, the dissimilarity between our long-term findings and those of 
others may be caused by the difference in what each study cited as a threshold to replace a 
lead or place an additional P/S lead. Gradual increasing or chronic high impedances without 
further signs of lead malfunction should not necessarily demand acute replacement. In 
daily practice, clinicians often choose to monitor further changes in electrical parameters 
before surgically intervening. The possibility that an important number of failing leads have 
been missed is small since all periodic three-six months device interrogations have been 
performed by the recommended protocol as described by Kleemann et al.8
Previous studies have identified risk factors for lead failure, such as subclavian approach, 
hypothesized to increase the chance for subclavian crush syndrome.26 Interestingly, neither 
the approach (subclavian vs. cephalic), nor other potential risk factors (passive vs. active 
lead fixation, dual vs. single coil, dedicated vs. integrated bipolar) demonstrated an additive 
value over the stratification by lead generation in the prediction of lead failure.
Differences in performance 
In daily practice, a clinician still has to rely on product performance reports constructed 
by manufacturers. In the 2007 reports, lead failure rates in the leads used in the current 
study with a follow-up longer than 24 months vary from 0.2 to 0.9 per 100 lead-years.27-30 
In contrast with our mean lead failure rate of 1.3 (95% CI 1.0-1.6) per 100 lead-years, 
it seems clear that these reports, often based on the return of failed products, suffer from 
a gross underestimation of clinical practice. Two main reasons for this underestimation 
can be sought in the return of failed leads. Firstly, once a lead fails, a clinician can extract 
the lead or, in case of malfunction in pacing or sensing without signs of insulation defects 
or fracture, place an additional P/S lead and cap the pace and sense port of the original 
lead. Although clearly having failed, these leads are not extracted and therefore will not 
be returned to the manufacturer. Secondly, the compliance of clinicians to return extracted 
leads will, even in the most willing, never reach hundred percent.12
Lead insulation
Different studies on the reason for lead failure have proven lead insulation defects to be the 
most frequent cause, accounting for 48 to 56% of all lead failures.8, 31 Mid 1990’s, several 
studies showed a higher then average failure rate caused by metal oxidation after inner 
insulation environmental stress cracking in polyurethane insulated leads. Hauser et al. 
demonstrated a higher failure rate up to an estimated 84% in 7-year old leads, confirmed 
by the manufacturer returned product analysis.12, 32 These findings caused a recall of more 
than 400,000 leads through 1995 and marked the end of polyurethane usage in newly 
implanted leads.33 Nowadays, since the vast majority of current leads use silicone rubber 
as insulation, insulation should not be a ground for differences in event rates. Even though 
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at elective abdominal device replacement Lurgio et al describe 79% abrasion lesions in 
silicone coated leads, this sporadically resulted in lead malfunction.34  
Small-diameter leads
Defibrillation leads characterized by a small-diameter body and coil exhibit several advan-
tages.  Their smaller thickness might makes it easier to implant additional leads, maintain 
venous blood flow, and reduce subclavian crush syndrome.26 Among the nine groups of 
leads formed in the present study were two containing small-diameter leads: Medtronic 7 
Fr, better known as the Sprint Fidelis family, and the St. Jude 7 Fr, consisting of the Riata ST 
7000 and 7002 series. Previous studies assessing their long-term functioning have shown a 
higher than expected failure rate in both groups of leads. For the Medtronic 7 Fr, these figures 
varied from no increase in failure rate35 to 1 per 100 patient-years when compared to the 
Medtronic 9 Fr.36 Lower rates than our findings (2.7 [95% CI 1.6-4.4] per 100 lead-years) 
can be explained by the fact that data was acquired from the Manufacturer and User Facility 
Device Experience (MAUDE) database. Since the MAUDE database obtains 95% of cases 
from manufacturer reports, the database will show similar figures as manufacturer reports.
Studies reporting failures in St. Jude 7 Fr leads focused on the potential risk of perfora-
tion of the right ventricle, hypothesized to be caused by an increased pressure and stiffness 
at the tip of the lead.37 However, the one case of St. Jude Medical 7 Fr failure in our cohort 
was caused by severely elevated thresholds and not by perforation. Note that the relatively 
small number of implanted leads from this group causes the 95% confidence interval to be 
wide (0.1-25.7).
Limitations
Cases of lead failure might occur without clinical symptoms or changes in electrical 
measurements, causing them to go unnoticed. Furthermore, in case of slight changes, or 
chronic elevated or depressed electrical measurements a clinician not always immediately 
chooses to replace the lead. Lastly, we assumed that patient death within six months after 
a follow-up visit without signs of lead failure was not lead-related. All three examples could 
lead to an underestimation of the actual rate of lead failure, although we believe these 
effects would have been small. 
Conclusions
This study has shown major differences in failure rates between different groups of leads. 
Small diameter leads of a specific manufacturer may have a higher risk of early lead failure. 
Furthermore, with the current lead survival rate of 73% after ten years, every effort should 
be addressed to improve lead performance. 
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Background: The Medtronic Sprint Fidelis (SF) implantable cardioverter-defibrillator (ICD) 
lead has a higher than expected failure rate. Because of patient safety, Medtronic an-
nounced two advisories consisting of (1) adjustments in device settings (October 2007) 
and (2) installation of a lead integrity algorithm (May 2008). The objective of this study 
was to evaluate the effect of Medtronic’s announcements on patient safety.
Methods: To comply with the advisories, two clinical evaluations were conducted. The 
effect of the advisories was assessed by the lead failure rate and the occurrence of inap-
propriate shocks due to lead failure. Three periods were distinguished in the comparison of 
event rates: lead implantation to advisory 1 (period A), in-between both advisories (period 
B) and advisory 2 to follow-up (period C).
Results: Since 2004, 372 patients received a Medtronic ICD and SF lead and were fol-
lowed from first implant (December 2004) to April 2009. Cumulative incidence rate of 
lead failure was 3.6% [95%CI 1.6 – 5.6] at 21 months and increased to 11.0% [95%CI 
6.1 – 15.9] at 42 months.  After implementation of both advisories, the occurrence of 
inappropriate shocks due to lead failure decreased from 1.5 [95% CI 0.59, 3.00] per 100 
lead-years in period A to 0.8 [95% CI 0.02, 4.25] per 100 lead-years in period C.
Conclusion: The current study demonstrates that despite an increasing risk for SF lead 
failure, implementation of the advisories decreased the occurrence of inappropriate shocks 
due to lead failure. 











Despite important life-saving advantages of implantable cardioverter-defibrillator (ICD) 
therapy, potential system-related complications pose major drawbacks.1, 2 One of the most 
important being failure of the defibrillation lead, which can reach up to 20% in 10 year old 
leads.3, 4 The 6.6 Fr Sprint Fidelis (SF) ICD lead (Medtronic Inc, Minneapolis, MN, United 
States) is an explicit example of a defibrillation lead with a higher than expected failure 
rate. Medtronic reported a failure rate of 2.4% 30 months after implantation and recent 
data demonstrate that the failure rate accelerates over time.5, 6 In case of lead failure, up 
to 50% of the patients may experience inappropriate defibrillator shocks, which are painful 
and can potentially trigger ventricular arrhythmia and consequent death.5, 7, 8 
In October 2007 – after 268.000 SF implants worldwide – Medtronic halted the distribu-
tion of the SF lead and issued recommendations on how to manage patients with SF leads 
and optimize patient safety.9 Initially, the advisories included adaptation of device settings 
and activation of the Patient Alerts™. Later, in May 2008, Medtronic announced new 
uploadable software to increase the likelihood of fracture detection prior to inappropriate 
device discharges and suggested the use of remote monitoring (CareLink®).10 In order to 
comply with these recommendations, all patients with a Medtronic ICD and SF lead were 
invited to the out-patient clinic for clinical evaluation and implementation of the advisories. 
Although the global compliance to advisories and safety alerts is increasing, relatively little 
is known about the effects of these recommendations in daily practice.8, 11 We conducted 




Since 1996, all patients who received an ICD system at the Leiden University Medical 
Center, the Netherlands, were registered in the departmental Cardiology Information Sys-
tem (EPD-Vision®, Leiden University Medical Center). By using this database, all patients 
implanted with a Medtronic ICD and a SF Lead (Models 6949, 6948, 6931, 6930) were 
invited for implementation of the safety advisories. In accordance with the safety recom-
mendations of Medtronic, two clinical evaluations were conducted. At each visit, patients 
were seen in a time period of one week. Both advisory implementations were based on the 
advisories of the company.







In agreement with the first advisory of Medtronic, the settings of the devices were adjusted.9 
The ventricular fibrillation detection for initial Number to Intervals to Detect (NID) was 
programmed to nominal settings (18/24) or longer at physician discretion and redetect NID 
to nominal settings (12/16). The Patient Alert™ for RV pacing, RV Defibrillation, and SVC 
Defibrillation impedance was turned on. Furthermore, the lead impedance alert threshold 
for RV Pacing was programmed to 1,000 Ω, if the typical chronic impedance for the patient 
is ≤ 700 Ω or to 1,500 Ω if the typical chronic impedance was > 700 Ω. For the RV 
Defibrillation and SVC Defibrillation the lead impedance alert threshold was set to 100 Ω.
Second Advisory
In May 2008, the Medtronic Sprint Fidelis Lead Performance Update announced upload-
able software (i.e. lead integrity algorithm or LIA) to increase the likelihood of fracture 
detection prior to inappropriate device discharge and suggested the use of a remote 
monitoring system to facilitate remote access to the device information.10 In case of a 
suspected lead failure, LIA automatically adjusts the programmed number of intervals to 
detect ventricular fibrillation to 30 out of 40 sensed beats and immediately initiates an 
audible alert. This warning signal will repeat every 4 hours and, if enabled, a wireless 
CareLink® alert is transmitted. Since LIA became available in September 2008, the second 
clinical evaluation was conducted in October 2008. During this visit, LIA was uploaded into 
all software compatible devices and the alert was tested for patient’s audibility. Hereafter, 
remote monitoring was offered to all patients and, after acceptance, patients received a 
CareLink® Monitor. For evaluation of correct installation, all patients were asked to perform 
a test transmission at home. In case of technical installation problems, patients were of-
fered on-site assistance.
Follow-up 
Patients were followed from lead implantation, occurring between December 2004 and 
October 2007, to April 2009. Periodic device interrogation was performed every three to 
six months (after implementation of the first advisory every 3 months in all patients) and 
during these examinations, all leads were systematically screened for integrity. A lead was 
considered failed if one of the following criteria was met: (1) undersensing or oversensing 
of normal electrical cardiac activity; (2) incapability of sensing, pacing or defibrillation; 
or (3) inappropriate shocks secondary to electrical noise artifacts; (4) out-of-range lead 
impedance or LIA triggering an ICD alert.5, 6 If a lead was removed or capped, the cause 
(lead failure or non-lead failure) was determined by the technician and medical supervisor. 
Furthermore, in case of lead failure, patient presentation and potentially triggered device 
alerts were assessed. Specifically, the occurrence of inappropriate shocks as the first sign of 
lead failure was noted. Finally, the feasibility of the safety advisories was evaluated. 











Three periods were distinguished in the comparison of event rates: lead implantation to 
advisory 1 (period A), in-between both advisory (period B) and advisory 2 to follow-up 
(period C). Continuous data are expressed as mean and standard deviation or range; 
nominal data are presented as numbers and percentages. In the estimation of the 95% CI 
for event rates, a Poisson distribution of the observed number of events was presumed. To 
calculate standardized event-rates, the number of events during a period was divided by 
the follow-up in lead-years during that period. The cumulative incidence of SF lead failure 
was calculated using the Kaplan-Meier methodology. 
Results
Patient characteristics
Between December 2004 and October 2007, 390 patients were implanted with a SF lead 
at the Leiden University Medical Center. In 18 (5%) patients a device by another manu-
facturer was implanted: 15 Biotronik (Berlin, Germany), 2 Guidant (St. Paul, MN, United 
States), 1 St Jude Medical (St Paul, MN, United States). The remaining 372 patients 
had a device manufactured by Medtronic and could therefore benefit for the advisories 
of Medtronic. The majority of the study population (n=372) was male (81%), and had 
ischemic heart disease (66%). Implanted SF leads consisted mostly of model 6931 (61%). 
Baseline patient characteristics are described in table 1. Patients were followed from im-
plantation to April 2009 with an average follow-up period of 2.5 ± 1.0 years. During this 
period, 45 patients died. To our knowledge, no patients died as a direct or indirect result of 
lead failure. In all 45 patients, the leads were intact at their last follow-up.
Table 1. Baseline clinical characteristics at implantation of 372 patients with a Sprint Fidelis lead and 
a Medtronic ICD
Age (yr) 62 ±12 (range 17 – 85)
Male gender (n) 301 (81%)
ICD indication
Primary prevention (n) 272 (73%)
Secondary prevention (n) 100 (27%)
LVEF (%) 31 ± 14 (range 4 – 80)
Ischemic heart disease (n) 246 (66%)





Continuous variables are expressed as mean ± SD. ICD = implantable cardioverter-defibrillator; LVEF = left 
ventricular ejection fraction.







Prior to the first advisory, 372 patients were implanted with a SF lead and Medtronic ICD. 
Twenty-eight (8%) patients died and 15 (4%) leads were removed or capped of which 9 
(2%) due to lead failure. In case of lead failure, 7 patients presented with inappropriate 
shocks, 1 patient was warned by the Patient Alert™ before an adverse event could occur 
and 1 patient was identified during routine device interrogation. (Figure 1 and table 2). Out 
of 15 removed leads, 5 were replaced by a new SF lead. 
Consequently, 334 patients (including the 5 patients with a new SF lead) received an 
invitation for the first clinical evaluation. Since 4 patients were under supervision of another 
hospital, 330 patients attended. The recommended device programming changes were 
implemented in all attendees. 
Period B 
In-between both advisories, another 16 (5%) patients died and 15 (5%) leads were re-
moved. Ten (3%) cases were classified as lead failure of which 4 cases presented with 
inappropriate shocks (range 1-25 shocks per patient), 2 cases were discovered by routine 
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Figure 1. Flow chart showing the occurrence of lead failures, inappropriate shocks due to 
lead failure (IAS) and the triggered lead failure alerts which warned the patients before 
the occurrence of inappropriate therapy.  
 
 
Figure 2. Kaplan Meier curve for Sprint Fidelis lead failure 
Figure 1. Flow chart showing the occurrence of lead failures, inappropriate shocks due to lead failure 
(IAS) and the triggered lead failure alerts which warned the patients before the occurrence of inappropri-
ate therapy.  










device follow-up and the remaining 4 cases were detected by the RV-impedance Patient 
Alert™. 
For implementation of the second advisory, 299 patients were invited of which 297 
patients attended. LIA was uploaded into all software compatible ICDs (n=254, 86%). 
Devices of the Marquis (n=41, 13%) and Consulta (n=2, 1%) family were at that time 
software incompatible. In January 2009, the newer version of LIA was uploaded in all ICDs 























Yes 12 No - -
4 Noise P/S Yes 1 No - -
5 Noise P/S Yes 8 No - -
6 Noise P/S Yes 18 No - -
7 Noise P/S Yes 1 No - -
8 Noise P/S Yes 2 No - -



















13 Noise P/S Yes 25 No - 1





















18 Noise P/S Yes 14 No - 1
19 SIC >3000 No - No - 1
20 Noise P/S No - Yes LIA 1+2
21 Noise P/S Yes 13 Yes LIA 1+2
22 Noise P/S No - Yes LIA 1+2
23 Noise P/S No - Yes LIA 1+2
P/S = Pace-sense conductor; SIC = Sensing Integrity Counter; IAS = Inappropriate Shocks due to lead failure; 
LIA = Lead Integrity Algorithm;






of the Marquis family. Hence, LIA was uploadable in 99% of all devices by January 2009. 
Assessment of the alert audibility revealed that 18 patients (6%) were unable to hear the 
alert. 
Remote monitoring was offered to all 297 patients of whom 93% (n=275) accepted 
its use. Causes of refusal were inaccessibility to a fixed telephone network (n=14, 4%), 
fear of constant confrontation with the ICD (n=6, 2%) or living abroad (n=2, 1%). Of the 
275 patients who received a monitor, 231 (84%) patients were able to perform a test 
transmission at home. The majority of installation problems were related to non-analogue 
telephone lines (54%). 
Period C
During the period following the 2nd advisory, 1 patient (<1%) died and 5 SF leads (2%) 
were removed. Four of these removals were due to lead failure and 1 was prophylactically 
replaced during ICD replacement. LIA was triggered in all cases of lead failure. However, 
as can be noted in table 2, one patient received inappropriate shocks regardless of the LIA 
warning, which was triggered only 5 minutes before the occurrence of inappropriate device 
discharges. 
Effect of advisories
During complete follow-up (period A, B and C) of 923 lead-years, a total of 23 cases of 
lead failure were identified of which 12 patients presented with inappropriate shocks. 
The cumulative incidence of lead failure was 3.6% [95%CI 1.6 – 5.6] at 21 months and 




Table 3. Requirement for re-intervention per consecutive implanted ICD. 
 Total 1st ICD 2nd ICD 3rd ICD 4th ICD 5th ICD 
Number of ICDs 3161 2415 609 107 24 6 
Events 145 90 46 5 3 1 
Total years implanted 7632.3 5949 1406 236 37 4.3 
















Figure 2. Kaplan Meier curve for Sprint Fidelis lead failure










cumulative incidence of lead failure appeared to accelerate over time. The rate of inap-
propriate shocks per lead failure decreased from 78% (7 out of 9 patients) to 25% (1 out 
of 4 patients) after implementing both advisories. Differentiation by the pre-defined periods 
revealed an event rate of inappropriate shocks per 100 lead-years of 1.5 [95% CI 0.59, 
3.00] in period A, 1.3 [95% CI 0.35, 3.29] in period B and 0.8 [95% CI 0.02, 4.25] in 
period C (Table 3). Noteworthy, in every patient with an adverse event, the advisory, prior 
to that event, was implemented. 
Non-Medtronic devices
In 18 cases (5%), the implanted ICD was not manufactured by Medtronic, which made 
it impossible to fully comply with the safety advisories. However, all patients were seen 
at the outpatient clinic every 3 months after the first advisory. During follow-up, 3 leads 
(17%) (all combined with an ICD by Biotronik) were removed, of which 2 cases (11%) 
were identified as lead failure. In addition, both cases of lead failure caused noise on the 
electrogram and subsequently multiple inappropriate shocks.  
Discussion
To comply with the safety advisories of Medtronic we conducted two clinical evaluations 
and presented the results of these recommendations in daily practice. The major findings 
of the current study can be summarized as follows: 1) the cumulative incidence of SF lead 
failure increased from 3.6% at 21 months to 11% at 42 months; 2) implementation of 
both advisories reduced the occurrence of inappropriate shocks due to lead failure from 1.5 
to 0.8 per 100 lead-years; 3) all advisories were easily conducted in most patients.
Device alerts
The ICD lead has frequently been described as the weakest link of the ICD system, being 
most vulnerable to failure.4 Taken in consideration that failure of this lead might render 
the system incapable of responding adequately in case of a life threatening arrhythmia, 
timely detection is desirable to maximize patient safety. Becker et al. reported that standard 
Table 3. Inappropriate shocks per period
Period Total lead-years
Cases of IAS 
(n)
Cases of IAS/100 lead-years (CI 95%)
A 481 7 1.5 [0.59, 3.00]
B 311 4 1.3 [0.35, 3.29]
C 131 1 0.8 [0.02, 4.25]
Total 923 12 1.3 [0.67, 2.27]
IAS = Inappropriate shocks due to lead failure






impedance-measurement-based patient alerts in ICDs are useful additional tools for early 
detection of lead failure.12 However, these impedance measurements alone seemed to be 
insufficient for inappropriate therapy prevention.13, 14 Accordingly, the research focus shifted 
to the combined use of impedance measurements with quantitative measures of oversens-
ing resulting in a better and earlier lead failure detection.15, 16 Swerdlow and co-workers 
developed an uploadable algorithm based on a nonphysiologically short R-R interval 
detection, the sensing integrity counter and the nonsustained tachycardia log.17 In their ret-
rospective analysis, this LIA improved advance warning of lead failure and, consequently, 
Medtronic advised installation of LIA in all Medtronic devices with a SF lead.10 The current, 
prospective analysis demonstrates that LIA can be uploaded in 99% of the Medtronic ICDs 
and its effect on the occurrence inappropriate shocks due to lead failure seems promising. 
Specifically, after implementation of LIA, all cases of lead failure were preceded by a LIA 
alert.  Unfortunately, in one patient, it was triggered only 5 minutes before 13 inappropriate 
device discharges. Nevertheless, the rate of patients receiving inappropriate shocks due to 
lead failure diminished from 1.5/100 lead-years to 0.8/100 lead-years after implementa-
tion of both advisories. Taken into account the results of the current analysis, LIA seems to 
be the most promising recommendation for reducing inappropriate device discharges due 
to failure of the SF lead. 
However, LIA is only uploadable in ICDs by Medtronic. Five percent (n=18) of the 
patients, implanted with a SF lead at our hospital, could not benefit for the advisories of 
Medtronic since a non-Medtronic ICD was implanted. Thus far, 2 patients experienced 
inappropriate shocks due to lead failure but the remaining 16 patients are still at risk for 
adverse events caused by lead failure. It is implausible that manufacturers, other than 
Medtronic, will address this issue with a Medtronic lead. To comply with future advisories 
and to maximize patient safety, it may be advisable to implant leads and pulse generator by 
the same manufacturer in most patients. 
In the general ICD treated population, Kleemann et al reported inappropriate shocks 
secondary to lead failure in 33% of patients.3 Although this percentage is significantly lower 
than observed in period A of the current study (78%), a beneficial effect of changing ICD 
programming similar to the SF advisories, might be achieved in patients with leads, other 
than SF. The current study assessed several methods for prevention of these adverse events 
and so far, the combination of lower lead impedance alerts and LIA seems to be the most 
promising way to improve early diagnosis of lead failures. In line with these results, it may 
be advisable for device manufactures to investigate the optimal lead impedance thresholds 
and the possibility to implement LIA or LIA-like software into all ICDs, regardless of the 
lead performance.











In case of a device alert, rapid response and quick analysis are warranted for several 
reasons. Firstly, besides LIA, every ICD by Medtronic is equipped with 6 other audible 
patient-alerts representing different urgencies and requiring different treatment strategies.12 
Secondly, the interval between indicators of lead failure and the first occurrence of inap-
propriate shocks is short; often only hours to days.17 However, in daily practice, these 
audible alerts appeared to be insensitive with an average time from audible alert to ICD 
interrogation of 5.3 days. Moreover, 5 patients reported having heard an audible alarm 
without documented event in the device memory.18 To address these limitations, remote 
monitoring seems an appropriate answer, facilitating quick remote access to the device 
information. In addition, the latest devices can automatically transmit a wireless remote 
monitoring alert to notify the physician. In the current study, only one patient used remote 
monitoring in response to a LIA-alert, resulting in timely identification of lead failure and 
consequent lead replacement. Nonetheless, remote monitoring might pose to be a safe and 
efficient means for ICD follow-up. 
Limitations
Although all ICDs and leads are periodically screened for integrity and adequate function, 
some cases of lead failure might occur without clinical symptoms or alerts, causing them 
to go unnoticed. This will eventually lead to an underestimation of the actual incidence of 
lead failure and an overestimation of the percentage of lead failures presented with adverse 
events. Furthermore, the current study demonstrated a strong decrease of inappropriate 
shocks due to lead failure which seemed to be the result of the advisory implementation, 
but other explanations are conceivable, including increase of alertness by patient and 
physician. However, even greater awareness can be considered as a positive effect of these 
advisories.
Conclusion
The current study demonstrates that despite an increasing risk for SF lead failure, imple-
mentation of SF lead advisories decreased the occurrence of inappropriate shocks due to 
lead failure. Of these advisories, LIA seems to be the most effective in the prevention of 
inappropriate device discharges by alerting 75% of all patients prior to the occurrence. 
These findings imply the beneficial effect of the advisories on patient safety.
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Objectives: To asses the requirement for pocket related surgical re-interventions following 
implantable cardioverter defibrillator (ICD) treatment and to evaluate the effect of device 
replacement.
Background: Despite the positive effect on mortality of ICD therapy in selected patients, 
limited service life of the ICD results in a necessity of replacement in the majority of 
patients. Data on the effect of replacement procedures on the occurrence of pocket related 
adverse events are scarce.
Methods and Results: Since 1992, a total of 3161 ICDs were implanted in 2415 con-
secutive patients (80% men, mean age 62 (SD 13) years) ICDs were grouped by the 
consecutive number in which they were implanted, resulting into a group of first implanted 
ICDs and multiple groups of consecutive replacement ICDs. All pocket related complica-
tions requiring surgical re-intervention following ICD implantation or replacement were 
noted. In total, 145 surgical re-interventions were required in 122 (3.9%) patients, with a 
median time to first re-intervention of 75 days. The three years cumulative incidence of first 
re-intervention was 4.7% (95% CI 3.9-5.5%) and the incidence of re-intervention was 1.9 
(95% CI 1.6-2.2) per 100 ICD-years. Event rate comparison of replacement ICDs versus 
first implanted ICDs showed a more than doubled need for re-interventions in replacement 
ICDs (rate ratio 2.2 [95% CI 1.5-3.0]). Further sub-division by the consecutive number 
of ICD replacements, shows an increase in the annual need for surgical re-intervention, 
ranging from 1.5% (95% CI 1.2-1.9%) in the first implanted ICD, to 8.1% (95% CI 1.7-
18.3%) in the fourth implanted ICD.
Conclusions: ICD replacement is associated with a doubled risk for pocket related surgical 
re-interventions. Furthermore, the occurrence of the need for re-intervention increases with 
every consecutive replacement.











Implantable cardioverter-defibrillators (ICDs) have shown to be an effective treatment 
modality in the primary and secondary prevention of sudden cardiac death in selected 
patients.1-7 With expending indications for ICD therapy, worldwide implantation rates have 
increased to an estimated 275.000 units in 2008.8, 9 Although these major advances have 
a positive effect on mortality, some serious drawbacks of ICD therapy should not be over-
seen. The most important being the limited service life of the pulse generator, resulting in 
device replacement approximately every 4-5 years.10, 11 With increased survival of patients 
it is estimated that over 70% of implanted patients require an ICD replacement due to 
end-of-life of the device and 40% even require a second replacement.11 These figures imply 
that the number of replacements can be expected to outnumber first implantations in the 
near future.12 Previous studies have demonstrated that surgical re-interventions, such as 
device replacements, are correlated to an increased occurrence of device infections.13, 14 
Additionally, Gould and Krahn reported that the consequences of an early re-intervention for 
a non-infectious cause can be considered more harmful than the underlying complication 
itself.15 However, the effect of replacement on non-infectious, pocket related complications 
and the effect of additional replacements has not yet been assessed. 
This current increase in ICD replacements warrants clear mapping of the associated risks 
for complications, such as hematoma or infection. In this analysis a comparison is made to 
determine the requirement for pocket related surgical re-intervention in first implanted ICDs 
and replacement ICDs in a large number of implanted ICDs (n= 3161). 
Methods
Patients 
The study population consisted of consecutive patients who received an ICD system in the 
Leiden University Medical Center. Since 1992 all implant procedures were registered in 
the departmental Cardiology Information System (EPD-Vision®, Leiden University Medical 
Center). Data of the implant procedure and all follow-up visits were recorded prospectively. 
The data collected for the current registry ranged up to August 2008. Abdominal implanted 
ICDs were excluded from the current analysis. 
Indications for ICD treatment were made according to international guidelines at that 
time. Due to evolution of these guidelines, indications will have changed over time. 8, 16 Ma-
jority of patients were indicated for ICD treatment in the presence of prior life-threatening 
ventricular arrhythmia or poor left ventricular ejection fraction [LVEF]. 






Device implantation and discharge
At implantation, patients were clinically assessed, as described previously.17-19 During the 
implant procedure testing of sensing and pacing thresholds and defibrillation threshold test-
ing was performed. Before discharge all patients underwent pocket inspection to exclude 
hematoma or early signs of infection. If no abnormalities were found and temperature was 
normal, patients were discharged.
End-point and follow-up
The primary end-point was the occurrence of a surgical re-intervention of the ICD pocket 
(not because of an elective device replacement, lead failure or device malfunction). Since 
the aim of the current study was to evaluate the differences in event-rates between first 
implanted ICDs and replacement ICDs, only pocket related causes were considered. If 
other causes, such as lead related complications or pulse generator malfunction were taken 
in account, comparison would be difficult, given the fact that commonly, leads are only 
implanted at the initial ICD implantation and can therefore not be compared to lead related 
complications at replacement. 
In the Dutch health care system, all patients are followed by the implanting center 
and periodical follow-up was performed every three to six months. This study included 
follow-ups performed up to September 2008. During periodical follow-up the pocket was 
inspected for abnormalities and ICDs were checked at their functionality and battery status.
Since periodical follow-up was performed every three to six months, patients with more 
than six months of missing data were considered as lost to follow-up.
Statistical analysis
Continuous data are expressed as mean and standard deviation or range, median and 
first and third quartile where appropriate; nominal data are presented as numbers and 
percentages. ICDs were grouped by the consecutive number in which they were implanted 
in the patient. This classification divides the implanted ICDs into a group of first implanted 
ICDs and multiple groups of replacement ICDs. The number of required re-interventions 
and the sum of years the ICDs were followed-up (ICD-years) were calculated for each 
group. Event rates were calculated by dividing the number of surgical re-interventions by 
the number of ICD-years, expressed with a two-sided 95% confidence interval (95% CI). In 
the calculation of the 95% CI for event rates, a Poisson distribution of the observed number 
of events was presumed. Rate ratios were used to assess the differences in event rates 
between groups. Cumulative incidences were analyzed with the method of Kaplan-Meier. 
For all tests, a p-value <0.05 was considered significant.












A total of 3328 ICDs were implanted in 2521 patients between 1992 and August 2008. 
For the current analysis, all abdominal (n= 102, 3%) placed ICDs were excluded. Sixty-five 
(2.0%) ICDs were lost to follow-up. The remaining 3161 devices, implanted in 2415 
patients were included in the analysis. These consisted of 2415 (76%) first implanted and 
746 (24%) replacement ICDs. Figure 1 shows the annual proportion of replacements out 
of all device implantations.
Patients and ICD characteristics
The majority of patients (80% men, mean age 62 (SD 13) years) had ischemic heart 
disease (62%) and a poor LVEF (33±15%) (Table 1). At implantation, QRS duration 
(124±37 ms) and renal clearance (79±38 ml/min) were measured. At discharge, patients 
were using beta-blockers (54%), ACE inhibitors/AT II antagonists (75%), diuretics (62%), 
aspirin (40%) and oral anticoagulants (50%). Implanted first ICDs were single chamber 
devices (n=335, 14%), dual chamber devices (n=1171, 48%) or cardiac resynchroniza-
tion therapy-defibrillators (CRT-Ds) (909, 38%). 
 35
 
Figure 1. Annual percentage of replacements out of all implanted ICDs (bald line) and 
trend line ( ashed line).  
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Incidence and causes of surgical re-intervention
During 7632.3 ICD-years of follow-up, 145 surgical re-interventions were required in 122 
(3.9%) patients.  Median time to first re-intervention was 75 days (interquartile range, 14 
to 258 days). 
Cumulative incidence of first surgical re-intervention after the most recent ICD implanta-
tion was 3.5% (95% CI 2.9-4.1%) after one year, 4.3% (95% CI 3.5-5.1%) after two 
years and 4.7% (95% CI 3.9-5.5%) after three years. Over-all the event-rate of a surgical 
re-intervention was 1.9 (95% CI 1.6-2.2) per 100 ICD-years. 
Ninety-five (66%) re-interventions were due to an infectious cause and the remaining 50 
(34%) were due to a non-infectious cause (Table 2). Infectious causes were pocket infec-
tions (57, 60%%) and decubic ulcers, requiring explantation (11, 12%) or relocation (27, 
28%). Hematoma, requiring evacuation was the most common (31, 21%) non-infectious 
cause for surgical re-intervention. Calculated event rate for the occurrence of surgical re-
intervention was 1.2 (95% CI 1.0-1.5) per 100 ICD-years for infectious cause and 0.7 
(95% CI 0.5-0.9) per 100 ICD-years for non-infectious cause.




     Age, mean (SD), years 62 (13)
     Male sex (%) 1921 (80)
     Primary indication (%) 1504 (62)
     Ejection fraction (%) 33 (15)
     QRS, mean (SD), ms 124 (37)
     Renal clearance, mean (SD), ml/min 79 (38)
Device type
    Single chamber (%) 335 (14)
    Dual chamber (%) 1171 (48)
    CRT-D (%) 909 (38)
Medication
     Beta-blocker (%) 1291 (54)
     Sotalol (%) 333 (14)
     ACE inhibitors/AT II antagonist (%) 1806 (75)
     Calcium antagonist (%) 220 (9)
     Diuretics (%) 1506 (62)
     Statins (%) 1395 (58)
     Nitrates (%) 430 (18)
     Amiodarone (%) 454 (19)
     Aspirin (%) 961 (40)
     Oral anticoagulants (%) 1217 (50)
CRT-D = cardiac resynchronization device-defibrillator










First implanted ICD vs. replacement ICD
In the first implanted ICD group (2415, 76%), 90 surgical re-interventions were required in 
77 different ICDs during a summed follow-up of 5949 ICD-years. The 746 (34%) replace-
ment ICDs required 55 surgical re-interventions in 45 patients during a summed follow-up 
of 1683 ICD-years. 
As shown in Figure 2, three years cumulative incidence of first surgical re-intervention 
was 3.9% (95% CI 3.1-4.7%) for first implanted ICDs and 7.5% (95% CI 5.3-9.7%) for 
replacement ICDs. The calculated event-rate per 100 ICD-years was 1.5 (95% CI 1.2-1.9) 
for the first implanted ICDs and 3.3 (95% CI 2.5-4.3) for replacement ICDs, corresponding 
to a more than doubled (rate ratio 2.2 [95% CI 1.5-3.0, p<0.001]) requirement for surgi-
cal re-intervention in replacement ICDs.
Further stratification demonstrated an event-rate of surgical re-intervention for an infec-
tious cause of 0.9 (95% CI 0.7-1.2) per 100 ICD-years in first implanted ICDs and 2.3 
(95% CI 1.6-3.2) per 100 ICD-years in replacement ICDs. Per 100 ICD-years, the need 
for surgical re-intervention for non-infectious causes was 0.6 (95% CI 0.4-0.8) in first 
implanted ICDs and 1.0 (95% CI 0.5-1.5) in replacement ICDs. When comparing replace-
ment ICDs with first implanted ICDs, the calculated rate ratios are 2.5 (95% CI 1.6-3.7, 
p<0.001) for infectious causes and 1.7 (95% CI 0.9-3.0, p=0.09) for non-infectious 
causes.
As is shown in Table 3, further sub-division in the consecutive number of ICD replace-
ments, shows an increase in the need for surgical re-intervention with every consecutive 
ICD replacement. Event-rates per 100 ICD-years range from 1.5 (95% CI 1.2-1.9) in the 
first implanted ICD, to 8.1 (95% CI 1.7-18.3) in the fourth implanted ICD.








    Pocket infection leading to explantation 57/57 38/38 19/19
    Decubic ulcer leading to explantation 11/11 7/7 4/4
    Decubic ulcer leading to relocation 27/22 11/9 16/13
Non-infectious
    Hematoma requiring evacuation 31/29 24/24 7/5
    Device migration leading to relocation 10/10 3/3 7/7
    Pain complaints of the patient leading to relocation 9/7 7/6 2/1
Total infectious causes 95/81* 56/47* 39/34*
Total non-infectious causes 50/45* 34/32* 16/13*
Total 145/122* 90/77* 55/45*
*Since multiple re-interventions could have been required in a single ICD treatment, the number of dif-
ferent ICDs does not add up to the total.







In this assessment of the requirement of pocket related surgical re-interventions after ICD 
treatment, the findings can be summarized as follows: 1) The three years cumulative inci-
dence of first surgical re-intervention in all implanted ICDs was 4.7% (95% CI 3.9-5.5%) 
with an event-rate of 1.9 (95% CI 1.6-2.2) per 100 ICD-years; 2) Replacement ICDs 
demonstrate a doubled occurrence of surgical re-interventions (rate ratio 2.2 [95% CI 
1.5-3.0]); 3) Infectious causes (rate ratio 2.5, 95% CI 1.6-3.7), as well as non-infectious 
causes (rate ratio 1.7 [95% CI 0.9-3.0, p=0.09) seem to be more frequent in replacement 
ICDs; 4) The occurrence of surgical re-interventions seem to increase with every consecu-
tive replacement.
Replacements
Since large randomized trials have proven ICD treatment to improve survival in the primary 
and secondary prevention of sudden cardiac death, worldwide implantation rates have 
amplified substantially.8, 9, 20 With increased survival of patients and limited service life of 
the devices, Hauser estimated that over 70% of the currently implanted patients outlive 
their ICD and therefore requires replacement.11 which is in line with the results of this 
study. Due to the significant increase of ICD implantations the number of replacements is 
increasing rapidly. However, with the limited service life of the current devices, it can be 
Table 3. Requirement for re-intervention per consecutive implanted ICD.
Total 1st ICD 2nd ICD 3rd ICD 4th ICD 5th ICD
Number of ICDs 3161 2415 609 107 24 6
Events 145 90 46 5 3 1
Total years implanted 7632.3 5949 1406 236 37 4.3
















Figure 1. Annual percentage of replacements out of all implanted ICDs (bald line) and 
trend line (dashed line).  
 
 










expected that replacements will increase drastically and potentially even outnumber first 
implanted ICDs.12 Previous studies have described the increasing risk for complications, 
associated with device replacements.11, 13, 21-24  The current study adds to prior literature 
in that it compares the event rates in a large population and differentiates in the cause of 
intervention (infectious or non-infectious) and in the consecutive number of ICD replace-
ments.
Re-interventions
The present study reports differences in the risk of surgical re-interventions between first 
implanted ICDs and replacement ICDs. In the comparison with previous trials, differences 
in defining end points should be taken into account. For a decent comparison between 
first implantation and replacement, the current analysis did not take causes in account 
that would distort comparison. Therefore, since leads are commonly only implanted at first 
implantation, lead related complications were not used in the analysis and only pocket 
related complications were noted.
The most frequent infectious cause for device explantation is cardiac device infection 
(CDI), a serious and potentially life threatening condition which is associated with signifi-
cant morbidity and mortality. Additionally, CDI is associated with additional medical costs 
which have been estimated at an average of $50.000 per patient. 
With the expansion of evidence based indications for cardiac devices the number of 
device related procedures has rapidly increased over the past decade which also resulted 
in an increased number of CDI. Furthermore it has been reported that the increase in CDI 
has outpaced the increase in implantation rate.25 Recent reported rates of CDI vary between 
approximately 0.5% and approximately 5%.13, 14, 24, 26
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Figure 2. Kaplan-Meier curve for first surgical re-intervention, first implanted ICD vs. replacement ICD.






It has been hypothesized that local perioperative wound contamination is a major mecha-
nism predisposing to local or systemic pacemaker infection.27 Da Costa et al. evaluated the 
role of local bacterial flora on pacemaker-related infection and skin erosion and concluded 
that their results strongly support this hypothesis.26 Furthermore, it has been reported 
that device revision procedures (generator exchange / lead related procedure) are associ-
ated with CDI. Gould and Krahn reported that ICD generator replacement in patients with 
advisory devices is associated with a substantial rate of infectious complications (1.9% 
after a mean follow up of 2.7 months). Furthermore it should be taken in account that the 
consequences of an early re-intervention for a non-infectious cause can be considered more 
harmful than the underlying complication itself.15 In their recent paper Lekkerkerker et al. 
reported that device revisions are an important risk factor for CDI with an odds ratio of 3.67 
(95% CI 1.51 to 8.96, p<0.01) for any device related revision procedure, or an odds ratio 
of 2.47 (95% CI 1.25 to 4.87, p<0.01) for a generator exchange and an odds ratio of 
6.67 (95% CI .33 to 33.49, p=0.02) for a lead related intervention.14 Furthermore Klug 
and co-workers also described an odds ratio of 2.2 for generator replacements, after 12 
months follow-up in 6319 implanted devices, of which 1854 being replacement devices.13 
In the current study, during 7623.3 ICD-years of follow-up, per 100 ICD-years, the need for 
surgical intervention for infectious causes was 0.6 (95% CI 0.4-0.8) in first implanted ICDs 
and 1.0 (95% CI 0.5-1.5) in replacement ICDs. When comparing replacement ICDs with 
first implanted ICDs, the corresponding rate ratio was 2.5 (95% CI 1.6-3.7, p<0.001). 
Considering the above, the need for device replacement should be reduced to a minimum 
and all effort should be made to improve device longevity. 
Conclusions
Replacement ICDs demonstrated a doubled occurrence of pocket related surgical re-
interventions when compared to first implanted ICDs. Furthermore, both the requirement 
for surgical re-intervention due to infectious cause and non-infectious cause seemed to 
be increased in replacement ICDs and the requirement for re-intervention increased with 
every consecutive replacement. Therefore, every effort should be addressed to improve ICD 
longevity, decreasing the need for device replacement.
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Summary
The general introduction (Chapter 1) of this thesis describes aspects of sudden cardiac death 
(SCD), ventricular arrhythmias, substrates for ventricular arrhythmias, and the relevant 
treatment options for ventricular arrhythmias, amongst others  implantable cardioverter 
defibrillator (ICD) therapy. Chapter 1 further specifies on the history of ICDs, the studies 
leading to the construction of the international guidelines, and questions still arising about 
ICD treatment.
The aim of this thesis was to improve understanding of several important clinical is-
sues concerning ICD treatment in daily clinical care by studying a large population of ICD 
patients outside the setting of a clinical trial. Firstly, the population currently receiving ICD 
treatment was assessed and long-term follow-up, as well as possibilities for baseline risk 
stratification, were evaluated (Part I). To improve risk stratification within the population, 
currently treated with an ICD, the added value of new parameters was studied (Part II). 
Finally, complications accompanying ICD treatment were studied (Part III).
Part I: Long-term follow-up and baseline risk stratification of ICD patients
Chapter 2 we assessed the frequency of patients in daily clinical practice who meet criteria 
for implantation of an ICD following acute myocardial infarction (MI) using a pre-hospital, 
in-hospital and out-patient clinical framework aimed at the prevention of SCD. A total of 
676 consecutive acute MI patients (78% male, mean age 59±12 years) were included 
in this analysis. Left ventricular ejection fraction (LVEF) at 3 months was 54±10%. Only 
39 (6%) patients met criteria for implantation of an ICD <1 year post-MI. These patients 
suffered more extensive infarctions as indicated by higher peak troponin T values (mean 
14.5±8.3µg/l vs. 6.5±14.7µg/l; p<0.001) and had more LAD related infarctions (79% 
vs. 46%; p<0.001). Cumulative first appropriate therapy rate was 15% (95% CI 4-27%) 
at 3 years follow-up. No sudden cardiac death was observed in the study population.
This study indicates that with the implementation of an aggressive optimized treatment 
protocol for acute MI patients, prophylactic ICD implantation was warranted in only 6% 
of patients. Additionally, this easy-to-use guideline-based protocol is able to reduce the 
occurrence of SCD substantially.
The aim of Chapter 3 was to assess the long-term mortality rate and the recurrence of 
potentially life-threatening ventricular arrhythmias in secondary prevention ICD patients 
and to construct a model for baseline risk stratification. For this purposes, 456 patients 
with ischemic heart disease, receiving ICD therapy for secondary prevention of sudden 
cardiac death were evaluated at implantation and during 54±35 months follow-up. During 
follow-up, 100 (22%) patients died and appropriate ICD therapy was noted in 216 (47%) 
patients of whom 138 (30%) for fast, potentially life-threatening ventricular arrhythmias. 
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Multivariate analysis revealed a history of atrial fibrillation (AF) or flutter, ventricular 
tachycardia (VT) as presenting arrhythmia, wide QRS and poor left ventricular ejection 
fraction as independent predictors of life-threatening ventricular arrhythmias. The strongest 
predictor was atrial fibrillation with a hazard ratio of 2.1 (95% CI: 1.3-3.2). Based on the 
available clinical data it was not possible to identify a group which exhibited no risk of 
recurrence of potentially life-threatening ventricular arrhythmias.
This study demonstrates the high recurrence rate of life-threatening arrhythmias in 
secondary prevention patients. Although factors correlating to an increased risk can be 
identified, no recurrence-free group could be distinguished. This stresses the importance of 
ICD treatment in this population.
In Chapter 4 the presence of a history of AF (paroxysmal, persistent or permanent) was 
evaluated in 913 ICD patients. Furthermore, the effect of AF on the occurrence of ap-
propriate or inappropriate device therapy, as well as mortality was noted. At implantation, 
73% of patients had no history of AF, 9% had a history of paroxysmal AF, 7% had a his-
tory of persistent AF and 11% had permanent AF. During 27±13 months follow-up, 117 
patients (13%) died, 228 patients (25%) experienced appropriate device discharge and 
139 patients (15%) received inappropriate shocks. Patients with permanent AF exhibited 
more than double the risk of mortality, ventricular arrhythmias triggering device discharge, 
and inappropriate device therapy. Patients with paroxysmal or persistent AF did not show a 
significantly increased risk of mortality or appropriate device therapy but demonstrated an 
almost threefold increased risk of inappropriate device therapy.
This study clearly demonstrates prognostic importance of this common arrhythmia in ICD 
treated patients.
Chapter 5 described the importance of new-onset AF in 223 ICD patients without a history 
of AF with symptomatic heart failure, who received a cardiac resynchronization therapy-
defibrillator device. Defining new-onset AF as atrial high-rate episodes >180 bpm during 
>10 minutes/day as detected by the device resulted in 55 patients (25%) who develop 
new-onset AF during a mean follow up of 32±16 months. When compared to the patients 
who maintained sinus rhythm during follow-up, patients developing AF showed less LV 
reverse remodeling (ΔLV end systolic volume 37±53 vs. 19±37 ml, p<0.05) and less 
improvement in LV function (ΔLV ejection fraction 6.7±8.9 vs. 3.5±10.3%, p<0.05). Im-
portantly, patients developing AF experienced more appropriate ICD shocks for ventricular 
arrhythmias, more inappropriate shocks and more hospitalizations for heart failure.
This study shows the importance of new-onset AF in this symptomatic population. Fur-
thermore, it demonstrates the possibilities for device-based diagnostics. 
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Chapter 6 assessed survival in 1036 primary prevention ICD patients with non-ischemic or 
ischemic heart disease and constructed a baseline mortality risk score. Non-ischemic and 
ischemic patients demonstrated similar survival but exhibited different factors that influ-
ence risk for mortality. A risk score, consisting of simple baseline variables could stratify 
patients in low, intermediate and high risk for mortality. In non-ischemic patients, annual 
mortality was 0.4% (95% CI 0.0-2.2%) in low risk and 9.4% (95% CI 6.6-13.1%) in high 
risk patients. In ischemic patients, annual mortality was 1.0% (95% CI 0.2-3.0%) in low 
risk and 17.8% (95% CI 13.6-22.9%) in high risk patients.
This chapter shows that utilisation of an easily applicable baseline risk score can create 
an individual patient-tailored estimation on mortality risk to aid clinicians in daily practice. 
In an attempt to identify patients who do not benefit from ICD treatment, Chapter 7 de-
fined non-benefit from ICD treatment as death, prior to appropriate ICD therapy. Out of 
a number of different routinely acquired baseline variables such as age, ejection fraction 
and diabetes, a baseline risk score was constructed to estimate risk for non-benefit in 900 
ischemic primary prevention ICD recipients. Stratification for non-benefit resulted in risk 
categorization of patients as low, intermediate or high-risk. Advanced age was the strongest 
predictor of non-benefit. Five-year cumulative incidence for non-benefit ranged from 12% 
(95%CI 5–18%) in low-risk patients to 49% (95%CI 38–60%) in high-risk patients. 
This study shows that the risk of non-benefit can be predicted which may have important 
clinical consequences. 
Part II: New parameters for risk stratification
Chapter 8 evaluated the relation between infarct tissue heterogeneity on contrast-enhanced 
magnetic resonance imaging (MRI) and the occurrence of spontaneous ventricular ar-
rhythmia in patients with previous myocardial infarction. For this study, 91 patients with 
previous MI scheduled for ICD implantation underwent cine-MRI to evaluate left ventricular 
function and volumes and contrast-enhanced MRI for characterization of scar tissue (infarct 
gray zone as measure of infarct tissue heterogeneity, infarct core and total infarct size). Ap-
propriate ICD therapy was documented in 18 patients (20%) during a median follow-up of 
8.5 months (interquartile range 2.1-20.3). Multivariable Cox proportional hazards analysis 
revealed that, out of all MRI parameters, the amount of infarct gray zone was the strongest 
predictor of the occurrence of spontaneous ventricular arrhythmia with subsequent ICD 
therapy (hazard ratio 1.49/10g, confidence interval 1.01-2.20). 
This study established the correlation between infarct tissue heterogeneity on contrast-
enhanced MRI and the occurrence of ventricular arrhythmias in patients with previous MI. 
In Chapter 9, the value of cardiac sympathetic denervation, measured with 123-iodine me-
taiodobenzylguanidine (123-I MIBG) imaging, was tested for the prediction of ventricular 
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arrhythmias causing appropriate ICD therapy (primary endpoint) and the composite of 
appropriate ICD therapy or cardiac death (secondary endpoint). Before ICD implantation, 
116 patients underwent 123-I MIBG and myocardial perfusion imaging. Early and late 
123-I MIBG (planar and SPECT) imaging was performed to assess cardiac innervation 
(heart-to-mediastinum ratio, cardiac washout rate and 123-I MIBG SPECT defect score). 
Stress-rest myocardial perfusion imaging was performed to assess myocardial infarction 
and perfusion abnormalities (perfusion defect scores). During 23±15 follow-up, appropri-
ate ICD therapy and cardiac death were documented. Late 123-I MIBG SPECT defect score 
demonstrated to be an independent predictor for both endpoints. Patients with a large late 
123-I MIBG SPECT defect (summed score >26) showed significantly more appropriate 
ICD therapy (52% vs 5%, p<0.01) and appropriate ICD therapy or cardiac death (57% vs 
10%, p<0.01) than patients with a small defect (summed score ≤26) at 3-year follow-up.
The study underscores the potential strong value of 123-I MIBG imaging in the stratifica-
tion for ventricular arrhythmia and SCD. 
Chapter 10 described the value of the ECG derived QRS-T angle for prediction of ICD 
therapy and mortality in primary prevention patients with ischemic heart disease. For this, 
412 ICD patients with ischemic heart disease and a left ventricular ejection fraction ≤ 40% 
were included. After device implantation, the occurrence of appropriate ICD therapy and 
mortality was noted. A survival analysis was performed comparing patients with a planar 
QRS-T angle ≤ 90º (n=124, 30%) to patients with a planar QRS-T angle > 90º before 
device implantation. Furthermore, patients with a spatial QRS-T angle ≤ 100º (n=56, 
14%) were compared to patients with a spatial QRS-T angle > 100º, prior to implant. For 
patients with a planar QRS-T angle >90º as compared to ≤ 90º, the adjusted hazard ratio 
for the occurrence of appropriate device therapy was 2.4 (95% CI 1.1-5.2);  a spatial QRS-
T angle > 100º was associated with an adjusted hazard ratio of 7.3 (95% CI 1.0-53.8). 
Furthermore, a spatial QRS-T angle ≤ 100º exhibited a positive predictive value of 98% 
(95% CI 95-100%) for the prediction of an appropriate therapy-free follow-up.
This study shows that an easy acquirable ECG derived parameter can be a powerful 
predictor of appropriate device therapy in primary prevention ICD recipients with isch-
emic heart disease. Furthermore, a spatial QRS-T angle ≤ 100º might be of value in the 
identification of patients in whom, although currently indicated, ICD treatment should be 
reconsidered.
Chapter 11 evaluated the prognostic value of myocardial excitability, as assessed by right 
ventricular stimulation threshold testing in 689 consecutive primary prevention ICD recipi-
ents with ischemic heart disease. Best dichotomous separation was reached at a cut-off 
of 1V. Cumulative appropriate shock incidence for patients with right ventricular threshold 
≥1V (n=166) was 16% at 1 year, 24% at 3 years and 34% at 5 years compared to 4%, 
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11% and 17% for patients with a right ventricular threshold <1V (n=523). Adjusted HR 
of right ventricular threshold ≥1V was 1.8 (95% CI 1.3-2.6) for appropriate therapy, 3.3 
(95%CI 2.0-5.4) for appropriate shocks and 1.6 (95%CI 1.1-2.5) for mortality.
This study shows that right ventricular stimulation threshold at ICD implant has a strong 
independent prognostic value for the occurrence of ventricular arrhythmias triggering ap-
propriate ICD therapy, appropriate shocks and mortality. 
Part III: Mechanical aspects and complications of device therapy
The incidence, predictors and outcome of inappropriate shocks in 1544 ICD patients was 
assessed in Chapter 12. During a follow-up period of 41 ± 18 months, 13% experienced 
one or more inappropriate shocks. The cumulative incidence steadily increased to 18% 
at 5 years follow-up. Independent baseline predictors for the occurrence of inappropriate 
shocks consisted of history of atrial fibrillation (HR 2.0, p<0.01) and age below 70 years 
(HR 1.8, p<0.01). Experiencing a single inappropriate shock resulted in an increased risk 
for all-cause mortality (HR 1.6, p=0.01). Mortality risk increased with every subsequent 
shock, up to a HR of 3.7 after 5 inappropriate shocks.
This study stresses the importance of inappropriate shocks in this population. Most 
important finding is the association between inappropriate shocks and mortality. 
The occurrence and cause of failure of 568 coronary sinus leads and 2161 defibrillation 
leads were assessed in Chapter 13 and Chapter 14 respectively. 
During follow-up, 7% of patients required a coronary sinus lead intervention. Cause of 
the intervention was an elevated threshold (n=13), loss of capture (n=20), or intractable 
phrenic nerve stimulation (n=6). Fifteen patients (38%) required a coronary sinus lead 
intervention before first scheduled follow-up (two months after implantation). Thirteen 
patients (33%) warranted a coronary sinus lead intervention more than six months after 
implantation. The first endovascular replacement was successful in 86% (32 out of 37), 
while a second endovascular approach failed in 66% (2 out of 3). 
During follow-up, 82 (3.8%) cases of defibrillation lead failure were identified. Cumula-
tive incidence of lead failure at one year was 0.6%, at five years 6.5% and 16.4% at ten 
years. The highest risk of lead failure was found in small-diameter leads. Adjusted hazard 
ratio was 6.4 (95% CI 3.2-12.8) for Medtronic 7 Fr leads, when compared to all other 
leads.
These studies provide insight in the occurrence of adverse events, accompanying ICD 
treatment.
Since the Medtronic Sprint Fidelis defibrillation lead has a higher than expected failure rate 
(Chapter 14), Medtronic announced two advisories consisting of (1) adjustments in device 
settings (October 2007) and (2) installation of a lead integrity algorithm (May 2008). The 
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objective of Chapter 15 was to evaluate the effect of these advisories on patient safety in 
372 implanted leads. Three periods were distinguished in the comparison of event rates: 
lead implantation to advisory 1 (period A), in-between both advisories (period B) and 
advisory 2 to follow-up (period C). Overall cumulative incidence rate of lead failure was 
3.6% (95%CI 1.6 – 5.6%) at 21 months and increased to 11.0% (95% CI 6.1 – 15.9%) 
at 42 months. After implementation of both advisories, the occurrence of inappropriate 
shocks due to lead failure decreased from 1.5 (95% CI 0.6 – 3.0) per 100 lead-years in 
period A to 0.8 (95% CI 0.0 – 4.3) per 100 lead-years in period C.
This study demonstrated that, despite an increasing risk for Sprint Fidelis lead failure, 
implementation of the advisories decreased the occurrence of inappropriate shocks due to 
lead failure.
In Chapter 16, the requirement for pocket related surgical re-interventions following 3161 
ICD implantations was evaluated and the effect of device replacement on the occurrence 
of re-interventions was assessed. In total, 145 surgical re-interventions were required in 
122 (3.9%) patients, with a median time to first re-intervention of 75 days. The three 
year cumulative incidence of first re-intervention was 4.7% (95% CI 3.9-5.5%) and the 
incidence of re-intervention was 1.9 (95% CI 1.6-2.2) per 100 ICD-years. Event rate 
comparison of replacement ICDs versus first implanted ICDs showed a more than doubled 
need for re-interventions in replacement ICDs (rate ratio 2.2 [95% CI 1.5-3.0]). Further 
sub-division by the consecutive number of ICD replacements, shows an increase in the 
annual need for surgical re-intervention, ranging from 1.5% (95% CI 1.2-1.9%) in the first 
implanted ICD, to 8.1% (95% CI 1.7-18.3%) in the fourth implanted ICD.
This study showed the effect of ICD replacement on the requirement of pocket related 
surgical re-interventions. 
Conclusions and future perspectives
Despite undisputed beneficial effects of ICD therapy in selected patients, as shown in large 
randomized trials, much remains unclear about ICD recipients in daily practice, outside 
the setting of a clinical trial. The current thesis clarified a few aspects of this increasing 
and important population of cardiac disease patients. Firstly, long-term follow-up has been 
assessed in different subgroups of ICD recipients, demonstrating rates of all-cause mortal-
ity, the occurrence of appropriate ICD therapy, triggered by ventricular arrhythmia, and the 
incidence of adverse events such as inappropriate device shocks. Secondly, the thesis has 
explored the possibilities for risk estimations using routinely acquired clinical variables 
(age, sex, clinical history, findings on ECG and echocardiography) without additional, 
less commonly applied modalities. Subsequently, the important role of atrial fibrillation 
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at baseline and during follow-up has been more thoroughly assessed. Thirdly, the value of 
novel parameters, acquired by additional modalities (MRI, MIBG, vector ECG) has been as-
sess for the prediction of ventricular arrhythmia to improve baseline risk stratification. More 
importantly, these novel parameters could prove valuable in the identification of patients 
who, although currently indicated for ICD treatment, have a very low occurrence of ven-
tricular arrhythmia during follow-up and should possibly be reconsidered for implantation. 
Additionally, clinically applicable risk scores have been proposed to make patient-tailored 
estimations of mortality risk and of the risk for mortality, prior to a first ICD discharge. 
Finally, the thesis has eluded on the occurrence of important drawbacks of ICD treatment 
such as inappropriate shocks and their prognostic importance, LV lead failure and the suc-
cess rate of endovascular replacement, and RV lead failure and the effect of lead advisories 
on patient safety.
Future research will primarily focus on the optimal allocation of ICD treatment. On one 
hand, patients at high risk for SCD but without an indication for ICD treatment according to 
the current guidelines will have to be identified. On the other hand, within the population 
presently being considered for an ICD, a large portion does not receive potentially life-
saving ICD therapy during long-term follow-up and should therefore be recognized prior to 
implantation and reconsidered. Furthermore, the occurrence of potential drawbacks of ICD 
treatment will have to be further assessed and options for its minimization tested.
Sudden cardiac death in the general population
According to the Maastricht data, SCD is the first manifestation of heart disease in approxi-
mately 50% of all cases. Of all cases of SCD in patients with prior myocardial infarction and 
echocardiographic data, 50% had an LVEF higher than 30% and 20% of patients had an 
LVEF higher than 50%,1 which is in line with the data from our own Leiden out-of-hospital 
cardiac arrest study.2, 3 Taken in consideration that, in general, the ICD treated patients will 
show survival benefit as long as the tested population has high enough risk for arrhythmia 
(as stated by Dr. Mower, co-developer of the ICD)4 one could conclude that the majority 
of the population needing defibrillator backup is not indicated according to the current 
international guidelines.5 Future research will therefore initially have to focus on the detec-
tion of this “unknown” population of patients at high risk for SCD and on the prevention and 
early identification of substrate development (e.g. prevention of acute myocardial infarction, 
identification of dilated cardiomyopathy). 
Since prior studies have proven the effect of ICD treatment for the primary prevention of 
SCD in patients with a poor left ventricular function, the extension of the indicated popula-
tion could aim at patients with known heart disease and a preserved LVEF or at patients 
without known heart disease but with higher risk for substrate for ventricular arrhythmia 
(e.g. positive family history for SCD) or a provocative lifestyle (e.g. competitive sports). 
Parameters identifying this “new” population at high risk will have to be applicable in a 
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large population and, therefore, should be non-invasive and easily acquirable. Parameter 
derived from basic clinical assessment and ECG recording would fit these demands. 
Currently ICD treated population
Large trials have clearly shown the potential of defibrillator treatment for the primary 
prevention of SCD in a large population at high risk. However, the relatively low rate of 
appropriate and potentially life-saving ICD therapy during long-term follow-up does cause 
the efficacy of ICD allocation to be questioned. Although the studied groups as a whole 
have clearly demonstrated survival benefit, this does not mean that all individual included 
patients have equal gain from ICD treatment. Within the indicated population, patients 
who can be assumed to have little benefit from ICD treatment can be distinguished by the 
following factors: 1) a poor prognosis, regardless of defibrillator backup (e.g. high rate of 
heart failure or non-cardiac death); 2) none or low occurrence of potentially life-saving 
appropriate ICD therapy during follow-up; 3) a combination of both factors (death prior to 
appropriate ICD therapy). In order to more efficiently allocate ICD treatment, these patients 
should be identified, prior to implantation. Since the currently indicated ICD population is 
characterized by high age (50% > 65 years; 14% > 75 years) and severe co-morbidity, the 
identification of patients with little benefit should at first focus on these patients.
The assessment of the effect of withholding a portion of the indicated population from 
ICD treatment would interfere with the guidelines and, therefore, is difficult. However, 
clinicians have expressed concern that the number needed to treat with a primary preven-
tion ICD might be too high and that the population, eligible for primary prevention ICD 
treatment, is of such magnitude that provision of ICD therapy will strain financial resources 
and the pool of trained personnel.6 If this is the case, clinicians should be guided in the 
differentiation between patients at high probability to benefit from ICD treatment (good 
prognosis, high risk for ventricular arrhythmia) and patient in whom the positive effects of 
implantation might not outweigh the risk for adverse events, related to device implantation.
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Samenvatting
De algemene introductie van dit proefschrift (hoofdstuk 1) beschrijft de betekenis van 
ventriculaire ritmestoornissen bij het optreden van plotse cardiale dood (SCD, Sudden 
Cardiac Death),  de oorzaken ervan en de behandelopties. Bij laatstgenoemde ligt in dit 
proefschrift het accent op de Implanteerbare Cardioverter Defibrillator (ICD). Daarom wordt 
in dit eerste hoofdstuk eerst dieper ingegaan op de geschiedenis en ontwikkeling van ICDs, 
de grote studies die hebben geleid tot de huidige internationale richtlijnen voor implantatie 
van ICDs en de belangrijke vragen die nog steeds bestaan omtrent ICDs. Het doel van dit 
proefschrift was om meer inzicht te krijgen in een aantal belangrijke kwesties met betrek-
king tot behandeling met ICDs in de dagelijkse klinische praktijk. Hiervoor is een grote 
patiëntenpopulatie, buiten de setting van gerandomiseerde studies, langdurig gevolgd. 
De resultaten van het onderzoek zijn in drie onderdelen van dit proefschrift beschreven. 
Deel I gaat over de mogelijkheden voor baseline risicostratificatie bij patiënten die volgens 
de huidige richtlijnen een indicatie voor een ICD hebben. Deel II beschrijft de resultaten 
van onderzoek naar de toegevoegde waarde van nieuwe parameters ter verbetering van 
risicostratificatie binnen die groep patiënten. In deel III worden de complicaties van een 
behandeling met ICD in kaart gebracht.
Deel I: Lange-termijn follow-up en risicostratificatie van ICD patiënten
In hoofdstuk 2 onderzochten we met behulp van een protocol dat gericht is op de preven-
tie van SCD hoeveel patiënten na een acuut myocardinfarct (MI) voldoen aan de criteria 
voor de implantatie van een ICD in het kader van de primaire preventie van ventriculaire 
ritmestoornissen. In totaal werden 676 patiënten met een acuut MI (78% mannen, gemid-
delde leeftijd 59 ± 12 jaar) in het onderzoek geïncludeerd. Drie maanden na het MI was 
de linkerventrikel ejectiefractie (LVEF) 54 ± 10%. Retrospectief bleken slechts 39 (6%) 
patiënten een jaar na MI aan de criteria voor de implantatie van een ICD te voldoen. Deze 
patiënten werden gekenmerkt door het feit dat zij grotere infarcten hadden, beoordeeld op 
grond van een hogere troponine piek (gemiddeld 14,5 ± 8.3µg / l vs 6,5 ± 14.7µg / l; p 
<0,001), en meer ‘left anterior descending’ coronair arterie gerelateerde infarcten (79% vs 
46%; p <0,001). De cumulatieve incidentie van een eerste terechte ICD therapie was 15% 
(95% CI 4-27%) na 3 jaar follow-up. In de onderzochte populatie kwam geen plotselinge 
cardiale dood voor. Deze studie toont aan dat met het toepassen van een strikt protocol 
voor de behandeling en het vervolgen van patiënten met een acuut myocardinfarct, slechts 
6% van de patiënten in aanmerking komt voor profylactische ICD-implantatie. Tevens is dit 
protocol in staat om het optreden van plotse cardiale dood aanzienlijk verminderen.
In hoofdstuk 3 hebben we bij patiënten met een ICD als secundaire preventie de mortaliteit 
en het optreden van potentieel levensbedreigende ventriculaire ritmestoornissen tijdens 
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een lange periode van follow-up in kaart gebracht en een model voor baseline risicostrati-
ficatie gemaakt. Hiervoor werden de pre-implantatie karakteristieken van 456 secundaire 
preventie ICD patiënten met ischemische hartziekte geëvalueerd en werden deze patiënten 
gedurende 54 ± 35 maanden gevolgd. Tijdens deze follow-up overleden 100 patiënten 
(22%) en bleken 216 patiënten (47%) terechte ICD therapie te hebben gekregen van 
wie 138 (30%) patiënten een snelle, potentieel levensbedreigende ventriculaire aritmie 
doormaakten. Multivariate analyse toonde aan dat een voorgeschiedenis van atriumfibril-
leren of –flutter (AF), ventriculaire tachycardie (VT) als indicatie stellende aritmie, een 
breed QRS complex en een lage LVEF onafhankelijk voorspelde voor het optreden van 
levensbedreigende ventriculaire aritmieën. Een voorgeschiedenis van AF was de sterkste 
voorspeller met een relatief risico van 2.1 (95% CI: 1.3-3.2). Op basis van de beschikbare 
klinische gegevens was het niet mogelijk om een groep te identificeren die geen risico had 
op een recidief van potentieel levensbedreigende ventriculaire aritmieën. Deze studie toont 
aan dat onder patiënten met een ICD als secundaire preventie van ritmestoornissen en 
mortaliteit het recidiefpercentage van levensbedreigende ritmestoornissen hoog is. Hoewel 
de factoren die correleren met een verhoogd risico kunnen worden geïdentificeerd, is het 
niet mogelijk een groep patiënten te identificeren die vrij blijft van recidief. Dit onderstreept 
het belang van ICDs in deze populatie.
In hoofdstuk 4 wordt het effect van een voorgeschiedenis van AF (paroxysmaal, persiste-
rend of permanent) geëvalueerd in 913 patiënten met een ICD. Hierbij onderzochten we 
of de relatie tussen enerzijds AF en anderzijds de mortaliteit en het optreden van terechte 
of onterechte ICD therapie. Ten tijde van de ICD implantatie had 73% van de patiënten 
geen voorgeschiedenis van AF. 9% had een voorgeschiedenis van paroxysmaal AF, 7% 
van persisterend AF en 11% had permanent AF. Gedurende een follow-up van 27 ± 13 
maanden overleden 117 patiënten (13%), bleken 228 patiënten (25%) terechte ICD the-
rapie te hebben gekregen en 139 patiënten (15%) onterechte ICD therapie. Patiënten met 
permanent AF hadden een meer dan dubbel risico op overlijden, ventriculaire aritmieën en 
onterechte therapie. Patiënten met paroxysmaal of persisterend AF toonden geen significant 
verhoogd risico op sterfte of terechte therapie, maar wel een bijna drievoudig verhoogd 
risico op onterechte ICD schokken. Deze studie toont het prognostische belang aan van 
deze veelvoorkomende ritmestoornis bij patiënten met een ICD behandeling.
Hoofdstuk 5 beschrijft het voorkomen en de karakteristieken van nieuwe episodes van 
AF bij 223 patiënten met een ICD zonder voorgeschiedenis van AF met symptomatisch 
hartfalen, waarvoor implantatie van een cardiale resynchronisatie therapie-defibrillator. 
Een nieuwe episode van AF werd gedefinieerd door een atriale frequentie > 180 bpm 
gedurende > 10 minuten / dag, zoals gedetecteerd door het geïmplanteerde device. Bij 
een gemiddelde follow-up van 32 ± 16 maanden kregen 55 patiënten (25%) een nieuwe 
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episode van AF. In vergelijking met de patiënten met een sinusritme tijdens de follow-up, 
hadden patiënten met episoden van AF minder LV reverse remodeling (ΔLV eind systolisch 
volume 37 ± 53 vs. 19 ± 37 ml, p <0.05) en minder verbetering in LV functie (ΔLVEF 
6.7 ± 8.9 vs 3.5 ± 10.3%, p <0.05). Tevens was de ontwikkeling van AF gerelateerd 
aan een verhoogde incidentie van (terechte en onterechte) ICD therapie en frequentere 
ziekenhuisopnames voor hartfalen. Deze studie toont het effect van nieuwe episoden van 
AF aan op het ziektebeloop in deze symptomatische populatie. Bovendien laat het de 
mogelijkheden van device-gebaseerde diagnostiek zien.
Hoofdstuk 6 beschrijft de overleving in 1036 patiënten met een ICD als primaire preventie 
met niet-ischemische of ischemische hartziekte en een gemakkelijk toepasbare sterfte 
risicoscore op basis van pre-implantatie parameters. Ondanks het feit dat de overleving in 
patiënten met non-ischemische en ischemische hartziekte hetzelfde was, bleken de twee 
groepen van elkaar onderscheiden te kunnen worden door verschillende factoren die van 
invloed zijn op het risico voor sterfte. Met behulp van een risicoscore, bestaande uit een-
voudige baseline variabelen, konden patiënten gestratificeerd worden in laag, middelhoog 
en hoog risico op overlijden. Bij niet-ischemische patiënten was de jaarlijkse sterfte 0.4% 
(95% CI 0.0-2.2%) in laag risico en 9.4% (95% CI 6.6-13.1%) in hoog risico patiënten. 
Bij ischemische patiënten was de jaarlijkse sterfte 1.0% (95% CI 0.2-3.0%) bij een laag 
risico en 17.8% (95% CI 13.6-22.9%) bij een hoog risico. Dit hoofdstuk toont dat men 
met behulp van een gemakkelijk toepasbare pre-implantatie risicoscore een sterfte risico-
schatting kan maken, toegespitst op een individuele patiënt. Gebruik van deze risicoscore 
kan clinici in de dagelijkse praktijk steunen in hun beleid bij deze patiënten.
Hoofdstuk 7 gaat over de identificatie van patiënten die geen baat hebben bij behande-
ling met een ICD de zogenaamde “non-benefit” groep. Dit zijn patiënten die overlijden, 
nog voordat zij een terechte ICD therapie hadden gekregen. Op grond van een aantal 
verschillende standaard vastgelegde baseline variabelen zoals leeftijd, ejectiefractie en 
comorbiditeit (diabetes mellitus), werd in 900 patiënten met ischemische hartziekte en 
een ICD als primaire preventie een risicoscore geconstrueerd om vóór implantatie het risico 
voor non-benefit te kunnen inschatten. Met behulp van deze risicoscore konden patiënten 
worden verdeeld in categorieën met een laag, gemiddeld of hoog risico, waarbij een hoge 
leeftijd de sterkste voorspeller was van non-benefit. De vijf-jaars cumulatieve incidentie 
voor non-benefit varieerde van 12% (95% CI 5-18%) in patiënten met een laag risico tot 
49% (95% CI 38-60%) in hoog-risico patiënten. Deze studie toont aan dat het risico van 
non-benefit voor implantatie kan worden voorspeld, hetgeen belangrijke klinische conse-
quenties kan hebben voor de overweging bij ICD implantatie.
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Deel II: Nieuwe parameters voor risicostratificatie
Hoofdstuk 8 beschrijft de voorspellende waarde van met contrast-enhanced magnetische 
resonantie imaging (MRI) gemeten heterogeniteit van littekenweefsel voor het optreden van 
door een ICD geregistreerde ventriculaire hartritmestoornissen. Bij 91 patiënten die een 
hartinfarct doorgemaakt hadden en vervolgens geselecteerd waren voor ICD implantatie, 
werd met behulp van MRI de linkerventrikel functie en volume gemeten en werd het litteken 
gekarakteriseerd (“infarct grey zone” als maat voor infarct heterogeniteit, infarct kern en 
de totale infarctgrootte). Gedurende een mediane follow-up van 8.5 maanden (25e – 75e 
percentiel 2.1-20.3) werd bij 18 patiënten (20%) een terechte ICD therapie geregis-
treerd. In een multivariabele Cox proportional hazards analyse bleek dat, in vergelijking 
met klinische en MRI variabelen  zoals totale infarctgrootte en linker ventrikel functie en 
volumes, de heterogeniteit van het hartinfarct de beste voorspeller was voor het optreden 
van ventriculaire hartritmestoornissen (relatieve risico 1.49/10g, betrouwbaarheidsinterval 
1.01-2.20). Deze studie bevestigt het verband tussen heterogeniteit van het littekenweefsel 
beoordeeld met een contrast-enhanced MRI en het optreden van ventriculaire aritmieën bij 
patiënten met een hartinfarct.
In hoofdstuk 9 wordt onderzoek beschreven naar de voorspellende waarde van cardiale 
sympathische denervatie, gemeten met 123-jood metaiodobenzylguanidine (123-I MIBG) 
beeldvorming, voor het optreden van ventriculaire hartritmestoornissen, leidend tot terechte 
ICD therapie (primair eindpunt) en een samengesteld eindpunt van terechte ICD therapie 
of cardiale sterfte (secundair eindpunt). Voorafgaand aan ICD implantatie, ondergingen 
116 patiënten 123-I MIBG en myocard perfusie beeldvorming. Vroege en late 123-I MIBG 
(planaire en SPECT) beeldvorming werden uitgevoerd om de cardiale innervatie (heart-to-
mediastinum ratio, cardiac washout rate en 123-I MIBG SPECT defect score) in kaart te 
brengen. Een stress-rest myocard perfusie scintigrafie werd uitgevoerd om een myocardiale 
infarcering en perfusie afwijkingen (perfusie defect scores) te beoordelen. Gedurende 23 
± 15 maanden follow-up werden terechte ICD therapie en hartdood gedocumenteerd. 
Late 123-I MIBG SPECT defect score bleek een onafhankelijke voorspeller voor beide 
eindpunten te zijn. Patiënten met een hoge late 123-I MIBG SPECT defect (totale score> 
26) hadden significant meer cumulatieve terechte ICD therapie (52% vs. 5%, p <0.01) en 
cumulatieve terechte ICD therapie of hartdood (57% vs. 10%, p < 0.01) dan patiënten met 
een klein defect (samengevat score ≤ 26) na 3-jaar follow-up. De studie onderstreept de 
sterke potentiële waarde van 123-I MIBG beeldvorming in de stratificatie voor ventriculaire 
hartritmestoornissen en SCD.
In hoofdstuk 10 beschrijven we de resultaten van onderzoek naar de voorspellende waarde 
van de QRS-T-hoek op een ECG voor ICD therapie en mortaliteit bij patiënten met ische-
mische hartziekte met een ICD als primaire preventie van ventriculaire ritmestoornissen. 
Hiervoor werden 412 ICD patiënten met een ischemische hartziekte en een linker ventrikel 
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ejectiefractie ≤ 40% geïncludeerd. Tijdens follow-up werden terechte ICD therapie en 
mortaliteit geregistreerd. Een survival analyse werd uitgevoerd waarbij patiënten met een 
kleine (≤ 90 º) QRS-T hoek (n = 124, 30%) voor ICD implantatie werden vergeleken met 
patiënten met een grote (>90 º) QRS-T-hoek . Tevens werden patiënten met een ruimte-
lijke QRS-T-hoek ≤ 100 º (n = 56, 14%) vergeleken met patiënten met een ruimtelijke 
QRS-T-hoek van > 100 º. Patiënten met een QRS-T-hoek > 90 º hadden een meer dan 
tweevoudig vergroot  risico op het optreden van terechte therapie dan patiënten met een 
hoek ≤ 90 º (relatieve risico 2.4 95% CI 1.1-5.2 ). Een ruimtelijke QRS-T-hoek van > 100 
º was geassocieerd met een gecorrigeerd relatief risico van 7.3 (95% CI 1.0-53.8). Een 
ruimtelijke QRS-T-hoek ≤ 100 º had een positief voorspellende waarde van 98% (95% 
CI 95-100%) voor een klinisch beloop zonder terechte therapie. Deze studie toont aan 
dat een eenvoudige van ECG afgeleide parameter een krachtige voorspeller kan zijn van 
terechte therapie bij patiënten met een ischemische hartziekte en een ICD als primaire 
preventie van ventriculaire ritmestoornissen. Bovendien kan een ruimtelijke QRS-T-hoek ≤ 
100 º van waarde zijn bij de identificatie van patiënten bij wie, hoewel volgens de richtlijn 
geïndiceerd, een ICD-behandeling heroverwogen dient te worden.
In hoofdstuk 11 hebben we in 689 primaire preventie ICD patiënten met ischemische hart-
ziekte de prognostische waarde van myocardiale exciteerbaarheid, beoordeeld met rechter 
ventrikel stimulatie drempel metingen, onderzocht. Bij een cut-off van 1 Volt werd de beste 
dichotome scheiding bereikt. De cumulatieve incidentie van terechte ICD schoktherapie 
voor patiënten met een rechter ventrikel drempel ≥ 1V (n = 166) was 16% na 1 jaar, 24% 
na 3 jaar en 34% na 5 jaar. Bij patiënten met een rechter ventriculaire drempel <1V (n = 
523) waren die percentages respectievelijk 4%, 11% en 17%. Het gecorrigeerde relatieve 
risico van rechter ventrikel drempel ≥ 1V was 1.8 (95% CI 1.3-2.6) voor terechte therapie, 
3.3 (95% CI 2.0-5.4) voor terechte ICD schok en 1.6 (95% CI 1.1 tot 2.5) voor sterfte. 
Deze studie laat zien dat rechter ventriculaire stimulatie drempelwaarde bij ICD implantatie 
een sterke, onafhankelijke prognostische waarde heeft voor het optreden van ventriculaire 
aritmieën en mortaliteit.
Deel III: Mechanische aspecten en complicaties van ICD therapie
De incidentie, voorspellende factoren en gevolgen van onterechte ICD schokken werd in 
1544 ICD patiënten onderzocht in hoofdstuk 12. Tijdens een follow-up van 41 ± 18 
maanden, ontving 13% van de patiënten een of meer onterechte schokken. De cumulatieve 
incidentie nam toe tot 18% na 5 jaar follow-up. Onafhankelijke voorspellers voor het op-
treden van onterechte schokken waren een voorgeschiedenis van AF (HR 2.0, p <0.01) en 
een leeftijd jonger dan 70 jaar (HR 1.8, p <0.01). Een onterechte ICD schok resulteerde 
in een verhoogd risico op mortaliteit (HR 1.6, p = 0.01). Tevens was elke volgende on-
terechte schok gerelateerd aan een verhoogd sterfterisico met een relatief risico van 3.7 
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na 5 onterechte schokken. Deze studie benadrukt het belang van onterechte schokken in 
deze populatie. De belangrijkste bevinding is de associatie tussen onterechte schokken en 
sterfte.
De hoofdstukken 13 en 14 beschrijven de incidentie en oorzaken van het falen van 
568 coronaire sinus leads (hoofdstuk 13) en 2161 defibrillatie leads (hoofdstuk 14). 
Tijdens follow-up was er in 7% van de patiënten met een coronaire sinus lead noodzaak 
tot interventie. Oorzaken hiervan waren een verhoogde drempel (n = 13), verlies van de 
capture (n = 20), of aanhoudende nervus phrenicus stimulatie (n = 6). Bij 15 patiënten 
(38%) was een ingreep noodzakelijk, nog vóór de eerste geplande follow-up (twee maanden 
na implantatie). Bij 13 patiënten (33%) was dit het geval meer dan zes maanden na de 
implantatie. De eerste endovasculaire vervanging was succesvol in 86% (32 van de 37) 
terwijl een tweede endovasculaire benadering 66% (2 uit 3) niet succesvol was. Bij de 
defibrillatie leads faalden 82 van de 2161 (3.8%) leads. De cumulatieve incidentie van 
lead falen was 0.6% na 1 jaar, 6.5% na 5 jaar en 16.4% na 10 jaar. Leads met een kleine 
diameter hadden een hogere risico op falen. Het gecorrigeerde relatieve risico was 6.4 
(95% CI 3.2-12.8) voor de Medtronic 7 Fr lead, vergeleken met alle andere leads.
Deze studies geven inzicht in het optreden van complicaties die samengaan met ICD 
behandeling.
Aangezien de Medtronic Sprint Fidelis defibrillatie leads een boven gemiddeld percentage 
uitval vertonen (hoofdstuk 14), kondigde Medtronic twee adviezen, af bestaande uit (1) 
aanpassingen in de instellingen van de ICD (oktober 2007) en (2) de installatie van een 
lead integriteit algoritme (mei 2008). Het doel van hoofdstuk 15 was de evaluatie van het 
effect van deze adviezen op de veiligheid van de geïmplanteerde leads voor de patiënt. In 
totaal werden 372 leads onderzocht. Bij de vergelijking van de event-rates  werden drie 
periodes onderscheiden: van lead implantatie tot aan advies 1 (periode A), van advies 1 
tot advies 2 (periode B) en van advies 2 tot aan het einde van de follow-up (periode C). De 
totale cumulatieve incidentie van lead falen in de drie periodes was 3.6% (95% CI 1.6 tot 
5.6%) na 21 maanden en steeg tot 11.0% (95% CI 6.1 tot 15.9%) na 42 maanden. Na 
uitvoering van de adviezen, daalde de incidentie ongewenste schokken als gevolg van lead 
falen van 1.5 leads (95% CI 0.6 tot 3.0) per 100 lead-jaren in periode A tot 0.8 (95% CI 
0.0 tot 4.3) per 100 lead-jaren in periode C. Deze studie toont aan dat, ondanks een steeds 
groter risico op Sprint Fidelis lead falen, de uitvoering van de adviezen het voorkomen van 
ongewenste schokken als gevolg van falen heeft doen afnemen.
Hoofdstuk 16 gaat over onderzoek naar de noodzaak tot pocket gerelateerde re-interventies 
en het effect van ICD vervanging op het optreden van re-interventies bij 3161 ICD implan-
taties. In totaal werden 145 re-interventies verricht bij 122 (3.9%) patiënten, met een 
mediane tijd tot de eerste re-interventie van 75 dagen. De cumulatieve incidentie van eerste 
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re-interventie was 4.7% (95% CI 3.9-5.5%) na 3 jaar en de incidentie van re-interventie 
was 1.9 (95% CI 1.6-2.2) per 100 ICD-jaren. Vergelijking van event-rates bij vervangen 
ICDs versus eerst geïmplanteerde ICDs toonde een meer dan verdubbelde incidentie van 
re-interventies na ICD vervanging (rate ratio 2.2 [95% CI 1.5-3.0]). Verdere onderverde-
ling op volgorde van ICD vervanging, toonde een stijging van de jaarlijkse noodzaak tot 
re-interventie, variërend van 1.5% (95% CI 1.2-1.9%) bij de eerst geïmplanteerde ICD tot 
8.1% (95% CI 1.7-18.3%) bij de vierde ICD. Dit onderzoek laat zien dat ICD vervanging 
de kans op de noodzaak tot re-interventie aanzienlijk vergroot.
Conclusies en toekomstperspectieven
In grote gerandomiseerde studies is onbetwist aangetoond dat ICD therapie gunstige 
effecten heeft in een geselecteerde patiëntenpopulatie. Voor patiënten in de dagelijkse 
praktijk, buiten de setting van een klinische studie, is er echter nog veel onduidelijk over 
deze behandeling. In dit proefschrift is een aantal aspecten van ICD behandeling bij deze 
belangrijke en groeiende groep patiënten nader onderzocht. Ten eerste zijn in verschillende 
subpopulaties van ICD patiënten tijdens een lange follow-up de incidentie van sterfte, 
ventriculaire aritmieën met terechte ICD therapie en van complicaties van de ICD zoals 
onterechte schokken, geëvalueerd. Ten tweede zijn in dit proefschrift de mogelijkheden 
voor risico-stratificatie onderzocht aan de hand van eenvoudige en routinematig verworven 
klinische gegevens (leeftijd, geslacht, klinische voorgeschiedenis, bevindingen op het 
ECG en echocardiografie) zonder gebruik te maken van meer geavanceerde parameters. 
Hierbij is de belangrijke rol van AF voor implantatie en tijdens follow-up uitgebreid in kaart 
gebracht. Ten derde is de waarde van nieuwe parameters, verkregen met behulp van aan-
vullende diagnostische technieken (MRI, MIBG, vector ECG) getest op hun voorspellende 
waarde op ventriculaire aritmieën met als doel de risicostratificatie te verbeteren. Tevens 
(en mogelijk nog belangrijker) is onderzocht of deze nieuwe parameters waardevol zijn bij 
het identificeren van patiënten die, hoewel volgens de huidige richtlijnen geïndiceerd voor 
een ICD, uiteindelijk tijdens de follow-up een zodanig lage incidentie van ventriculaire 
aritmieën blijken te hebben, dat de vraag gesteld moet worden of deze patiënten wel een 
ICD moeten krijgen. Daarnaast zijn klinisch toepasbare risicoscores geconstrueerd om voor 
de individuele patiënt een inschatting van het sterfterisico te kunnen maken. Ten slotte 
heeft het proefschrift in kaart gebracht hoe vaak belangrijke nadelen en complicaties van 
een behandeling met ICDs voorkomen, zoals onterechte schokken en hun prognostische 
waarde, coronaire sinus lead falen en het succespercentage van endovasculaire vervanging, 
en defibrillatie lead falen en het effect van lead adviezen op de veiligheid van ICD behande-
ling voor de patiënt.
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Toekomstig onderzoek zal zich vooral richten op de optimale plaats van ICD behandeling 
ter preventie van overlijden door ventriculaire aritmie. Aan de ene kant zullen patiënten met 
een hoog risico voor plotse hartdood die een ICD nodig hebben maar volgens de huidige 
richtlijnen geen indicatie daarvoor hebben, moeten worden geïdentificeerd. Aan de andere 
kant ontvangt een groot deel van de patiënten een ICD omdat zij daar volgens de richtlijn 
voor in aanmerking komen zonder dat deze gedurende een lange follow-up therapeutisch 
is. Deze categerie patiënten moet daarom vóór de implantatie worden herkend zodat het 
besluit van ICD implantatie kan worden heroverwogen. 
Plotselinge hartdood in de algemene bevolking
In een groot populatie onderzoek in de regio Maastricht blijkt dat plotse hartdood in ongeveer 
50% van alle gevallen de eerste manifestatie van hart-en vaatziekten is. Van alle gevallen 
van plotse hartdood bij patiënten die eerder een myocardinfarct en waarvan echocardio-
grafische gegevens beschikbaar waren, had 50% een LVEF hoger dan 30% en 20% een 
LVEF hoger dan 50%.1 Onze eigen bevindingen in de Leiden out-of-hospital cardiac arrest 
study bevestigen dat.2, 3 Annemend dat een ICD een overlevingsvoordeel op zal leveren 
zolang het risico voor aritmie in de geteste bevolking hoog genoeg is (zoals gesteld door Dr 
Mower, mede-ontwikkelaar van de ICD),4 kan men concluderen dat een groot deel van de 
populatie die baat zou kunnen hebben bij een ICD daar volgens de huidige internationale 
richtlijnen niet voor in aanmerking komt.5 Toekomstig onderzoek zal zich daarom in eerste 
instantie moeten richten op de identificatie van deze “onbekende” patiënten met een hoog 
risico op plotse hartdood en op de preventie en vroegtijdig identificatie van het ontstaan 
van orgaanschade die aritmie kan veroorzaken (bv. preventie van acuut myocardinfarct, de 
identificatie van gedilateerde cardiomyopathie).
Aangezien eerdere studies een gunstig effect van ICDs als primaire preventie van plotse 
hartdood hebben aangetoond bij patiënten met een slechte linker ventrikel functie, zou de 
uitbreiding van het indicatiegebied zich kunnen richten op patiënten met hart-en vaatziek-
ten die nog een normale LVEF hebben, of op patiënten zonder bekende hart-en vaatziekten 
die echter een hoog risicoprofiel hebben voor het ontstaan van ventriculaire aritmieën (bijv. 
positieve familie-anamnese voor plotse hartdood) of een provocerende levensstijl hebben 
(bijv. competitieve sport). 
De huidige ICD geïndiceerde populatie
Grote studies hebben het belang van ICDs als de primaire preventie van plotse hartdood 
duidelijk aangetoond. Deze studies hebben in het algemeen in grote hoog-risico pa-
tiëntenpopulaties plaatsgevonden. De relatief lage incidentie van terechte en potentieel 
levensreddende ICD therapie tijdens lange follow-up trekt de effectiviteit van de huidige 
indicatiestelling van ICDs echter in twijfel. Hoewel op populatieniveau ICDs een duidelijk 
overlevingsvoordeel hebben, betekent dit niet dat alle individuele onderzochte patiënten 
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in gelijke mate profiteren van ICD behandeling. Onder de patiënten met een ICD indicatie 
volgens de huidige richtlijnen, zijn patiënten waarvan kan worden aangenomen dat zij om 
verschillende redenen te weinig profiteren van de ICD-behandeling. Deze patiënten hebben 
(1) een slechte prognose, ongeacht de ICD (bijv. door hartfalen of niet-cardiale dood), (2) 
geen of weinig potentieel levensreddende terechte ICD therapie gedurende follow-up of (3) 
een combinatie van beide factoren (sterfte vóór een eerste terechte ICD therapie). Om ICDs 
efficiënter toe te wijzen, is het nodig om deze categorie patiënten voorafgaand aan im-
plantatie te identificeren. Aangezien veel van de huidige patiënten die een ICD krijgen een 
relatief hoge leeftijd hebben (50% > 65 jaar, 14% > 75 jaar) en ernstige co-morbiditeit, 
zal de identificatie van patiënten met weinig baat van implantatie zich in eerste instantie 
moeten richten op deze patiëntengroepen.
Een goede evaluatie van een restrictiever ICD beleid is lastig omdat dat het interfereert 
met de huidige richtlijnen. Toch zijn er ook andere factoren die wellicht kunnen bijdragen 
aan een restrictiever beleid. Onder clinici ontstaat in toenemende mate de zorg dat de 
richtlijnen voor een primaire preventie ICD te veel gebaseerd zijn op onderzoeksgegevens 
op populatieniveau waardoor bij de individuele patiënt het gevaar van “overbehandeling” 
kan ontstaan. Door de grote hoeveelheid patiënten die nu voor primaire preventie ICD be-
handeling in aanmerking komt dreigt een tekort aan financiële middelen en gekwalificeerd 
personeel te ontstaan.6 In dat geval zullen artsen beter moeten kunnen differentiëren tussen 
patiënten met een grote kans om te profiteren van ICD behandeling (goede prognose, een 
hoog risico op ventriculaire aritmie) en patiënt bij wie die kans geringer is en de positieve 
effecten van implantatie niet opwegen tegen het risico op bijwerkingen. De resultaten van 
dit proefschrift bieden aanknopingspunten voor de discussie over dit onderwerp en voor 
aanvullend onderzoek om een nieuw ICD beleid vorm te kunnen geven.
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De artikelen die in dit proefschrift zijn beschreven zijn tot stand gekomen op de afdeling 
cardiologie van het Leids Universitair Medisch Centrum. Graag zou ik iedereen bedanken 
met wie ik de in deze periode heb mogen samenwerken en wil ik een aantal mensen in het 
bijzonder noemen.
Allereerst iedereen die het mogelijk heeft gemaakt om patiënten te screenen en de on-
derzoeken uit te voeren. Te beginnen met de verpleging op de afdeling cardiologie, de 
echolaboranten, Renée, het secretariaat (Cora, Marina en Talitha). De studie-nurses Ellen 
en Josien, Enno voor het maken van de grote moeder-databases en iedereen die de afgelo-
pen drie jaren geholpen heeft om alles in goede banen te leiden.
Frits, Anske en Susanne voor mijn scholing en doorlopende nascholing in de Epidemiologie. 
Dank dat jullie onze studies elke keer weer geduldig uit de epidemiologische knoop hebben 
gehaald en mij volledig nieuwe methoden hebben laten zien om mijn (soms onduidelijke) 
boodschap helder te presenteren.
Niemand heb ik de afgelopen drie jaar zo onvoorstelbaar veel gezien als mijn collega’s in ‘de 
Tuin’. Het Feit dat ik hier nu met zoveel plezier aan terugdenk komt dan ook hoofdzakelijk 
door hen: Joanne, Robert, Claudia, Laurens, Sjoerd, Yvo, Daniël, Ellen, Roxana, Stijntje, 
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Joëlla, Carine, Joep, Mihály, Cees, Eline. 
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De auteur van dit proefschrift werd geboren op 8 augustus 1981 in Pijnacker. In 1999 be-
haalde hij zijn eindexamen aan het Christelijk Gymnasium te Utrecht. Na een jaar Human 
Biology aan Oxford Brookes University (Oxford, Engeland) begon hij in 2000 met de studie 
Geneeskunde aan de Universiteit Utrecht, waar hij in 2007 zijn artsexamen behaalde. 
Tijdens zijn studie deed hij onderzoek naar implanteerbare cardioverter defibrillatoren 
in het Meander Medisch Centrum Amersfoort (Dr. A. Mosterd). Direct na zijn afstuderen 
startte hij in het Leids Universitair Medisch Centrum zijn promotieonderzoek onder leiding 
van Prof. Dr. M.J. Schalij en Prof. Dr. J.J. Bax. De resultaten hiervan staan beschreven in 
dit proefschrift.
Per 1 april 2010 is hij begonnen met zijn opleiding tot cardioloog vanuit het Leids 
Universitair Medisch Centrum (opleider: Prof. Dr. E.E. van der Wall). Momenteel volgt hij 
de vooropleiding Interne Geneeskunde in het Bronovo Ziekenhuis te Den Haag (opleider: Dr. 
J.W. van ’t Wout). Hij is getrouwd met Kim Wynands.
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